record_id,source_id,smiles,inchi,inchikey,status,errors,MolWt,ExactMolWt,LogP,TPSA,HBD,HBA,NumRotatableBonds,RingCount,NumAromaticRings,FractionCSP3,HeavyAtomCount,QED,lipinski_pass,lipinski_violations,pains_pass,pains_violations,pains_violation_details,molecule_chembl_id,standard_value,standard_units,standard_relation,pchembl_value,assay_chembl_id,assay_description,confidence_score,n_measurements,pIC50,activity_class,activity_label,lipinski_violation_details
e5745591,,Nc1nc(-c2ccccc2)nc2c1[n+]([O-])c1ccccc1[n+]2[O-],,,raw,,305.297,305.09127459200005,1.2989999999999997,105.67999999999999,1,5,1,4,4,0.0,23,0.3239670522318874,True,0,False,1,PAINS match: het_pyridiniums_A(39),CHEMBL443221,1600.0,nM,=,5.8,CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,0.8,1,5.7959,0,inactive,
f5f2bc8c,,Cc1cc(Cl)cc(C(=O)Nc2cc(S(=O)(=O)c3ccc(Cl)cc3)ccc2Cl)c1O,,,raw,,470.7610000000002,468.970911968,5.7459200000000035,83.47,2,4,4,3,3,0.05,29,0.5086739176411135,True,1,True,0,,CHEMBL334590,3300.0,nM,=,5.48,CHEMBL651293,Inhibitory activity against Bcl-2,0.8,1,5.4815,0,inactive,LogP=5.75 > 5.0
8c6b0a03,,COc1ccc2c(c1)CCc1cc(OC)ccc1/[N+]([O-])=[N+]\2[O-],,,raw,,300.314,300.111006992,3.238400000000002,70.6,0,4,2,3,2,0.25,22,0.6303046821639888,True,0,True,0,,CHEMBL344184,7200.0,nM,=,4.98,CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,0.8,2,5.1427,0,inactive,
bffbca0f,,N=C(N)c1ccc(/N=N/c2c(O)ccc3c2[nH]c2ccccc23)cc1,,,raw,,329.36300000000006,329.1276601,4.726170000000002,110.61000000000001,4,4,3,4,4,0.0,25,0.24745028511097808,True,0,False,1,PAINS match: azo_A(324),CHEMBL540363,5800.0,nM,=,5.24,CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,0.8,1,5.2366,0,inactive,
e69e7549,,CCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C,,,raw,,520.5790000000003,520.2420807319999,2.7001999999999997,157.32999999999998,3,9,10,2,1,0.5769230769230769,37,0.1825319394938917,True,1,True,0,,CHEMBL436605,2000.0,nM,=,5.7,CHEMBL651293,Inhibitory activity against Bcl-2,0.8,1,5.699,0,inactive,MW=520.6 > 500.0
2ed1767d,,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,raw,,3117.507999999991,3115.541020520002,-13.96060000000009,1386.2999999999993,46,42,106,5,5,0.5474452554744526,220,0.009762944628531665,False,3,True,0,,CHEMBL411747,300.0,nM,=,6.52,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,6.5229,1,active,MW=3117.5 > 500.0; HBD=46 > 5; HBA=42 > 10
109f1b31,,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)O,,,raw,,2584.8659999999954,2583.24008752,-12.426099999999975,1194.5499999999997,39,35,87,4,4,0.5405405405405406,182,0.011086216180902685,False,3,True,0,,CHEMBL269555,5600.0,nM,=,5.25,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,5.2518,0,inactive,MW=2584.9 > 500.0; HBD=39 > 5; HBA=35 > 10
a84f6b07,,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,raw,,3160.5369999999916,3158.5580675520023,-15.953100000000118,1450.6999999999991,48,43,108,5,5,0.5401459854014599,223,0.009762943188062985,False,3,True,0,,CHEMBL437858,49.0,nM,=,7.31,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,7.3098,1,active,MW=3160.5 > 500.0; HBD=48 > 5; HBA=43 > 10
ba4bf32d,,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,raw,,3001.384999999992,2999.5035723920014,-14.35590000000009,1344.4899999999996,44,41,104,3,3,0.5846153846153846,211,0.014173250304649537,False,3,True,0,,CHEMBL409227,410.0,nM,=,6.39,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,6.3872,1,active,MW=3001.4 > 500.0; HBD=44 > 5; HBA=41 > 10
315db9cf,,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,raw,,3101.5089999999914,3099.5461059000017,-12.933000000000087,1366.0699999999993,45,41,105,5,5,0.5474452554744526,219,0.009762948559693037,False,3,True,0,,CHEMBL427653,800.0,nM,=,6.1,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,6.0969,1,active,MW=3101.5 > 500.0; HBD=45 > 5; HBA=41 > 10
cbc7096d,,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,raw,,3041.409999999992,3039.509720392002,-15.18340000000008,1386.2999999999993,46,42,104,4,4,0.5725190839694656,214,0.01108620499370426,False,3,True,0,,CHEMBL412528,1360.0,nM,=,5.87,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,5.8665,0,inactive,MW=3041.4 > 500.0; HBD=46 > 5; HBA=42 > 10
26d76814,,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC,,,raw,,2879.1669999999945,2877.403917932001,-18.387300000000124,1349.6499999999996,45,43,98,2,1,0.6470588235294118,201,0.01635687589657922,False,3,True,0,,CHEMBL440058,3030.0,nM,=,5.52,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,5.5186,0,inactive,MW=2879.2 > 500.0; HBD=45 > 5; HBA=43 > 10
ae1bc97b,,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC,,,raw,,2813.2209999999955,2811.5143947840006,-12.537400000000043,1228.62,40,37,95,3,3,0.616,199,0.01417326182794673,False,3,True,0,,CHEMBL409228,650.0,nM,=,6.19,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,6.1871,1,active,MW=2813.2 > 500.0; HBD=40 > 5; HBA=37 > 10
0401a2f5,,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O,,,raw,,2952.3199999999947,2950.4375861440017,-16.693800000000106,1367.2699999999995,46,46,108,0,0,0.7024793388429752,204,0.011635093571136271,False,3,True,0,,CHEMBL441574,2880.0,nM,=,5.54,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,5.5406,0,inactive,MW=2952.3 > 500.0; HBD=46 > 5; HBA=46 > 10
a236ef64,,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,raw,,2922.4069999999933,2920.548062996001,-10.90510000000003,1228.07,43,41,103,3,3,0.6461538461538462,205,0.010797832503092119,False,3,True,0,,CHEMBL265917,1330.0,nM,=,5.88,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,5.8761,0,inactive,MW=2922.4 > 500.0; HBD=43 > 5; HBA=41 > 10
7f462135,,CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C,,,raw,,2927.3539999999944,2925.5144118480007,-14.373200000000065,1298.8399999999997,43,40,98,4,4,0.5984251968503937,206,0.011086205674809677,False,3,True,0,,CHEMBL442325,1560.0,nM,=,5.81,CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,0.8,1,5.8069,0,inactive,MW=2927.4 > 500.0; HBD=43 > 5; HBA=40 > 10
fa4cdfed,,O=C(NS(=O)(=O)c1ccc(NCCSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1,,,raw,,551.6210000000002,551.098491024,5.723800000000004,118.41,2,7,10,4,4,0.07407407407407407,38,0.11192948196619279,False,2,True,0,,CHEMBL371861,3196.5,nM,=,5.2,CHEMBL858941,Inhibitory activity against Bcl-XL in presence of HSA3 from 1% human serum,0.8,2,5.4953,0,inactive,MW=551.6 > 500.0; LogP=5.72 > 5.0
3c58a747,,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,raw,,518.5620000000004,518.19406792,6.382240000000009,155.52,6,8,5,4,4,0.26666666666666666,38,0.1312357685384841,False,3,False,1,PAINS match: catechol_A(92),CHEMBL51483,600.0,nM,=,6.3,CHEMBL909445,Binding affinity to human Bcl2 by ELISA,0.8,7,6.2218,1,active,MW=518.6 > 500.0; LogP=6.38 > 5.0; HBD=6 > 5
34cdcf87,,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,raw,,3269.7049999999913,3267.6359835240028,-11.530900000000074,1432.9599999999994,46,42,107,6,5,0.5586206896551724,231,0.009762973346084733,False,3,True,0,,CHEMBL2371929,11.0,nM,=,7.96,CHEMBL909445,Binding affinity to human Bcl2 by ELISA,0.8,1,7.9586,1,active,MW=3269.7 > 500.0; HBD=46 > 5; HBA=42 > 10
9a3c1933,,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O,,,raw,,573.7110000000004,573.2185088399999,6.900200000000008,123.93,4,6,7,4,4,0.24242424242424243,41,0.17836215523307064,False,2,False,1,PAINS match: catechol_A(92),CHEMBL217354,450.0,nM,=,6.16,CHEMBL909445,Binding affinity to human Bcl2 by ELISA,0.8,2,6.3468,1,active,MW=573.7 > 500.0; LogP=6.90 > 5.0
5463c561,,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cc(Cc2ccccc2)c(O)c(O)c1O,,,raw,,475.5220000000002,475.1089583919999,4.479300000000004,123.93,4,6,6,4,4,0.038461538461538464,34,0.30497402721372263,True,0,False,1,PAINS match: catechol_A(92),CHEMBL217223,2800.0,nM,=,5.8,CHEMBL909445,Binding affinity to human Bcl2 by ELISA,0.8,2,5.5528,0,inactive,
1af07254,,O=C(Nc1ccccc1)c1cc(Cc2ccccc2)c(O)c(O)c1O,,,raw,,335.35900000000004,335.11575802399994,3.6465000000000023,89.79,4,4,4,3,3,0.05,25,0.5479745939627466,True,0,False,1,PAINS match: catechol_A(92),CHEMBL214965,6100.0,nM,=,5.14,CHEMBL909445,Binding affinity to human Bcl2 by ELISA,0.8,2,5.2147,0,inactive,
ed4229e4,,CN(CCCc1ccccc1)S(=O)(=O)c1cc(C(=O)N2CCc3ccc(S(=O)(=O)NCCc4ccccc4)cc3C2)c(O)c(O)c1O,,,raw,,679.8170000000003,679.2022071440001,3.776200000000004,164.55,4,8,12,5,4,0.2647058823529412,47,0.16446223068734656,True,1,False,1,PAINS match: catechol_A(92),CHEMBL376055,330.0,nM,=,6.48,CHEMBL918623,Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay,0.8,1,6.4815,1,active,MW=679.8 > 500.0
72d9495e,,CC(C)c1cc(C(=O)N2CCc3ccc(S(=O)(=O)NCCc4ccccc4)cc3C2)c(O)c(O)c1O,,,raw,,510.61200000000025,510.1824576799999,3.6463000000000045,127.17000000000002,4,6,7,4,3,0.2962962962962963,36,0.35954044685846376,True,1,False,1,PAINS match: catechol_A(92),CHEMBL219775,6600.0,nM,=,5.18,CHEMBL918623,Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay,0.8,1,5.1805,0,inactive,MW=510.6 > 500.0
fbbaf972,,O=C(c1ccc(Oc2ccccc2)cc1)c1cc(C(=O)c2nc3ccccc3s2)c(O)c(O)c1O,,,raw,,483.5010000000002,483.0776582639999,5.667400000000005,116.95000000000002,3,8,6,5,5,0.0,35,0.21047187387346422,True,1,False,1,PAINS match: catechol_A(92),CHEMBL258819,170.0,nM,=,6.77,CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,0.8,1,6.7696,1,active,LogP=5.67 > 5.0
b9711ffc,,O=C(c1ccc(Oc2ccccc2)cc1)c1cc(C(=O)c2cccc3ccccc23)c(O)c(O)c1O,,,raw,,476.4840000000002,476.1259883599999,6.210900000000007,104.06000000000002,3,6,6,5,5,0.0,36,0.19880389738359505,True,1,False,1,PAINS match: catechol_A(92),CHEMBL259034,290.0,nM,=,6.54,CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,0.8,1,6.5376,1,active,LogP=6.21 > 5.0
8076ce79,,CC(C)C(=O)c1cc(C(=O)c2ccc(Oc3ccccc3)cc2)c(O)c(O)c1O,,,raw,,392.4070000000001,392.1259883599999,4.665400000000004,104.06000000000002,3,6,6,3,3,0.13043478260869565,29,0.41611432497337486,True,0,False,1,PAINS match: catechol_A(92),CHEMBL259033,2600.0,nM,=,5.58,CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,0.8,1,5.585,0,inactive,
306ed6ac,,CC(C)c1cc(C(=O)c2ccc(Oc3ccccc3)cc2)c(O)c(O)c1O,,,raw,,364.3970000000001,364.1310737399999,4.950100000000005,86.99000000000001,3,5,5,3,3,0.13636363636363635,27,0.44036312651682824,True,0,False,1,PAINS match: catechol_A(92),CHEMBL270268,3400.0,nM,=,5.47,CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,0.8,1,5.4685,0,inactive,
d5119d1e,,Cc1cc(C(=O)N2CCc3ccccc3C2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,raw,,476.5800000000003,476.221226136,4.577720000000004,58.440000000000005,0,4,3,6,4,0.23333333333333334,36,0.4350512714699941,True,0,True,0,,CHEMBL464268,1500.0,nM,=,5.82,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.8239,0,inactive,
deb1af84,,Cc1cc(C(=O)N(C)c2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,raw,,450.5420000000003,450.205576072,4.655820000000005,58.440000000000005,0,4,4,5,4,0.17857142857142858,34,0.4545763416780153,True,0,True,0,,CHEMBL466801,2500.0,nM,=,5.6,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.6021,0,inactive,
8064df33,,Cc1cc(C(=O)N(C)c2cccc(F)c2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,raw,,468.5320000000003,468.19615426,4.794920000000004,58.440000000000005,0,4,4,5,4,0.17857142857142858,35,0.43259148561910155,True,0,True,0,,CHEMBL518858,2300.0,nM,=,5.64,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.6383,0,inactive,
8f6a7c91,,Cc1cc(C(=O)N(C)c2ccccc2F)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,raw,,468.5320000000003,468.19615426,4.794920000000004,58.440000000000005,0,4,4,5,4,0.17857142857142858,35,0.43259148561910155,True,0,True,0,,CHEMBL480008,3000.0,nM,=,5.52,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.5229,0,inactive,
e559e1eb,,CCN(C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1)c1ccccc1,,,raw,,464.56900000000024,464.221226136,5.045920000000005,58.440000000000005,0,4,5,5,4,0.20689655172413793,35,0.41551829677707497,True,1,True,0,,CHEMBL480009,1900.0,nM,=,5.72,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.7212,0,inactive,LogP=5.05 > 5.0
ad2aa8a8,,Cc1cc(C(=O)N(c2ccccc2)C2CCCCC2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,raw,,518.6610000000002,518.268176328,6.358720000000006,58.440000000000005,0,4,5,6,4,0.30303030303030304,39,0.3089664070272797,False,2,True,0,,CHEMBL516633,1400.0,nM,=,5.85,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.8539,0,inactive,MW=518.7 > 500.0; LogP=6.36 > 5.0
8256acd6,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,raw,,512.6130000000003,512.221226136,6.357720000000008,58.440000000000005,0,4,5,6,5,0.12121212121212122,39,0.27543949722569844,False,2,True,0,,CHEMBL517577,800.0,nM,=,6.1,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.0969,1,active,MW=512.6 > 500.0; LogP=6.36 > 5.0
73be8ab2,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,raw,,542.6390000000004,542.23179082,5.7186200000000085,78.67,1,5,6,6,5,0.14705882352941177,41,0.2978105726433941,False,2,True,0,,CHEMBL444140,190.0,nM,=,6.72,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.7212,1,active,MW=542.6 > 500.0; LogP=5.72 > 5.0
55bf2e80,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,raw,,541.6550000000002,541.247775232,5.685020000000007,84.46000000000001,1,5,6,6,5,0.14705882352941177,41,0.2995902838672562,False,2,True,0,,CHEMBL453380,110.0,nM,=,6.96,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.9586,1,active,MW=541.7 > 500.0; LogP=5.69 > 5.0
da930ec3,,COC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,raw,,556.6660000000002,556.2474408840001,6.372720000000006,67.67,0,5,7,6,5,0.17142857142857143,42,0.23359003709011622,False,2,True,0,,CHEMBL501871,160.0,nM,=,6.8,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.7959,1,active,MW=556.7 > 500.0; LogP=6.37 > 5.0
8d6e6222,,CC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,raw,,583.6920000000001,583.2583399160001,5.8624200000000055,87.54,1,5,7,6,5,0.16666666666666666,44,0.2599896158946564,False,2,True,0,,CHEMBL510332,730.0,nM,=,6.14,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.1367,1,active,MW=583.7 > 500.0; LogP=5.86 > 5.0
56a472e7,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CNS(C)(=O)=O,,,raw,,619.7470000000003,619.2253255360001,5.275520000000006,104.60999999999999,1,6,8,6,5,0.17142857142857143,45,0.2547664075687995,False,2,True,0,,CHEMBL446607,1050.0,nM,=,5.98,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.9788,0,inactive,MW=619.7 > 500.0; LogP=5.28 > 5.0
1325b11e,,CCOC(=O)[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,raw,,584.6760000000002,584.242355504,6.289420000000006,84.74,0,6,7,6,5,0.16666666666666666,44,0.21006901782475304,False,2,True,0,,CHEMBL446480,5610.0,nM,=,5.25,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,5.251,0,inactive,MW=584.7 > 500.0; LogP=6.29 > 5.0
69168a33,,COC(=O)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,raw,,584.6760000000002,584.242355504,6.289420000000006,84.74,0,6,7,6,5,0.16666666666666666,44,0.21006901782475304,False,2,True,0,,CHEMBL453466,280.0,nM,=,6.55,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.5528,1,active,MW=584.7 > 500.0; LogP=6.29 > 5.0
d0eab005,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,569.7090000000002,569.27907536,6.2879200000000095,61.68000000000001,0,5,7,6,5,0.19444444444444445,43,0.23126073170753955,False,2,True,0,,CHEMBL500574,150.0,nM,=,6.82,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.8239,1,active,MW=569.7 > 500.0; LogP=6.29 > 5.0
c502a78c,,CNC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,raw,,555.6820000000001,555.263425296,5.945720000000006,70.47,1,5,7,6,5,0.17142857142857143,42,0.2696791220366732,False,2,True,0,,CHEMBL500866,140.0,nM,=,6.85,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.8539,1,active,MW=555.7 > 500.0; LogP=5.95 > 5.0
6cba82be,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1C,,,raw,,526.6400000000003,526.2368762,6.746220000000008,58.440000000000005,0,4,5,6,5,0.14705882352941177,40,0.2546645329054644,False,2,True,0,,CHEMBL514298,110.0,nM,=,6.96,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.9586,1,active,MW=526.6 > 500.0; LogP=6.75 > 5.0
2639f1d8,,Cc1c(Br)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,raw,,621.5350000000002,620.1423028880001,6.481120000000009,78.67,1,5,6,6,5,0.14705882352941177,42,0.23556512472192387,False,2,True,0,,CHEMBL509788,125.0,nM,=,7.4,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,6.9031,1,active,MW=621.5 > 500.0; LogP=6.48 > 5.0
ed7f4b7a,,Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,raw,,577.0840000000002,576.192818468,6.372020000000008,78.67,1,5,6,6,5,0.14705882352941177,42,0.25462857211772155,False,2,True,0,,CHEMBL460173,265.0,nM,=,7.3,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,6.5768,1,active,MW=577.1 > 500.0; LogP=6.37 > 5.0
df6b1dac,,Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,raw,,576.1,575.20880288,6.338420000000007,84.46000000000001,1,5,6,6,5,0.14705882352941177,42,0.2560259088210225,False,2,True,0,,CHEMBL503454,30.0,nM,=,7.52,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,3,7.5229,1,active,MW=576.1 > 500.0; LogP=6.34 > 5.0
d8c811b6,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,472.63300000000027,472.283826392,5.421620000000006,58.440000000000005,0,4,9,4,3,0.41379310344827586,35,0.41771344989783904,True,1,True,0,,CHEMBL513318,1120.0,nM,=,6.64,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,5.9508,0,inactive,LogP=5.42 > 5.0
703bae1a,,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,537.1040000000004,536.2554187239999,5.4359200000000065,78.67,1,5,10,4,3,0.43333333333333335,38,0.37424351662444444,False,2,True,0,,CHEMBL467229,440.0,nM,=,7.0,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,6.3565,1,active,MW=537.1 > 500.0; LogP=5.44 > 5.0
c0ad587a,,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,raw,,536.1200000000003,535.271403136,5.402320000000005,84.46000000000001,1,5,10,4,3,0.43333333333333335,38,0.3763631469451161,False,2,True,0,,CHEMBL481581,90.0,nM,=,7.7,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,7.0458,1,active,MW=536.1 > 500.0; LogP=5.40 > 5.0
468257cb,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,522.0930000000003,521.2557530720001,5.657220000000006,84.46,1,5,9,4,3,0.41379310344827586,37,0.36823265646540954,False,2,True,0,,CHEMBL481775,395.0,nM,=,7.05,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,6.4034,1,active,MW=522.1 > 500.0; LogP=5.66 > 5.0
e17e65ae,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,626.201,625.2819678200001,7.327320000000008,87.54,1,5,11,5,4,0.3333333333333333,45,0.1890675093450408,False,2,True,0,,CHEMBL446802,3235.0,nM,=,6.09,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,5.4901,0,inactive,MW=626.2 > 500.0; LogP=7.33 > 5.0
1b0594de,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,640.2280000000001,639.2976178840001,7.256220000000009,87.54,1,5,12,5,4,0.35135135135135137,46,0.17680089871995328,False,2,True,0,,CHEMBL449546,155.0,nM,=,7.4,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,6.8097,1,active,MW=640.2 > 500.0; LogP=7.26 > 5.0
3b2c3558,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,656.2270000000001,655.2925325040001,7.092520000000008,96.77,1,6,13,5,4,0.35135135135135137,47,0.16587629396796538,False,2,True,0,,CHEMBL504480,85.0,nM,=,7.4,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,7.0706,1,active,MW=656.2 > 500.0; LogP=7.09 > 5.0
829cac3b,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,676.283,675.264603504,7.016920000000009,104.61,1,6,13,5,4,0.3611111111111111,47,0.16409899382956405,False,2,True,0,,CHEMBL450954,1700.0,nM,=,6.6,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,5.7696,0,inactive,MW=676.3 > 500.0; LogP=7.02 > 5.0
9cb71677,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,606.7670000000002,606.320605824,6.683320000000007,84.74,0,6,13,5,4,0.35135135135135137,45,0.15854806565776708,False,2,True,0,,CHEMBL509208,175.0,nM,=,7.7,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,6.757,1,active,MW=606.8 > 500.0; LogP=6.68 > 5.0
41dc6e03,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)O)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,546.6680000000002,546.284220316,4.885020000000004,104.97,1,6,12,4,3,0.41935483870967744,40,0.3470506084563673,True,1,True,0,,CHEMBL473446,70.0,nM,=,8.0,CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,2,7.1549,1,active,MW=546.7 > 500.0
84a3e9f3,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NC(=O)CSc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,637.8499999999999,637.3086612359999,7.152420000000007,87.53999999999999,1,6,13,5,4,0.35135135135135137,46,0.15740176243955795,False,2,True,0,,CHEMBL502066,600.0,nM,=,6.22,CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.2218,1,active,MW=637.8 > 500.0; LogP=7.15 > 5.0
de1a9f4b,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,621.782,621.3315048559999,6.439120000000007,96.77000000000001,1,6,13,5,4,0.35135135135135137,46,0.1854250122825788,False,2,True,0,,CHEMBL451856,510.0,nM,=,6.29,CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.2924,1,active,MW=621.8 > 500.0; LogP=6.44 > 5.0
3f2a191e,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,raw,,551.1350000000003,550.282302168,4.984520000000003,110.47999999999999,2,6,10,4,3,0.43333333333333335,39,0.34565559798904744,True,1,True,0,,CHEMBL518649,380.0,nM,=,6.42,CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.4202,1,active,MW=551.1 > 500.0
2d721c0d,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,raw,,685.2689999999999,684.3190816,6.419820000000006,122.78999999999999,2,7,14,5,4,0.3684210526315789,49,0.15810991438102223,False,2,True,0,,CHEMBL508392,30.0,nM,=,7.52,CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,7.5229,1,active,MW=685.3 > 500.0; LogP=6.42 > 5.0
45626c77,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NCc3ccncc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,raw,,642.2479999999999,641.3245013280001,6.409420000000006,109.38,2,7,13,5,4,0.3888888888888889,46,0.1746410946786618,False,2,True,0,,CHEMBL498873,650.0,nM,=,6.19,CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,0.8,1,6.1871,1,active,MW=642.2 > 500.0; LogP=6.41 > 5.0
e9beff54,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cccc(C)c2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,raw,,515.7020000000003,515.326025552,5.0573400000000035,84.46000000000001,1,5,10,4,3,0.45161290322580644,38,0.4091772567956892,False,2,True,0,,CHEMBL454406,175.0,nM,=,6.76,CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,0.8,1,6.757,1,active,MW=515.7 > 500.0; LogP=5.06 > 5.0
54594d46,,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@@H]1CO,,,raw,,556.6660000000003,556.247440884,6.027040000000008,78.67,1,5,6,6,5,0.17142857142857143,42,0.2771961536992389,False,2,True,0,,CHEMBL503783,1100.0,nM,=,6.41,CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,0.8,3,5.9586,0,inactive,MW=556.7 > 500.0; LogP=6.03 > 5.0
fa4a62db,,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@H]1CO,,,raw,,556.6660000000003,556.247440884,6.027040000000008,78.67,1,5,6,6,5,0.17142857142857143,42,0.2771961536992389,False,2,True,0,,CHEMBL508211,210.0,nM,=,6.68,CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,0.8,1,6.6778,1,active,MW=556.7 > 500.0; LogP=6.03 > 5.0
649dd690,,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2CC1CO,,,raw,,556.6660000000003,556.247440884,6.027040000000008,78.67,1,5,6,6,5,0.17142857142857143,42,0.2771961536992389,False,2,True,0,,CHEMBL509760,600.0,nM,=,6.22,CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,0.8,1,6.2218,1,active,MW=556.7 > 500.0; LogP=6.03 > 5.0
56298d7d,,CCCCN(CCCC)C(=O)c1nn(-c2cccc(C)c2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,raw,,550.1470000000004,549.2870532000001,5.710740000000006,84.46000000000001,1,5,10,4,3,0.45161290322580644,39,0.3508191265478246,False,2,True,0,,CHEMBL454411,42.0,nM,=,7.38,CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,0.8,1,7.3768,1,active,MW=550.1 > 500.0; LogP=5.71 > 5.0
e39f8a8e,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cccc(Cl)c2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,raw,,536.1200000000002,535.271403136,5.402320000000005,84.46000000000001,1,5,10,4,3,0.43333333333333335,38,0.3763631469451161,False,2,True,0,,CHEMBL452586,1070.0,nM,=,5.97,CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,0.8,1,5.9706,0,inactive,MW=536.1 > 500.0; LogP=5.40 > 5.0
3a5ed718,,Cc1cc2c(CCc3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(CCc3ccccc3)c(O)c(O)cc2c1O,,,raw,,586.6840000000004,586.235538808,8.080840000000004,121.38000000000001,6,6,7,6,6,0.15789473684210525,44,0.10522128009493859,False,3,False,1,PAINS match: catechol_A(92),CHEMBL552735,480.0,nM,=,6.32,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,6.3188,1,active,MW=586.7 > 500.0; LogP=8.08 > 5.0; HBD=6 > 5
bb6a7cc8,,Cc1cc2c(C(=O)NC3Cc4ccccc4C3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC3Cc4ccccc4C3)c(O)c(O)cc2c1O,,,raw,,696.7560000000003,696.2471661120001,6.304840000000009,179.57999999999998,8,8,5,8,6,0.19047619047619047,52,0.09671677772322364,False,3,False,1,PAINS match: catechol_A(92),CHEMBL541427,700.0,nM,=,6.16,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,6.1549,1,active,MW=696.8 > 500.0; LogP=6.30 > 5.0; HBD=8 > 5
bda51447,,Cc1cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c1O,,,raw,,700.7880000000005,700.2784662400001,7.577440000000009,179.57999999999998,8,8,9,6,6,0.19047619047619047,52,0.07112861559914023,False,3,False,1,PAINS match: catechol_A(92),CHEMBL538616,320.0,nM,=,6.5,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,3,6.4949,1,active,MW=700.8 > 500.0; LogP=7.58 > 5.0; HBD=8 > 5
bacda7e1,,Cc1cc2c(C(=O)NCCc3cccc(Cl)c3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCCc3cccc(Cl)c3)c(O)c(O)cc2c1O,,,raw,,741.6240000000003,740.169221408,7.762240000000006,179.57999999999998,8,8,9,6,6,0.15,52,0.06928912766972287,False,3,False,1,PAINS match: catechol_A(92),CHEMBL553474,4400.0,nM,=,5.36,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,5.3565,0,inactive,MW=741.6 > 500.0; LogP=7.76 > 5.0; HBD=8 > 5
d063fb6a,,CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c(O)c(-c4c(C)cc5c(C(=O)NCCc6ccc(CC)cc6)c(O)c(O)cc5c4O)c(C)cc23)cc1,,,raw,,728.8420000000003,728.309766368,7.58024000000001,179.57999999999998,8,8,11,6,6,0.22727272727272727,54,0.06291453831833403,False,3,False,1,PAINS match: catechol_A(92),CHEMBL541496,670.0,nM,=,6.17,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,6.1739,1,active,MW=728.8 > 500.0; LogP=7.58 > 5.0; HBD=8 > 5
45d566ef,,Cc1cc2c(C(=O)NCCc3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCCc3ccccc3)c(O)c(O)cc2c1O,,,raw,,672.7340000000005,672.2471661120001,6.45544000000001,179.57999999999998,8,8,9,6,6,0.15,50,0.08068329076171761,False,3,False,1,PAINS match: catechol_A(92),CHEMBL552287,150.0,nM,=,6.82,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,6.8239,1,active,MW=672.7 > 500.0; LogP=6.46 > 5.0; HBD=8 > 5
2a4f2ec8,,Cc1cc2c(C(=O)NCC3CCCCC3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC3CCCCC3)c(O)c(O)cc2c1O,,,raw,,656.7760000000002,656.309766368,7.13064000000001,179.57999999999998,8,8,7,6,4,0.42105263157894735,48,0.09676829218938297,False,3,False,1,PAINS match: catechol_A(92),CHEMBL541004,710.0,nM,=,6.15,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,6.1487,1,active,MW=656.8 > 500.0; LogP=7.13 > 5.0; HBD=8 > 5
97320869,,Cc1cc2c(C(=O)NC(C)c3ccc(Cl)cc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC(C)c3ccc(Cl)cc3)c(O)c(O)cc2c1O,,,raw,,741.6240000000003,740.169221408,8.799239999999996,179.57999999999998,8,8,7,6,6,0.15,52,0.0748061853608654,False,3,False,1,PAINS match: catechol_A(92),CHEMBL539481,490.0,nM,=,6.31,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,6.3098,1,active,MW=741.6 > 500.0; LogP=8.80 > 5.0; HBD=8 > 5
6191828a,,Cc1cc(C)c(CNC(=O)c2c(O)c(O)cc3c(O)c(-c4c(C)cc5c(C(=O)NCc6c(C)cc(C)cc6C)c(O)c(O)cc5c4O)c(C)cc23)c(C)c1,,,raw,,728.8420000000003,728.309766368,8.22096000000001,179.57999999999998,8,8,7,6,6,0.22727272727272727,54,0.07576302004284868,False,3,False,1,PAINS match: catechol_A(92),CHEMBL554545,700.0,nM,=,6.16,CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,0.8,1,6.1549,1,active,MW=728.8 > 500.0; LogP=8.22 > 5.0; HBD=8 > 5
244ee3ca,,COc1ccccc1C1C2=C(N=c3s/c(=C\c4cccc(OCC(=O)O)c4)c(=O)n31)c1ccccc1CC2,,,raw,,524.5980000000003,524.140592868,3.790700000000002,90.12,1,7,6,6,4,0.16666666666666666,38,0.41463430975742654,True,1,True,0,,CHEMBL1097075,3100.0,nM,=,5.51,CHEMBL1120826,Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay,0.8,1,5.5086,0,inactive,MW=524.6 > 500.0
4dd42051,,COc1ccc(C2C3=C(N=c4s/c(=C\c5ccc(OCc6cccc(C(=O)O)c6)c(OC)c5)c(=O)n42)c2ccccc2CC3)cc1,,,raw,,630.7220000000001,630.18245768,5.613100000000005,99.35000000000002,1,8,8,7,5,0.16216216216216217,46,0.23933048742217689,False,2,True,0,,CHEMBL1098324,3200.0,nM,=,5.5,CHEMBL1120826,Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay,0.8,1,5.4949,0,inactive,MW=630.7 > 500.0; LogP=5.61 > 5.0
8733149c,,Oc1cc(Cc2ccccc2)c(Cc2ccccc2)cc1O,,,raw,,290.362,290.130679816,4.279400000000003,40.46,2,2,4,3,3,0.1,22,0.7040716661898213,True,0,False,1,PAINS match: catechol_A(92),CHEMBL481409,4700.0,nM,=,5.33,CHEMBL1107438,Displacement of FITC-conjugated BH3-Bim peptide from human recombinant Bcl-2 expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay,0.8,1,5.3279,0,inactive,
c5297720,,Cc1cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c1O,,,raw,,700.7880000000005,700.2784662400001,7.577440000000009,179.57999999999998,8,8,9,6,6,0.19047619047619047,52,0.07112861559914023,False,3,False,1,PAINS match: catechol_A(92),CHEMBL1094366,430.0,nM,=,6.37,CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,2,6.3665,1,active,MW=700.8 > 500.0; LogP=7.58 > 5.0; HBD=8 > 5
832de9bd,,Cc1cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c1O,,,raw,,700.7880000000005,700.2784662400001,7.577440000000009,179.57999999999998,8,8,9,6,6,0.19047619047619047,52,0.07112861559914023,False,3,False,1,PAINS match: catechol_A(92),CHEMBL1094250,320.0,nM,=,5.94,CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,6.4949,1,active,MW=700.8 > 500.0; LogP=7.58 > 5.0; HBD=8 > 5
d28dfa10,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O,,,raw,,490.5080000000003,490.1627677919999,4.847000000000005,149.2,4,8,3,4,2,0.2857142857142857,36,0.44630608398440647,True,0,False,1,PAINS match: quinone_A(370),CHEMBL1272170,370.0,nM,=,6.43,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,6.4318,1,active,
37a4a73c,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)NCC(C)c3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)NCC(C)c3ccccc3)c2C1=O,,,raw,,728.7540000000001,728.2369953519999,5.667200000000007,207.39999999999995,6,10,9,6,4,0.19047619047619047,54,0.11649363756203798,False,3,False,1,PAINS match: quinone_A(370),CHEMBL1269070,230.0,nM,=,6.64,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,6.6383,1,active,MW=728.8 > 500.0; LogP=5.67 > 5.0; HBD=6 > 5
30e31666,,CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c2C(=O)C(C)=C(C2=C(C)C(=O)c4c(cc(O)c(O)c4C(=O)NCCc4ccc(CC)cc4)C2=O)C3=O)cc1,,,raw,,756.8080000000001,756.2682954799999,5.670000000000007,207.39999999999998,6,10,11,6,4,0.22727272727272727,56,0.10341659421652229,False,3,False,1,PAINS match: quinone_A(370),CHEMBL1269012,210.0,nM,=,6.68,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,6.6778,1,active,MW=756.8 > 500.0; LogP=5.67 > 5.0; HBD=6 > 5
4c01645d,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)Cc3ccccc3)c2C1=O,,,raw,,642.6160000000002,642.152597032,5.451000000000008,183.33999999999995,4,10,7,6,4,0.10526315789473684,48,0.1493275120416929,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269072,220.0,nM,=,6.66,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,6.6576,1,active,MW=642.6 > 500.0; LogP=5.45 > 5.0
04a1343f,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC(C)C)C2=O)C(=O)c2cc(O)c(O)c(CC(C)C)c2C1=O,,,raw,,518.5620000000004,518.1940679199998,4.997200000000006,149.2,4,8,5,4,2,0.3333333333333333,38,0.40422726124548736,True,1,False,1,PAINS match: quinone_A(370),CHEMBL1272224,250.0,nM,=,6.6,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,6.6021,1,active,MW=518.6 > 500.0
5099157c,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC3CCCC3)C2=O)C(=O)c2cc(O)c(O)c(CC3CCCC3)c2C1=O,,,raw,,570.6380000000003,570.225368048,6.065600000000006,149.2,4,8,5,6,2,0.4117647058823529,42,0.3167655830639942,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269073,2270.0,nM,=,5.64,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,5.644,0,inactive,MW=570.6 > 500.0; LogP=6.07 > 5.0
d5911acf,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCC3CCCCC3)C2=O)C(=O)c2cc(O)c(O)c(CCC3CCCCC3)c2C1=O,,,raw,,626.7460000000001,626.287968304,7.626000000000009,149.2,4,8,7,6,2,0.47368421052631576,46,0.2293082669240577,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269074,6730.0,nM,=,5.17,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,5.172,0,inactive,MW=626.7 > 500.0; LogP=7.63 > 5.0
6f415432,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O,,,raw,,614.6500000000003,614.19406792,6.170600000000009,149.2,4,8,7,6,4,0.15789473684210525,46,0.18065428142109982,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269075,2570.0,nM,=,5.59,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,5.5901,0,inactive,MW=614.7 > 500.0; LogP=6.17 > 5.0
3c276a86,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccc(C)cc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O,,,raw,,642.7040000000002,642.225368048,6.787440000000009,149.2,4,8,7,6,4,0.2,48,0.16114031792145506,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269076,3120.0,nM,=,5.51,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,5.5058,0,inactive,MW=642.7 > 500.0; LogP=6.79 > 5.0
96c2e287,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCCc3ccccc3)c2C1=O,,,raw,,642.7040000000002,642.225368048,6.95080000000001,149.2,4,8,9,6,4,0.2,48,0.14337085235413866,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269077,2170.0,nM,=,5.66,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,5.6635,0,inactive,MW=642.7 > 500.0; LogP=6.95 > 5.0
91e64035,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O,,,raw,,586.5960000000002,586.162767792,5.781800000000008,149.2,4,8,5,6,4,0.1111111111111111,44,0.21506513951139658,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269107,290.0,nM,=,6.54,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,6,6.5376,1,active,MW=586.6 > 500.0; LogP=5.78 > 5.0
ba975d4a,,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccc(Cl)cc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccc(Cl)cc3)c2C1=O,,,raw,,655.4860000000001,654.084823088,7.0886000000000084,149.2,4,8,5,6,4,0.1111111111111111,46,0.16665768240982118,False,2,False,1,PAINS match: quinone_A(370),CHEMBL1269110,340.0,nM,=,6.47,CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,0.8,3,6.4685,1,active,MW=655.5 > 500.0; LogP=7.09 > 5.0
04b7bfe3,,N#CC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,raw,,331.4000000000001,331.077933036,3.0130800000000013,56.46,0,4,1,5,2,0.21052631578947367,24,0.8059013609952292,True,0,False,1,PAINS match: anil_di_alk_B(251),CHEMBL595134,500.0,nM,=,6.54,CHEMBL1677787,Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA,0.8,2,6.301,1,active,
85b02637,,CCC(C)(C)c1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1,,,raw,,408.5260000000001,408.12963426000005,6.298680000000006,53.22,0,3,4,5,3,0.19230769230769232,30,0.5090058232689271,True,1,True,0,,CHEMBL1672080,342.0,nM,=,6.47,CHEMBL1677787,Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA,0.8,1,6.466,1,active,LogP=6.30 > 5.0
e32b7d98,,N#CC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13,,,raw,,353.4060000000001,353.06228297200005,4.1932800000000015,79.24,1,4,2,5,3,0.0,26,0.7005839376223951,True,0,True,0,,CHEMBL1672082,316.5,nM,=,6.52,CHEMBL1677787,Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA,0.8,2,6.4996,1,active,
d939d9b6,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,813.4460000000001,812.25813822,7.880600000000009,128.13,2,10,16,6,5,0.2619047619047619,56,0.057731341530079264,False,2,True,0,,CHEMBL376408,828.95,nM,=,8.21,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,12,6.0815,1,active,MW=813.4 > 500.0; LogP=7.88 > 5.0
a146efe2,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)cc1[N+](=O)[O-],,,raw,,837.472,836.2693716000002,8.505900000000006,136.84,2,11,16,7,6,0.2558139534883721,58,0.05518448009565537,False,3,True,0,,CHEMBL1689139,8.7,nM,=,8.06,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,8.0605,1,active,MW=837.5 > 500.0; LogP=8.51 > 5.0; HBA=11 > 10
1ba953cc,,O=[N+]([O-])c1cc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)ccc1N[C@H](CCN1CCOCC1)CSc1ccccc1,,,raw,,879.5089999999996,878.279936284,8.276500000000008,146.07,2,12,16,8,6,0.28888888888888886,61,0.05483890976269282,False,3,True,0,,CHEMBL1689140,21.0,nM,=,7.68,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,7.6778,1,active,MW=879.5 > 500.0; LogP=8.28 > 5.0; HBA=12 > 10
73c3d013,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)cc1S(=O)(=O)C(F)(F)F,,,raw,,924.5370000000001,923.2335782600003,8.891200000000003,127.84,2,11,16,7,6,0.2727272727272727,62,0.09044317724893805,False,3,True,0,,CHEMBL1689141,13.0,nM,=,7.89,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,7.8861,1,active,MW=924.5 > 500.0; LogP=8.89 > 5.0; HBA=11 > 10
38c9cf99,,O=S(=O)(Nc1ncnc2cc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)ccc12)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1,,,raw,,966.5739999999998,965.244142944,8.661800000000003,137.07,2,12,16,8,6,0.30434782608695654,65,0.08990740187934733,False,3,True,0,,CHEMBL1689142,81.0,nM,=,7.09,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,7.0915,1,active,MW=966.6 > 500.0; LogP=8.66 > 5.0; HBA=12 > 10
7ca54b1f,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(CC5=C(c6ccc(Cl)cc6)CCC(C)(C)C5)CC4)ccc23)cc1[N+](=O)[O-],,,raw,,869.5579999999997,868.3319718560002,9.302600000000002,136.84,2,11,16,7,5,0.37777777777777777,60,0.05579767039722416,False,3,True,0,,CHEMBL1689143,12.0,nM,=,7.92,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,7.9208,1,active,MW=869.6 > 500.0; LogP=9.30 > 5.0; HBA=11 > 10
fb4ffeb3,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc4c(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c([N+](=O)[O-])c5)ncnc4c3)CC2)C1,,,raw,,911.5949999999995,910.34253654,9.073200000000003,146.07,2,12,16,8,5,0.40425531914893614,63,0.055347405706380144,False,3,True,0,,CHEMBL1689144,21.0,nM,=,7.68,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,7.6778,1,active,MW=911.6 > 500.0; LogP=9.07 > 5.0; HBA=12 > 10
5e3288f5,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(CC5=C(c6ccc(Cl)cc6)CCC(C)(C)C5)CC4)ccc23)cc1S(=O)(=O)C(F)(F)F,,,raw,,956.6229999999998,955.2961785160003,9.687899999999999,127.84,2,11,16,7,5,0.391304347826087,64,0.09185710329673054,False,3,True,0,,CHEMBL1689145,5.0,nM,=,8.3,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,8.301,1,active,MW=956.6 > 500.0; LogP=9.69 > 5.0; HBA=11 > 10
dc74b3d4,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc4c(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)ncnc4c3)CC2)C1,,,raw,,998.6599999999996,997.3067432,9.4585,137.07,2,12,16,8,5,0.4166666666666667,67,0.09119881091106377,False,3,True,0,,CHEMBL1689146,84.0,nM,=,7.08,CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,0.8,1,7.0757,1,active,MW=998.7 > 500.0; LogP=9.46 > 5.0; HBA=12 > 10
e9ba4ff1,,CCOC(=O)c1nn(-c2ccccc2)c(C)c1-c1ccc(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1C(=O)N1CCc2ccccc2C1,,,raw,,698.8009999999999,698.219905808,6.494820000000006,127.66999999999997,1,8,8,7,6,0.15,51,0.18002307080639227,False,2,True,0,,CHEMBL2030844,4190.0,nM,=,5.38,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,5.3778,0,inactive,MW=698.8 > 500.0; LogP=6.49 > 5.0
3d377801,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccccc1,,,raw,,740.882,740.266856,7.529000000000008,127.67000000000002,1,8,11,7,6,0.20930232558139536,54,0.13614774780042663,False,2,True,0,,CHEMBL2030845,660.0,nM,=,6.18,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.1805,1,active,MW=740.9 > 500.0; LogP=7.53 > 5.0
8a9d3070,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)O)nn1-c1ccccc1,,,raw,,712.8280000000001,712.235555872,7.050500000000007,138.67000000000002,2,7,10,7,6,0.17073170731707318,52,0.15525690383328972,False,2,True,0,,CHEMBL2030846,170.0,nM,=,6.77,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.7696,1,active,MW=712.8 > 500.0; LogP=7.05 > 5.0
8154ebb8,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccccc1,,,raw,,698.845,698.256291316,6.844600000000008,121.6,2,7,10,7,6,0.1951219512195122,51,0.16160958309165663,False,2,True,0,,CHEMBL2030847,61.0,nM,=,7.21,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.2147,1,active,MW=698.8 > 500.0; LogP=6.84 > 5.0
55a56327,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(OC)cc1,,,raw,,770.9079999999999,770.277420684,7.537600000000008,136.9,1,9,12,7,6,0.22727272727272727,56,0.12619209614119928,False,2,True,0,,CHEMBL2030848,1790.0,nM,=,5.75,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,5.7471,0,inactive,MW=770.9 > 500.0; LogP=7.54 > 5.0
639aee19,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1cccc(Oc2ccccc2)c1,,,raw,,832.9789999999999,832.293070748,9.321299999999999,136.9,1,9,13,8,7,0.1836734693877551,61,0.11362496360736758,False,2,True,0,,CHEMBL2030849,140.0,nM,=,6.85,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.8539,1,active,MW=833.0 > 500.0; LogP=9.32 > 5.0
de8520ab,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2ccccc2)cc1,,,raw,,832.9789999999999,832.293070748,9.321299999999999,136.9,1,9,13,8,7,0.1836734693877551,61,0.11362496360736758,False,2,True,0,,CHEMBL2030850,100.0,nM,=,7.0,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.0,1,active,MW=833.0 > 500.0; LogP=9.32 > 5.0
f50565af,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccccc2)cc1,,,raw,,790.942,790.282506064,8.636900000000004,130.82999999999998,2,8,12,8,7,0.1702127659574468,58,0.1267688474422987,False,2,True,0,,CHEMBL2030851,130.0,nM,=,6.89,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,6.8861,1,active,MW=790.9 > 500.0; LogP=8.64 > 5.0
51b149a4,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccc(Cl)cc2)cc1,,,raw,,825.387,824.243533712,9.290299999999998,130.82999999999998,2,8,12,8,7,0.1702127659574468,59,0.12564878516944342,False,2,True,0,,CHEMBL2030852,20.0,nM,=,7.66,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.699,1,active,MW=825.4 > 500.0; LogP=9.29 > 5.0
29e2ef0b,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,raw,,825.387,824.243533712,9.290299999999998,130.82999999999998,2,8,12,8,7,0.1702127659574468,59,0.12564878516944342,False,2,True,0,,CHEMBL2030853,7.83,nM,=,8.1,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,8.1062,1,active,MW=825.4 > 500.0; LogP=9.29 > 5.0
941eb14e,,CCCCOc1ccc(-n2nc(CO)c(-c3ccc(C(=O)NS(=O)(=O)c4ccc5ccccc5c4)cc3C(=O)N3CCc4ccccc4C3)c2CCCC)cc1,,,raw,,770.9519999999995,770.313806192,8.023500000000007,130.82999999999998,2,8,14,7,6,0.26666666666666666,56,0.1073546923178641,False,2,True,0,,CHEMBL2030854,45.0,nM,=,7.35,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.3468,1,active,MW=771.0 > 500.0; LogP=8.02 > 5.0
dbfaad33,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(-c2ccccc2)cc1,,,raw,,774.943,774.287591444,8.511600000000005,121.6,2,7,11,8,7,0.1702127659574468,57,0.1360260607586324,False,2,True,0,,CHEMBL2030855,7.0,nM,=,8.15,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,8.1549,1,active,MW=774.9 > 500.0; LogP=8.51 > 5.0
a4df2752,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCO)cc1,,,raw,,742.8979999999999,742.282506064,6.379400000000008,141.82999999999998,3,8,12,7,6,0.23255813953488372,54,0.132211370818864,False,2,True,0,,CHEMBL2030856,20.0,nM,=,7.7,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.699,1,active,MW=742.9 > 500.0; LogP=6.38 > 5.0
db781b4b,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCCO)cc1,,,raw,,756.9249999999998,756.298156128,6.769500000000009,141.82999999999998,3,8,13,7,6,0.25,55,0.11817362568715253,False,2,True,0,,CHEMBL2030857,14.0,nM,=,7.85,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.8539,1,active,MW=756.9 > 500.0; LogP=6.77 > 5.0
17640263,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1cccc(CO)c1,,,raw,,728.871,728.266856,6.336900000000009,141.82999999999998,3,8,11,7,6,0.21428571428571427,53,0.14150019234588895,False,2,True,0,,CHEMBL2030858,71.0,nM,=,7.15,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.1487,1,active,MW=728.9 > 500.0; LogP=6.34 > 5.0
207470d6,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(CO)nn1-c1ccccc1,,,raw,,728.871,728.266856,6.205500000000008,141.83,3,8,11,7,6,0.21428571428571427,53,0.14420396415891878,False,2,True,0,,CHEMBL2030859,10.0,nM,=,7.96,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,8.0,1,active,MW=728.9 > 500.0; LogP=6.21 > 5.0
04f19b56,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(CO)nn1-c1ccccc1,,,raw,,727.8869999999998,727.2828404119999,6.171900000000006,147.62,3,8,11,7,6,0.21428571428571427,53,0.14463924800700378,False,2,True,0,,CHEMBL2030860,24.0,nM,=,7.62,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.6198,1,active,MW=727.9 > 500.0; LogP=6.17 > 5.0
9d513d76,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC[Si](C)(C)C)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccccc1,,,raw,,672.9240000000001,672.2801680379999,5.9705000000000075,121.6,2,7,12,5,4,0.3611111111111111,47,0.17901780862608135,False,2,True,0,,CHEMBL2030861,190.0,nM,=,6.72,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.7212,1,active,MW=672.9 > 500.0; LogP=5.97 > 5.0
633115eb,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,raw,,727.2830000000002,726.227883648,7.097900000000009,130.82999999999998,2,8,12,6,5,0.2564102564102564,51,0.14032047581307522,False,2,True,0,,CHEMBL2030862,190.0,nM,=,6.72,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.7212,1,active,MW=727.3 > 500.0; LogP=7.10 > 5.0
198aae78,,CCCCCS(=O)(=O)NC(=O)c1ccc(-c2c(CO)nn(-c3ccc(Oc4cccc(Cl)c4)cc3)c2CCCC)c(C(=O)N2CCc3ccccc3C2)c1,,,raw,,769.3639999999996,768.27483384,8.268200000000009,130.83,2,8,15,6,5,0.30952380952380953,54,0.10260085701827358,False,2,True,0,,CHEMBL2030863,65.0,nM,=,7.19,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.1871,1,active,MW=769.4 > 500.0; LogP=8.27 > 5.0
3246c4ae,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,raw,,859.832,858.2045613600001,9.943699999999994,130.82999999999998,2,8,12,8,7,0.1702127659574468,60,0.12513016001532942,False,2,True,0,,CHEMBL2030864,6.37,nM,=,8.22,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,8.1959,1,active,MW=859.8 > 500.0; LogP=9.94 > 5.0
1b2fbcb6,,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,675.8549999999998,675.2879257919999,7.020600000000008,112.57,1,7,12,6,5,0.28205128205128205,49,0.1512802459101662,False,2,True,0,,CHEMBL2030865,700.0,nM,=,6.16,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.1549,1,active,MW=675.9 > 500.0; LogP=7.02 > 5.0
4fecc7d4,,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,710.2999999999998,709.2489534399998,7.674000000000009,112.57,1,7,12,6,5,0.28205128205128205,50,0.14148009910319423,False,2,True,0,,CHEMBL2030866,120.0,nM,=,6.92,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.9208,1,active,MW=710.3 > 500.0; LogP=7.67 > 5.0
2d93ec7e,,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,801.7509999999996,801.1845737599998,7.625200000000009,112.57,1,7,12,6,5,0.28205128205128205,50,0.12930534780246233,False,2,True,0,,CHEMBL2031001,140.0,nM,=,6.85,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.8539,1,active,MW=801.8 > 500.0; LogP=7.63 > 5.0
b2e22535,,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,825.8629999999998,824.2678303119999,8.736900000000006,115.81,1,8,14,7,5,0.3181818181818182,57,0.11831238109020685,False,2,True,0,,CHEMBL2031002,120.0,nM,=,6.92,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.9208,1,active,MW=825.9 > 500.0; LogP=8.74 > 5.0
2da152ca,,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,raw,,704.8969999999997,704.3144748879998,6.347900000000006,138.58999999999997,2,8,13,6,5,0.3,51,0.14472818192582163,False,2,True,0,,CHEMBL2031003,430.0,nM,=,6.37,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.3665,1,active,MW=704.9 > 500.0; LogP=6.35 > 5.0
b435ef8e,,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,740.3259999999999,739.2595181239999,7.03490000000001,132.8,2,8,13,6,5,0.3,52,0.13155676789722226,False,2,True,0,,CHEMBL2031004,160.0,nM,=,6.8,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.7959,1,active,MW=740.3 > 500.0; LogP=7.03 > 5.0
4f955c53,,CCCCN(CCCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,710.2999999999998,709.2489534399999,7.674000000000009,112.57,1,7,12,6,5,0.28205128205128205,50,0.14148009910319423,False,2,True,0,,CHEMBL2031005,160.0,nM,=,6.8,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.7959,1,active,MW=710.3 > 500.0; LogP=7.67 > 5.0
bcee9dcc,,CCCCN(CCCC)c1ncc(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,689.8819999999998,689.3035758559998,7.329020000000009,112.57,1,7,12,6,5,0.3,50,0.14602790959241357,False,2,True,0,,CHEMBL2031006,110.0,nM,=,6.96,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.9586,1,active,MW=689.9 > 500.0; LogP=7.33 > 5.0
01734c8a,,CCCN(CCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,647.8009999999999,647.2566256639999,6.240400000000006,112.57,1,7,10,6,5,0.24324324324324326,47,0.19100398149897607,False,2,True,0,,CHEMBL2031007,150.0,nM,=,6.82,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.8239,1,active,MW=647.8 > 500.0; LogP=6.24 > 5.0
62ee41b8,,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,raw,,745.7329999999998,744.2052300559999,6.874500000000008,138.58999999999997,2,8,11,6,5,0.2631578947368421,51,0.14943658826139464,False,2,True,0,,CHEMBL2031008,5.09,nM,=,7.82,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,8.2933,1,active,MW=745.7 > 500.0; LogP=6.87 > 5.0
bc3d81b8,,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,746.717,745.1892456439999,6.908100000000009,132.8,2,8,11,6,5,0.2631578947368421,51,0.14917771945153052,False,2,True,0,,CHEMBL2031009,8.78,nM,=,8.05,CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,8.0565,1,active,MW=746.7 > 500.0; LogP=6.91 > 5.0
094b3069,,O=C(c1ccc(CN(Cc2ccc(F)cc2)S(=O)(=O)c2cc(Cl)cc(Cl)c2O)cc1)N(Cc1ccc(F)cc1)Cc1cc(Cl)cc(Cl)c1,,,raw,,750.4780000000001,748.033545472,9.517699999999994,77.92,1,4,11,5,5,0.11428571428571428,48,0.14601578300099485,False,2,False,1,PAINS match: sulfonamide_A(43),CHEMBL2031010,35.0,nM,=,7.46,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.4559,1,active,MW=750.5 > 500.0; LogP=9.52 > 5.0
103aba00,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3O)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,747.1449999999996,745.165923356,7.8882200000000084,124.84000000000002,2,7,12,5,4,0.34285714285714286,49,0.15203039832339318,False,2,False,1,PAINS match: sulfonamide_A(43),CHEMBL2031011,910.0,nM,=,6.04,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.041,1,active,MW=747.1 > 500.0; LogP=7.89 > 5.0
3213d77e,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,740.3259999999998,739.2595181239999,7.346920000000009,121.67999999999999,1,7,12,6,5,0.3,52,0.14292763692823945,False,2,True,0,,CHEMBL2031012,30.0,nM,=,7.5,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.5229,1,active,MW=740.3 > 500.0; LogP=7.35 > 5.0
c49f6e1f,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(S(=O)(=O)CC)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,832.4449999999996,831.2527184919999,7.140520000000008,155.82,1,9,14,6,5,0.3333333333333333,57,0.12387922948717862,False,2,True,0,,CHEMBL2031013,180.0,nM,=,6.75,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.7447,1,active,MW=832.4 > 500.0; LogP=7.14 > 5.0
c60a4058,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,869.4849999999994,868.3384967159999,7.057920000000008,143.38000000000002,1,10,16,7,5,0.391304347826087,61,0.11035096824055554,False,2,True,0,,CHEMBL2031014,110.0,nM,=,6.96,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,6.9586,1,active,MW=869.5 > 500.0; LogP=7.06 > 5.0
0369b62b,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCN5CCOCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,869.4849999999996,868.3384967159999,7.057920000000008,143.38000000000002,1,10,16,7,5,0.391304347826087,61,0.11035096824055554,False,2,True,0,,CHEMBL2031015,400.0,nM,=,6.4,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.3979,1,active,MW=869.5 > 500.0; LogP=7.06 > 5.0
fa79e1f0,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCc5ccc(C(=O)O)cc5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,890.4589999999998,889.2912121759998,8.624120000000005,168.21,2,9,16,7,6,0.2708333333333333,63,0.09668900279053529,False,2,True,0,,CHEMBL2031016,15.0,nM,=,7.82,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.8239,1,active,MW=890.5 > 500.0; LogP=8.62 > 5.0
92be5cc8,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,866.2219999999996,865.1561660919999,7.951520000000008,121.67999999999999,1,7,12,6,5,0.3,53,0.1272319046651394,False,2,True,0,,CHEMBL2031017,40.0,nM,=,7.46,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.3979,1,active,MW=866.2 > 500.0; LogP=7.95 > 5.0
65e12e44,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,866.2219999999996,865.1561660919999,7.951520000000008,121.67999999999999,1,7,12,6,5,0.3,53,0.1272319046651394,False,2,True,0,,CHEMBL2031018,40.0,nM,=,7.43,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.3979,1,active,MW=866.2 > 500.0; LogP=7.95 > 5.0
c727e7f4,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,731.3189999999998,730.270417156,6.161720000000007,133.71,2,8,12,6,4,0.3684210526315789,51,0.17840473700227139,False,2,True,0,,CHEMBL2031019,32.0,nM,=,7.5,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.4949,1,active,MW=731.3 > 500.0; LogP=6.16 > 5.0
d2a6a7c9,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)c3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,904.3169999999998,902.2186871999999,8.703420000000005,141.99,1,8,13,7,5,0.3111111111111111,61,0.12465800271422223,False,2,True,0,,CHEMBL2031020,280.0,nM,=,6.55,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.5528,1,active,MW=904.3 > 500.0; LogP=8.70 > 5.0
4d1b3713,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,759.3729999999998,758.3017172839998,6.5761200000000075,124.92,1,8,13,6,4,0.4,53,0.16350995180717565,False,2,True,0,,CHEMBL2031021,60.0,nM,=,7.11,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.2218,1,active,MW=759.4 > 500.0; LogP=6.58 > 5.0
4a19eebb,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,890.3339999999997,888.2394226439999,9.063220000000003,124.92,1,8,14,7,5,0.3333333333333333,60,0.11803935559555757,False,2,True,0,,CHEMBL2031022,20.0,nM,=,7.8,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.699,1,active,MW=890.3 > 500.0; LogP=9.06 > 5.0
e0187a02,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2C)c(C)c1Cl,,,raw,,754.3529999999998,753.2751681879998,7.90792000000001,121.67999999999999,1,7,12,6,5,0.3170731707317073,53,0.1382981272071076,False,2,True,0,,CHEMBL2031023,710.0,nM,=,6.15,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.1487,1,active,MW=754.4 > 500.0; LogP=7.91 > 5.0
141c7946,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,770.3519999999999,769.270082808,6.707820000000009,141.91,2,8,13,6,5,0.3170731707317073,54,0.13569127502601327,False,2,True,0,,CHEMBL2031024,50.0,nM,=,7.46,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.301,1,active,MW=770.4 > 500.0; LogP=6.71 > 5.0
bba34522,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCCOC)c(C)c1Cl,,,raw,,842.4589999999996,841.3275976839999,7.768620000000009,140.14,1,9,18,6,5,0.37777777777777777,59,0.08836840497727015,False,2,True,0,,CHEMBL2031025,20.0,nM,=,7.66,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,7.699,1,active,MW=842.5 > 500.0; LogP=7.77 > 5.0
1a640156,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCN(C)C)c(C)c1Cl,,,raw,,841.4749999999996,840.343582096,7.293720000000008,134.15,1,9,17,6,5,0.37777777777777777,59,0.09659385004894859,False,2,True,0,,CHEMBL2031026,10.0,nM,=,7.43,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,8.0,1,active,MW=841.5 > 500.0; LogP=7.29 > 5.0
378a67e2,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,raw,,769.3679999999997,768.2860672199998,6.674220000000006,147.7,2,8,13,6,5,0.3170731707317073,54,0.135964616234456,False,2,True,0,,CHEMBL2031027,8.41,nM,=,8.05,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,8.0752,1,active,MW=769.4 > 500.0; LogP=6.67 > 5.0
80895c31,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(C)c1Cl,,,raw,,852.5019999999994,851.3595665079998,6.962920000000008,128.16,1,9,14,7,5,0.391304347826087,60,0.12712618225985176,False,2,True,0,,CHEMBL2031028,140.0,nM,=,6.85,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,6.8539,1,active,MW=852.5 > 500.0; LogP=6.96 > 5.0
189660cc,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(C)c1Cl,,,raw,,839.4589999999995,838.3279320319999,7.047720000000008,134.14999999999998,1,9,14,7,5,0.37777777777777777,59,0.1259248439733018,False,2,True,0,,CHEMBL2031029,14.0,nM,=,7.85,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.8539,1,active,MW=839.5 > 500.0; LogP=7.05 > 5.0
6bce8b08,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCCC2)c(C)c1Cl,,,raw,,823.4599999999995,822.3330174119998,7.81132000000001,124.91999999999999,1,8,14,7,5,0.37777777777777777,58,0.12122220199330065,False,2,True,0,,CHEMBL2031030,47.0,nM,=,7.33,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.3279,1,active,MW=823.5 > 500.0; LogP=7.81 > 5.0
288cd4fa,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2COc3ccccc3C2)c(C)c1Cl,,,raw,,742.2979999999999,741.23878268,7.140720000000009,130.91,1,8,12,6,5,0.28205128205128205,52,0.14387446358853154,False,2,True,0,,CHEMBL2031031,120.0,nM,=,6.92,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,3,6.9208,1,active,MW=742.3 > 500.0; LogP=7.14 > 5.0
986a742a,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CNc3ccccc3C2)c(C)c1Cl,,,raw,,741.3139999999999,740.2547670919998,7.173820000000008,133.70999999999998,2,8,12,6,5,0.28205128205128205,52,0.1385550849575902,False,2,True,0,,CHEMBL2031032,26.0,nM,=,7.58,CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,0.8,1,7.585,1,active,MW=741.3 > 500.0; LogP=7.17 > 5.0
94522f4a,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,1135.8549999999996,1134.4586289119998,7.464100000000011,209.1,5,16,25,8,6,0.3793103448275862,79,0.01631400728120672,False,3,True,0,,CHEMBL2063882,8.7,nM,=,8.06,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.0605,1,active,MW=1135.9 > 500.0; LogP=7.46 > 5.0; HBA=16 > 10
7a11d3cf,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,1107.8449999999993,1106.4637142919998,8.14620000000001,192.03,5,15,25,8,6,0.38596491228070173,77,0.01597422272840708,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063883,1.3,nM,=,8.89,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.8861,1,active,MW=1107.8 > 500.0; LogP=8.15 > 5.0; HBA=15 > 10
10ceeb64,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(-c3cn(-c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)nn3)cc2)cc1[N+](=O)[O-],,,raw,,1090.7739999999994,1089.4120130679999,8.067300000000012,216.26,5,16,25,8,7,0.32727272727272727,76,0.015846540136329686,False,3,True,0,,CHEMBL2063884,1.4,nM,=,8.85,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.8539,1,active,MW=1090.8 > 500.0; LogP=8.07 > 5.0; HBA=16 > 10
468b3f1e,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(C#Cc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-],,,raw,,1075.7549999999994,1074.389880656,7.53730000000001,202.62,5,14,23,7,6,0.32142857142857145,75,0.01386936781891027,False,3,True,0,,CHEMBL2063885,1.9,nM,=,8.72,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.7212,1,active,MW=1075.8 > 500.0; LogP=7.54 > 5.0; HBA=14 > 10
9f2895cb,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(C#Cc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-],,,raw,,1047.7449999999994,1046.3949660360001,8.219400000000011,185.55,5,13,23,7,6,0.32727272727272727,73,0.013645210558916212,False,3,True,0,,CHEMBL2063886,6.6,nM,=,8.18,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.1805,1,active,MW=1047.7 > 500.0; LogP=8.22 > 5.0; HBA=13 > 10
d1438e0d,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(NCCNc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-],,,raw,,1081.8069999999996,1080.448064228,8.34360000000001,209.61,7,15,28,7,6,0.36363636363636365,75,0.01066983929860139,False,4,True,0,,CHEMBL2063887,60.6,nM,=,7.22,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,7.2175,1,active,MW=1081.8 > 500.0; LogP=8.34 > 5.0; HBD=7 > 5; HBA=15 > 10
8ceab5a4,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4ccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)cc4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,1107.8449999999993,1106.4637142919998,8.146200000000011,192.03,5,15,25,8,6,0.38596491228070173,77,0.01597422272840708,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063888,33.9,nM,=,7.47,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,7.4698,1,active,MW=1107.8 > 500.0; LogP=8.15 > 5.0; HBA=15 > 10
39868d08,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,785.4360000000001,784.2632236000001,8.562700000000007,111.06,2,9,16,6,5,0.2682926829268293,54,0.0577882209430368,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063889,85.3,nM,=,7.07,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,7.0691,1,active,MW=785.4 > 500.0; LogP=8.56 > 5.0
33060651,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(C)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,1033.7659999999992,1032.42693486,8.939900000000005,151.57,3,13,21,8,6,0.35185185185185186,72,0.02734016749121949,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063892,0.6,nM,=,9.22,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,9.2218,1,active,MW=1033.8 > 500.0; LogP=8.94 > 5.0; HBA=13 > 10
62ad096a,,CNC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)cn1C,,,raw,,907.5629999999999,906.3112364119999,8.932200000000003,145.09,3,11,17,7,6,0.2553191489361702,63,0.0461124367623474,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063893,5.3,nM,=,8.28,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.2757,1,active,MW=907.6 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
e893cf84,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cn(C)cc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,850.511,849.289772696,9.5726,115.99000000000001,2,10,16,7,6,0.24444444444444444,59,0.05583837169205838,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063894,82.6,nM,=,7.08,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,7.083,1,active,MW=850.5 > 500.0; LogP=9.57 > 5.0
9d9c5472,,CCOC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)cn1C,,,raw,,922.574,921.3109020640001,9.749299999999998,142.29000000000002,2,12,18,7,6,0.2708333333333333,64,0.03683943824097079,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063895,45.8,nM,=,7.34,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,7.3391,1,active,MW=922.6 > 500.0; LogP=9.75 > 5.0; HBA=12 > 10
28dc7b59,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(C)c5C(=O)O)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,894.52,893.2796019360001,9.270800000000003,153.29,3,11,17,7,6,0.2391304347826087,62,0.045638752796848925,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063896,1.7,nM,=,8.77,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.7696,1,active,MW=894.5 > 500.0; LogP=9.27 > 5.0; HBA=11 > 10
80bacb0e,,CCc1c(-c2ccc(Cl)cc2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(C(=O)O)n1C,,,raw,,922.5739999999997,921.3109020640002,9.833200000000001,153.29,3,11,18,7,6,0.2708333333333333,64,0.04291243928474231,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2063897,4.1,nM,=,8.39,CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,0.8,1,8.3872,1,active,MW=922.6 > 500.0; LogP=9.83 > 5.0; HBA=11 > 10
07ff17b5,,CCCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,raw,,1093.7569999999998,1092.3326236000003,11.122719999999989,164.51999999999998,4,12,20,8,6,0.35185185185185186,74,0.05358656711840707,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170840,78.2,nM,=,7.11,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,7.1068,1,active,MW=1093.8 > 500.0; LogP=11.12 > 5.0; HBA=12 > 10
7c89466b,,CCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,raw,,1079.73,1078.3169735360002,10.732619999999992,164.51999999999998,4,12,19,8,6,0.33962264150943394,73,0.05686013828508965,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170839,30.1,nM,=,7.52,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,7.5214,1,active,MW=1079.7 > 500.0; LogP=10.73 > 5.0; HBA=12 > 10
c3f06296,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C,,,raw,,1079.7299999999998,1078.3169735360002,10.903519999999991,164.51999999999998,4,12,18,8,6,0.33962264150943394,73,0.06033338724791536,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170838,4.0,nM,=,8.4,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,8.3979,1,active,MW=1079.7 > 500.0; LogP=10.90 > 5.0; HBA=12 > 10
b0a06428,,CCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,raw,,1065.703,1064.3013234720001,10.342519999999995,164.51999999999998,4,12,18,8,6,0.3269230769230769,72,0.060348657510622676,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170837,5.4,nM,=,8.27,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,8.2676,1,active,MW=1065.7 > 500.0; LogP=10.34 > 5.0; HBA=12 > 10
3d3b2d21,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(C)(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,1065.703,1064.3013234720001,10.249719999999996,164.51999999999998,4,12,17,8,6,0.3269230769230769,72,0.06404539884938647,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170836,18.6,nM,=,7.73,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,7.7305,1,active,MW=1065.7 > 500.0; LogP=10.25 > 5.0; HBA=12 > 10
103daa95,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,1051.676,1050.285673408,9.859619999999998,164.51999999999998,4,12,17,8,6,0.3137254901960784,71,0.0640736989233582,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170835,10.2,nM,=,7.99,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,7.9914,1,active,MW=1051.7 > 500.0; LogP=9.86 > 5.0; HBA=12 > 10
df4054d8,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CC(O)C6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,1023.622,1022.25437328,9.079420000000004,164.51999999999998,4,12,17,8,6,0.2857142857142857,69,0.06422940951347497,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170851,7.7,nM,=,8.11,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,8.1135,1,active,MW=1023.6 > 500.0; LogP=9.08 > 5.0; HBA=12 > 10
7b244ebb,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCCCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,1035.677,1034.290758788,10.888819999999992,144.29,3,11,17,8,6,0.3137254901960784,70,0.07511260235865073,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170850,15.6,nM,=,7.81,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,7.8069,1,active,MW=1035.7 > 500.0; LogP=10.89 > 5.0; HBA=11 > 10
dd83e8f7,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,1021.65,1020.275108724,10.498719999999993,144.29,3,11,17,8,6,0.3,69,0.07512740513564353,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170849,8.3,nM,=,8.08,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,8.0809,1,active,MW=1021.6 > 500.0; LogP=10.50 > 5.0; HBA=11 > 10
ec387687,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,1007.623,1006.2594586600001,10.108619999999995,144.29,3,11,17,8,6,0.2857142857142857,68,0.07515298957061098,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170848,7.5,nM,=,8.12,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,8.1249,1,active,MW=1007.6 > 500.0; LogP=10.11 > 5.0; HBA=11 > 10
1df57820,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,1037.649,1036.2700233440003,9.735119999999998,153.51999999999998,3,12,17,8,6,0.3,70,0.07460231676498749,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170847,55.2,nM,=,7.26,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,7.2581,1,active,MW=1037.6 > 500.0; LogP=9.74 > 5.0; HBA=12 > 10
9798a5cd,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,995.6120000000001,994.2594586600001,9.964519999999997,144.29,3,11,17,7,6,0.2708333333333333,67,0.07517053939497287,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170846,9.2,nM,=,8.04,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,8.0362,1,active,MW=995.6 > 500.0; LogP=9.96 > 5.0; HBA=11 > 10
991da67d,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(=O)(=O)C6CC6)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,884.5689999999998,883.3316375080002,6.751720000000007,127.30000000000001,2,10,14,8,5,0.3695652173913043,61,0.1165846914161334,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170845,844.0,nM,=,6.07,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.0737,1,active,MW=884.6 > 500.0; LogP=6.75 > 5.0
763cfb01,,CCS(=O)(=O)c1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,raw,,872.5579999999995,871.3316375080002,6.609220000000008,127.29999999999998,2,10,14,7,5,0.35555555555555557,60,0.11869988696573196,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170844,828.0,nM,=,6.08,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.082,1,active,MW=872.6 > 500.0; LogP=6.61 > 5.0
81f76989,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(C)(=O)=O)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,858.531,857.3159874440001,6.219120000000006,127.30000000000001,2,10,13,7,5,0.3409090909090909,59,0.1328963597619061,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170843,2543.0,nM,=,5.59,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,5.5947,0,inactive,MW=858.5 > 500.0; LogP=6.22 > 5.0
be29d89d,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,912.5010000000001,911.2877220080002,7.109120000000008,127.30000000000001,2,10,13,7,5,0.3409090909090909,62,0.11900367275491268,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170842,153.0,nM,=,6.82,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.8153,1,active,MW=912.5 > 500.0; LogP=7.11 > 5.0
65b25509,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(OC(C)C)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,838.5189999999999,837.3803019520001,7.602820000000008,102.39000000000001,2,9,14,7,5,0.3695652173913043,59,0.11043120783487341,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170841,2021.0,nM,=,5.69,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,5.6944,0,inactive,MW=838.5 > 500.0; LogP=7.60 > 5.0
86778a31,,CCOc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,raw,,824.4919999999998,823.3646518880001,7.214320000000008,102.39000000000001,2,9,14,7,5,0.35555555555555557,58,0.1134464121314585,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171011,1624.0,nM,=,5.79,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,5.7894,0,inactive,MW=824.5 > 500.0; LogP=7.21 > 5.0
23a07772,,COc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,raw,,810.4649999999999,809.3490018240001,6.8242200000000075,102.39000000000001,2,9,13,7,5,0.3409090909090909,57,0.12510271289323793,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2169898,802.0,nM,=,6.1,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.0958,1,active,MW=810.5 > 500.0; LogP=6.82 > 5.0
ff189f7f,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(OC(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,864.4350000000001,863.3207363880001,7.714220000000009,102.39000000000001,2,9,13,7,5,0.3409090909090909,60,0.11625317466811301,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171010,763.0,nM,=,6.12,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.1175,1,active,MW=864.4 > 500.0; LogP=7.71 > 5.0
89a7aae3,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(C(C)(C)C)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,836.5469999999998,835.401037396,8.11312000000001,93.16000000000003,2,8,12,7,5,0.3829787234042553,59,0.122835285989664,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171009,1908.0,nM,=,5.72,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,5.7194,0,inactive,MW=836.5 > 500.0; LogP=8.11 > 5.0
8132dbe7,,CCc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,raw,,808.4929999999998,807.369737268,7.378020000000009,93.16,2,8,13,7,5,0.35555555555555557,57,0.12012535313837025,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171008,621.0,nM,=,6.21,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.2069,1,active,MW=808.5 > 500.0; LogP=7.38 > 5.0
701d6913,,Cc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,raw,,794.4659999999999,793.3540872039999,7.124040000000009,93.16,2,8,12,7,5,0.3409090909090909,56,0.13009357481408781,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171007,689.0,nM,=,6.16,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.1618,1,active,MW=794.5 > 500.0; LogP=7.12 > 5.0
50e7d93b,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,848.436,847.325821768,7.834420000000009,93.16000000000003,2,8,12,7,5,0.3409090909090909,59,0.12380947849788117,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171006,582.0,nM,=,6.24,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.2351,1,active,MW=848.4 > 500.0; LogP=7.83 > 5.0
a16c064e,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(Br)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,859.3349999999999,857.2489492080001,7.578120000000008,93.16000000000003,2,8,12,7,5,0.32558139534883723,56,0.12518190556382217,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171005,255.0,nM,=,6.59,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.5935,1,active,MW=859.3 > 500.0; LogP=7.58 > 5.0
98827983,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(Cl)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,814.8839999999999,813.299464788,7.469020000000008,93.16000000000003,2,8,12,7,5,0.32558139534883723,56,0.12644376546312663,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171004,660.0,nM,=,6.18,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.1805,1,active,MW=814.9 > 500.0; LogP=7.47 > 5.0
bddb3b95,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,798.429,797.329015328,6.954720000000007,93.16000000000003,2,8,12,7,5,0.32558139534883723,56,0.13212681934680592,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2171003,977.0,nM,=,6.01,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.0101,1,active,MW=798.4 > 500.0; LogP=6.95 > 5.0
711b7424,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccccc5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,780.439,779.33843714,6.815620000000007,93.16000000000003,2,8,12,7,5,0.32558139534883723,55,0.134517741033792,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170853,2200.0,nM,=,5.66,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,5.6576,0,inactive,MW=780.4 > 500.0; LogP=6.82 > 5.0
74ee2c91,,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,825.4359999999999,824.323515348,6.723820000000007,136.30000000000004,2,10,13,7,5,0.32558139534883723,58,0.0753646130439919,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2170852,117.0,nM,=,6.93,CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,0.8,1,6.9318,1,active,MW=825.4 > 500.0; LogP=6.72 > 5.0
f4b294ca,,CCCOC(=O)C1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,raw,,392.4800000000002,392.11946350000005,3.442700000000002,58.97,0,5,4,5,2,0.3181818181818182,28,0.5892684621574981,True,0,False,1,PAINS match: anil_di_alk_B(251),CHEMBL2312467,2100.0,nM,=,5.68,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,5.6778,0,inactive,
597d39e9,,CCOC(=O)C1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,raw,,378.45300000000015,378.103813436,3.0526000000000018,58.97,0,5,3,5,2,0.2857142857142857,27,0.6069034467138315,True,0,False,1,PAINS match: anil_di_alk_B(251),CHEMBL2312468,2200.0,nM,=,5.66,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,5.6576,0,inactive,
27235b78,,O=C1N=C2C(=C1NCCCCCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13,,,raw,,467.63800000000026,467.203133548,5.4496000000000056,44.7,1,4,8,6,3,0.3103448275862069,34,0.4476359895040169,True,1,False,1,PAINS match: anil_di_alk_B(251),CHEMBL2312480,1300.0,nM,=,5.89,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,5.8861,0,inactive,LogP=5.45 > 5.0
8e5ea03c,,CC(C)c1ccc(Oc2ccc3c4c(cccc24)C2=NC(=O)C(NCCCc4ccccc4)=C23)cc1,,,raw,,472.58800000000025,472.215078136,7.031900000000008,50.69,1,3,8,6,4,0.1875,36,0.2800937921487694,True,1,True,0,,CHEMBL2312476,42.0,nM,=,7.38,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,7.3768,1,active,LogP=7.03 > 5.0
bf375645,,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Oc4ccc(C(C)C)cc4)ccc2c13,,,raw,,438.5710000000002,438.2307282,6.979400000000006,50.69,1,3,9,5,3,0.3103448275862069,33,0.36671493262962973,True,1,True,0,,CHEMBL2312475,184.0,nM,=,6.74,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.7352,1,active,LogP=6.98 > 5.0
cc0a2da1,,CCCCNC1=C2C(=NC1=O)c1cccc3c(Oc4ccc(C(C)C)cc4)ccc2c13,,,raw,,410.5170000000001,410.199428072,6.199200000000006,50.69,1,3,7,5,3,0.25925925925925924,31,0.471928874957236,True,1,True,0,,CHEMBL2312474,322.0,nM,=,6.49,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.4921,1,active,LogP=6.20 > 5.0
d2e23a4f,,CC(C)c1ccc(Oc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1,,,raw,,364.4040000000001,364.121177752,5.375580000000006,62.449999999999996,0,3,3,5,3,0.125,28,0.6270316691600425,True,1,True,0,,CHEMBL1672071,739.0,nM,=,6.13,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.1314,1,active,LogP=5.38 > 5.0
97b27ea2,,O=C1N=C2C(=C1NCCCc1ccccc1)c1ccc(Sc3ccc(OO)cc3)c3cccc2c13,,,raw,,478.5730000000002,478.13511356399994,6.119200000000005,70.92,2,5,8,6,4,0.10344827586206896,35,0.1813905436303194,True,1,True,0,,CHEMBL2312473,57.0,nM,=,7.24,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,7.2441,1,active,LogP=6.12 > 5.0
c1d28e0e,,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(OC)cc4)ccc2c13,,,raw,,442.5840000000002,442.17149907199996,6.223500000000006,50.69,1,4,9,5,3,0.25925925925925924,32,0.39957198739501343,True,1,True,0,,CHEMBL2312472,206.0,nM,=,6.69,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.6861,1,active,LogP=6.22 > 5.0
735ff703,,CCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(OC)cc4)ccc2c13,,,raw,,414.53000000000014,414.14019894399996,5.443300000000004,50.69,1,4,7,5,3,0.2,30,0.5229446287847086,True,1,True,0,,CHEMBL2312471,356.0,nM,=,6.45,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.4486,1,active,LogP=5.44 > 5.0
6f4008b4,,COc1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1,,,raw,,368.41700000000014,368.061948624,4.619680000000004,62.449999999999996,0,4,3,5,3,0.045454545454545456,27,0.6766795279269342,True,0,True,0,,CHEMBL1672077,945.0,nM,=,6.03,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.0246,1,active,
4f19fd7e,,Nc1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(NCCCc4ccccc4)=C23)cc1,,,raw,,461.59000000000026,461.15618335600004,5.849600000000005,67.47999999999999,2,4,7,6,4,0.10344827586206896,34,0.2676140275942767,True,1,True,0,,CHEMBL2312470,20.0,nM,=,7.7,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,7.699,1,active,LogP=5.85 > 5.0
77049336,,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13,,,raw,,427.57300000000015,427.17183342000004,5.797100000000005,67.48,2,4,8,5,3,0.23076923076923078,31,0.3522626125467985,True,1,True,0,,CHEMBL2312469,80.0,nM,=,7.1,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,7.0969,1,active,LogP=5.80 > 5.0
44ef2e3a,,CCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13,,,raw,,399.5190000000001,399.14053329200004,5.016900000000003,67.48,2,4,6,5,3,0.16666666666666666,29,0.451244161240078,True,1,True,0,,CHEMBL2312484,190.0,nM,=,6.72,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.7212,1,active,LogP=5.02 > 5.0
57771d03,,O=C1N=C2C(=C1NCCCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13,,,raw,,439.5840000000003,439.17183342,4.669400000000005,44.7,1,4,6,6,3,0.25925925925925924,32,0.5671868948205859,True,0,False,1,PAINS match: anil_di_alk_B(251),CHEMBL2312483,49.0,nM,=,7.31,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,7.3098,1,active,
63b673ad,,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,raw,,405.56700000000023,405.187483484,4.616900000000004,44.7,1,4,7,5,2,0.4166666666666667,29,0.683080270629428,True,0,False,1,PAINS match: anil_di_alk_B(251),CHEMBL2312482,96.0,nM,=,7.02,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,7.0177,1,active,
0b4cc199,,CCCCNC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,raw,,377.51300000000015,377.156183356,3.836700000000003,44.7,1,4,5,5,2,0.36363636363636365,27,0.804455185435806,True,0,False,1,PAINS match: anil_di_alk_B(251),CHEMBL2312481,198.0,nM,=,6.7,CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,0.8,1,6.7033,1,active,
1de46395,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nc(C(F)(F)F)nc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,raw,,996.5659999999997,995.252263016,9.4573,127.84,2,11,16,7,5,0.37777777777777777,66,0.07254208505001875,False,3,True,0,,CHEMBL2322022,46.0,nM,=,7.34,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.3372,1,active,MW=996.6 > 500.0; LogP=9.46 > 5.0; HBA=11 > 10
a868c7ff,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nc(Cl)nc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,raw,,963.0139999999999,961.2259060360001,9.091900000000003,127.84,2,11,16,7,5,0.36363636363636365,63,0.0726695622226926,False,3,True,0,,CHEMBL2322021,32.0,nM,=,7.5,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.4949,1,active,MW=963.0 > 500.0; LogP=9.09 > 5.0; HBA=11 > 10
b11f3400,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4cc(F)ccc4-c4ccc(Cl)cc4)CC2)C3=O)cc1S(=O)(=O)C(F)(F)F,,,raw,,960.5420000000001,959.2347211320003,8.217800000000008,144.91,2,11,16,7,5,0.3409090909090909,64,0.07295525304103255,False,3,True,0,,CHEMBL2322020,142.0,nM,=,6.85,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,6.8477,1,active,MW=960.5 > 500.0; LogP=8.22 > 5.0; HBA=11 > 10
420ceb6b,,CC(c1ccccc1-c1ccc(Cl)cc1)N1CCC(N2CCc3c(ncnc3NS(=O)(=O)c3ccc(N[C@H](CCN(C)C)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)C2)CC1,,,raw,,942.5959999999999,941.2805284520001,8.999500000000003,127.84,2,11,16,7,5,0.37777777777777777,63,0.0921059230513803,False,3,True,0,,CHEMBL2326747,35.0,nM,=,7.46,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.4559,1,active,MW=942.6 > 500.0; LogP=9.00 > 5.0; HBA=11 > 10
7629006a,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4cc(F)ccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,raw,,946.5590000000001,945.2554565760003,8.577600000000006,127.84,2,11,16,7,5,0.36363636363636365,63,0.07299786889173975,False,3,True,0,,CHEMBL2326746,33.0,nM,=,7.48,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.4815,1,active,MW=946.6 > 500.0; LogP=8.58 > 5.0; HBA=11 > 10
e60244c9,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,raw,,928.5690000000001,927.2648783880003,8.438500000000007,127.84,2,11,16,7,5,0.36363636363636365,62,0.09265453365643667,False,3,True,0,,CHEMBL2326745,19.0,nM,=,7.72,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.7212,1,active,MW=928.6 > 500.0; LogP=8.44 > 5.0; HBA=11 > 10
f28c6415,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nnc3n2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)CC3)cc1S(=O)(=O)C(F)(F)F,,,raw,,931.573,930.2757774200003,7.740000000000009,132.76999999999998,2,12,16,7,5,0.3953488372093023,62,0.09428195411095064,False,3,True,0,,CHEMBL2326744,25.0,nM,=,7.6,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.6021,1,active,MW=931.6 > 500.0; LogP=7.74 > 5.0; HBA=12 > 10
50c1df01,,O=S(=O)(Nc1ncnc2c1CN(C1CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC1)C2)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1,,,raw,,956.5789999999998,955.2597930080001,8.166600000000008,137.07,2,12,16,8,5,0.37777777777777777,64,0.09241910491730486,False,3,True,0,,CHEMBL2322029,740.0,nM,=,6.13,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,6.1308,1,active,MW=956.6 > 500.0; LogP=8.17 > 5.0; HBA=12 > 10
0f5813a3,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC2=NS(=O)(=O)c3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc32)cc1[N+](=O)[O-],,,raw,,874.5109999999999,873.220372808,7.189300000000008,157.56,2,11,15,7,5,0.2619047619047619,59,0.062368029580047855,False,3,True,0,,CHEMBL2322027,17.0,nM,=,7.77,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.7696,1,active,MW=874.5 > 500.0; LogP=7.19 > 5.0; HBA=11 > 10
9a6c59cc,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)cnn23)cc1[N+](=O)[O-],,,raw,,827.437,826.2598695360001,7.000400000000008,154.14000000000001,2,13,16,7,6,0.275,57,0.05869568740465848,False,3,True,0,,CHEMBL2322026,25.0,nM,=,7.6,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.6021,1,active,MW=827.4 > 500.0; LogP=7.00 > 5.0; HBA=13 > 10
94b9aa8f,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2cccc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)cnc23)cc1[N+](=O)[O-],,,raw,,836.484,835.2741226320001,9.1109,123.95000000000002,2,10,16,7,6,0.25,58,0.05546128670271751,False,2,True,0,,CHEMBL2322024,68.0,nM,=,7.17,CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,0.8,1,7.1675,1,active,MW=836.5 > 500.0; LogP=9.11 > 5.0
01d8a990,,Cc1c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C,,,raw,,1013.7089999999996,1012.3200868440001,9.61432,179.23,3,13,19,7,6,0.3,69,0.03981698886022627,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325764,1.8,nM,=,8.74,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.7447,1,active,MW=1013.7 > 500.0; LogP=9.61 > 5.0; HBA=13 > 10
ce2cadbf,,CCn1c(C)c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,raw,,999.6819999999997,998.3044367800001,9.053320000000005,179.23,3,13,19,7,6,0.2857142857142857,68,0.03990133960266579,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325763,1.8,nM,=,8.74,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.7447,1,active,MW=999.7 > 500.0; LogP=9.05 > 5.0; HBA=13 > 10
42fc9adc,,CCCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,raw,,950.6279999999998,949.3422021920001,10.842319999999992,153.29,3,11,20,7,6,0.3,66,0.0380694329228463,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325762,23.0,nM,=,7.64,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,7.6383,1,active,MW=950.6 > 500.0; LogP=10.84 > 5.0; HBA=11 > 10
f55be114,,CCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,raw,,936.6009999999999,935.3265521280001,10.452219999999995,153.29,3,11,19,7,6,0.2857142857142857,65,0.040405725341722265,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325761,10.0,nM,=,8.0,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.0,1,active,MW=936.6 > 500.0; LogP=10.45 > 5.0; HBA=11 > 10
8f94dbbe,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C,,,raw,,936.6009999999999,935.3265521280001,10.623119999999993,153.29,3,11,18,7,6,0.2857142857142857,65,0.04287263295518805,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2159740,1.4,nM,=,8.85,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.8539,1,active,MW=936.6 > 500.0; LogP=10.62 > 5.0; HBA=11 > 10
d267be85,,Cc1oc(-c2ccc(Cl)cc2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1C(=O)O,,,raw,,895.5039999999998,894.2636175240001,9.83372,161.5,3,11,17,7,6,0.2391304347826087,62,0.045238715918697825,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325760,3.8,nM,=,8.42,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.4202,1,active,MW=895.5 > 500.0; LogP=9.83 > 5.0; HBA=11 > 10
a46bfc66,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)nn(C)c5C(=O)O)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,895.5079999999999,894.274850904,8.665800000000006,166.18,3,12,17,7,6,0.24444444444444444,62,0.045397690178872005,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325759,3.7,nM,=,8.43,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.4318,1,active,MW=895.5 > 500.0; LogP=8.67 > 5.0; HBA=12 > 10
3d5b46c5,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)nn(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,895.5079999999999,894.274850904,8.665800000000006,166.18000000000004,3,12,17,7,6,0.24444444444444444,62,0.045397690178872005,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325758,7.1,nM,=,8.15,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.1487,1,active,MW=895.5 > 500.0; LogP=8.67 > 5.0; HBA=12 > 10
89849f99,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NS(C)(=O)=O)cnn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,958.5889999999999,957.2527355560001,7.442200000000009,192.12,3,14,18,7,6,0.24444444444444444,65,0.043798721344985435,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325757,5.4,nM,=,8.27,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.2676,1,active,MW=958.6 > 500.0; LogP=7.44 > 5.0; HBA=14 > 10
e2d2d4c5,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NS(C)(=O)=O)ncn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,958.5889999999999,957.2527355560001,7.442200000000009,192.12,3,14,18,7,6,0.24444444444444444,65,0.043798721344985435,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2326039,3.8,nM,=,8.42,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.4202,1,active,MW=958.6 > 500.0; LogP=7.44 > 5.0; HBA=14 > 10
6116ea09,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cnoc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,838.456,837.2533871879999,9.222100000000001,137.09,2,11,16,7,6,0.23255813953488372,58,0.054854341774906716,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2326038,350.0,nM,=,6.46,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,6.4559,1,active,MW=838.5 > 500.0; LogP=9.22 > 5.0; HBA=11 > 10
f02de659,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cn(C)nc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,851.4989999999999,850.2850216639999,8.967600000000004,128.88,2,11,16,7,6,0.25,59,0.055351174445511145,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2326037,140.0,nM,=,6.85,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,6.8539,1,active,MW=851.5 > 500.0; LogP=8.97 > 5.0; HBA=11 > 10
72755814,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cnn(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,851.4989999999999,850.2850216639999,8.967600000000004,128.88000000000002,2,11,16,7,6,0.25,59,0.055351174445511145,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325774,210.0,nM,=,6.68,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,6.6778,1,active,MW=851.5 > 500.0; LogP=8.97 > 5.0; HBA=11 > 10
e3de2f33,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5ccnn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,837.472,836.2693716,8.752800000000004,128.88000000000002,2,11,16,7,6,0.23255813953488372,58,0.05550171698106068,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325773,110.0,nM,=,6.96,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,6.9586,1,active,MW=837.5 > 500.0; LogP=8.75 > 5.0; HBA=11 > 10
4966db98,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cncn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,837.472,836.2693716,8.752800000000004,128.88000000000002,2,11,16,7,6,0.23255813953488372,58,0.05550171698106068,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325772,46.0,nM,=,7.34,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,7.3372,1,active,MW=837.5 > 500.0; LogP=8.75 > 5.0; HBA=11 > 10
8b13eafe,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)c(Cl)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,928.9649999999999,927.2406295840001,9.924199999999997,153.29000000000002,3,11,17,7,6,0.2391304347826087,63,0.045526240763028525,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325771,1.5,nM,=,8.82,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.8239,1,active,MW=929.0 > 500.0; LogP=9.92 > 5.0; HBA=11 > 10
19b76232,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)c(C(F)(F)F)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,962.517,961.266986564,10.289599999999997,153.29000000000002,3,11,17,7,6,0.2553191489361702,66,0.0454856917702358,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325770,1.1,nM,=,8.96,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.9586,1,active,MW=962.5 > 500.0; LogP=10.29 > 5.0; HBA=11 > 10
18ba3c84,,Cc1c(C#N)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,889.5479999999999,888.300671728,9.752699999999997,139.78,2,11,16,7,6,0.2553191489361702,62,0.05486814710581122,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325769,17.0,nM,=,7.77,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,7.7696,1,active,MW=889.5 > 500.0; LogP=9.75 > 5.0; HBA=11 > 10
0001b927,,Cc1c(C(F)(F)F)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,932.5349999999999,931.292807388,10.899819999999991,115.99000000000001,2,10,16,7,6,0.2765957446808511,64,0.05559241108800889,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325768,271.0,nM,=,6.57,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,6.567,1,active,MW=932.5 > 500.0; LogP=10.90 > 5.0
c8aefd17,,Cc1c(Cl)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,898.9829999999998,897.2664504080001,10.534419999999992,115.99000000000001,2,10,16,7,6,0.2608695652173913,61,0.05564711590567504,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325767,260.0,nM,=,6.58,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,6.585,1,active,MW=899.0 > 500.0; LogP=10.53 > 5.0
d25b9cdb,,Cc1c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,985.6549999999996,984.2887867160001,8.570420000000007,179.23,3,13,18,7,6,0.2708333333333333,67,0.04252165174280818,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325766,0.9,nM,=,9.05,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,9.0458,1,active,MW=985.7 > 500.0; LogP=8.57 > 5.0; HBA=13 > 10
05f835a1,,Cc1c(C(=O)N2CC(C)(O)C2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,977.6539999999997,976.353101224,9.087820000000004,156.53,3,12,17,8,6,0.3137254901960784,68,0.04553988011136257,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2325765,5.6,nM,=,8.25,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.2518,1,active,MW=977.7 > 500.0; LogP=9.09 > 5.0; HBA=12 > 10
3205e02f,,Cc1c(C(=O)N[C@H]2C[C@@](C)(O)C2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,991.6809999999996,990.3687512880001,9.52422,165.32,4,12,18,8,6,0.3269230769230769,69,0.036835393617317795,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2326041,7.5,nM,=,8.12,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.1249,1,active,MW=991.7 > 500.0; LogP=9.52 > 5.0; HBA=12 > 10
60b088ce,,Cc1c(C(N)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,907.5629999999999,906.3112364120001,8.979920000000003,159.08,3,11,17,7,6,0.2553191489361702,63,0.04583509417807814,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2326040,19.0,nM,=,7.72,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,7.7212,1,active,MW=907.6 > 500.0; LogP=8.98 > 5.0; HBA=11 > 10
d46c64a6,,CNC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n(C)c1C,,,raw,,921.5899999999998,920.3268864759999,9.240620000000002,145.09,3,11,17,7,6,0.2708333333333333,64,0.04601956174525012,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2159736,5.0,nM,=,8.3,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.301,1,active,MW=921.6 > 500.0; LogP=9.24 > 5.0; HBA=11 > 10
d3399976,,Cc1cc(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,864.538,863.30542276,9.881019999999996,115.99000000000001,2,10,16,7,6,0.2608695652173913,60,0.05575944156902043,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2159738,99.0,nM,=,7.0,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,7.0044,1,active,MW=864.5 > 500.0; LogP=9.88 > 5.0
b5e31744,,CCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,raw,,922.5739999999998,921.3109020640001,10.062119999999997,153.29,3,11,18,7,6,0.2708333333333333,64,0.042900438115129974,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2159739,2.0,nM,=,8.7,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.699,1,active,MW=922.6 > 500.0; LogP=10.06 > 5.0; HBA=11 > 10
1fe89d8d,,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,raw,,908.5469999999999,907.2952520000001,9.57922,153.29,3,11,17,7,6,0.2553191489361702,63,0.04557610986414566,False,3,False,1,PAINS match: anil_di_alk_A(478),CHEMBL2159737,1.3,nM,=,8.89,CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,0.8,1,8.8861,1,active,MW=908.5 > 500.0; LogP=9.58 > 5.0; HBA=11 > 10
ebb0310c,,Nn1c(SCc2cccc([N+](=O)[O-])c2)nnc1-c1c[nH]c2ccccc12,,,raw,,366.40600000000006,366.089894688,3.340700000000002,115.66,2,7,5,4,4,0.058823529411764705,26,0.242149312508044,True,0,True,0,,CHEMBL2376835,1430.0,nM,=,5.84,CHEMBL2379961,Competitive binding affinity to his-tagged Bcl-2 (unknown origin) after 1 hr by ELISA in presence of Bim peptide,0.8,1,5.8447,0,inactive,
6042b2f6,,O=C(O)c1cc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)ccn1,,,raw,,414.4900000000002,414.115046816,5.209000000000003,87.47,2,6,4,5,4,0.13043478260869565,30,0.4477579196771556,True,1,True,0,,CHEMBL2398263,5000.0,nM,=,5.3,CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,0.8,1,5.301,0,inactive,LogP=5.21 > 5.0
09f2b318,,O=C(O)c1csc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)n1,,,raw,,420.51900000000023,420.07146775200005,5.270500000000003,87.47,2,7,4,5,4,0.14285714285714285,29,0.4392111802026122,True,1,True,0,,CHEMBL2398260,5000.0,nM,=,5.3,CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,0.8,1,5.301,0,inactive,LogP=5.27 > 5.0
ff7014a0,,O=C(O)c1csc(-c2ccc3c(c2)/C(=N/Nc2nc4ccccc4s2)CCC3)n1,,,raw,,420.51900000000023,420.07146775200005,5.270500000000003,87.47,2,7,4,5,4,0.14285714285714285,29,0.4392111802026122,True,1,True,0,,CHEMBL3287283,5000.0,nM,=,5.3,CHEMBL3291800,Antagonist activity at Bcl-2 (unknown origin),0.8,1,5.301,0,inactive,LogP=5.27 > 5.0
fe5a5b49,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,942.5479999999998,941.2329095639998,8.036500000000009,128.35999999999999,2,11,16,7,5,0.3111111111111111,63,0.0934156945760598,False,3,True,0,,CHEMBL3311329,12.5,nM,=,7.96,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,2,7.9031,1,active,MW=942.5 > 500.0; LogP=8.04 > 5.0; HBA=11 > 10
7e8559b7,,N=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,941.5639999999997,940.2488939759999,8.221670000000008,135.14000000000001,3,11,16,7,5,0.3111111111111111,63,0.05050225892192379,False,3,True,0,,CHEMBL3311330,19.0,nM,=,7.72,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.7212,1,active,MW=941.6 > 500.0; LogP=8.22 > 5.0; HBA=11 > 10
fdd86ca2,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nn1,,,raw,,944.5239999999997,943.2234074999998,6.826500000000008,154.14,2,13,16,7,5,0.32558139534883723,63,0.09958621001999708,False,3,True,0,,CHEMBL3311479,270.0,nM,=,6.57,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,6.5686,1,active,MW=944.5 > 500.0; LogP=6.83 > 5.0; HBA=13 > 10
1f792f85,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1cnc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nc1,,,raw,,944.5239999999997,943.2234074999998,6.826500000000008,154.14,2,13,16,7,5,0.32558139534883723,63,0.09958621001999708,False,3,True,0,,CHEMBL3311480,179.0,nM,=,7.75,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,2,6.7471,1,active,MW=944.5 > 500.0; LogP=6.83 > 5.0; HBA=13 > 10
39eb4eba,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1csc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)n1,,,raw,,949.5649999999997,948.1845794679999,7.493000000000009,141.25,2,13,16,7,5,0.3333333333333333,62,0.09477619489386932,False,3,True,0,,CHEMBL3311481,119.0,nM,=,6.92,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,6.9245,1,active,MW=949.6 > 500.0; LogP=7.49 > 5.0; HBA=13 > 10
b32a4d84,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCP(=O)(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,975.5139999999999,974.1985118139999,9.097600000000003,142.19,2,11,16,7,5,0.3111111111111111,64,0.07227240338031045,False,3,True,0,,CHEMBL3311484,54.0,nM,=,7.27,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.2676,1,active,MW=975.5 > 500.0; LogP=9.10 > 5.0; HBA=11 > 10
c74ed381,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(Oc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,943.5319999999999,942.216925152,8.762100000000004,134.35,2,11,16,7,5,0.3111111111111111,63,0.09205439120051348,False,3,True,0,,CHEMBL3311485,250.0,nM,=,6.6,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,6.6021,1,active,MW=943.5 > 500.0; LogP=8.76 > 5.0; HBA=11 > 10
3e4c8518,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(C(=O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,955.5429999999999,954.216925152,8.813600000000005,142.19,2,11,16,7,5,0.30434782608695654,64,0.07242661253771533,False,3,True,0,,CHEMBL3311486,65.0,nM,=,7.19,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.1871,1,active,MW=955.5 > 500.0; LogP=8.81 > 5.0; HBA=11 > 10
15bd2cde,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(Sc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,959.5999999999999,958.194081532,9.4754,125.11999999999999,2,11,16,7,5,0.3111111111111111,63,0.09198366701053706,False,3,True,0,,CHEMBL3311487,61.0,nM,=,7.21,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.2147,1,active,MW=959.6 > 500.0; LogP=9.48 > 5.0; HBA=11 > 10
6cfe1d89,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,975.5989999999999,974.188996152,8.490900000000007,148.17999999999998,2,11,16,7,5,0.3111111111111111,64,0.07249491874518922,False,3,True,0,,CHEMBL3311488,226.5,nM,=,7.72,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,2,6.6449,1,active,MW=975.6 > 500.0; LogP=8.49 > 5.0; HBA=11 > 10
0adba787,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,975.5989999999999,974.188996152,8.490900000000007,148.17999999999998,2,11,16,7,5,0.3111111111111111,64,0.07249491874518922,False,3,True,0,,CHEMBL3311489,545.0,nM,=,6.26,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,6.2636,1,active,MW=975.6 > 500.0; LogP=8.49 > 5.0; HBA=11 > 10
5aa99cf3,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(S(=O)(=O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,991.598,990.1839107720001,8.157000000000009,159.26,2,12,16,7,5,0.3111111111111111,65,0.09158712596481047,False,3,True,0,,CHEMBL3309283,87.0,nM,=,7.06,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.0605,1,active,MW=991.6 > 500.0; LogP=8.16 > 5.0; HBA=12 > 10
a871d984,,CCOC(=O)C1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1013.6229999999998,1012.258789964,9.106700000000004,151.42,2,12,18,7,5,0.3469387755102041,68,0.0636696126585659,False,3,True,0,,CHEMBL3311492,17.0,nM,=,7.77,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.7696,1,active,MW=1013.6 > 500.0; LogP=9.11 > 5.0; HBA=12 > 10
90118fd5,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(CO)(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,971.5859999999998,970.24822528,8.535900000000007,145.35,3,11,17,7,5,0.3404255319148936,65,0.07717287575247189,False,3,True,0,,CHEMBL3311493,59.0,nM,=,7.23,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.2291,1,active,MW=971.6 > 500.0; LogP=8.54 > 5.0; HBA=11 > 10
d5809860,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ncc(Cl)cn3)CC2)cc1,,,raw,,944.5239999999997,943.2234074999998,6.826500000000008,154.14,2,13,16,7,5,0.32558139534883723,63,0.09958621001999708,False,3,True,0,,CHEMBL3311494,21.0,nM,=,7.68,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.6778,1,active,MW=944.5 > 500.0; LogP=6.83 > 5.0; HBA=13 > 10
51f82aab,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3cccnc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,943.5359999999997,942.2281585319998,7.431500000000009,141.25,2,12,16,7,5,0.3181818181818182,63,0.09514680665547255,False,3,True,0,,CHEMBL3309308,26.0,nM,=,7.58,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.585,1,active,MW=943.5 > 500.0; LogP=7.43 > 5.0; HBA=12 > 10
a36f23f6,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3cn[nH]c3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,932.5129999999997,931.2234074999998,6.759600000000008,157.04,3,12,16,7,5,0.3333333333333333,62,0.08958748539736504,False,3,True,0,,CHEMBL3309309,40.0,nM,=,7.4,CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,0.8,1,7.3979,1,active,MW=932.5 > 500.0; LogP=6.76 > 5.0; HBA=12 > 10
db7493b9,,N#CC1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,966.5699999999997,965.2329095640001,9.067180000000002,148.91,2,11,16,7,5,0.3191489361702128,65,0.09130678590105093,False,3,True,0,,CHEMBL3311490,545.0,nM,=,6.26,CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,0.8,1,6.2636,1,active,MW=966.6 > 500.0; LogP=9.07 > 5.0; HBA=11 > 10
c4f6471b,,CN(C)C(=O)COc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1043.653,1042.280588028,7.503500000000009,157.89999999999998,2,13,19,7,5,0.3469387755102041,70,0.07848654834339006,False,3,True,0,,CHEMBL3309311,45.0,nM,=,7.35,CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,0.8,1,7.3468,1,active,MW=1043.7 > 500.0; LogP=7.50 > 5.0; HBA=13 > 10
75059e86,,CN(C)C(=O)COc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1,,,raw,,1043.653,1042.280588028,7.503500000000008,157.89999999999998,2,13,19,7,5,0.3469387755102041,70,0.07848654834339006,False,3,True,0,,CHEMBL3309262,187.0,nM,=,6.73,CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,0.8,1,6.7282,1,active,MW=1043.7 > 500.0; LogP=7.50 > 5.0; HBA=13 > 10
d8769dd7,,CN(C)CCOc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1029.6699999999998,1028.3013234720001,7.976900000000009,140.82999999999998,2,13,20,7,5,0.3673469387755102,69,0.072953167938852,False,3,True,0,,CHEMBL3309312,4.0,nM,=,8.4,CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,0.8,1,8.3979,1,active,MW=1029.7 > 500.0; LogP=7.98 > 5.0; HBA=13 > 10
aedc4d5c,,CN(C)CCOc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1,,,raw,,1029.6699999999998,1028.3013234720001,7.9769000000000085,140.82999999999998,2,13,20,7,5,0.3673469387755102,69,0.072953167938852,False,3,True,0,,CHEMBL3309313,22.0,nM,=,7.66,CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,0.8,1,7.6576,1,active,MW=1029.7 > 500.0; LogP=7.98 > 5.0; HBA=13 > 10
008f0340,,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,959.5750000000002,958.2482252800002,8.646300000000005,156.35,4,11,19,6,5,0.32608695652173914,64,0.058811977523816596,False,3,True,0,,CHEMBL3703601,0.5,nM,=,9.3,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.301,1,active,MW=959.6 > 500.0; LogP=8.65 > 5.0; HBA=11 > 10
a6cf5329,,CCN(CC)CC1CN(CC[C@H](CSc2ccccc2)Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC([C@@H](O)c5ccccc5-c5ccc(Cl)cc5)CC4)cc3)cc2S(=O)(=O)C(F)(F)F)CCO1,,,raw,,1042.709,1041.321724568,9.3747,148.58999999999997,3,12,20,7,5,0.39215686274509803,70,0.06384281555932704,False,3,True,0,,CHEMBL3703622,0.4,nM,=,9.4,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.3979,1,active,MW=1042.7 > 500.0; LogP=9.37 > 5.0; HBA=12 > 10
5a2c28a4,,N#C[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,966.5699999999997,965.2329095640001,9.23808,148.91,2,11,16,7,5,0.3191489361702128,65,0.0912326715197426,False,3,True,0,,CHEMBL3703615,1195.0,nM,=,5.92,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,5.9226,0,inactive,MW=966.6 > 500.0; LogP=9.24 > 5.0; HBA=11 > 10
d361b73d,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,987.5849999999999,986.2431399,8.02520000000001,165.57999999999998,4,12,17,7,5,0.3404255319148936,66,0.06646239655737932,False,3,True,0,,CHEMBL3703618,0.6,nM,=,9.22,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.2218,1,active,MW=987.6 > 500.0; LogP=8.03 > 5.0; HBA=12 > 10
41a6c1de,,CNCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1027.6539999999998,1026.285673408,8.007600000000009,166.24999999999997,4,12,19,7,5,0.3469387755102041,69,0.059020759496293,False,3,True,0,,CHEMBL3703627,27.0,nM,=,7.57,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,7.5686,1,active,MW=1027.7 > 500.0; LogP=8.01 > 5.0; HBA=12 > 10
189b8bcf,,CCN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,1039.5539999999999,1038.214555802,8.763300000000005,202.87999999999997,5,12,21,6,5,0.32608695652173914,68,0.034476430139245784,False,3,True,0,,CHEMBL3703605,0.9,nM,=,9.05,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.0458,1,active,MW=1039.6 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
1553d2f3,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,957.559,956.232575216,8.664300000000006,145.35,3,11,16,7,5,0.32608695652173914,64,0.08178065765115981,False,3,True,0,,CHEMBL3703611,253.0,nM,=,6.6,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,6.5969,1,active,MW=957.6 > 500.0; LogP=8.66 > 5.0; HBA=11 > 10
d5d2a6f8,,N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,966.5699999999997,965.2329095640001,9.23808,148.91,2,11,16,7,5,0.3191489361702128,65,0.0912326715197426,False,3,True,0,,CHEMBL3703614,4.5,nM,=,8.15,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,6,8.3468,1,active,MW=966.6 > 500.0; LogP=9.24 > 5.0; HBA=11 > 10
54b626f3,,CC(C)(C)OP(=O)(O)OCO[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1123.672,1122.272070678,10.578199999999994,190.10999999999999,3,14,21,7,5,0.39215686274509803,74,0.035710892034215826,False,3,True,0,,CHEMBL3703623,4.0,nM,=,8.4,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,8.3979,1,active,MW=1123.7 > 500.0; LogP=10.58 > 5.0; HBA=14 > 10
1a638347,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,957.559,956.232575216,8.664300000000006,145.35,3,11,16,7,5,0.32608695652173914,64,0.08178065765115981,False,3,True,0,,CHEMBL3703612,3.0,nM,=,8.52,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,8.5229,1,active,MW=957.6 > 500.0; LogP=8.66 > 5.0; HBA=11 > 10
60333f71,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,987.5849999999999,986.2431399,8.02520000000001,165.57999999999998,4,12,17,7,5,0.3404255319148936,66,0.06646239655737932,False,3,True,0,,CHEMBL3703620,0.4,nM,=,9.4,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.3979,1,active,MW=987.6 > 500.0; LogP=8.03 > 5.0; HBA=12 > 10
10c7c55a,,CN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,1025.5269999999998,1024.198905738,8.373200000000006,202.87999999999997,5,12,20,6,5,0.3111111111111111,67,0.03675226491091962,False,3,True,0,,CHEMBL3703606,0.9,nM,=,9.05,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.0458,1,active,MW=1025.5 > 500.0; LogP=8.37 > 5.0; HBA=12 > 10
8b9caa38,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCO)CCO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,975.574,974.2431399,7.61870000000001,176.57999999999998,5,12,20,6,5,0.32608695652173914,65,0.04835889445851227,False,3,True,0,,CHEMBL3703602,0.8,nM,=,9.1,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.0969,1,active,MW=975.6 > 500.0; LogP=7.62 > 5.0; HBA=12 > 10
25573dd8,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,870.4939999999999,869.2683685559998,8.279000000000009,154.35,3,11,16,7,5,0.3111111111111111,60,0.049888675883524726,False,3,True,0,,CHEMBL3703613,0.8,nM,=,9.1,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.0969,1,active,MW=870.5 > 500.0; LogP=8.28 > 5.0; HBA=11 > 10
2cb68b73,,NCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1013.6269999999997,1012.270023344,7.746900000000009,180.23999999999998,4,12,18,7,5,0.3333333333333333,68,0.06285990841486014,False,3,True,0,,CHEMBL3703628,38.0,nM,=,7.42,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,7.4202,1,active,MW=1013.6 > 500.0; LogP=7.75 > 5.0; HBA=12 > 10
cebb80fe,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(C[C@H](O)CF)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,1032.645,1031.281002628,8.28010000000001,159.58999999999997,4,12,19,7,5,0.3673469387755102,69,0.0464218648729753,False,3,True,0,,CHEMBL3703603,1.0,nM,=,9.0,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.0,1,active,MW=1032.6 > 500.0; LogP=8.28 > 5.0; HBA=12 > 10
d2ace599,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,987.5849999999999,986.2431399,8.02520000000001,165.57999999999998,4,12,17,7,5,0.3404255319148936,66,0.06646239655737932,False,3,True,0,,CHEMBL3703619,1.0,nM,=,9.0,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.0,1,active,MW=987.6 > 500.0; LogP=8.03 > 5.0; HBA=12 > 10
0a85bfdd,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,987.5849999999999,986.2431399,8.02520000000001,165.57999999999998,4,12,17,7,5,0.3404255319148936,66,0.06646239655737932,False,3,True,0,,CHEMBL3703621,0.4,nM,=,9.4,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.3979,1,active,MW=987.6 > 500.0; LogP=8.03 > 5.0; HBA=12 > 10
40acc301,,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCN(CCO)CC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,999.6439999999996,998.2907587880002,7.90840000000001,165.37999999999997,4,12,18,7,5,0.3541666666666667,67,0.0628623859492592,False,3,True,0,,CHEMBL3703610,16.0,nM,=,7.8,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,7.7959,1,active,MW=999.6 > 500.0; LogP=7.91 > 5.0; HBA=12 > 10
80ba7ad6,,COP(=O)(O)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1051.565,1050.2145558020002,9.4354,180.88,3,13,19,7,5,0.3404255319148936,69,0.05256651999462828,False,3,True,0,,CHEMBL3703625,1.0,nM,=,9.0,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.0,1,active,MW=1051.6 > 500.0; LogP=9.44 > 5.0; HBA=13 > 10
05c546b4,,CN(C)[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,984.6289999999998,983.2798597560002,9.233600000000003,128.35999999999999,2,11,17,7,5,0.3541666666666667,66,0.08663423037283355,False,3,True,0,,CHEMBL3703629,24.0,nM,=,7.62,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,7.6198,1,active,MW=984.6 > 500.0; LogP=9.23 > 5.0; HBA=11 > 10
611dd60b,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCOP(=O)(O)O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,1080.6070000000004,1079.241104898,8.059000000000012,206.11999999999995,5,13,20,7,5,0.3541666666666667,71,0.036935092545423716,False,3,True,0,,CHEMBL3703607,0.7,nM,=,9.15,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.1549,1,active,MW=1080.6 > 500.0; LogP=8.06 > 5.0; HBA=13 > 10
bec2400c,,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,956.5749999999997,955.2485596280002,8.630700000000004,151.14,3,11,16,7,5,0.32608695652173914,64,0.08162131416324724,False,3,True,0,,CHEMBL3703626,30.0,nM,=,7.52,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,7.5229,1,active,MW=956.6 > 500.0; LogP=8.63 > 5.0; HBA=11 > 10
f2d398b1,,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,958.591,957.2642096920001,8.612700000000006,162.14,4,11,19,6,5,0.32608695652173914,64,0.05869312212151482,False,3,True,0,,CHEMBL3703609,3.0,nM,=,8.52,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,8.5229,1,active,MW=958.6 > 500.0; LogP=8.61 > 5.0; HBA=11 > 10
1b4cafa5,,CCOP(=O)(OCC)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,raw,,1093.646,1092.2615059940003,10.869699999999991,169.88,2,14,22,7,5,0.38,72,0.04956646010560931,False,3,True,0,,CHEMBL3703624,30.0,nM,=,7.52,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,7.5229,1,active,MW=1093.6 > 500.0; LogP=10.87 > 5.0; HBA=14 > 10
16e68433,,CCN(CC)C[C@@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,1042.7089999999998,1041.321724568,9.374700000000002,148.58999999999997,3,12,20,7,5,0.39215686274509803,70,0.06384281555932704,False,3,True,0,,CHEMBL3703617,0.3,nM,=,9.52,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,2,9.5229,1,active,MW=1042.7 > 500.0; LogP=9.37 > 5.0; HBA=12 > 10
c88de857,,CCN(CC)C[C@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,1042.7089999999998,1041.321724568,9.374700000000002,148.58999999999997,3,12,20,7,5,0.39215686274509803,70,0.06384281555932704,False,3,True,0,,CHEMBL3703616,0.3,nM,=,9.52,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,2,9.5229,1,active,MW=1042.7 > 500.0; LogP=9.37 > 5.0; HBA=12 > 10
49d9b00a,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCOP(=O)(O)O)CCOP(=O)(O)O)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,raw,,1135.5320000000002,1134.175800944,7.852700000000013,269.64,7,14,24,6,5,0.32608695652173914,73,0.02288787181579677,False,4,True,0,,CHEMBL3703604,2.0,nM,=,8.7,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,8.699,1,active,MW=1135.5 > 500.0; LogP=7.85 > 5.0; HBD=7 > 5; HBA=14 > 10
c146e2da,,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,raw,,828.4570000000001,827.257803872,8.508400000000007,145.12,3,10,16,6,5,0.27906976744186046,57,0.05031572572156696,False,2,True,0,,CHEMBL3703599,0.3,nM,=,9.52,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,9.5229,1,active,MW=828.5 > 500.0; LogP=8.51 > 5.0
cf1176d6,,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,944.5640000000002,943.2485596280002,8.222600000000007,162.14,4,11,18,6,5,0.3111111111111111,63,0.06268864807802897,False,3,True,0,,CHEMBL3703608,4.0,nM,=,8.4,CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",0.8,3,8.3979,1,active,MW=944.6 > 500.0; LogP=8.22 > 5.0; HBA=11 > 10
f45ab06c,,CC(C)Oc1ccc(C(=O)Nc2c(C(=O)O)nn(-c3ccc(Oc4ccccc4)cc3)c2-c2ccc(OC(C)C)cc2)cc1,,,raw,,591.6640000000002,591.236935776,7.856500000000007,111.91,2,7,11,5,5,0.17142857142857143,44,0.16081500019418557,False,2,True,0,,CHEMBL3799447,5000.0,nM,=,5.3,CHEMBL3801206,Inhibition of Bcl2 in human DMS53 cells assessed as growth inhibition,0.8,1,5.301,0,inactive,MW=591.7 > 500.0; LogP=7.86 > 5.0
54478f4f,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,,,raw,,317.3920000000001,317.152812228,4.486940000000003,53.169999999999995,2,2,3,4,3,0.15,24,0.7346360353495455,True,0,True,0,,CHEMBL408194,1110.0,nM,=,5.96,CHEMBL3822337,Inhibition of FITC-labeled Bid BH3 peptide binding to human GST-tagged BCL2 lacking C-terminal transmembrane domain expressed in Escherichia coli XL-1 Blue cells preincubated for 10 mins followed by FITC-labeled Bid BH3 peptide addition measured after 20 mins by fluorescence polarization assay,0.8,2,5.9547,0,inactive,
f8178592,,COC(=O)CN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,raw,,646.6930000000003,646.252645416,5.197640000000005,191.71999999999997,6,11,7,4,2,0.3142857142857143,47,0.17119781624396488,False,4,True,0,,CHEMBL3929718,103.0,nM,=,6.99,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,1,6.9872,1,active,MW=646.7 > 500.0; LogP=5.20 > 5.0; HBD=6 > 5; HBA=11 > 10
77aeb455,,COC(=O)CCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,raw,,688.7740000000002,688.299595608,5.384440000000006,191.71999999999997,6,12,11,4,2,0.3684210526315789,50,0.10046604145650409,False,4,True,0,,CHEMBL3957283,286.0,nM,=,6.54,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,1,6.5436,1,active,MW=688.8 > 500.0; LogP=5.38 > 5.0; HBD=6 > 5; HBA=12 > 10
675cd136,,COC(=O)CCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,raw,,716.8280000000003,716.330895736,6.164640000000007,191.71999999999997,6,12,13,4,2,0.4,52,0.07868927251552679,False,4,True,0,,CHEMBL3918448,452.0,nM,=,6.08,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,3,6.3449,1,active,MW=716.8 > 500.0; LogP=6.16 > 5.0; HBD=6 > 5; HBA=12 > 10
e2d1f63d,,COC(=O)CCCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,raw,,744.8820000000002,744.3621958640001,6.944840000000008,191.71999999999997,6,12,15,4,2,0.42857142857142855,54,0.06262493643394305,False,4,True,0,,CHEMBL3932954,483.0,nM,=,6.32,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,1,6.3161,1,active,MW=744.9 > 500.0; LogP=6.94 > 5.0; HBD=6 > 5; HBA=12 > 10
72186a29,,COC(=O)CCCCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,raw,,772.936,772.3934959920001,7.72504000000001,191.71999999999997,6,12,17,4,2,0.45454545454545453,56,0.052200229496115115,False,4,True,0,,CHEMBL3971530,840.0,nM,=,6.08,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,1,6.0757,1,active,MW=772.9 > 500.0; LogP=7.73 > 5.0; HBD=6 > 5; HBA=12 > 10
a99810bc,,Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCC(=O)O)C(=O)C(O)=C2C(C)C,,,raw,,632.6660000000003,632.2369953519999,4.427440000000002,213.71999999999997,8,10,9,4,2,0.29411764705882354,46,0.18037984139764002,False,2,True,0,,CHEMBL1962390,573.0,nM,=,6.24,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,1,6.2418,1,active,MW=632.7 > 500.0; HBD=8 > 5
7de7dcb5,,Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCCCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCCCC(=O)O)C(=O)C(O)=C2C(C)C,,,raw,,688.7740000000002,688.299595608,5.987840000000003,213.71999999999997,8,10,13,4,2,0.3684210526315789,50,0.0900521674715,False,3,True,0,,CHEMBL3951720,596.0,nM,=,6.22,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,1,6.2248,1,active,MW=688.8 > 500.0; LogP=5.99 > 5.0; HBD=8 > 5
c5bdda26,,Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCCCCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCCCCC(=O)O)C(=O)C(O)=C2C(C)C,,,raw,,716.8280000000001,716.330895736,6.7680400000000045,213.71999999999997,8,10,15,4,2,0.4,52,0.07085659542418242,False,3,True,0,,CHEMBL1962393,458.0,nM,=,6.34,CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,0.8,1,6.3391,1,active,MW=716.8 > 500.0; LogP=6.77 > 5.0; HBD=8 > 5
eda5da36,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,737.8569999999997,737.321334096,6.804320000000011,101.64000000000001,1,9,7,9,6,0.2727272727272727,55,0.1923850392465834,False,2,True,0,,CHEMBL3704808,3.7,nM,=,8.43,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4318,1,active,MW=737.9 > 500.0; LogP=6.80 > 5.0
92fa6379,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,684.7929999999999,684.2947850000002,6.31262000000001,96.71000000000001,1,8,7,8,5,0.2682926829268293,51,0.21470168677854518,False,2,True,0,,CHEMBL3704809,11.1,nM,=,7.96,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.9547,1,active,MW=684.8 > 500.0; LogP=6.31 > 5.0
377a667e,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c(C)n2C)c1,,,raw,,670.8100000000003,670.3155204440001,6.592520000000008,87.48000000000002,1,7,8,7,5,0.2682926829268293,50,0.20053250769404457,False,2,True,0,,CHEMBL3704810,6.0,nM,=,8.22,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2218,1,active,MW=670.8 > 500.0; LogP=6.59 > 5.0
4c10f0b8,,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C,,,raw,,698.8239999999997,698.3216684440001,5.622820000000007,103.60999999999999,1,9,7,8,5,0.2926829268292683,52,0.2337854753896587,False,2,True,0,,CHEMBL3704811,8.5,nM,=,8.07,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0706,1,active,MW=698.8 > 500.0; LogP=5.62 > 5.0
fd855966,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)ncn3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,729.2809999999997,728.287781472,7.12402000000001,96.07,1,8,7,8,6,0.2619047619047619,53,0.18816706152339313,False,2,True,0,,CHEMBL3704812,7.7,nM,=,8.11,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1135,1,active,MW=729.3 > 500.0; LogP=7.12 > 5.0
5cb3c75e,,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,685.7809999999998,685.2900339680001,5.7076200000000075,109.6,1,9,7,8,5,0.275,51,0.23234245679217452,False,2,True,0,,CHEMBL3704813,8.0,nM,=,8.1,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0969,1,active,MW=685.8 > 500.0; LogP=5.71 > 5.0
e0eba294,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)N4CCN(C)CC4)c(C(F)(F)F)n2C)OCO3)CC1,,,raw,,773.8569999999997,773.3512522320001,4.768900000000004,97.19999999999999,1,10,7,8,4,0.4146341463414634,56,0.2853058033768047,True,1,True,0,,CHEMBL3704814,52.9,nM,=,7.28,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.2765,1,active,MW=773.9 > 500.0
8c44ab7e,,COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3ccn(C)c3c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,782.8979999999998,782.3427978120001,6.079800000000008,123.75999999999999,1,11,10,9,6,0.3111111111111111,58,0.17626547254520117,False,3,True,0,,CHEMBL3704815,15.9,nM,=,7.8,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7986,1,active,MW=782.9 > 500.0; LogP=6.08 > 5.0; HBA=11 > 10
d7f47fd6,,Cc1c(C(=O)N(C2=CC3C(C=CN3C)N=C2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,731.2969999999998,730.3034315359998,6.070220000000009,93.85,1,8,7,8,4,0.30952380952380953,53,0.2483747876109408,False,2,True,0,,CHEMBL3704816,2.0,nM,=,8.7,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.699,1,active,MW=731.3 > 500.0; LogP=6.07 > 5.0
2813bbc2,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccc(F)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,662.7659999999997,662.3016819479999,5.4565200000000065,96.07,1,8,7,7,5,0.2894736842105263,49,0.24901122231054892,False,2,True,0,,CHEMBL3704817,447.0,nM,=,6.35,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,6.3497,1,active,MW=662.8 > 500.0; LogP=5.46 > 5.0
027fe14f,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,594.115,593.2193675639999,6.658520000000007,83.6,1,6,5,6,5,0.20588235294117646,43,0.24699777621111688,False,2,True,0,,CHEMBL3701291,5.0,nM,=,8.3,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.301,1,active,MW=594.1 > 500.0; LogP=6.66 > 5.0
b085acdc,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)cn2C)CC1,,,raw,,713.2819999999999,712.2928668519999,7.325400000000009,88.05000000000001,2,6,7,8,6,0.23809523809523808,52,0.1811775569003484,False,2,True,0,,CHEMBL3701292,24.6,nM,=,7.61,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6091,1,active,MW=713.3 > 500.0; LogP=7.33 > 5.0
2c9824aa,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C)CC1,,,raw,,727.3089999999999,726.3085169159998,7.33580000000001,77.19,1,7,7,8,6,0.2558139534883721,53,0.1865198808694254,False,2,True,0,,CHEMBL3701293,21.2,nM,=,7.67,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6737,1,active,MW=727.3 > 500.0; LogP=7.34 > 5.0
353060c8,,CCn1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,741.3359999999997,740.32416698,7.818700000000011,77.18999999999998,1,7,8,8,6,0.2727272727272727,54,0.1723622433852485,False,2,True,0,,CHEMBL3701294,25.2,nM,=,7.6,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.5986,1,active,MW=741.3 > 500.0; LogP=7.82 > 5.0
d36da310,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C2CC2)CC1,,,raw,,753.3469999999998,752.3241669799999,8.133700000000008,77.19,1,7,8,9,6,0.28888888888888886,55,0.1700460125249457,False,2,True,0,,CHEMBL3701295,25.6,nM,=,7.59,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.5918,1,active,MW=753.3 > 500.0; LogP=8.13 > 5.0
c49c5b10,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)cn2C)OCO3)CC1,,,raw,,736.8729999999999,736.337318508,6.411100000000008,95.65,1,9,7,9,6,0.2727272727272727,55,0.20255940605911144,False,2,True,0,,CHEMBL3701296,22.4,nM,=,7.65,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6498,1,active,MW=736.9 > 500.0; LogP=6.41 > 5.0
4efaa77c,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,658.7739999999998,658.295533948,6.723020000000009,78.25,1,6,7,7,5,0.25,49,0.21015505550511826,False,2,True,0,,CHEMBL3701297,16.2,nM,=,7.79,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7905,1,active,MW=658.8 > 500.0; LogP=6.72 > 5.0
699a88ce,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1CCCO,,,raw,,702.8269999999997,702.321748696,6.56842000000001,98.48,2,7,10,7,5,0.2857142857142857,52,0.17104452848299373,False,2,True,0,,CHEMBL3701298,14.2,nM,=,7.85,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8477,1,active,MW=702.8 > 500.0; LogP=6.57 > 5.0
701b5e77,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,712.8259999999998,712.3173320120001,6.609720000000009,96.07,1,8,7,8,6,0.2619047619047619,53,0.20034773866250097,False,2,True,0,,CHEMBL3701299,5.5,nM,=,8.26,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2596,1,active,MW=712.8 > 500.0; LogP=6.61 > 5.0
99cad0b2,,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cc1F,,,raw,,716.8100000000004,716.301013252,6.7601400000000105,96.71000000000002,1,8,7,8,5,0.2857142857142857,53,0.19898048404809257,False,2,True,0,,CHEMBL3701300,4.4,nM,=,8.36,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3565,1,active,MW=716.8 > 500.0; LogP=6.76 > 5.0
f4dc5e8d,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,702.7829999999998,702.285363188,6.451720000000011,96.71000000000001,1,8,7,8,5,0.2682926829268293,52,0.20835132977153697,False,2,True,0,,CHEMBL3701301,12.6,nM,=,7.9,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8996,1,active,MW=702.8 > 500.0; LogP=6.45 > 5.0
05a69599,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,675.2289999999997,674.2659834079999,7.23732000000001,78.25,1,6,7,7,5,0.25,49,0.19705997369463482,False,2,True,0,,CHEMBL3701302,8.0,nM,=,8.1,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0969,1,active,MW=675.2 > 500.0; LogP=7.24 > 5.0
e0879644,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)OCO3)n1CCO,,,raw,,728.8459999999998,728.3209997480001,6.15802000000001,116.94000000000001,2,9,10,8,5,0.3023255813953488,54,0.17588327357019617,False,2,True,0,,CHEMBL3701303,3.9,nM,=,8.41,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4089,1,active,MW=728.8 > 500.0; LogP=6.16 > 5.0
0994c96a,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccncc3)c3ccc(O)cc3)c(C)n2C)c1,,,raw,,586.6920000000001,586.258005568,6.6752200000000075,87.9,1,6,6,6,5,0.19444444444444445,44,0.24001617373654963,False,2,True,0,,CHEMBL3701304,4.9,nM,=,8.31,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3098,1,active,MW=586.7 > 500.0; LogP=6.68 > 5.0
95da5c31,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C,,,raw,,702.8119999999998,702.316583064,5.088620000000007,114.53,1,10,7,8,5,0.325,52,0.24978297321409104,False,2,True,0,,CHEMBL3701305,4.7,nM,=,8.33,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3279,1,active,MW=702.8 > 500.0; LogP=5.09 > 5.0
d1ebe338,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C,,,raw,,698.8199999999998,698.3104350640002,6.35512000000001,96.71000000000001,1,8,7,8,5,0.2857142857142857,52,0.2116139788299108,False,2,True,0,,CHEMBL3701306,6.6,nM,=,8.18,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1805,1,active,MW=698.8 > 500.0; LogP=6.36 > 5.0
a250eb49,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCO,,,raw,,633.7050000000002,633.25873384,5.189120000000007,122.29,2,9,7,7,5,0.25,47,0.2530729147854735,False,2,True,0,,CHEMBL3701307,3.6,nM,=,8.44,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4437,1,active,MW=633.7 > 500.0; LogP=5.19 > 5.0
04ef4012,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1,,,raw,,674.8020000000001,674.3216684439999,5.326020000000006,105.30000000000001,1,9,8,7,5,0.3076923076923077,50,0.2375126504698152,False,2,True,0,,CHEMBL3701308,6.2,nM,=,8.21,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2076,1,active,MW=674.8 > 500.0; LogP=5.33 > 5.0
912ed6aa,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,679.2209999999997,678.2721314079998,5.970820000000008,96.07,1,8,7,7,5,0.2894736842105263,49,0.22799902297813582,False,2,True,0,,CHEMBL3701309,3.45,nM,=,8.4,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,4,8.4622,1,active,MW=679.2 > 500.0; LogP=5.97 > 5.0
c1eddf9a,,CNCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,raw,,646.7480000000002,646.2903683159999,5.416220000000006,114.09,2,9,8,7,5,0.2702702702702703,48,0.23165592333381235,False,2,True,0,,CHEMBL3701310,4.1,nM,=,8.39,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3872,1,active,MW=646.7 > 500.0; LogP=5.42 > 5.0
32bb0ea9,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C,,,raw,,660.775,660.30601838,5.758420000000006,105.3,1,9,8,7,5,0.2894736842105263,49,0.22581392296307237,False,2,True,0,,CHEMBL3701311,5.2,nM,=,8.28,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.284,1,active,MW=660.8 > 500.0; LogP=5.76 > 5.0
1e2588ca,,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,591.111,590.2084685319999,7.320020000000008,78.66999999999999,1,5,5,6,5,0.17142857142857143,43,0.23255564949712265,False,2,True,0,,CHEMBL3701312,7.5,nM,=,8.12,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1249,1,active,MW=591.1 > 500.0; LogP=7.32 > 5.0
70fc4dcb,,CC1=C(C(=O)N(c2ccccc2)c2ccc(O)cc2)CC(c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2COCCN2CCOCC2)N1C,,,raw,,721.2979999999997,720.30784822,6.977000000000009,85.79,1,7,10,7,4,0.3333333333333333,52,0.17717186105986582,False,2,True,0,,CHEMBL3701313,6.6,nM,=,8.18,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1805,1,active,MW=721.3 > 500.0; LogP=6.98 > 5.0
f8195633,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN,,,raw,,632.721,632.274718252,5.1555200000000045,128.08,2,9,7,7,5,0.25,47,0.25390042885635516,False,2,True,0,,CHEMBL3701314,4.7,nM,=,8.33,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3279,1,active,MW=632.7 > 500.0; LogP=5.16 > 5.0
22921336,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1,,,raw,,589.6960000000001,589.2689045999999,6.013720000000008,92.83000000000001,1,7,6,6,5,0.22857142857142856,44,0.2618061185447185,False,2,True,0,,CHEMBL3701315,7.2,nM,=,8.14,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1427,1,active,MW=589.7 > 500.0; LogP=6.01 > 5.0
350107f0,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)Oc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,642.7560000000002,642.284220316,6.858320000000009,104.11000000000001,2,6,7,6,5,0.20512820512820512,48,0.20200014376194766,False,2,True,0,,CHEMBL3701316,13.3,nM,=,7.88,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8761,1,active,MW=642.8 > 500.0; LogP=6.86 > 5.0
b2bd2d3b,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,693.2189999999997,692.256561596,7.37642000000001,78.25,1,6,7,7,5,0.25,50,0.1927550007340277,False,2,True,0,,CHEMBL3701317,10.9,nM,=,7.96,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.9626,1,active,MW=693.2 > 500.0; LogP=7.38 > 5.0
050dccc3,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,693.2189999999997,692.256561596,7.37642000000001,78.25,1,6,7,7,5,0.25,50,0.1927550007340277,False,2,True,0,,CHEMBL3701318,8.2,nM,=,8.09,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0862,1,active,MW=693.2 > 500.0; LogP=7.38 > 5.0
758ce746,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,656.7830000000001,656.2998703799999,6.264920000000006,104.11000000000001,2,6,9,6,5,0.225,49,0.19490508655610772,False,2,True,0,,CHEMBL3701319,50.0,nM,=,7.3,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.301,1,active,MW=656.8 > 500.0; LogP=6.26 > 5.0
31326c48,,CCNC(=O)NCc1ccc(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2C)c1,,,raw,,593.7280000000002,593.3002047279999,5.388820000000005,106.90999999999998,3,5,7,5,4,0.2857142857142857,44,0.2672136443545913,False,2,True,0,,CHEMBL3701320,71.4,nM,=,7.15,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.1463,1,active,MW=593.7 > 500.0; LogP=5.39 > 5.0
0db0ac4a,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)NCc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,655.7990000000001,655.315854792,6.569120000000007,106.91,3,5,8,6,5,0.225,49,0.17588869959199452,False,2,True,0,,CHEMBL3701321,60.4,nM,=,7.22,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.219,1,active,MW=655.8 > 500.0; LogP=6.57 > 5.0
9eee23b8,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1C,,,raw,,606.1220000000001,605.208134184,6.89742000000001,86.01000000000002,2,5,6,6,5,0.16666666666666666,44,0.2205016828981256,False,2,True,0,,CHEMBL3701322,7.5,nM,=,8.12,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1249,1,active,MW=606.1 > 500.0; LogP=6.90 > 5.0
b8fa60b7,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,raw,,603.6790000000002,603.248169156,5.733820000000007,102.06,1,8,5,7,5,0.22857142857142856,45,0.2752703734394036,False,2,True,0,,CHEMBL3701323,7.2,nM,=,8.14,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1427,1,active,MW=603.7 > 500.0; LogP=5.73 > 5.0
58da311b,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)Oc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,642.7560000000001,642.284220316,6.858320000000008,104.11000000000001,2,6,7,6,5,0.20512820512820512,48,0.20200014376194766,False,2,True,0,,CHEMBL3701324,64.4,nM,=,7.19,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.1911,1,active,MW=642.8 > 500.0; LogP=6.86 > 5.0
652cb175,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,raw,,617.6770000000001,617.232599344,7.139420000000008,84.24000000000001,1,6,5,7,5,0.1891891891891892,46,0.2267491596067675,False,2,True,0,,CHEMBL3701325,10.0,nM,=,8.0,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0,1,active,MW=617.7 > 500.0; LogP=7.14 > 5.0
64b9b9ba,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,raw,,653.7390000000001,653.2638192200001,6.887020000000007,102.06,1,8,5,8,6,0.20512820512820512,49,0.2176118250893155,False,2,True,0,,CHEMBL3701326,5.2,nM,=,8.28,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.284,1,active,MW=653.7 > 500.0; LogP=6.89 > 5.0
ee2fe40f,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,raw,,599.6870000000002,599.2420211560001,7.000320000000009,84.24000000000001,1,6,5,7,5,0.1891891891891892,45,0.23524191988960327,False,2,True,0,,CHEMBL3701327,5.1,nM,=,8.29,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2924,1,active,MW=599.7 > 500.0; LogP=7.00 > 5.0
5b2aa564,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,738.8449999999998,738.3165830640002,6.199320000000008,114.53,1,10,7,9,6,0.27906976744186046,55,0.20618788091259416,False,2,True,0,,CHEMBL3701328,3.0,nM,=,8.52,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5229,1,active,MW=738.8 > 500.0; LogP=6.20 > 5.0
0a73e735,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCN(C(=O)O)c3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,656.7830000000001,656.2998703799999,7.296820000000009,106.32,2,5,8,6,5,0.225,49,0.18244085587569894,False,2,True,0,,CHEMBL3701329,38.9,nM,=,7.41,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.4101,1,active,MW=656.8 > 500.0; LogP=7.30 > 5.0
7bf045c6,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,670.8100000000001,670.315520444,6.307420000000007,104.11000000000001,2,6,10,6,5,0.24390243902439024,50,0.18144501949433636,False,2,True,0,,CHEMBL3701330,76.6,nM,=,7.12,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.1158,1,active,MW=670.8 > 500.0; LogP=6.31 > 5.0
800fb160,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,688.7849999999999,688.300933,5.046120000000006,114.53,1,10,7,8,5,0.3076923076923077,51,0.2530498709280599,False,2,True,0,,CHEMBL3701331,5.9,nM,=,8.23,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2291,1,active,MW=688.8 > 500.0; LogP=5.05 > 5.0
c0cd9347,,COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3C)OCO4)n(C)c2C)c2ccc(O)cc2)cn1,,,raw,,631.6890000000003,631.2430837759999,5.798920000000007,119.25,1,9,6,7,5,0.2222222222222222,47,0.24992445331154622,False,2,True,0,,CHEMBL3701332,4.4,nM,=,8.36,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3565,1,active,MW=631.7 > 500.0; LogP=5.80 > 5.0
fffca44a,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,740.8609999999999,740.3322331280001,5.699920000000007,112.84,1,10,7,9,5,0.32558139534883723,55,0.22475348303761475,False,2,True,0,,CHEMBL3701333,4.0,nM,=,8.4,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3979,1,active,MW=740.9 > 500.0; LogP=5.70 > 5.0
b456ba1e,,COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cn1,,,raw,,716.7950000000002,716.2958476199999,5.111220000000006,131.72000000000003,1,11,8,8,5,0.3,53,0.2312212402120572,False,3,True,0,,CHEMBL3701334,5.9,nM,=,8.23,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2291,1,active,MW=716.8 > 500.0; LogP=5.11 > 5.0; HBA=11 > 10
67af1b75,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,655.7990000000001,655.315854792,6.569120000000007,106.91,3,5,8,6,5,0.225,49,0.17588869959199452,False,2,True,0,,CHEMBL3701335,26.7,nM,=,7.57,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.5735,1,active,MW=655.8 > 500.0; LogP=6.57 > 5.0
e7bec48a,,CCNC(=O)NCc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c1,,,raw,,593.7280000000002,593.3002047279999,5.388820000000006,106.91,3,5,7,5,4,0.2857142857142857,44,0.2672136443545912,False,2,True,0,,CHEMBL3701336,28.9,nM,=,7.54,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.5391,1,active,MW=593.7 > 500.0; LogP=5.39 > 5.0
f1e7f619,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,656.7830000000001,656.2998703799999,6.264920000000006,104.11000000000001,2,6,9,6,5,0.225,49,0.19490508655610772,False,2,True,0,,CHEMBL3701337,43.5,nM,=,7.36,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.3615,1,active,MW=656.8 > 500.0; LogP=6.26 > 5.0
4d0ce0de,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,772.906,772.337318508,7.853520000000009,121.93,2,8,10,8,7,0.19148936170212766,58,0.14614843188728713,False,2,True,0,,CHEMBL3701338,18.0,nM,=,7.75,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7447,1,active,MW=772.9 > 500.0; LogP=7.85 > 5.0
f3cf9125,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNS(=O)(=O)CCc3ccc(F)cc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,722.8829999999999,722.2938196959999,6.413420000000007,111.94999999999999,2,6,11,6,5,0.2682926829268293,52,0.1637430203137979,False,2,True,0,,CHEMBL3701339,209.6,nM,=,6.68,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,6.6786,1,active,MW=722.9 > 500.0; LogP=6.41 > 5.0
0a058799,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,669.826,669.3315048559999,6.6116200000000065,106.91,3,5,9,6,5,0.24390243902439024,50,0.16424997962106053,False,2,True,0,,CHEMBL3701340,75.0,nM,=,7.12,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.1249,1,active,MW=669.8 > 500.0; LogP=6.61 > 5.0
cb37a664,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Cc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,654.8110000000001,654.320605824,6.471120000000006,94.88,2,5,9,6,5,0.24390243902439024,49,0.19056854593414163,False,2,True,0,,CHEMBL3701341,80.0,nM,=,7.1,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.0969,1,active,MW=654.8 > 500.0; LogP=6.47 > 5.0
636ec9ee,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,655.7990000000001,655.315854792,6.933920000000007,106.91,3,5,8,6,5,0.225,49,0.16852832601442486,False,2,True,0,,CHEMBL3701342,133.3,nM,=,6.88,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,6.8752,1,active,MW=655.8 > 500.0; LogP=6.93 > 5.0
e5b88759,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNS(=O)(=O)CCc3ccc(F)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,708.856,708.278169632,6.370920000000006,111.94999999999999,2,6,10,6,5,0.25,51,0.1752643634759733,False,2,True,0,,CHEMBL3701343,134.0,nM,=,6.87,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,6.8729,1,active,MW=708.9 > 500.0; LogP=6.37 > 5.0
91da1e96,,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,raw,,600.6750000000002,600.237270124,6.395320000000006,97.13,1,7,5,7,5,0.19444444444444445,45,0.25101215762406404,False,2,True,0,,CHEMBL3701344,4.5,nM,=,8.35,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3468,1,active,MW=600.7 > 500.0; LogP=6.40 > 5.0
b3593562,,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)cc1F,,,raw,,607.6860000000001,607.2594827880001,6.152820000000007,92.83000000000001,1,7,6,6,5,0.22857142857142856,45,0.24996742858530502,False,2,True,0,,CHEMBL3701345,14.3,nM,=,7.84,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8447,1,active,MW=607.7 > 500.0; LogP=6.15 > 5.0
0cfd45da,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,644.1750000000001,643.235017628,7.811720000000009,83.6,1,6,5,7,6,0.18421052631578946,47,0.20769867626464378,False,2,True,0,,CHEMBL3701346,5.1,nM,=,8.29,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2924,1,active,MW=644.2 > 500.0; LogP=7.81 > 5.0
d0cff406,,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,722.8459999999998,722.321668444,6.4937200000000095,94.30000000000001,0,9,7,9,6,0.27906976744186046,54,0.18601198468759392,False,2,True,0,,CHEMBL3701347,21.9,nM,=,7.66,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6596,1,active,MW=722.8 > 500.0; LogP=6.49 > 5.0
c0d9d14c,,Cc1ccc(OC(=O)NCc2ccc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)c(C(=O)N3Cc4ccccc4C[C@H]3C)c2)cc1,,,raw,,656.7830000000002,656.29987038,7.166740000000008,104.11,2,6,7,6,5,0.225,49,0.19345625682556905,False,2,True,0,,CHEMBL3701348,16.9,nM,=,7.77,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7721,1,active,MW=656.8 > 500.0; LogP=7.17 > 5.0
3211551b,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,662.7659999999997,662.3016819479999,5.4565200000000065,96.07,1,8,7,7,5,0.2894736842105263,49,0.24901122231054892,False,2,True,0,,CHEMBL3701349,9.3,nM,=,7.9,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,4,8.0315,1,active,MW=662.8 > 500.0; LogP=5.46 > 5.0
ee1580ba,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,593.6590000000001,593.243832724,5.8498200000000065,103.82999999999998,2,7,5,6,5,0.20588235294117646,44,0.26619586512478316,False,2,True,0,,CHEMBL3701350,2.1,nM,=,8.68,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.6778,1,active,MW=593.7 > 500.0; LogP=5.85 > 5.0
c17b061f,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C,,,raw,,751.8879999999997,751.3482175400001,6.114520000000008,108.53999999999999,1,10,7,9,6,0.29545454545454547,56,0.20829824632081345,False,2,True,0,,CHEMBL3701351,5.3,nM,=,8.28,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2757,1,active,MW=751.9 > 500.0; LogP=6.11 > 5.0
d5cc2e7a,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,729.2809999999997,728.287781472,7.12402000000001,96.07,1,8,7,8,6,0.2619047619047619,53,0.18816706152339313,False,2,True,0,,CHEMBL3701352,6.1,nM,=,8.21,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2147,1,active,MW=729.3 > 500.0; LogP=7.12 > 5.0
e63f01cb,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(CN3CCOCC3)n1C)OCO2,,,raw,,688.7849999999997,688.3009330000001,5.257600000000005,114.53000000000003,1,10,7,8,5,0.3076923076923077,51,0.2466231259373752,False,2,True,0,,CHEMBL3701353,19.5,nM,=,7.71,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.71,1,active,MW=688.8 > 500.0; LogP=5.26 > 5.0
de28d60f,,CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,raw,,702.8120000000002,702.3165830639999,5.529020000000005,114.53,1,10,8,8,5,0.325,52,0.22477795350152577,False,2,True,0,,CHEMBL3701354,8.4,nM,=,8.08,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0757,1,active,MW=702.8 > 500.0; LogP=5.53 > 5.0
99ceb2a6,,COCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,raw,,732.8380000000002,732.3271477479999,5.155520000000005,123.75999999999999,1,11,10,8,5,0.34146341463414637,54,0.20767010981826373,False,3,True,0,,CHEMBL3701355,19.7,nM,=,7.71,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7055,1,active,MW=732.8 > 500.0; LogP=5.16 > 5.0; HBA=11 > 10
43ac618b,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CCF,,,raw,,720.8019999999998,720.307161252,5.478620000000007,114.53,1,10,9,8,5,0.325,53,0.21322076352402988,False,2,True,0,,CHEMBL3701356,8.6,nM,=,8.07,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0655,1,active,MW=720.8 > 500.0; LogP=5.48 > 5.0
6f72ef3e,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CC(F)F,,,raw,,738.7919999999999,738.29773944,5.774220000000008,114.53,1,10,9,8,5,0.325,54,0.20285717368778905,False,2,True,0,,CHEMBL3701357,7.0,nM,=,8.15,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1549,1,active,MW=738.8 > 500.0; LogP=5.77 > 5.0
e9c7e449,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1,,,raw,,702.8119999999998,702.316583064,5.529020000000006,114.53,1,10,8,8,5,0.325,52,0.22477795350152566,False,2,True,0,,CHEMBL3701358,13.5,nM,=,7.87,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8697,1,active,MW=702.8 > 500.0; LogP=5.53 > 5.0
861856a8,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1,,,raw,,698.8199999999998,698.3104350640001,6.7955200000000096,96.71000000000001,1,8,8,8,5,0.2857142857142857,52,0.19063698941975576,False,2,True,0,,CHEMBL3701359,19.0,nM,=,7.72,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7212,1,active,MW=698.8 > 500.0; LogP=6.80 > 5.0
c16c5196,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C,,,raw,,656.783,656.29987038,7.02492000000001,87.48,1,7,8,7,5,0.25,49,0.19318735347721439,False,2,True,0,,CHEMBL3701360,7.6,nM,=,8.12,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1192,1,active,MW=656.8 > 500.0; LogP=7.02 > 5.0
94504ba4,,COCCN(C)CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,raw,,704.8280000000002,704.3322331279999,5.775020000000007,114.53,1,10,11,7,5,0.325,52,0.18437133499845776,False,2,True,0,,CHEMBL3701361,6.4,nM,=,8.19,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1938,1,active,MW=704.8 > 500.0; LogP=5.78 > 5.0
588aae5a,,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2[nH]c(C)c(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c2C)cc1F,,,raw,,692.7920000000003,692.3122466319999,5.763140000000007,116.16,2,8,8,7,5,0.3076923076923077,51,0.21249350954506022,False,2,True,0,,CHEMBL3701362,22.9,nM,=,7.64,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6402,1,active,MW=692.8 > 500.0; LogP=5.76 > 5.0
800e0c8c,,COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F,,,raw,,692.7919999999998,692.3122466320001,5.465120000000005,105.3,1,9,8,7,5,0.3076923076923077,51,0.23028957411066167,False,2,True,0,,CHEMBL3701363,21.1,nM,=,7.68,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6757,1,active,MW=692.8 > 500.0; LogP=5.47 > 5.0
d01e25b1,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)n1C,,,raw,,742.3239999999996,741.3194159479999,7.039220000000011,90.07999999999998,1,8,7,8,6,0.27906976744186046,54,0.18899875814873698,False,2,True,0,,CHEMBL3701364,2.0,nM,=,8.7,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.699,1,active,MW=742.3 > 500.0; LogP=7.04 > 5.0
72348c8e,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,703.2429999999997,702.2721314079998,6.447500000000009,106.97,1,8,7,7,5,0.275,51,0.20912895499728082,False,2,True,0,,CHEMBL3701365,3.15,nM,=,8.41,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,4,8.5017,1,active,MW=703.2 > 500.0; LogP=6.45 > 5.0
a7663629,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,701.2269999999997,700.256481344,6.504000000000009,114.93,1,8,7,7,5,0.25,51,0.2060994644116558,False,2,True,0,,CHEMBL3701366,91.5,nM,=,7.04,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.0386,1,active,MW=701.2 > 500.0; LogP=6.50 > 5.0
38c73963,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)ccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,701.2269999999997,700.256481344,6.504000000000008,114.93,1,8,7,7,5,0.25,51,0.2060994644116559,False,2,True,0,,CHEMBL3701367,8.5,nM,=,8.07,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0706,1,active,MW=701.2 > 500.0; LogP=6.50 > 5.0
b4e8ed3b,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@@H]3C2)n1C,,,raw,,734.3009999999995,733.3143305679998,5.6550200000000075,99.31,1,9,7,8,5,0.34146341463414637,53,0.2308584982702248,False,2,True,0,,CHEMBL3701368,3.6,nM,=,8.44,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4437,1,active,MW=734.3 > 500.0; LogP=5.66 > 5.0
492e2eb5,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@H]3C2)n1C,,,raw,,734.3009999999995,733.3143305679998,5.6550200000000075,99.31,1,9,7,8,5,0.34146341463414637,53,0.2308584982702248,False,2,True,0,,CHEMBL3701369,3.4,nM,=,8.47,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4685,1,active,MW=734.3 > 500.0; LogP=5.66 > 5.0
1ca5d26d,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,705.2589999999998,704.2877814719999,6.768720000000009,96.07,1,8,8,8,5,0.325,51,0.1917096035679597,False,2,True,0,,CHEMBL3701370,3.4,nM,=,8.47,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4685,1,active,MW=705.3 > 500.0; LogP=6.77 > 5.0
9deb5adf,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,721.2579999999998,720.282696092,6.005120000000008,105.29999999999998,1,9,8,8,5,0.325,52,0.2096406455702579,False,2,True,0,,CHEMBL3701371,4.2,nM,=,8.38,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3768,1,active,MW=721.3 > 500.0; LogP=6.01 > 5.0
de15b328,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,735.2849999999999,734.298346156,6.395220000000008,105.29999999999998,1,9,8,8,5,0.34146341463414637,53,0.19698723735440604,False,2,True,0,,CHEMBL3701372,5.3,nM,=,8.28,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2757,1,active,MW=735.3 > 500.0; LogP=6.40 > 5.0
337b39d3,,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,715.2979999999998,714.3085169159999,6.9190200000000095,74.15,0,7,7,8,5,0.30952380952380953,52,0.18240947631647475,False,2,True,0,,CHEMBL3701373,18.1,nM,=,7.74,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7423,1,active,MW=715.3 > 500.0; LogP=6.92 > 5.0
75b82ab5,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CC3(CCO3)C2)n1C,,,raw,,691.2319999999996,690.2721314079998,6.113320000000009,96.07,1,8,7,8,5,0.3076923076923077,50,0.22145533761675049,False,2,True,0,,CHEMBL3701374,4.6,nM,=,8.34,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3372,1,active,MW=691.2 > 500.0; LogP=6.11 > 5.0
12bab75f,,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(ccn4C)c3)c(C)n2C)cc1F,,,raw,,742.8520000000001,742.3278966959998,6.618320000000009,105.30000000000001,1,9,8,8,6,0.27906976744186046,55,0.1870945112974646,False,2,True,0,,CHEMBL3701375,7.4,nM,=,8.13,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1308,1,active,MW=742.9 > 500.0; LogP=6.62 > 5.0
59c6398b,,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(c3)CCN4C)c(C)n2C)cc1F,,,raw,,744.8679999999999,744.3435467599999,6.118920000000007,103.61000000000001,1,9,8,8,5,0.32558139534883723,55,0.2030051352482924,False,2,True,0,,CHEMBL3701376,8.8,nM,=,8.06,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0555,1,active,MW=744.9 > 500.0; LogP=6.12 > 5.0
011eb5ce,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,688.8039999999997,688.317332012,6.254420000000008,96.07,1,8,8,8,5,0.325,51,0.20711906047125822,False,2,True,0,,CHEMBL3701377,6.3,nM,=,8.2,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2007,1,active,MW=688.8 > 500.0; LogP=6.25 > 5.0
4817262b,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,686.7879999999998,686.3016819479999,5.933200000000007,106.97,1,8,7,7,5,0.275,51,0.22755237593298194,False,2,True,0,,CHEMBL3701378,5.1,nM,=,8.29,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2924,1,active,MW=686.8 > 500.0; LogP=5.93 > 5.0
6140e0da,,COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,784.9139999999999,784.358447876,5.580400000000007,122.07,1,11,10,9,5,0.35555555555555557,58,0.1922677160342821,False,3,True,0,,CHEMBL3701379,14.8,nM,=,7.83,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8297,1,active,MW=784.9 > 500.0; LogP=5.58 > 5.0; HBA=11 > 10
0e7f17fb,,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,659.7619999999997,659.290782916,6.1180200000000085,91.13999999999999,1,7,7,7,5,0.2564102564102564,49,0.22664275746990956,False,2,True,0,,CHEMBL3701380,9.7,nM,=,8.01,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0132,1,active,MW=659.8 > 500.0; LogP=6.12 > 5.0
f1dd5c89,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,712.8259999999998,712.3173320120001,6.609720000000009,96.07,1,8,7,8,6,0.2619047619047619,53,0.20034773866250097,False,2,True,0,,CHEMBL3701381,5.7,nM,=,8.24,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2441,1,active,MW=712.8 > 500.0; LogP=6.61 > 5.0
d03caeab,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,717.2700000000002,716.287781472,6.7559200000000095,106.97,1,8,7,7,5,0.2926829268292683,52,0.1997145244551173,False,2,True,0,,CHEMBL3701382,2.15,nM,=,8.59,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,6,8.6676,1,active,MW=717.3 > 500.0; LogP=6.76 > 5.0
01ff42a7,,CC(Nc1ncnc(N)c1C#N)c1cc(Cl)c2ccnnc2c1-c1cccc(F)c1,,,raw,,419.8510000000001,419.1061493800001,4.506280000000002,113.4,2,7,4,4,4,0.09523809523809523,30,0.4999170337491501,True,0,True,0,,CHEMBL3701383,20.6,nM,=,7.69,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6861,1,active,
a3e7cbd5,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,731.2969999999998,730.303431536,6.62462000000001,94.38,1,8,7,8,5,0.30952380952380953,53,0.2011969463805011,False,2,True,0,,CHEMBL3701384,3.6,nM,=,8.44,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4437,1,active,MW=731.3 > 500.0; LogP=6.62 > 5.0
7c5472c1,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc3ccn(C)c3cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,729.2809999999997,728.287781472,7.12402000000001,96.07,1,8,7,8,6,0.2619047619047619,53,0.18816706152339313,False,2,True,0,,CHEMBL3701385,14.7,nM,=,7.83,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8327,1,active,MW=729.3 > 500.0; LogP=7.12 > 5.0
f971d43d,,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,713.2819999999997,712.292866852,7.41842000000001,75.84,0,7,7,8,6,0.2619047619047619,52,0.17234777630057185,False,2,True,0,,CHEMBL3701386,21.2,nM,=,7.67,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6737,1,active,MW=713.3 > 500.0; LogP=7.42 > 5.0
64173f5b,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,729.2809999999997,728.287781472,7.12402000000001,96.07,1,8,7,8,6,0.2619047619047619,53,0.18816706152339313,False,2,True,0,,CHEMBL3640002,30.3,nM,=,7.52,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.5186,1,active,MW=729.3 > 500.0; LogP=7.12 > 5.0
aefe033f,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,raw,,703.2829999999996,702.2972835359999,8.017520000000012,78.25,1,6,9,7,5,0.2857142857142857,51,0.1684275561965745,False,2,True,0,,CHEMBL3701387,3.8,nM,=,8.42,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4202,1,active,MW=703.3 > 500.0; LogP=8.02 > 5.0
2a095599,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,raw,,757.3349999999996,756.3190816,7.90422000000001,96.07,1,8,9,8,6,0.29545454545454547,55,0.16126719517139854,False,2,True,0,,CHEMBL3701388,2.1,nM,=,8.68,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.6778,1,active,MW=757.3 > 500.0; LogP=7.90 > 5.0
50c4f1bd,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,raw,,759.3509999999997,758.334731664,7.404820000000011,94.38,1,8,9,8,5,0.3409090909090909,55,0.1675054041683621,False,2,True,0,,CHEMBL3701389,2.5,nM,=,8.6,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.6021,1,active,MW=759.4 > 500.0; LogP=7.40 > 5.0
1bfe2222,,COc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N,,,raw,,730.265,729.2717970599999,7.117600000000009,111.27000000000001,1,8,8,7,5,0.2619047619047619,53,0.1811911915215705,False,2,True,0,,CHEMBL3701390,3.5,nM,=,8.46,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4559,1,active,MW=730.3 > 500.0; LogP=7.12 > 5.0
f1c50110,,Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,raw,,706.7749999999997,706.291511188,5.1852200000000055,114.53,1,10,7,8,5,0.3076923076923077,52,0.24638276646351873,False,2,True,0,,CHEMBL3701391,15.7,nM,=,7.8,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8041,1,active,MW=706.8 > 500.0; LogP=5.19 > 5.0
8ba51a1c,,COc1ncc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,raw,,707.2310000000001,706.267046028,6.035920000000007,113.26000000000002,1,9,8,7,5,0.28205128205128205,51,0.20810375787617663,False,2,True,0,,CHEMBL3701392,4.5,nM,=,8.35,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3468,1,active,MW=707.2 > 500.0; LogP=6.04 > 5.0
56dd86f2,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,700.2389999999997,699.261232376,7.109000000000011,102.03999999999999,1,7,7,7,5,0.24390243902439024,51,0.19440484032789102,False,2,True,0,,CHEMBL3701393,3.9,nM,=,8.41,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4089,1,active,MW=700.2 > 500.0; LogP=7.11 > 5.0
5490c267,,Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,697.2109999999997,696.2627095959999,6.109920000000009,96.07,1,8,7,7,5,0.2894736842105263,50,0.22079199309368658,False,2,True,0,,CHEMBL3701394,9.9,nM,=,8.0,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0044,1,active,MW=697.2 > 500.0; LogP=6.11 > 5.0
d014172d,,COC(=O)c1ccnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1,,,raw,,734.253,733.26671168,6.418920000000008,117.43999999999998,1,9,8,7,5,0.2682926829268293,53,0.18182880888775463,False,2,True,0,,CHEMBL3701395,49.0,nM,=,7.31,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.3098,1,active,MW=734.3 > 500.0; LogP=6.42 > 5.0
ae158e2d,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,718.2289999999997,717.251810564,7.24810000000001,102.03999999999999,1,7,7,7,5,0.24390243902439024,52,0.19046455729272924,False,2,True,0,,CHEMBL3701396,8.0,nM,=,8.1,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0969,1,active,MW=718.2 > 500.0; LogP=7.25 > 5.0
2cb2fb37,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn([C@H]3CCOC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,718.8299999999998,718.3278966959999,5.880920000000008,105.29999999999998,1,9,8,8,5,0.34146341463414637,53,0.21381174452538443,False,2,True,0,,CHEMBL3701397,25.15,nM,=,7.58,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,4,7.5995,1,active,MW=718.8 > 500.0; LogP=5.88 > 5.0
2121cb9e,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccnc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,702.2149999999997,701.251730312,5.899000000000008,127.82,1,9,7,7,5,0.2564102564102564,51,0.22235405221145163,False,2,True,0,,CHEMBL3701398,24.4,nM,=,7.61,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6126,1,active,MW=702.2 > 500.0; LogP=5.90 > 5.0
2a7b2ce8,,Cc1c(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,682.8250000000003,682.3267538240001,6.102520000000006,106.97,1,8,7,7,5,0.2926829268292683,51,0.2224301461483389,False,2,True,0,,CHEMBL3701399,4.2,nM,=,8.38,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3768,1,active,MW=682.8 > 500.0; LogP=6.10 > 5.0
2e3c03ef,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)c(F)c3)c3cnn(C)c3)c(C)n2C)c1,,,raw,,692.7920000000001,692.3122466319999,5.465120000000006,105.30000000000001,1,9,8,7,5,0.3076923076923077,51,0.23028957411066164,False,2,True,0,,CHEMBL3701400,20.6,nM,=,7.69,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6861,1,active,MW=692.8 > 500.0; LogP=5.47 > 5.0
14d839a4,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c1,,,raw,,712.851,712.3373185079998,6.111120000000008,116.20000000000002,1,9,8,7,5,0.30952380952380953,53,0.20649468485506156,False,2,True,0,,CHEMBL3701401,5.4,nM,=,8.27,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2676,1,active,MW=712.9 > 500.0; LogP=6.11 > 5.0
0545c2c9,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,694.8359999999998,694.3267538240001,6.470620000000009,96.07,1,8,7,8,6,0.2619047619047619,52,0.20597117765285566,False,2,True,0,,CHEMBL3701402,12.2,nM,=,7.91,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.9136,1,active,MW=694.8 > 500.0; LogP=6.47 > 5.0
4c8dd576,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,696.8519999999999,696.342403888,5.971220000000008,94.38,1,8,7,8,5,0.30952380952380953,52,0.2242340577979144,False,2,True,0,,CHEMBL3701403,9.9,nM,=,8.0,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0044,1,active,MW=696.9 > 500.0; LogP=5.97 > 5.0
e560871e,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1CCN1CCOCC1,,,raw,,693.2479999999996,692.2877814719999,6.453720000000009,96.07,1,8,8,7,5,0.3076923076923077,50,0.20084710544541856,False,2,True,0,,CHEMBL3701404,5.5,nM,=,8.26,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2596,1,active,MW=693.2 > 500.0; LogP=6.45 > 5.0
d6fc263a,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,745.3240000000001,744.3190816,7.53612000000001,106.97,1,8,9,7,5,0.32558139534883723,54,0.16730031989283373,False,2,True,0,,CHEMBL3701405,3.1,nM,=,8.51,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5086,1,active,MW=745.3 > 500.0; LogP=7.54 > 5.0
06dc5e71,,Cc1c(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCCO4)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,740.8610000000001,740.3322331279999,5.873720000000008,125.43000000000004,1,10,7,8,5,0.32558139534883723,55,0.21976489109272654,False,2,True,0,,CHEMBL3701406,3.1,nM,=,8.51,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5086,1,active,MW=740.9 > 500.0; LogP=5.87 > 5.0
d19bfe50,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,703.2430000000003,702.272131408,6.44750000000001,106.97,1,8,7,7,5,0.275,51,0.20912895499728082,False,2,True,0,,CHEMBL3701407,3.8,nM,=,8.42,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4202,1,active,MW=703.2 > 500.0; LogP=6.45 > 5.0
17d772f5,,COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1,,,raw,,712.851,712.3373185080001,6.111120000000007,116.2,1,9,8,7,5,0.30952380952380953,53,0.20649468485506156,False,2,True,0,,CHEMBL3701408,3.0,nM,=,8.52,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5229,1,active,MW=712.9 > 500.0; LogP=6.11 > 5.0
f3679ecc,,COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1,,,raw,,674.8019999999999,674.3216684440001,5.326020000000004,105.3,1,9,8,7,5,0.3076923076923077,50,0.23751265046981526,False,2,True,0,,CHEMBL3701409,10.1,nM,=,8.0,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.9957,1,active,MW=674.8 > 500.0; LogP=5.33 > 5.0
86e9b44d,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,683.7839999999998,683.290782916,6.594700000000009,102.03999999999999,1,7,7,7,5,0.24390243902439024,51,0.2077230056039364,False,2,True,0,,CHEMBL3701410,2.8,nM,=,8.55,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5528,1,active,MW=683.8 > 500.0; LogP=6.59 > 5.0
a0fa32ce,,Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,700.8150000000002,700.3173320120001,6.241620000000007,106.97,1,8,7,7,5,0.2926829268292683,52,0.2155732741428259,False,2,True,0,,CHEMBL3701411,2.5,nM,=,8.6,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.6021,1,active,MW=700.8 > 500.0; LogP=6.24 > 5.0
a6797f03,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,644.7759999999998,644.3111037599999,5.3174200000000065,96.07,1,8,7,7,5,0.2894736842105263,48,0.25794424086129436,False,2,True,0,,CHEMBL3701412,9.2,nM,=,8.04,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0362,1,active,MW=644.8 > 500.0; LogP=5.32 > 5.0
bb84dd92,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,704.8029999999998,704.312246632,5.490820000000007,105.29999999999998,1,9,8,8,5,0.325,52,0.22793384458271762,False,2,True,0,,CHEMBL3701413,11.7,nM,=,7.93,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.9318,1,active,MW=704.8 > 500.0; LogP=5.49 > 5.0
fb2f94b3,,COc1ncc(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,raw,,672.7860000000003,672.30601838,5.382520000000007,113.26000000000002,1,9,8,7,5,0.28205128205128205,50,0.2339066382274301,False,2,True,0,,CHEMBL3701414,13.6,nM,=,7.87,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8665,1,active,MW=672.8 > 500.0; LogP=5.38 > 5.0
01a1db6a,,COc1cc(C#N)cc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1,,,raw,,713.8100000000001,713.3013476,6.603300000000009,111.27,1,8,8,7,5,0.2619047619047619,53,0.19295166963404944,False,2,True,0,,CHEMBL3701415,4.2,nM,=,8.38,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3768,1,active,MW=713.8 > 500.0; LogP=6.60 > 5.0
d7bb0c15,,COc1ncc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,raw,,690.7760000000002,690.2965965679999,5.521620000000006,113.26000000000002,1,9,8,7,5,0.28205128205128205,51,0.22664483923869647,False,2,True,0,,CHEMBL3704775,5.2,nM,=,8.28,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.284,1,active,MW=690.8 > 500.0; LogP=5.52 > 5.0
4c843980,,COc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N,,,raw,,713.8100000000002,713.3013476,6.603300000000008,111.27000000000001,1,8,8,7,5,0.2619047619047619,53,0.19295166963404944,False,2,True,0,,CHEMBL3704776,2.2,nM,=,8.66,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.6576,1,active,MW=713.8 > 500.0; LogP=6.60 > 5.0
3011a4c7,,Cc1c(N(C(=O)c2cc(-c3ccc(F)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,700.8150000000002,700.3173320120001,6.241620000000007,106.97,1,8,7,7,5,0.2926829268292683,52,0.2155732741428259,False,2,True,0,,CHEMBL3704777,3.5,nM,=,8.46,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4559,1,active,MW=700.8 > 500.0; LogP=6.24 > 5.0
54676525,,COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F,,,raw,,730.8409999999999,730.327896696,6.250220000000008,116.2,1,9,8,7,5,0.30952380952380953,54,0.2008033863576643,False,2,True,0,,CHEMBL3704778,3.1,nM,=,8.51,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5086,1,active,MW=730.8 > 500.0; LogP=6.25 > 5.0
7787d823,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3CC2C(F)(F)F)n1C,,,raw,,698.1450000000002,697.206752192,8.354120000000007,83.6,1,6,5,7,6,0.18421052631578946,50,0.19635963566985035,False,2,True,0,,CHEMBL3704779,19.9,nM,=,7.7,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7011,1,active,MW=698.1 > 500.0; LogP=8.35 > 5.0
b97ed2c0,,Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1,,,raw,,693.248,692.287781472,6.279240000000007,96.07000000000001,1,8,7,7,5,0.3076923076923077,50,0.21588070505167317,False,2,True,0,,CHEMBL3704780,3.0,nM,=,8.52,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5229,1,active,MW=693.2 > 500.0; LogP=6.28 > 5.0
3192028e,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C,,,raw,,693.2480000000003,692.287781472,6.279240000000009,96.07,1,8,7,7,5,0.3076923076923077,50,0.21588070505167317,False,2,True,0,,CHEMBL3704781,3.4,nM,=,8.47,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4685,1,active,MW=693.2 > 500.0; LogP=6.28 > 5.0
36ce0958,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,668.7979999999998,668.3111037599999,5.794100000000007,106.97,1,8,7,7,5,0.275,50,0.23532896671502357,False,2,True,0,,CHEMBL3704782,2.6,nM,=,8.59,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.585,1,active,MW=668.8 > 500.0; LogP=5.79 > 5.0
6d4f9d92,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,714.8419999999999,714.332982076,6.110320000000009,94.38,1,8,7,8,5,0.30952380952380953,53,0.21760949506447974,False,2,True,0,,CHEMBL3704783,3.5,nM,=,8.46,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4559,1,active,MW=714.8 > 500.0; LogP=6.11 > 5.0
9c23c3c3,,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)ccn3)c(C)n2C)cc1F,,,raw,,714.7980000000001,714.2965965679998,5.9983000000000075,124.16,1,9,8,7,5,0.2682926829268293,53,0.2078176044020364,False,2,True,0,,CHEMBL3704784,14.9,nM,=,7.83,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8268,1,active,MW=714.8 > 500.0; LogP=6.00 > 5.0
06cb81c3,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(C#N)s2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,706.2679999999997,705.217653312,7.17050000000001,102.03999999999999,1,8,7,7,5,0.2564102564102564,50,0.19275510046239797,False,2,True,0,,CHEMBL3704785,49.1,nM,=,7.31,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.3089,1,active,MW=706.3 > 500.0; LogP=7.17 > 5.0
f5e13f5a,,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,701.7739999999998,701.2813611040001,6.7338000000000084,102.03999999999999,1,7,7,7,5,0.24390243902439024,52,0.2020042515212577,False,2,True,0,,CHEMBL3704786,4.4,nM,=,8.36,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.3565,1,active,MW=701.8 > 500.0; LogP=6.73 > 5.0
70a2027a,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,677.2049999999997,676.2564813439999,6.0273200000000084,104.03,1,8,7,7,5,0.2631578947368421,49,0.2246701586336658,False,2,True,0,,CHEMBL3704787,11.3,nM,=,7.95,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.9469,1,active,MW=677.2 > 500.0; LogP=6.03 > 5.0
f588219d,,COc1ncc(N(C(=O)c2cc(-c3cc(F)c(OC)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,raw,,720.802,720.307161252,5.530220000000006,122.48999999999998,1,10,9,7,5,0.3,53,0.20958035875114298,False,2,True,0,,CHEMBL3704788,6.1,nM,=,8.21,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2147,1,active,MW=720.8 > 500.0; LogP=5.53 > 5.0
dd1177b3,,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)cc1F,,,raw,,730.841,730.3278966959998,6.250220000000008,116.20000000000002,1,9,8,7,5,0.30952380952380953,54,0.2008033863576643,False,2,True,0,,CHEMBL3704789,2.6,nM,=,8.59,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.585,1,active,MW=730.8 > 500.0; LogP=6.25 > 5.0
13a44681,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C,,,raw,,701.2710000000002,700.292866852,7.050320000000009,86.74000000000001,0,7,7,7,5,0.2926829268292683,51,0.18172564811392863,False,2,True,0,,CHEMBL3704790,3.5,nM,=,8.46,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.4559,1,active,MW=701.3 > 500.0; LogP=7.05 > 5.0
e6cc83c1,,Cc1c(C(=O)N(c2ccc(O)cc2)c2csc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,706.2679999999997,705.217653312,7.170500000000011,102.03999999999999,1,8,7,7,5,0.2564102564102564,50,0.19275510046239797,False,2,True,0,,CHEMBL3704791,3.0,nM,=,8.52,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5229,1,active,MW=706.3 > 500.0; LogP=7.17 > 5.0
45082480,,COc1cnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,raw,,707.2310000000001,706.267046028,6.035920000000007,113.26000000000002,1,9,8,7,5,0.28205128205128205,51,0.20810375787617663,False,2,True,0,,CHEMBL3704792,5.5,nM,=,8.26,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.2596,1,active,MW=707.2 > 500.0; LogP=6.04 > 5.0
066eead5,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(F)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,695.1949999999997,694.247059532,6.1664200000000085,104.03,1,8,7,7,5,0.2631578947368421,50,0.2175369242322748,False,2,True,0,,CHEMBL3704793,7.8,nM,=,8.11,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1079,1,active,MW=695.2 > 500.0; LogP=6.17 > 5.0
53e3ad84,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)nn2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,704.2309999999998,703.267380376,5.842500000000007,119.85999999999999,1,9,7,7,5,0.28205128205128205,51,0.22619108282906722,False,2,True,0,,CHEMBL3704794,2.7,nM,=,8.57,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5686,1,active,MW=704.2 > 500.0; LogP=5.84 > 5.0
5a29502d,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,713.8139999999997,713.31258098,6.004720000000008,108.95999999999998,1,9,7,8,6,0.2682926829268293,53,0.21619950174017025,False,2,True,0,,CHEMBL3704795,2.9,nM,=,8.54,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5376,1,active,MW=713.8 > 500.0; LogP=6.00 > 5.0
0055d29f,,Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1,,,raw,,676.7930000000002,676.3173320120001,5.764940000000006,96.07000000000001,1,8,7,7,5,0.3076923076923077,50,0.23555457244517666,False,2,True,0,,CHEMBL3704796,8.3,nM,=,8.08,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.0809,1,active,MW=676.8 > 500.0; LogP=5.76 > 5.0
14c59b60,,Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C,,,raw,,676.7930000000002,676.3173320120001,5.764940000000006,96.07,1,8,7,7,5,0.3076923076923077,50,0.23555457244517666,False,2,True,0,,CHEMBL3704797,6.9,nM,=,8.16,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1612,1,active,MW=676.8 > 500.0; LogP=5.76 > 5.0
5cdd035c,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4CC3C(F)(F)F)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,raw,,686.134,685.206752192,7.986020000000008,94.5,1,6,5,6,5,0.21621621621621623,49,0.20300743627692078,False,2,True,0,,CHEMBL3704798,6.5,nM,=,8.19,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.1871,1,active,MW=686.1 > 500.0; LogP=7.99 > 5.0
f938d7e5,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(CCN3CCOCC3)c2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,731.297,730.3034315359998,7.238820000000009,106.97,1,8,8,7,5,0.30952380952380953,53,0.18054663477786118,False,2,True,0,,CHEMBL3704799,1.9,nM,=,8.72,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.7212,1,active,MW=731.3 > 500.0; LogP=7.24 > 5.0
da44a1ac,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(OCCN3CCOCC3)nc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,raw,,721.2579999999999,720.2826960919999,6.426020000000007,113.25999999999999,1,9,9,7,5,0.3,52,0.18561967244004138,False,2,True,0,,CHEMBL3704800,2.7,nM,=,8.57,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5686,1,active,MW=721.3 > 500.0; LogP=6.43 > 5.0
cea66523,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn(C)c1C#N,,,raw,,717.2700000000002,716.287781472,6.7559200000000095,106.97,1,8,7,7,5,0.2926829268292683,52,0.1997145244551173,False,2,True,0,,CHEMBL3704801,10.5,nM,=,7.98,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.9788,1,active,MW=717.3 > 500.0; LogP=6.76 > 5.0
66976ada,,CCn1c(C#N)cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1C,,,raw,,731.297,730.303431536,7.238820000000009,106.96999999999998,1,8,8,7,5,0.30952380952380953,53,0.18054663477786118,False,2,True,0,,CHEMBL3704802,2.5,nM,=,8.6,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.6021,1,active,MW=731.3 > 500.0; LogP=7.24 > 5.0
be5c838a,,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,raw,,763.3389999999997,762.329646284,7.17542000000001,105.29999999999998,1,9,10,8,5,0.37209302325581395,55,0.16090200559570828,False,2,True,0,,CHEMBL3704803,2.8,nM,=,8.55,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5528,1,active,MW=763.3 > 500.0; LogP=7.18 > 5.0
b4581a54,,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C,,,raw,,729.325,728.32416698,7.830520000000011,86.74000000000001,0,7,9,7,5,0.32558139534883723,53,0.15451897330946773,False,2,True,0,,CHEMBL3704804,3.1,nM,=,8.51,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,8.5086,1,active,MW=729.3 > 500.0; LogP=7.83 > 5.0
5f11c346,,Cc1cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)no1,,,raw,,680.2050000000003,679.2561469960001,6.53374000000001,104.28,1,8,7,7,5,0.2894736842105263,49,0.20854808782824708,False,2,True,0,,CHEMBL3704805,13.3,nM,=,7.88,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.8761,1,active,MW=680.2 > 500.0; LogP=6.53 > 5.0
7bbd2b99,,Cc1c(C(=O)N(c2cnc3c(ccn3C)c2)c2ccc(O)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,raw,,730.2689999999998,729.28303044,6.519020000000009,108.95999999999998,1,9,7,8,6,0.2682926829268293,53,0.19945583692744484,False,2,True,0,,CHEMBL3704806,36.6,nM,=,7.44,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.4365,1,active,MW=730.3 > 500.0; LogP=6.52 > 5.0
d462f3ff,,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2CCc3ccccc3C2)n1C,,,raw,,576.0960000000001,575.1975695,7.536520000000008,65.78,1,4,5,6,5,0.14285714285714285,42,0.23538967313958625,False,2,True,0,,CHEMBL3704807,19.2,nM,=,7.72,CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7167,1,active,MW=576.1 > 500.0; LogP=7.54 > 5.0
b11587aa,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)OCC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,639.1930000000002,638.2871127759998,5.377820000000007,114.20000000000002,1,8,14,4,3,0.47058823529411764,45,0.23596023617457698,False,2,True,0,,CHEMBL3948552,448.0,nM,=,6.29,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,6.3487,1,active,MW=639.2 > 500.0; LogP=5.38 > 5.0
e84a8a20,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,611.1390000000002,610.2558126479998,4.899320000000006,125.20000000000002,2,7,13,4,3,0.4375,43,0.2819489375374597,True,1,True,0,,CHEMBL3920752,142.91,nM,=,6.82,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,6.8449,1,active,MW=611.1 > 500.0
561b7c23,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)Nc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,686.253,685.3030971879999,6.453420000000008,117.0,2,7,14,5,4,0.3684210526315789,49,0.15757188776753445,False,2,True,0,,CHEMBL3929521,438.35,nM,=,6.34,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,6.3582,1,active,MW=686.3 > 500.0; LogP=6.45 > 5.0
6cab2415,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,604.7480000000003,604.3260851279999,4.724420000000006,114.2,1,8,14,4,3,0.47058823529411764,44,0.2648979404087228,True,1,True,0,,CHEMBL3926219,1019.56,nM,=,5.9,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,5.9916,0,inactive,MW=604.7 > 500.0
ef0d470d,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,576.6940000000002,576.2947849999999,4.245920000000004,125.2,2,7,13,4,3,0.4375,42,0.3117317224842915,True,1,True,0,,CHEMBL3927241,93.415,nM,=,6.99,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,7.0296,1,active,MW=576.7 > 500.0
830a7306,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,651.8080000000001,651.34206954,5.800020000000006,117.0,2,7,14,5,4,0.3684210526315789,48,0.17810583945107622,False,2,True,0,,CHEMBL3899211,1689.7949999999998,nM,=,5.68,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,5.7722,0,inactive,MW=651.8 > 500.0; LogP=5.80 > 5.0
a9928a9f,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,666.8190000000001,666.341735192,5.904720000000007,114.2,1,8,15,5,4,0.38461538461538464,49,0.15715942587352877,False,2,True,0,,CHEMBL3908169,1411.02,nM,=,5.81,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,5.8505,0,inactive,MW=666.8 > 500.0; LogP=5.90 > 5.0
a465c87a,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,669.798,669.332647728,5.939120000000006,117.0,2,7,14,5,4,0.3684210526315789,49,0.17178938197472515,False,2,True,0,,CHEMBL3932621,2329.92,nM,=,5.53,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,5.6327,0,inactive,MW=669.8 > 500.0; LogP=5.94 > 5.0
c96f3f97,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,553.1030000000003,552.250333344,5.141520000000006,98.9,2,6,10,4,3,0.43333333333333335,39,0.36263516796455275,False,2,True,0,,CHEMBL3895678,522.72,nM,=,6.21,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,6.2817,1,active,MW=553.1 > 500.0; LogP=5.14 > 5.0
1cf2ae45,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,567.1300000000002,566.2659834079999,5.444520000000007,87.9,1,6,11,4,3,0.45161290322580644,40,0.33359323801359675,False,2,True,0,,CHEMBL3923681,1210.735,nM,=,5.82,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,5.917,0,inactive,MW=567.1 > 500.0; LogP=5.44 > 5.0
bdc3ba1c,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,518.6580000000002,518.289305696,4.488120000000005,98.9,2,6,10,4,3,0.43333333333333335,38,0.41215257688815604,True,1,True,0,,CHEMBL3914781,262.67,nM,=,6.55,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,6.5806,1,active,MW=518.7 > 500.0
40478a43,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,532.6850000000003,532.30495576,4.791120000000006,87.9,1,6,11,4,3,0.45161290322580644,39,0.3836696381275955,True,1,True,0,,CHEMBL3918229,376.425,nM,=,6.33,CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",0.8,4,6.4243,1,active,MW=532.7 > 500.0
4931b194,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)c3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,657.8370000000001,657.2984904759999,5.583320000000006,124.83999999999999,2,7,13,5,4,0.3611111111111111,47,0.19343660655021036,False,2,True,0,,CHEMBL3909422,605.655,nM,=,6.16,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2178,1,active,MW=657.8 > 500.0; LogP=5.58 > 5.0
0211d6a4,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(C)(=O)=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,595.7660000000001,595.2828404119999,4.1540200000000045,124.83999999999999,2,7,12,4,3,0.45161290322580644,42,0.324166763220619,True,1,True,0,,CHEMBL3937363,335.955,nM,=,6.42,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.4737,1,active,MW=595.8 > 500.0
a84486bb,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)C(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,623.8200000000002,623.3141405399999,4.932620000000005,124.83999999999999,2,7,13,4,3,0.48484848484848486,44,0.27822412926474227,True,1,True,0,,CHEMBL3900418,108.5,nM,=,6.9,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.9646,1,active,MW=623.8 > 500.0
a45a6bcb,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc([S+]([O-])c4ccccc4)cs3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,772.0309999999998,771.2582825399999,7.145420000000011,136.82,2,9,15,6,5,0.325,53,0.1080158957919631,False,2,True,0,,CHEMBL3924890,737.395,nM,=,6.1,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.1323,1,active,MW=772.0 > 500.0; LogP=7.15 > 5.0
5bcb0404,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(C)=O)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,683.875,683.3141405399999,6.119820000000007,130.82999999999998,2,8,14,5,4,0.3684210526315789,49,0.12100738572233145,False,2,True,0,,CHEMBL3927159,510.745,nM,=,6.21,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2918,1,active,MW=683.9 > 500.0; LogP=6.12 > 5.0
76aff9fc,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc(Cl)cc3Br)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,761.2079999999997,759.1315365079998,7.3946200000000095,113.76,2,8,13,5,4,0.38235294117647056,47,0.137530789815966,False,2,True,0,,CHEMBL3902718,513.97,nM,=,6.25,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2891,1,active,MW=761.2 > 500.0; LogP=7.39 > 5.0
a55f07e7,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,799.6299999999998,797.124599992,7.4422200000000105,113.76,2,7,13,5,4,0.3611111111111111,48,0.13610251473204313,False,2,True,0,,CHEMBL3890069,555.935,nM,=,6.2,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.255,1,active,MW=799.6 > 500.0; LogP=7.44 > 5.0
dc8c0ca0,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(-c4ccccc4)noc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,722.9119999999999,722.3250395719999,6.8806400000000085,139.79000000000002,2,9,14,6,5,0.35,52,0.11835286667784405,False,2,True,0,,CHEMBL3959104,750.06,nM,=,6.08,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.1249,1,active,MW=722.9 > 500.0; LogP=6.88 > 5.0
ec1c9d75,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCN3C(=O)c4ccccc4C3=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,738.911,738.319954192,5.1543200000000065,151.14,2,9,15,6,4,0.375,53,0.12558803180275457,False,2,True,0,,CHEMBL3974550,274.635,nM,=,6.53,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.5612,1,active,MW=738.9 > 500.0; LogP=5.15 > 5.0
e60db926,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Oc4ccc(C)cc4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,747.9619999999999,747.3454406679999,8.01794000000001,122.99,2,8,15,6,5,0.32558139534883723,54,0.10408252987074874,False,2,True,0,,CHEMBL3945127,5746.96,nM,=,5.18,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.2406,0,inactive,MW=748.0 > 500.0; LogP=8.02 > 5.0
85f43274,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cc(Cl)cc(Cl)c4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,786.8259999999999,785.25693128,8.891020000000003,113.76,2,7,14,6,5,0.30952380952380953,54,0.10883109429051914,False,2,True,0,,CHEMBL3962530,5744.695,nM,=,5.14,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.2407,0,inactive,MW=786.8 > 500.0; LogP=8.89 > 5.0
e7508954,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,676.2829999999999,675.264603504,6.57062000000001,113.76,2,7,13,5,4,0.3611111111111111,47,0.15506809063403704,False,2,True,0,,CHEMBL3938600,636.585,nM,=,6.15,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.1961,1,active,MW=676.3 > 500.0; LogP=6.57 > 5.0
9fe2b48c,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)cc3CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,748.7879999999998,747.245388052,7.242120000000011,113.76,2,7,14,5,4,0.39473684210526316,49,0.13159796876838162,False,2,True,0,,CHEMBL3959636,2003.52,nM,=,5.66,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.6982,0,inactive,MW=748.8 > 500.0; LogP=7.24 > 5.0
971e0352,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cn(C)cn3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,645.8300000000002,645.3097238559999,4.650720000000005,131.57999999999998,2,9,13,5,4,0.4117647058823529,46,0.2024713175739124,True,1,True,0,,CHEMBL3890556,557.515,nM,=,6.19,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2537,1,active,MW=645.8 > 500.0
00920fab,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(Cl)ccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,694.2729999999999,693.255181692,6.70972000000001,113.76,2,7,13,5,4,0.3611111111111111,48,0.15061972075992136,False,2,True,0,,CHEMBL3967288,903.355,nM,=,6.02,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.0441,1,active,MW=694.3 > 500.0; LogP=6.71 > 5.0
6da51c92,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(=O)OC)o3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,689.8349999999999,689.2883197159998,5.2968200000000065,153.2,2,10,14,5,4,0.3888888888888889,49,0.13274363347790244,False,2,True,0,,CHEMBL3899521,520.675,nM,=,6.23,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2834,1,active,MW=689.8 > 500.0; LogP=5.30 > 5.0
e65fa132,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccn(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,721.9279999999999,721.3410239839999,6.317720000000007,131.57999999999998,2,9,14,6,5,0.35,52,0.1284578414446635,False,2,True,0,,CHEMBL3904990,806.11,nM,=,6.07,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.0936,1,active,MW=721.9 > 500.0; LogP=6.32 > 5.0
1bf97581,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4ccn(C)c34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,694.9019999999999,694.330124952,6.408920000000007,118.68999999999998,2,8,13,6,5,0.358974358974359,50,0.13767466911872211,False,2,True,0,,CHEMBL3917653,1204.98,nM,=,5.87,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.919,0,inactive,MW=694.9 > 500.0; LogP=6.41 > 5.0
8a9f6cbb,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,724.7549999999999,723.2412812159998,7.365120000000011,113.76,2,7,14,5,4,0.3783783783783784,49,0.13149346496565653,False,2,True,0,,CHEMBL3942106,1817.08,nM,=,5.78,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.7406,0,inactive,MW=724.8 > 500.0; LogP=7.37 > 5.0
399db0fd,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])N(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,608.8090000000001,608.314474888,4.334720000000004,117.0,2,8,13,4,3,0.46875,43,0.277509237191272,True,1,True,0,,CHEMBL3926618,2061.885,nM,=,5.62,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.6857,0,inactive,MW=608.8 > 500.0
277e26bf,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(C)nn(C)c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,673.884,673.3410239839999,5.267560000000007,131.57999999999998,2,9,13,5,4,0.4444444444444444,48,0.18505221056570526,False,2,True,0,,CHEMBL3890050,559.0550000000001,nM,=,6.19,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2525,1,active,MW=673.9 > 500.0; LogP=5.27 > 5.0
bc7c123c,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(NC(C)=O)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,733.3349999999998,732.28606722,6.529020000000008,142.86,3,8,14,5,4,0.3684210526315789,51,0.12522406320964924,False,2,True,0,,CHEMBL3977288,340.79,nM,=,6.37,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.4675,1,active,MW=733.3 > 500.0; LogP=6.53 > 5.0
b6f152b3,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Cl)c3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,710.728,709.2256311519999,7.22402000000001,113.76,2,7,13,5,4,0.3611111111111111,48,0.14176887868429577,False,2,True,0,,CHEMBL3948036,431.99,nM,=,6.31,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.3645,1,active,MW=710.7 > 500.0; LogP=7.22 > 5.0
a01b3e57,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,659.8280000000001,659.294154044,6.0563200000000075,113.76,2,7,13,5,4,0.3611111111111111,47,0.1689440311481314,False,2,True,0,,CHEMBL3985364,384.55,nM,=,6.34,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.415,1,active,MW=659.8 > 500.0; LogP=6.06 > 5.0
ba0cf8e9,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,699.8739999999999,699.3090551599998,5.7038200000000066,140.06,2,9,14,5,4,0.3684210526315789,50,0.12621327778136046,False,2,True,0,,CHEMBL3953351,379.275,nM,=,6.35,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.421,1,active,MW=699.9 > 500.0; LogP=5.70 > 5.0
66cd2c3c,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCc3cccc4ccccc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,719.9519999999999,719.3505260479999,7.2540200000000095,113.76,2,7,15,6,5,0.35714285714285715,52,0.11028312535588336,False,2,True,0,,CHEMBL3893085,619.22,nM,=,6.15,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2082,1,active,MW=720.0 > 500.0; LogP=7.25 > 5.0
adbd6b1b,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,815.4619999999999,814.2737882839999,7.562120000000011,142.86,3,9,16,6,5,0.3333333333333333,56,0.0873328605036721,False,2,True,0,,CHEMBL3962105,2509.645,nM,=,5.58,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.6004,0,inactive,MW=815.5 > 500.0; LogP=7.56 > 5.0
aedf6e19,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(F)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,751.9249999999998,751.320368792,7.848620000000011,122.99,2,8,15,6,5,0.30952380952380953,54,0.10455330027688131,False,2,True,0,,CHEMBL3902056,4472.775000000001,nM,=,5.27,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.3494,0,inactive,MW=751.9 > 500.0; LogP=7.85 > 5.0
5ecf30eb,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc4c(c3)OCCO4)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,699.874,699.3090551599998,5.688420000000007,132.22000000000003,2,9,13,6,4,0.39473684210526316,50,0.17035954687505186,False,2,True,0,,CHEMBL3976266,571.53,nM,=,6.2,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.243,1,active,MW=699.9 > 500.0; LogP=5.69 > 5.0
cc6c0495,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(-c4ccn(C)n4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,721.9279999999999,721.3410239839999,6.317720000000007,131.57999999999998,2,9,14,6,5,0.35,52,0.1284578414446635,False,2,True,0,,CHEMBL3912231,4429.26,nM,=,5.28,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,5.3537,0,inactive,MW=721.9 > 500.0; LogP=6.32 > 5.0
239f1971,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4noc(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,723.8999999999999,723.32028854,6.275640000000006,152.68,2,10,14,6,5,0.358974358974359,52,0.1262333259120289,False,2,True,0,,CHEMBL3982160,742.2950000000001,nM,=,6.07,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.1294,1,active,MW=723.9 > 500.0; LogP=6.28 > 5.0
f4a3a81d,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4nonc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,683.8349999999999,683.288988412,5.453420000000006,152.68,2,10,13,6,5,0.3611111111111111,49,0.15429825422395438,False,2,True,0,,CHEMBL3948609,264.46,nM,=,6.57,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.5776,1,active,MW=683.8 > 500.0; LogP=5.45 > 5.0
d51405c5,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc4ccc(F)cc4c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,729.9439999999998,729.2818751079999,7.579440000000011,113.76,2,8,13,6,5,0.358974358974359,51,0.12093365660384989,False,2,True,0,,CHEMBL3932360,955.18,nM,=,5.97,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.0199,1,active,MW=729.9 > 500.0; LogP=7.58 > 5.0
5f8f40ac,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(F)c(Br)cc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,756.7139999999998,755.1952442999999,6.95792000000001,113.76,2,7,13,5,4,0.3611111111111111,49,0.11279017416978429,False,2,True,0,,CHEMBL3972844,298.375,nM,=,6.57,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.5252,1,active,MW=756.7 > 500.0; LogP=6.96 > 5.0
99d1607e,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3scc(C(=O)OC)c3OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,735.929,735.2760407799998,5.773920000000007,149.29000000000002,2,11,15,5,4,0.40540540540540543,51,0.1146143605779103,False,3,True,0,,CHEMBL3900742,598.9449999999999,nM,=,6.2,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2226,1,active,MW=735.9 > 500.0; LogP=5.77 > 5.0; HBA=11 > 10
eff677d5,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(C#N)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,666.848,666.298824824,5.788900000000006,137.55,2,8,13,5,4,0.35135135135135137,48,0.1724417003266306,False,2,True,0,,CHEMBL3897154,617.405,nM,=,6.17,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2094,1,active,MW=666.8 > 500.0; LogP=5.79 > 5.0
8776da1e,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(N)ccc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,670.88,670.330124952,5.807840000000006,139.77999999999997,3,8,13,5,4,0.3783783783783784,48,0.12056312901025303,False,2,True,0,,CHEMBL3957281,595.5699999999999,nM,=,6.18,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2251,1,active,MW=670.9 > 500.0; LogP=5.81 > 5.0
881a6d0b,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3N)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,656.8530000000001,656.314474888,5.499420000000006,139.77999999999997,3,8,13,5,4,0.3611111111111111,47,0.1275875839714104,False,2,True,0,,CHEMBL3985961,262.535,nM,=,6.57,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.5808,1,active,MW=656.9 > 500.0; LogP=5.50 > 5.0
a9d19872,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])C[C@]34CC[C@H](CC3=O)C4(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,715.9610000000001,715.3767407959999,6.253520000000008,130.82999999999998,2,8,14,6,3,0.55,51,0.18875229479736474,False,2,True,0,,CHEMBL4111735,766.625,nM,=,6.09,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.1154,1,active,MW=716.0 > 500.0; LogP=6.25 > 5.0
de33f48c,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cnco4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,708.8849999999999,708.3093895079999,6.572220000000009,139.79000000000002,2,9,14,6,5,0.3333333333333333,51,0.12355761796226888,False,2,True,0,,CHEMBL3916294,703.36,nM,=,6.05,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.1528,1,active,MW=708.9 > 500.0; LogP=6.57 > 5.0
56e70711,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccsc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,705.9029999999999,705.2654760959998,5.765320000000006,140.06,2,10,14,5,4,0.3888888888888889,49,0.12466733921637228,False,2,True,0,,CHEMBL3946968,386.44,nM,=,6.32,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.4129,1,active,MW=705.9 > 500.0; LogP=5.77 > 5.0
b90186ca,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,655.8650000000001,655.31922592,6.058320000000006,113.76,2,7,14,5,4,0.3783783783783784,47,0.15984169941771992,False,2,True,0,,CHEMBL3950260,570.38,nM,=,6.18,CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,4,6.2438,1,active,MW=655.9 > 500.0; LogP=6.06 > 5.0
70af2dbb,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccccc4C)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,747.9619999999999,747.3454406679999,8.01794000000001,122.99,2,8,15,6,5,0.32558139534883723,54,0.10408252987074874,False,2,True,0,,CHEMBL3950403,3349.66,nM,=,5.47,CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",0.8,2,5.475,0,inactive,MW=748.0 > 500.0; LogP=8.02 > 5.0
474ebe56,,CN(C)C[C@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,1014.6549999999999,1013.29042444,8.594500000000007,148.58999999999997,3,12,18,7,5,0.3673469387755102,68,0.07226357176405412,False,3,True,0,,CHEMBL4108604,0.3,nM,=,9.52,CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",0.8,1,9.5229,1,active,MW=1014.7 > 500.0; LogP=8.59 > 5.0; HBA=12 > 10
3aaf7c3c,,CCNC[C@@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,1014.6549999999999,1013.29042444,8.642400000000006,157.38,4,12,19,7,5,0.3673469387755102,68,0.058528647932087466,False,3,True,0,,CHEMBL4111781,0.3,nM,=,9.52,CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",0.8,1,9.5229,1,active,MW=1014.7 > 500.0; LogP=8.64 > 5.0; HBA=12 > 10
84c07547,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)cccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,774.7709999999997,773.2205457719999,8.000320000000007,121.67999999999999,1,7,12,6,5,0.3,53,0.1372205023215632,False,2,True,0,,CHEMBL3928986,200.0,nM,=,6.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.699,1,active,MW=774.8 > 500.0; LogP=8.00 > 5.0
fb3e1360,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,774.7709999999997,773.2205457719999,8.000320000000007,121.67999999999999,1,7,12,6,5,0.3,53,0.1372205023215632,False,2,True,0,,CHEMBL3901024,30.0,nM,=,7.52,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.5229,1,active,MW=774.8 > 500.0; LogP=8.00 > 5.0
2be3163e,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(C#N)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,765.3359999999998,764.2547670919998,7.218600000000009,145.47,1,8,12,6,5,0.2926829268292683,54,0.14125613476699536,False,2,True,0,,CHEMBL3923567,920.0,nM,=,6.04,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.0362,1,active,MW=765.3 > 500.0; LogP=7.22 > 5.0
3358fd4c,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(Cl)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,774.7709999999997,773.2205457719999,8.000320000000007,121.67999999999999,1,7,12,6,5,0.3,53,0.1372205023215632,False,2,True,0,,CHEMBL3892056,90.0,nM,=,7.05,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.0458,1,active,MW=774.8 > 500.0; LogP=8.00 > 5.0
27cd16fe,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCc5ccccc5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,846.4499999999998,845.3013829359998,8.925920000000003,130.91000000000003,1,8,15,7,6,0.2765957446808511,60,0.10927500496854023,False,2,True,0,,CHEMBL3914542,10.0,nM,=,8.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0,1,active,MW=846.4 > 500.0; LogP=8.93 > 5.0
fb2008e5,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,798.4059999999997,797.3013829359998,8.13412000000001,130.91000000000003,1,8,14,6,5,0.3488372093023256,56,0.12010604406256029,False,2,True,0,,CHEMBL3984367,50.0,nM,=,7.3,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.301,1,active,MW=798.4 > 500.0; LogP=8.13 > 5.0
82923fe8,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(N(C)C)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,862.2909999999997,860.212229352,8.175420000000008,124.92,1,8,13,6,5,0.3333333333333333,56,0.12671409998677374,False,2,True,0,,CHEMBL3904423,30.0,nM,=,7.52,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.5229,1,active,MW=862.3 > 500.0; LogP=8.18 > 5.0
1bf3be6e,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,883.5119999999995,882.3541467799998,7.448020000000009,143.38000000000002,1,10,17,7,5,0.40425531914893614,62,0.09430376915990807,False,2,True,0,,CHEMBL3978452,290.0,nM,=,6.54,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.5376,1,active,MW=883.5 > 500.0; LogP=7.45 > 5.0
11c78d43,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCOCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,883.5119999999995,882.3541467799998,7.448020000000009,143.38000000000002,1,10,17,7,5,0.40425531914893614,62,0.09430376915990807,False,2,True,0,,CHEMBL3952199,290.0,nM,=,6.54,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.5376,1,active,MW=883.5 > 500.0; LogP=7.45 > 5.0
8e75f684,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,896.5549999999994,895.385781256,7.363220000000008,137.39000000000001,1,10,17,7,5,0.4166666666666667,63,0.0950062540528189,False,2,True,0,,CHEMBL3981017,510.0,nM,=,6.29,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.2924,1,active,MW=896.6 > 500.0; LogP=7.36 > 5.0
96752e42,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)CN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,841.4749999999997,840.343582096,7.67582000000001,134.15,1,9,16,6,5,0.37777777777777777,59,0.10706679098381201,False,2,True,0,,CHEMBL3957469,490.0,nM,=,6.31,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.3098,1,active,MW=841.5 > 500.0; LogP=7.68 > 5.0
27f40966,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(CNS(=O)(=O)c3ccc4ccc(OCCC5CCCN5C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,853.5299999999996,852.3799676039998,8.569820000000007,117.08,1,8,17,7,5,0.425531914893617,60,0.09969145389722783,False,2,True,0,,CHEMBL3891889,860.0,nM,=,6.07,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.0655,1,active,MW=853.5 > 500.0; LogP=8.57 > 5.0
2aa4421a,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,841.4749999999997,840.343582096,7.6774200000000095,134.15,1,9,17,6,5,0.37777777777777777,59,0.09437815861704148,False,2,True,0,,CHEMBL3968488,1460.0,nM,=,5.84,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,5.8356,0,inactive,MW=841.5 > 500.0; LogP=7.68 > 5.0
147426af,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,867.5129999999995,866.3592321599999,8.211620000000009,134.15,1,9,17,7,5,0.40425531914893614,61,0.09255178223527771,False,2,True,0,,CHEMBL3936837,3780.0,nM,=,5.42,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,5.4225,0,inactive,MW=867.5 > 500.0; LogP=8.21 > 5.0
7e73f273,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,853.6669999999996,851.1310578399998,8.762820000000003,121.67999999999999,1,7,12,6,5,0.3,54,0.13406902968087608,False,2,True,0,,CHEMBL3980078,3.93,nM,=,8.41,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.4056,1,active,MW=853.7 > 500.0; LogP=8.76 > 5.0
34f4e698,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,809.2159999999997,807.18157342,8.653720000000003,121.67999999999999,1,7,12,6,5,0.3,54,0.13476345021448577,False,2,True,0,,CHEMBL3893121,7.25,nM,=,8.14,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.1397,1,active,MW=809.2 > 500.0; LogP=8.65 > 5.0
31692cba,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,866.4849999999996,865.3388310639999,6.734520000000007,145.23,1,9,13,7,5,0.3695652173913043,61,0.13722831046423298,False,2,True,0,,CHEMBL3890787,90.0,nM,=,7.05,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.0458,1,active,MW=866.5 > 500.0; LogP=6.73 > 5.0
8ad2ce8d,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,811.4049999999997,810.2966319039999,7.048720000000008,141.99,1,8,13,6,5,0.32558139534883723,57,0.13442136604766733,False,2,True,0,,CHEMBL3918855,150.0,nM,=,6.82,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.8239,1,active,MW=811.4 > 500.0; LogP=7.05 > 5.0
45e6f5db,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)C3CCCCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,841.4749999999995,840.343582096,7.66312000000001,141.99,1,8,13,7,4,0.4444444444444444,59,0.14575568195250002,False,2,True,0,,CHEMBL3927598,250.0,nM,=,6.6,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.6021,1,active,MW=841.5 > 500.0; LogP=7.66 > 5.0
5e69c257,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,918.3439999999997,916.2343372639998,8.632320000000005,141.99,1,8,14,7,5,0.32608695652173914,62,0.11761428283438306,False,2,True,0,,CHEMBL3955216,200.0,nM,=,6.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.699,1,active,MW=918.3 > 500.0; LogP=8.63 > 5.0
6789d460,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CCSc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,867.5379999999998,866.3050884119999,8.348520000000008,124.92,1,9,16,7,5,0.34782608695652173,60,0.09826379209512476,False,2,True,0,,CHEMBL3948491,50.0,nM,=,7.3,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.301,1,active,MW=867.5 > 500.0; LogP=8.35 > 5.0
d04e0817,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,888.3179999999996,886.22377258,9.50352,126.61,1,8,14,7,6,0.28888888888888886,60,0.1162032233904919,False,2,True,0,,CHEMBL3893154,50.0,nM,=,7.3,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.301,1,active,MW=888.3 > 500.0; LogP=9.50 > 5.0
5aeaa375,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)N3CCOCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,844.4349999999995,843.3180956199999,6.008420000000006,154.46,1,9,12,7,4,0.4186046511627907,59,0.18211791012744122,False,2,True,0,,CHEMBL3912236,340.0,nM,=,6.47,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.4685,1,active,MW=844.4 > 500.0; LogP=6.01 > 5.0
6d8b1db3,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4CCCN4CCOCC4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,856.4899999999996,855.354481128,6.8707200000000075,139.08,1,10,16,7,5,0.4222222222222222,60,0.1135727938522377,False,2,True,0,,CHEMBL3917408,390.0,nM,=,6.41,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.4089,1,active,MW=856.5 > 500.0; LogP=6.87 > 5.0
718a09c4,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(Cl)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,791.8019999999997,790.2470948679999,7.82172000000001,126.61,1,8,13,6,5,0.35,54,0.1296822171449532,False,2,True,0,,CHEMBL3954188,20.0,nM,=,7.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.699,1,active,MW=791.8 > 500.0; LogP=7.82 > 5.0
76ca52c7,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(I)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,883.2529999999995,882.1827151879999,7.77292000000001,126.61,1,8,13,6,5,0.35,54,0.12057071566385133,False,2,True,0,,CHEMBL3947141,7.69,nM,=,8.11,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.1141,1,active,MW=883.3 > 500.0; LogP=7.77 > 5.0
617f8e65,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)c(Br)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,915.1489999999995,912.1070913559998,8.693320000000003,126.61,1,8,13,6,5,0.35,55,0.12607212077217853,False,2,True,0,,CHEMBL3962921,4.19,nM,=,8.38,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.3778,1,active,MW=915.1 > 500.0; LogP=8.69 > 5.0
4e594775,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@@H]2C(=O)O)c(C)c1Cl,,,raw,,784.3349999999999,783.249347364,6.800120000000007,158.98,2,8,13,6,5,0.2926829268292683,55,0.1320033000614324,False,2,True,0,,CHEMBL3893974,1650.0,nM,=,5.78,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,5.7825,0,inactive,MW=784.3 > 500.0; LogP=6.80 > 5.0
e8e380e4,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccc(C(=O)O)cc3C2)c(C)c1Cl,,,raw,,784.3349999999998,783.249347364,7.045120000000008,158.98,2,8,13,6,5,0.2926829268292683,55,0.12866951568244894,False,2,True,0,,CHEMBL3898017,4710.0,nM,=,5.33,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,5.327,0,inactive,MW=784.3 > 500.0; LogP=7.05 > 5.0
ccf14a2a,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3S(=O)(=O)C2)c(C)c1Cl,,,raw,,790.3639999999999,789.2057683,6.535620000000008,155.82,1,9,12,6,5,0.28205128205128205,54,0.14956705380477614,False,2,True,0,,CHEMBL3963540,440.0,nM,=,6.36,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.3565,1,active,MW=790.4 > 500.0; LogP=6.54 > 5.0
54921993,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CNC2CCN(C)CC2)c(C)c1Cl,,,raw,,866.5289999999994,865.3752165719998,7.399320000000008,136.95,2,9,15,7,5,0.40425531914893614,61,0.11122196922553237,False,2,True,0,,CHEMBL3963300,20.0,nM,=,7.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.699,1,active,MW=866.5 > 500.0; LogP=7.40 > 5.0
039d70de,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(CCO)CC2)c(C)c1Cl,,,raw,,882.5279999999993,881.3701311919999,6.325420000000007,148.39,2,10,16,7,5,0.40425531914893614,62,0.11617597745706006,False,2,True,0,,CHEMBL3964058,90.0,nM,=,7.05,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.0458,1,active,MW=882.5 > 500.0; LogP=6.33 > 5.0
01773844,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCO)c(C)c1Cl,,,raw,,814.4049999999997,813.2962975559999,6.724420000000008,151.14,2,9,16,6,5,0.3488372093023256,57,0.10428448168798944,False,2,True,0,,CHEMBL3975289,50.0,nM,=,7.3,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.301,1,active,MW=814.4 > 500.0; LogP=6.72 > 5.0
c193a111,,CCCCN(CCc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,857.2599999999998,855.18157342,9.096320000000002,121.67999999999999,1,7,12,7,6,0.22727272727272727,58,0.1311709995984356,False,2,True,0,,CHEMBL3942482,30.0,nM,=,7.52,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.5229,1,active,MW=857.3 > 500.0; LogP=9.10 > 5.0
2b83ba8f,,CCCCN(CCCC(F)(F)F)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,794.2959999999997,793.2312526879998,7.889320000000008,121.67999999999999,1,7,12,6,5,0.3,55,0.13724151386051806,False,2,True,0,,CHEMBL3960836,110.0,nM,=,6.96,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.9586,1,active,MW=794.3 > 500.0; LogP=7.89 > 5.0
76bf9e31,,Cc1c(Cl)c(C(=O)N(CCC(F)(F)F)CCC(F)(F)F)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1C(=O)N1CCc2ccccc2C1,,,raw,,820.2119999999996,819.171687124,7.651520000000008,121.67999999999999,1,7,10,6,5,0.2631578947368421,56,0.1446696205479981,False,2,True,0,,CHEMBL3986056,80.0,nM,=,7.1,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.0969,1,active,MW=820.2 > 500.0; LogP=7.65 > 5.0
b3633da7,,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc2c(c1)OCCO2,,,raw,,818.3519999999999,817.2336973000001,7.522620000000008,140.14,1,9,10,8,6,0.22727272727272727,58,0.1498274789037462,False,2,True,0,,CHEMBL3954559,70.0,nM,=,7.16,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.1549,1,active,MW=818.4 > 500.0; LogP=7.52 > 5.0
3941bcf5,,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1,,,raw,,870.8589999999999,869.2205457720002,10.071819999999995,121.67999999999999,1,7,11,8,7,0.16666666666666666,61,0.13820445121956978,False,2,True,0,,CHEMBL3940231,50.0,nM,=,7.3,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.301,1,active,MW=870.9 > 500.0; LogP=10.07 > 5.0
e87e3171,,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc(C(=O)OC)cc1,,,raw,,818.352,817.2336973000001,7.538020000000008,147.98,1,9,11,7,6,0.20454545454545456,58,0.1320312706901684,False,2,True,0,,CHEMBL3937806,90.0,nM,=,7.05,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.0458,1,active,MW=818.4 > 500.0; LogP=7.54 > 5.0
652d2c28,,CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,881.4999999999998,880.3497300959999,5.300520000000008,157.26,2,10,15,7,5,0.3695652173913043,62,0.14255024804863303,False,2,True,0,,CHEMBL3889549,70.0,nM,=,7.16,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.1549,1,active,MW=881.5 > 500.0; LogP=5.30 > 5.0
f7efbb7a,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)cc1C,,,raw,,705.8809999999999,705.2984904759999,6.6935200000000075,121.67999999999999,1,7,12,6,5,0.3,51,0.15440990784668976,False,2,True,0,,CHEMBL3917569,230.0,nM,=,6.64,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.6383,1,active,MW=705.9 > 500.0; LogP=6.69 > 5.0
f482a6e1,,CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,969.1289999999998,967.062571324,9.658419999999998,121.67999999999999,1,7,11,7,6,0.20930232558139536,58,0.12923167087166815,False,2,True,0,,CHEMBL3945459,20.0,nM,=,7.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.699,1,active,MW=969.1 > 500.0; LogP=9.66 > 5.0
5804ffda,,CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,907.7039999999998,905.1375156880001,9.068120000000002,141.91,2,8,12,7,6,0.22727272727272727,60,0.12486603398719086,False,2,True,0,,CHEMBL3906577,8.49,nM,=,8.07,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0711,1,active,MW=907.7 > 500.0; LogP=9.07 > 5.0
965ffc61,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,920.3599999999998,918.2499873280001,8.424120000000006,145.15,2,9,15,7,5,0.34782608695652173,62,0.10656731194400927,False,2,True,0,,CHEMBL3938217,10.0,nM,=,8.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0,1,active,MW=920.4 > 500.0; LogP=8.42 > 5.0
a6161d42,,CCCCN(CCCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,712.3159999999998,711.264603504,7.711120000000009,104.61,1,7,12,6,5,0.3076923076923077,50,0.14222777648513252,False,2,True,0,,CHEMBL3964186,260.0,nM,=,6.58,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.585,1,active,MW=712.3 > 500.0; LogP=7.71 > 5.0
b1d3b08a,,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,714.288,713.2438680599998,6.2918200000000075,124.84,2,8,11,6,5,0.2894736842105263,50,0.1648776832379054,False,2,True,0,,CHEMBL3931099,60.0,nM,=,7.22,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.2218,1,active,MW=714.3 > 500.0; LogP=6.29 > 5.0
9e5aace9,,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C(F)(F)F)c1Cl,,,raw,,802.703,801.1766302719999,7.655600000000007,124.84,2,8,11,6,5,0.2894736842105263,54,0.14065664563477784,False,2,True,0,,CHEMBL3894163,30.0,nM,=,7.52,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.5229,1,active,MW=802.7 > 500.0; LogP=7.66 > 5.0
e14af0ed,,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(F)(F)F)c1Cl,,,raw,,772.6769999999999,771.166065588,8.294700000000004,104.61,1,7,10,6,5,0.2702702702702703,52,0.15331908265595662,False,2,True,0,,CHEMBL3968982,40.0,nM,=,7.4,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.3979,1,active,MW=772.7 > 500.0; LogP=8.29 > 5.0
d4c0c623,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,918.3439999999997,916.234337264,8.864420000000003,146.84,2,9,15,7,6,0.30434782608695654,62,0.1046819809349223,False,2,True,0,,CHEMBL3936947,8.85,nM,=,8.05,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0531,1,active,MW=918.3 > 500.0; LogP=8.86 > 5.0
11249ac5,,CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,1031.5079999999994,1029.329634616,7.01682000000001,160.5,2,11,17,8,5,0.39215686274509803,70,0.09919251423777277,False,3,True,0,,CHEMBL3927011,1010.0,nM,=,6.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,5.9957,0,inactive,MW=1031.5 > 500.0; LogP=7.02 > 5.0; HBA=11 > 10
47d1107e,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,raw,,803.8129999999996,802.2470948679999,7.327620000000008,147.7,2,8,13,6,5,0.3170731707317073,55,0.12676912549657351,False,2,True,0,,CHEMBL3901575,10.0,nM,=,8.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0,1,active,MW=803.8 > 500.0; LogP=7.33 > 5.0
be2d3ed7,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)CCN4CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,868.2949999999995,866.2227940359999,6.699520000000009,145.15,2,9,14,6,4,0.4146341463414634,56,0.14262315318806493,False,2,True,0,,CHEMBL3931548,9.15,nM,=,8.04,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0386,1,active,MW=868.3 > 500.0; LogP=6.70 > 5.0
1c5634b9,,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,827.6289999999998,825.1154077760001,7.70772000000001,124.84,2,8,11,6,5,0.2894736842105263,52,0.13990948481145568,False,2,True,0,,CHEMBL3927392,7.84,nM,=,8.11,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.1057,1,active,MW=827.6 > 500.0; LogP=7.71 > 5.0
be1a3ebd,,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(ccn4CC)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,raw,,866.2789999999997,864.2071439720002,7.2917200000000095,146.84,2,9,14,6,5,0.36585365853658536,56,0.1192573924986635,False,2,True,0,,CHEMBL3912610,3.59,nM,=,8.45,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.4449,1,active,MW=866.3 > 500.0; LogP=7.29 > 5.0
7d15dd19,,CCCCN(Cc1ccc(-c2ccc(CC(=O)O)cc2)cc1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,raw,,1058.4849999999992,1056.260552012,10.757419999999993,162.22,2,9,16,9,7,0.23214285714285715,73,0.0959245739930877,False,2,True,0,,CHEMBL3963735,10.0,nM,=,8.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0,1,active,MW=1058.5 > 500.0; LogP=10.76 > 5.0
f5500373,,Cc1c(Cl)c(C(=O)NCc2ccc(-c3ccc(CC(=O)O)cc3)cc2)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3c(c2)CCN3Cc2ccc(Cl)c(Cl)c2)cc1C(=O)N1CCc2ccccc2C1,,,raw,,1002.3769999999994,1000.1979517559998,9.24492,171.01,3,9,13,9,7,0.17307692307692307,69,0.10191468561065066,False,2,True,0,,CHEMBL3918064,50.0,nM,=,7.3,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.301,1,active,MW=1002.4 > 500.0; LogP=9.24 > 5.0
d2bf8646,,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1,,,raw,,984.1999999999996,981.0920854880001,11.487719999999985,121.67999999999999,1,7,11,8,7,0.16666666666666666,63,0.13775744584451455,False,2,True,0,,CHEMBL3890955,10.0,nM,=,8.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0,1,active,MW=984.2 > 500.0; LogP=11.49 > 5.0
355cd3e3,,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1,,,raw,,939.7489999999997,937.142601068,11.378619999999986,121.67999999999999,1,7,11,8,7,0.16666666666666666,63,0.13783770310764992,False,2,True,0,,CHEMBL3960038,40.0,nM,=,7.4,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.3979,1,active,MW=939.7 > 500.0; LogP=11.38 > 5.0
88c809de,,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1,,,raw,,939.7489999999997,937.142601068,11.378619999999986,121.67999999999999,1,7,11,8,7,0.16666666666666666,63,0.13783770310764992,False,2,True,0,,CHEMBL3899265,70.0,nM,=,7.16,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.1549,1,active,MW=939.7 > 500.0; LogP=11.38 > 5.0
9ddd8f6d,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,raw,,867.4239999999999,866.2540983959999,9.974699999999995,136.9,1,9,13,8,7,0.1836734693877551,62,0.1131967099244472,False,2,True,0,,CHEMBL3927294,20.0,nM,=,7.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.699,1,active,MW=867.4 > 500.0; LogP=9.97 > 5.0
6a03e82b,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC[Si](C)(C)C)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccccc1,,,raw,,714.961,714.290732722,6.654900000000008,127.67000000000002,1,8,13,5,4,0.3684210526315789,50,0.1213183398692226,False,2,True,0,,CHEMBL3939961,580.0,nM,=,6.24,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.2366,1,active,MW=715.0 > 500.0; LogP=6.65 > 5.0
6576753c,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,raw,,980.7649999999995,978.1256381119999,11.390599999999987,136.9,1,9,13,8,7,0.1836734693877551,64,0.1128035423535339,False,2,True,0,,CHEMBL3966210,20.0,nM,=,7.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.699,1,active,MW=980.8 > 500.0; LogP=11.39 > 5.0
052c2391,,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(OCC(O)CO)cc1,,,raw,,788.923,788.287985368,5.576600000000007,171.28999999999996,4,10,14,7,6,0.25,57,0.11012162248200058,False,2,True,0,,CHEMBL3982792,8.13,nM,=,8.09,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0899,1,active,MW=788.9 > 500.0; LogP=5.58 > 5.0
42044dff,,CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,705.8809999999999,705.2984904759999,6.599900000000008,121.67999999999998,1,7,12,6,5,0.3,51,0.15622316202986072,False,2,True,0,,CHEMBL3912906,110.0,nM,=,6.96,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.9586,1,active,MW=705.9 > 500.0; LogP=6.60 > 5.0
e868be5e,,CCCCN(CCCC)C(=O)c1cn(CC(=O)NC)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,762.9329999999999,762.319954192,5.808900000000006,150.77999999999997,2,8,14,6,5,0.30952380952380953,55,0.14505291765864842,False,2,True,0,,CHEMBL3890311,430.0,nM,=,6.37,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.3665,1,active,MW=762.9 > 500.0; LogP=5.81 > 5.0
097fffdd,,CCCCN(CCCC)C(=O)c1cn(CCCN(C)C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,777.0039999999998,776.3719897639999,7.014600000000009,124.91999999999999,1,8,16,6,5,0.36363636363636365,56,0.11433905714243424,False,2,True,0,,CHEMBL3921891,200.0,nM,=,6.7,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.699,1,active,MW=777.0 > 500.0; LogP=7.01 > 5.0
24167c37,,CCCCN(CCCC)C(=O)c1cn(CC(=O)O)c(-c2ccc(C(=O)NS(=O)(=O)c3cccc4ccccc34)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,749.8899999999998,749.2883197159999,6.147500000000006,158.98000000000002,2,8,14,6,5,0.2926829268292683,54,0.1369242983786537,False,2,True,0,,CHEMBL3962772,140.0,nM,=,6.85,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.8539,1,active,MW=749.9 > 500.0; LogP=6.15 > 5.0
8566cf13,,CCCCN(CCCC)C(=O)c1cn(CCN2CCOCC2)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,835.04,834.377469068,5.7560000000000064,154.38,2,10,16,7,5,0.391304347826087,60,0.12646800259867655,False,2,True,0,,CHEMBL3893805,120.0,nM,=,6.92,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.9208,1,active,MW=835.0 > 500.0; LogP=5.76 > 5.0
b53385db,,CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,raw,,860.8189999999996,860.22168754,6.531800000000007,147.7,2,8,13,6,5,0.3170731707317073,54,0.12807283292474292,False,2,True,0,,CHEMBL3897725,6.97,nM,=,8.16,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.1568,1,active,MW=860.8 > 500.0; LogP=6.53 > 5.0
4ec2ae55,,CCCCN(CCCC)C(=O)c1cccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,702.8769999999998,702.287591444,7.261400000000008,116.75,1,6,12,6,5,0.2682926829268293,51,0.14635034557792315,False,2,True,0,,CHEMBL3965698,600.0,nM,=,6.22,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,6.2218,1,active,MW=702.9 > 500.0; LogP=7.26 > 5.0
a74b4d94,,CCCCN(CCCC)c1ccc(Br)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,788.2079999999997,786.16421654,9.041500000000003,99.68,1,6,12,6,5,0.275,51,0.1355788468978922,False,2,True,0,,CHEMBL3986556,10.0,nM,=,8.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0,1,active,MW=788.2 > 500.0; LogP=9.04 > 5.0
b3f3685a,,CCCCN(CCCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,raw,,740.3259999999999,739.259518124,7.03490000000001,132.8,2,8,13,6,5,0.3,52,0.13155676789722226,False,2,True,0,,CHEMBL3957861,60.0,nM,=,7.22,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,7.2218,1,active,MW=740.3 > 500.0; LogP=7.03 > 5.0
670a1212,,CCCCN(Cc1ccc(Cl)c(Cl)c1)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,raw,,847.6519999999998,845.11638632,10.034299999999995,112.57,1,7,11,7,6,0.19047619047619047,56,0.1381972021092176,False,2,True,0,,CHEMBL3912240,10.0,nM,=,8.0,CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",0.8,2,8.0,1,active,MW=847.7 > 500.0; LogP=10.03 > 5.0
d659566b,,Clc1cccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)c1,,,raw,,310.744,310.062138652,4.614900000000001,66.74000000000001,2,4,3,4,4,0.0,22,0.5793980025220212,True,0,True,0,,CHEMBL4075044,660.0,nM,=,6.18,CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,6.1805,1,active,
62d86993,,O=[N+]([O-])c1ccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)cc1,,,raw,,321.29600000000005,321.086189212,3.8697000000000017,109.88000000000001,2,6,4,4,4,0.0,24,0.4359086232700896,True,0,True,0,,CHEMBL4066452,3830.0,nM,=,5.42,CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,5.4168,0,inactive,
93e694b5,,O=[N+]([O-])c1ccccc1Nc1nnc(-c2c[nH]c3ccccc23)o1,,,raw,,321.29600000000005,321.086189212,3.869700000000001,109.88000000000001,2,6,4,4,4,0.0,24,0.4359086232700896,True,0,True,0,,CHEMBL4102399,2755.0,nM,=,5.91,CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,2,5.5599,0,inactive,
772e5423,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3CC2)C1,,,raw,,959.6189999999997,958.2846107880002,9.111800000000002,125.12,2,10,15,7,4,0.425531914893617,64,0.1116039890674848,False,2,True,0,,CHEMBL4215940,193.0,nM,=,6.71,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,6.7144,1,active,MW=959.6 > 500.0; LogP=9.11 > 5.0
9be4ab53,,Cn1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)n1,,,raw,,582.1700000000002,581.222738692,4.978100000000005,87.53999999999999,1,7,7,5,3,0.4,40,0.4234643608327768,True,1,True,0,,CHEMBL4218253,67.4,nM,=,7.17,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.1713,1,active,MW=582.2 > 500.0
937ff7fb,,CN1CCN(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)CC1,,,raw,,600.229,599.2696888840001,4.347900000000005,76.19999999999999,1,6,7,5,2,0.5161290322580645,41,0.5100996087118234,True,1,True,0,,CHEMBL4213316,168.0,nM,=,6.78,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,6.7747,1,active,MW=600.2 > 500.0
e592cd89,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(C)(=O)=O)cc3)CC2)C1,,,raw,,516.1070000000002,515.200940628,4.815300000000005,69.72,1,5,6,4,2,0.4444444444444444,35,0.5972303453735658,True,1,True,0,,CHEMBL4204650,495.0,nM,=,6.3,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,6.3054,1,active,MW=516.1 > 500.0
d876a3a7,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,raw,,868.457,867.3180956199999,8.659900000000006,172.03,3,11,13,8,5,0.37777777777777777,61,0.07640809714093555,False,3,True,0,,CHEMBL3137309,7.39,nM,=,8.13,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,11,8.1314,1,active,MW=868.5 > 500.0; LogP=8.66 > 5.0; HBA=11 > 10
1ad082b5,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,974.6339999999997,973.2955098200001,8.833200000000007,128.35999999999999,2,11,16,7,4,0.425531914893617,65,0.10464896749919123,False,3,True,0,,CHEMBL443684,10.3,nM,=,7.99,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,3,7.9872,1,active,MW=974.6 > 500.0; LogP=8.83 > 5.0; HBA=11 > 10
4121a79d,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CNC2(Cn3cnc4cc(C(=O)NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)ccc43)CC2)C1,,,raw,,999.6439999999997,998.2907587880002,9.183100000000001,151.73,3,12,18,8,5,0.4166666666666667,67,0.07213809382605904,False,3,True,0,,CHEMBL4218405,108.0,nM,=,6.97,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,6.9666,1,active,MW=999.6 > 500.0; LogP=9.18 > 5.0; HBA=12 > 10
bf02d28f,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3nc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)sc3C2)C1,,,raw,,952.6089999999998,951.2206306280002,8.525800000000007,138.01,2,12,15,7,4,0.4418604651162791,62,0.11103164684085133,False,3,True,0,,CHEMBL4216380,38.1,nM,=,7.42,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.4191,1,active,MW=952.6 > 500.0; LogP=8.53 > 5.0; HBA=12 > 10
19b81a7f,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3sc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3C2)C1,,,raw,,951.6209999999996,950.2253816600002,9.130800000000002,125.12,2,11,15,7,4,0.4318181818181818,62,0.11160583020831286,False,3,True,0,,CHEMBL4211496,57.9,nM,=,7.24,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.2373,1,active,MW=951.6 > 500.0; LogP=9.13 > 5.0; HBA=11 > 10
4964fd58,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3cc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)ccc3C2)C1,,,raw,,945.5919999999999,944.2689607240002,9.069300000000004,125.12,2,10,15,7,4,0.41304347826086957,63,0.11165180180465246,False,2,True,0,,CHEMBL4216466,12.6,nM,=,7.9,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.8996,1,active,MW=945.6 > 500.0; LogP=9.07 > 5.0
7bf11d6e,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(CN6CC(F)(F)C6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,900.4329999999998,899.2576450040001,6.917500000000008,128.35999999999999,2,10,13,7,3,0.4878048780487805,60,0.17479040401004572,False,2,True,0,,CHEMBL4211198,17.3,nM,=,7.76,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.762,1,active,MW=900.4 > 500.0; LogP=6.92 > 5.0
eb64a4ba,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5(CN6CCOCC6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,895.4629999999996,894.2710689000002,6.265700000000008,134.79,1,11,13,7,3,0.5,60,0.20839769261386965,False,3,True,0,,CHEMBL4207006,14.5,nM,=,7.84,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.8386,1,active,MW=895.5 > 500.0; LogP=6.27 > 5.0; HBA=11 > 10
a9d606af,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@@H](CC5CC5)CN5CCOCC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,892.5069999999996,891.3077887560001,7.450900000000009,128.35999999999999,2,10,14,7,3,0.5116279069767442,60,0.16859284250749695,False,2,True,0,,CHEMBL4206829,20.7,nM,=,7.68,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.684,1,active,MW=892.5 > 500.0; LogP=7.45 > 5.0
aae332f6,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@@H](CC5CC5)C(=O)N5CCOCC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,906.4899999999997,905.2870533120001,6.977500000000008,145.42999999999998,2,10,13,7,3,0.4883720930232558,61,0.18448414688263362,False,2,True,0,,CHEMBL4208633,68.2,nM,=,7.17,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.1662,1,active,MW=906.5 > 500.0; LogP=6.98 > 5.0
d045417f,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5(CN6CC(F)(F)C6)CC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,870.4069999999998,869.2470803200001,7.433500000000009,119.13,2,9,12,7,3,0.475,58,0.17934022832851979,False,2,True,0,,CHEMBL4202464,34.8,nM,=,7.46,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.4584,1,active,MW=870.4 > 500.0; LogP=7.43 > 5.0
f82e1bd5,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5(CN6CCOCC6)CC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,864.4529999999996,863.2764886280002,6.814800000000008,128.35999999999999,2,10,12,7,3,0.4878048780487805,58,0.2005258600152952,False,2,True,0,,CHEMBL4209752,40.7,nM,=,7.39,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.3904,1,active,MW=864.5 > 500.0; LogP=6.81 > 5.0
c058cd4e,,CN(CCO)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,783.335,782.2186394040001,5.966600000000007,127.32999999999998,2,9,11,5,3,0.4166666666666667,52,0.24221246093628268,False,2,True,0,,CHEMBL4209621,46.0,nM,=,7.34,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.3372,1,active,MW=783.3 > 500.0; LogP=5.97 > 5.0
f0945fe5,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N5CC(F)(F)C5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,801.3000000000002,800.1892310960002,6.993400000000009,107.1,1,8,9,6,3,0.4166666666666667,53,0.2311058823283588,False,2,True,0,,CHEMBL4206007,46.6,nM,=,7.33,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.3316,1,active,MW=801.3 > 500.0; LogP=6.99 > 5.0
a6bb68ff,,CN(C)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,753.3090000000003,752.2080747200001,6.604100000000008,107.1,1,8,9,5,3,0.4,50,0.2607342029011338,False,2,True,0,,CHEMBL4210809,65.1,nM,=,7.19,CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.1864,1,active,MW=753.3 > 500.0; LogP=6.60 > 5.0
ba892e70,,C[C@@H]1CC[C@H]2[C@@H](C)C(OCCNC3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,raw,,960.1199999999997,959.4098913920001,7.003600000000008,226.96999999999994,4,16,15,11,4,0.5833333333333334,68,0.04069483774859156,False,3,True,0,,CHEMBL4284025,1.9,nM,=,8.72,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.7212,1,active,MW=960.1 > 500.0; LogP=7.00 > 5.0; HBA=16 > 10
e2c3640c,,C[C@@H]1CC[C@H]2[C@@H](C)C(OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)C[C@@H]3CO)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,raw,,976.1189999999998,975.4048060120001,5.928100000000006,238.40999999999997,4,17,15,11,4,0.5833333333333334,69,0.06135588139472243,False,3,True,0,,CHEMBL4294620,28.7,nM,=,7.54,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.5421,1,active,MW=976.1 > 500.0; LogP=5.93 > 5.0; HBA=17 > 10
d88dc114,,C[C@@H]1CC[C@H]2[C@@H](C)C(OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)C[C@H]3CO)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,raw,,976.1189999999998,975.4048060120001,5.928100000000006,238.40999999999997,4,17,15,11,4,0.5833333333333334,69,0.06135588139472243,False,3,True,0,,CHEMBL4287383,67.1,nM,=,7.17,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.1733,1,active,MW=976.1 > 500.0; LogP=5.93 > 5.0; HBA=17 > 10
8ad475b3,,C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@]3(C)O[C@]24[C@H]1CC[C@@H](C)[C@@H]4C[C@H]3O,,,raw,,944.0769999999999,943.378591264,5.549000000000007,237.01999999999995,4,15,12,10,4,0.5531914893617021,67,0.1006824012085489,False,3,True,0,,CHEMBL4279468,50.1,nM,=,7.3,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.3002,1,active,MW=944.1 > 500.0; LogP=5.55 > 5.0; HBA=15 > 10
a17c01e2,,C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@]3(C)O[C@]24[C@H]1CC[C@@H](C)[C@@H]4C[C@H]3O,,,raw,,946.093,945.3942413279999,5.606400000000005,229.17999999999998,4,16,14,10,4,0.574468085106383,67,0.08900654749913109,False,3,True,0,,CHEMBL4290795,31.9,nM,=,7.5,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.4962,1,active,MW=946.1 > 500.0; LogP=5.61 > 5.0; HBA=16 > 10
25f6a637,,C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3,,,raw,,928.0779999999997,927.3836766439999,6.578200000000007,216.78999999999996,3,14,12,10,4,0.5531914893617021,66,0.10112686238704993,False,3,True,0,,CHEMBL4282932,3.5,nM,=,8.46,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.4559,1,active,MW=928.1 > 500.0; LogP=6.58 > 5.0; HBA=14 > 10
a653dd72,,C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3,,,raw,,930.0939999999998,929.399326708,6.635600000000006,208.95,3,15,14,10,4,0.574468085106383,66,0.08951738561736854,False,3,True,0,,CHEMBL4294191,2.2,nM,=,8.66,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.6576,1,active,MW=930.1 > 500.0; LogP=6.64 > 5.0; HBA=15 > 10
09eca12b,,C[C@H]1[C@@H](CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3,,,raw,,914.0949999999999,913.4044120880001,7.051600000000008,199.71999999999997,3,14,13,10,4,0.574468085106383,65,0.09104402511188718,False,3,True,0,,CHEMBL4286311,1.8,nM,=,8.74,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.7447,1,active,MW=914.1 > 500.0; LogP=7.05 > 5.0; HBA=14 > 10
766d88a5,,C[C@@H]1CC[C@H]2C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)=C(C(F)(F)F)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32O4,,,raw,,952.022,951.344846524,7.473200000000008,199.71999999999997,3,14,12,10,4,0.5217391304347826,67,0.09331011822240808,False,3,True,0,,CHEMBL4279038,2.8,nM,=,8.55,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.5528,1,active,MW=952.0 > 500.0; LogP=7.47 > 5.0; HBA=14 > 10
f104504c,,CO[C@H]1OC2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@]1(C)CC(=O)N1CCN(c5ccc(C(=O)NS(=O)(=O)c6ccc(NCC7CCOCC7)c([N+](=O)[O-])c6)c(Oc6cnc7[nH]ccc7c6)c5)CC1)[C@@]24OO3,,,raw,,974.1029999999996,973.389155948,6.483900000000006,235.24999999999991,3,16,13,11,4,0.5625,69,0.07383060884563913,False,3,True,0,,CHEMBL4278774,34.7,nM,=,7.46,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.4597,1,active,MW=974.1 > 500.0; LogP=6.48 > 5.0; HBA=16 > 10
4a57647a,,C[C@@H]1CC[C@@H]2[C@]34OO[C@](C)(CC[C@@H]13)O[C@H]4O[C@]2(C)C(=O)N1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,916.0229999999996,915.347291136,5.873700000000004,226.01999999999995,3,15,11,11,4,0.5333333333333333,65,0.09083291267442405,False,3,True,0,,CHEMBL4286682,13.0,nM,=,7.89,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.8861,1,active,MW=916.0 > 500.0; LogP=5.87 > 5.0; HBA=15 > 10
d32700f3,,C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,raw,,944.0769999999998,943.378591264,6.509800000000007,226.01999999999995,3,15,12,11,4,0.5531914893617021,67,0.07819453068973407,False,3,True,0,,CHEMBL4277317,11.9,nM,=,7.92,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.9245,1,active,MW=944.1 > 500.0; LogP=6.51 > 5.0; HBA=15 > 10
561cfbec,,C[C@H]1[C@H](N(C)CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,raw,,959.1359999999999,958.425875804,6.4824000000000055,212.18999999999997,3,16,14,11,4,0.5833333333333334,68,0.07010187725134537,False,3,True,0,,CHEMBL4285268,16.7,nM,=,7.78,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.7773,1,active,MW=959.1 > 500.0; LogP=6.48 > 5.0; HBA=16 > 10
2e2e53d0,,C[C@@H]1CC[C@H]2[C@@](C)(O)[C@@H](OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,raw,,962.0919999999996,961.389155948,5.682100000000005,238.40999999999994,4,17,14,11,4,0.574468085106383,68,0.06752892074872152,False,3,True,0,,CHEMBL4280705,86.5,nM,=,7.06,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,7.063,1,active,MW=962.1 > 500.0; LogP=5.68 > 5.0; HBA=17 > 10
071f69c1,,C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,raw,,946.0929999999998,945.3942413279999,6.567200000000006,218.17999999999998,3,16,14,11,4,0.574468085106383,67,0.06920403414625748,False,3,True,0,,CHEMBL4288614,5.0,nM,=,8.3,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.301,1,active,MW=946.1 > 500.0; LogP=6.57 > 5.0; HBA=16 > 10
756cfa2a,,C[C@H]1[C@@H](CCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,raw,,944.1209999999999,943.414976772,7.373300000000008,208.94999999999996,3,15,14,11,4,0.5833333333333334,67,0.06404541779366256,False,3,True,0,,CHEMBL4295247,1.2,nM,=,8.92,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.9208,1,active,MW=944.1 > 500.0; LogP=7.37 > 5.0; HBA=15 > 10
87f3331e,,C[C@H]1[C@@H](CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,raw,,930.0939999999999,929.399326708,6.983200000000008,208.94999999999996,3,15,13,11,4,0.574468085106383,66,0.07018474651898514,False,3,True,0,,CHEMBL4278369,9.7,nM,=,8.01,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.0132,1,active,MW=930.1 > 500.0; LogP=6.98 > 5.0; HBA=15 > 10
67b0b843,,C[C@@H]1CC[C@H]2C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)=C(C(F)(F)F)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,raw,,968.0210000000001,967.339761144,7.404800000000008,208.94999999999996,3,15,12,11,4,0.5217391304347826,68,0.07177966244323225,False,3,True,0,,CHEMBL4292460,6.2,nM,=,8.21,CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,0.8,1,8.2076,1,active,MW=968.0 > 500.0; LogP=7.40 > 5.0; HBA=15 > 10
9f94bcf0,,N#CC1=C(C#N)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,raw,,417.28700000000015,415.961896008,5.750560000000003,64.65,0,4,2,4,3,0.0,26,0.5326564762640277,True,1,True,0,,CHEMBL4470807,1505.0,nM,=,5.64,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,2,5.8225,0,inactive,LogP=5.75 > 5.0
b49c76a4,,CC(C)(C)c1ccc(C(=O)NCCN2C(=O)c3cccc4c(Sc5ccc(Br)cc5)ccc(c34)C2=O)cc1,,,raw,,587.5390000000001,586.092575824,7.077000000000006,66.48,1,4,6,5,4,0.1935483870967742,38,0.24511631272976306,False,2,True,0,,CHEMBL4530348,2645.0,nM,=,5.5,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,2,5.5776,0,inactive,MW=587.5 > 500.0; LogP=7.08 > 5.0
a71adf82,,COC(=O)CCNC1=C(C#N)C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc1c23,,,raw,,493.3820000000001,492.014325504,5.3371800000000045,79.19,1,6,6,4,3,0.125,31,0.46757556688803686,True,1,True,0,,CHEMBL4552126,4520.0,nM,=,5.34,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,5.3449,0,inactive,LogP=5.34 > 5.0
a485002b,,COC(=O)CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O,,,raw,,569.4770000000001,568.0667550000001,5.199100000000004,92.78,1,6,10,4,3,0.25925925925925924,36,0.20513733885908542,False,2,True,0,,CHEMBL4591149,4780.0,nM,=,5.32,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,5.3206,0,inactive,MW=569.5 > 500.0; LogP=5.20 > 5.0
9d4f56f9,,O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,raw,,909.8599999999994,908.2202955,6.216000000000005,191.16,4,10,19,7,4,0.3333333333333333,61,0.06213338584107956,False,2,True,0,,CHEMBL4460727,540.0,nM,=,6.27,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,6.2676,1,active,MW=909.9 > 500.0; LogP=6.22 > 5.0
0621d34b,,O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCOCCOCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,raw,,941.8579999999995,940.2101247400001,4.688800000000002,209.62,4,12,21,7,4,0.3333333333333333,63,0.06631543636726658,False,2,True,0,,CHEMBL4565306,4940.0,nM,=,5.31,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,5.3063,0,inactive,MW=941.9 > 500.0; HBA=12 > 10
d12010a4,,N#CC1=C(NCCC(=O)NCCCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,raw,,833.7650000000001,832.1678660040001,6.354080000000006,177.57,4,10,15,7,4,0.2619047619047619,56,0.07796159469339858,False,2,True,0,,CHEMBL4533471,1940.0,nM,=,5.71,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,5.7122,0,inactive,MW=833.8 > 500.0; LogP=6.35 > 5.0
1cc045f5,,N#CC1=C(NCCC(=O)NCCOCCOCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,raw,,865.763,864.157695244,4.826880000000005,196.03,4,12,17,7,4,0.2619047619047619,58,0.08359190748407007,False,2,True,0,,CHEMBL4579464,2240.0,nM,=,5.65,CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,0.8,1,5.6498,0,inactive,MW=865.8 > 500.0; HBA=12 > 10
d30fdb7f,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,raw,,899.4709999999999,898.3239092719997,8.299100000000006,212.12999999999997,5,12,17,7,5,0.35555555555555557,63,0.0258221052434818,False,3,True,0,,CHEMBL4579774,230.0,nM,=,6.64,CHEMBL4332203,Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay,0.8,1,6.6383,1,active,MW=899.5 > 500.0; LogP=8.30 > 5.0; HBA=12 > 10
2ac7bd47,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,raw,,913.4979999999999,912.339559336,8.689200000000005,212.12999999999997,5,12,18,7,5,0.3695652173913043,64,0.024187581742701518,False,3,True,0,,CHEMBL4469267,240.0,nM,=,6.62,CHEMBL4332203,Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay,0.8,1,6.6198,1,active,MW=913.5 > 500.0; LogP=8.69 > 5.0; HBA=12 > 10
bafd1a6e,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,raw,,927.5250000000001,926.3552093999999,9.079300000000002,212.12999999999997,5,12,19,7,5,0.3829787234042553,65,0.02271938178346437,False,3,True,0,,CHEMBL4592343,250.0,nM,=,6.6,CHEMBL4332203,Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay,0.8,1,6.6021,1,active,MW=927.5 > 500.0; LogP=9.08 > 5.0; HBA=12 > 10
141c772c,,CO[C@H]1/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3,,,raw,,613.2200000000004,612.2424710920001,5.898400000000006,84.94,1,6,1,6,2,0.5454545454545454,42,0.4039076684977777,False,2,True,0,,CHEMBL4446378,1930.0,nM,=,5.71,CHEMBL4356645,Inhibition of recombinant C-terminal His10x-tagged human Bcl-2 (2 to 211 residues) expressed in Escherichia coli cells interaction with biotinylated human Bim (51 to 76 residues) incubated for 60 mins by HTRF assay,0.8,1,5.7144,0,inactive,MW=613.2 > 500.0; LogP=5.90 > 5.0
e3235a80,,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O,,,raw,,3049.341999999993,3047.463164124003,-14.558220000000059,1441.4999999999993,50,42,105,3,3,0.5859375,214,0.014173249995201349,False,3,True,0,,CHEMBL2442251,3.3,nM,=,8.48,CHEMBL4378480,Inhibition of human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells by surface plasmon resonance assay,0.8,1,8.4815,1,active,MW=3049.3 > 500.0; HBD=50 > 5; HBA=42 > 10
d687c1c5,,COc1cc2c(cc1C(CN1CCCC1)c1ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(C[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)cc1)OCO2,,,raw,,980.1619999999999,979.2817779040001,8.404100000000009,140.77999999999997,1,12,18,8,5,0.3673469387755102,67,0.08438224067317643,False,3,True,0,,CHEMBL4519659,20.0,nM,=,7.7,CHEMBL4378481,Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay,0.8,1,7.699,1,active,MW=980.2 > 500.0; LogP=8.40 > 5.0; HBA=12 > 10
4a687bd3,,C[N+](C)(CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-])CC(=O)O,,,raw,,872.4900000000001,871.2708939760901,7.4800000000000075,162.19,3,10,18,6,5,0.2727272727272727,60,0.034659400870835216,False,2,True,0,,CHEMBL4453237,500.0,nM,=,6.3,CHEMBL4378481,Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay,0.8,1,6.301,1,active,MW=872.5 > 500.0; LogP=7.48 > 5.0
9ba840ea,,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,raw,,501.6750000000003,501.31037548800003,4.748920000000004,84.46000000000001,1,5,10,4,3,0.43333333333333335,37,0.43454985412904723,True,1,True,0,,CHEMBL4438456,1300.0,nM,=,5.89,CHEMBL4378481,Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay,0.8,1,5.8861,0,inactive,MW=501.7 > 500.0
c685ca22,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)c(S(=O)(=O)F)c1,,,raw,,746.8360000000004,746.135033424,5.472900000000006,165.01999999999998,2,11,14,5,4,0.24242424242424243,50,0.07275379742161993,False,3,True,0,,CHEMBL4529727,2000.0,nM,=,5.7,CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,0.8,1,5.699,0,inactive,MW=746.8 > 500.0; LogP=5.47 > 5.0; HBA=11 > 10
55f263b1,,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1,,,raw,,664.7810000000003,664.1825549959999,5.8147000000000055,130.88,2,9,13,5,4,0.24242424242424243,46,0.10324122977143539,False,2,True,0,,CHEMBL4592905,6300.0,nM,=,5.2,CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,0.8,1,5.2007,0,inactive,MW=664.8 > 500.0; LogP=5.81 > 5.0
12146023,,C#CCN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(-c3ccc(F)cc3)c(S(=O)(=O)F)c2)cc1S(=O)(=O)C(F)(F)F,,,raw,,815.8860000000005,815.0886754000002,6.091000000000006,146.79,2,10,15,4,4,0.20588235294117646,53,0.06259218216038542,False,2,True,0,,CHEMBL4474764,1300.0,nM,=,5.89,CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,0.8,1,5.8861,0,inactive,MW=815.9 > 500.0; LogP=6.09 > 5.0
0e1f070d,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2C(F)(F)F)C1,,,raw,,936.4540000000001,935.3054802479999,9.6787,172.03,3,11,13,8,5,0.391304347826087,65,0.07583818704507284,False,3,True,0,,CHEMBL4863897,0.86,nM,=,9.07,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,9.0655,1,active,MW=936.5 > 500.0; LogP=9.68 > 5.0; HBA=11 > 10
12a0889c,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,902.0090000000001,901.3444526,9.025300000000003,172.03,3,11,13,8,5,0.391304347826087,64,0.07607827324782367,False,3,True,0,,CHEMBL4868427,1.5,nM,=,8.82,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.8239,1,active,MW=902.0 > 500.0; LogP=9.03 > 5.0; HBA=11 > 10
2996357f,,COc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)CCC(C)(C)C2)cc1,,,raw,,864.0379999999998,863.3676326559998,8.01510000000001,181.26000000000002,3,12,14,8,5,0.391304347826087,62,0.07239386377851723,False,3,True,0,,CHEMBL4873467,3.8,nM,=,8.42,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.4202,1,active,MW=864.0 > 500.0; LogP=8.02 > 5.0; HBA=12 > 10
a2f1e90a,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccccc2C(F)(F)F)C1,,,raw,,902.0090000000001,901.3444526,9.025300000000003,172.03,3,11,13,8,5,0.391304347826087,64,0.07607827324782367,False,3,True,0,,CHEMBL4861424,1.7,nM,=,8.77,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.7696,1,active,MW=902.0 > 500.0; LogP=9.03 > 5.0; HBA=11 > 10
fa5a4c43,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)c(Cl)c2)C1,,,raw,,936.4540000000001,935.3054802479999,9.6787,172.03,3,11,13,8,5,0.391304347826087,65,0.07583818704507284,False,3,True,0,,CHEMBL4867128,0.8,nM,=,9.1,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,9.0969,1,active,MW=936.5 > 500.0; LogP=9.68 > 5.0; HBA=11 > 10
4232c837,,CN(C)CCCNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,raw,,889.0139999999998,888.360437012,8.550400000000007,166.04000000000002,3,11,15,7,5,0.37777777777777777,63,0.052401017753353596,False,3,True,0,,CHEMBL4860213,0.89,nM,=,9.05,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,9.0506,1,active,MW=889.0 > 500.0; LogP=8.55 > 5.0; HBA=11 > 10
27f1dc7c,,CCN(CC)CCCNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,raw,,917.0679999999998,916.3917371399999,9.330600000000002,166.04000000000002,3,11,17,7,5,0.40425531914893614,65,0.04623997161382268,False,3,True,0,,CHEMBL4852442,0.3,nM,=,9.52,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,9.5229,1,active,MW=917.1 > 500.0; LogP=9.33 > 5.0; HBA=11 > 10
dbd12e87,,CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,raw,,901.0249999999996,900.360437012,8.550400000000005,166.04000000000002,3,11,13,8,5,0.391304347826087,64,0.07659703356447037,False,3,True,0,,CHEMBL4858569,2.4,nM,=,8.62,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.6198,1,active,MW=901.0 > 500.0; LogP=8.55 > 5.0; HBA=11 > 10
58adc129,,CC(C)C(=O)N1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,971.1159999999998,970.4023018240001,9.493300000000001,183.10999999999999,3,11,14,8,5,0.42,69,0.07119290957831848,False,3,True,0,,CHEMBL4847514,2.4,nM,=,8.62,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.6198,1,active,MW=971.1 > 500.0; LogP=9.49 > 5.0; HBA=11 > 10
26319cb0,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,887.9820000000001,887.3288025359998,8.635200000000005,172.03,3,11,13,8,5,0.37777777777777777,63,0.07636163148831933,False,3,True,0,,CHEMBL4862150,4.7,nM,=,8.33,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.3279,1,active,MW=888.0 > 500.0; LogP=8.64 > 5.0; HBA=11 > 10
3df105ce,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,873.955,873.3131524719998,8.387600000000006,172.03,3,11,12,8,5,0.36363636363636365,62,0.0812416795882537,False,3,True,0,,CHEMBL4860155,1.9,nM,=,8.72,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.7212,1,active,MW=874.0 > 500.0; LogP=8.39 > 5.0; HBA=11 > 10
0c47f278,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,902.9930000000002,902.3284681879999,8.992200000000002,169.23,2,11,13,8,5,0.391304347826087,64,0.08545403470863988,False,3,True,0,,CHEMBL4878326,1.0,nM,=,9.0,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,9.0,1,active,MW=903.0 > 500.0; LogP=8.99 > 5.0; HBA=11 > 10
f071322a,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,888.9660000000001,888.3128181239997,8.744600000000004,169.23,2,11,12,8,5,0.37777777777777777,63,0.09076636812443901,False,3,True,0,,CHEMBL4878411,8.4,nM,=,8.08,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.0757,1,active,MW=889.0 > 500.0; LogP=8.74 > 5.0; HBA=11 > 10
9fa645af,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,888.9660000000001,888.3128181239997,8.602100000000005,169.23,2,11,13,8,5,0.37777777777777777,63,0.08578729765336478,False,3,True,0,,CHEMBL4855086,4.4,nM,=,8.36,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.3565,1,active,MW=889.0 > 500.0; LogP=8.60 > 5.0; HBA=11 > 10
9ccb8669,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,902.9930000000002,902.3284681879999,8.992200000000002,169.23,2,11,13,8,5,0.391304347826087,64,0.08545403470863988,False,3,True,0,,CHEMBL4855736,3.0,nM,=,8.52,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.5229,1,active,MW=903.0 > 500.0; LogP=8.99 > 5.0; HBA=11 > 10
77cf321e,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCSCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,raw,,919.0610000000001,918.3056245679998,9.708799999999998,159.99999999999997,2,11,13,8,5,0.391304347826087,64,0.08552750316387889,False,3,True,0,,CHEMBL4858527,1.65,nM,=,8.78,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.7825,1,active,MW=919.1 > 500.0; LogP=9.71 > 5.0; HBA=11 > 10
33f6e116,,CC(Oc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-])C1CCOCC1,,,raw,,917.0199999999995,916.3441182519999,9.380700000000001,169.23,2,11,13,8,5,0.40425531914893614,65,0.0852697525527461,False,3,True,0,,CHEMBL4866646,9.2,nM,=,8.04,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,8.0362,1,active,MW=917.0 > 500.0; LogP=9.38 > 5.0; HBA=11 > 10
31b64846,,CN1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,raw,,902.0089999999997,901.3444526000001,8.517300000000006,163.24,2,11,13,8,5,0.391304347826087,64,0.08605729306058775,False,3,True,0,,CHEMBL4851700,0.75,nM,=,9.12,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,9.1249,1,active,MW=902.0 > 500.0; LogP=8.52 > 5.0; HBA=11 > 10
dcffbfe8,,CCN1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,930.0629999999996,929.3757527280001,9.297500000000003,163.24,2,11,14,8,5,0.4166666666666667,66,0.08062359296599937,False,3,True,0,,CHEMBL4851332,0.5,nM,=,9.3,CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,0.8,1,9.301,1,active,MW=930.1 > 500.0; LogP=9.30 > 5.0; HBA=11 > 10
faa1c3d9,,N#CC1=C(C#N)c2ccc(N3CCSCC3)c3cccc(c23)C1=O,,,raw,,331.40000000000003,331.077933036,3.390060000000002,67.89,0,5,1,4,2,0.21052631578947367,24,0.8010305965261142,True,0,False,1,PAINS match: anil_di_alk_B(251),CHEMBL4848284,800.0,nM,=,6.1,CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,0.8,1,6.0969,1,active,
d71da945,,N#CC1=C(C#N)c2ccc(Sc3ccccc3)c3cccc(c23)C1=O,,,raw,,338.3910000000001,338.05138393999994,4.9880600000000035,64.65,0,4,2,4,3,0.0,25,0.6602139816094742,True,0,True,0,,CHEMBL4855924,1800.0,nM,=,5.75,CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,0.8,1,5.7447,0,inactive,
d1b0dcc5,,CC(C)c1ccc(Sc2ccc3c4c(cccc24)C(=O)C(C#N)=C3C#N)cc1,,,raw,,380.47200000000015,380.09833413200005,6.1114600000000046,64.65,0,4,3,4,3,0.125,28,0.5495907836031755,True,1,True,0,,CHEMBL4851461,2800.0,nM,=,5.55,CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,0.8,1,5.5528,0,inactive,LogP=6.11 > 5.0
b7e35dfe,,COc1ccc(Sc2ccc3c4c(cccc24)C(=O)C(C#N)=C3C#N)cc1,,,raw,,368.41700000000014,368.061948624,4.996660000000003,73.88,0,5,3,4,3,0.045454545454545456,27,0.6504928196393555,True,0,True,0,,CHEMBL4854644,6100.0,nM,=,5.21,CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,0.8,1,5.2147,0,inactive,
e41e7705,,N#CC1=C(NCc2ccccc2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,raw,,424.56900000000036,424.16093438799993,6.4853800000000055,52.89,1,4,5,5,3,0.25925925925925924,31,0.508822522398023,True,1,True,0,,CHEMBL4852221,5200.0,nM,=,5.28,CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,0.8,1,5.284,0,inactive,LogP=6.49 > 5.0
b54357f9,,N#CC1=C(NCC2CCCCC2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,raw,,430.6170000000003,430.2078845799999,6.865480000000007,52.89,1,4,5,5,2,0.48148148148148145,31,0.562472133742945,True,1,True,0,,CHEMBL4858808,4800.0,nM,=,5.32,CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,0.8,1,5.3188,0,inactive,LogP=6.87 > 5.0
0c57e9f6,,CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,896.5109999999996,895.349395748,9.438500000000001,172.02999999999997,3,11,14,8,5,0.40425531914893614,63,0.07164047318997945,False,3,True,0,,CHEMBL4228713,1.4,nM,=,8.85,CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,0.8,2,8.8539,1,active,MW=896.5 > 500.0; LogP=9.44 > 5.0; HBA=11 > 10
75f8d1bb,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,904.368,903.242879992,8.882000000000003,172.03,3,11,13,8,6,0.2727272727272727,63,0.07468975990631171,False,3,True,0,,CHEMBL4551344,296.0,nM,=,6.53,CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,0.8,2,6.5287,1,active,MW=904.4 > 500.0; LogP=8.88 > 5.0; HBA=11 > 10
eb873265,,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1,,,raw,,669.8040000000001,669.187974724,6.329800000000007,107.89,2,9,10,6,5,0.2571428571428571,47,0.13132092184065924,False,2,True,0,,CHEMBL3342332,382.0,nM,=,6.42,CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,0.8,2,6.4179,1,active,MW=669.8 > 500.0; LogP=6.33 > 5.0
615c956b,,O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(CCOc3ccc(-n4ncc5cncnc54)cc3)s1)CC2,,,raw,,674.7680000000001,674.1518433120001,6.016400000000004,148.25,2,12,9,8,7,0.14705882352941177,48,0.1863559815752975,False,3,True,0,,CHEMBL3342191,3780.0,nM,=,5.42,CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,0.8,1,5.4225,0,inactive,MW=674.8 > 500.0; LogP=6.02 > 5.0; HBA=12 > 10
721bd3e0,,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,raw,,945.5480000000003,944.2325752160001,8.256200000000007,156.35,4,11,18,6,5,0.3111111111111111,63,0.0627947811646497,False,3,True,0,,CHEMBL3703600,3.9,nM,=,8.41,CHEMBL5108715,Displacement of synthetic peptide tracer conjugated to fluorescein isothiocyanate from C-terminal 6xHis-tagged Bcl-2 (1 to 204 residues) (unknown origin) preincubated for 1 hr followed by tracer addition measured after 20 mins by fluorescence polarization assay,0.8,1,8.4089,1,active,MW=945.5 > 500.0; LogP=8.26 > 5.0; HBA=11 > 10
dae15336,,COC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,478.34600000000006,477.0688036,5.6189000000000044,71.0,1,4,4,4,3,0.125,31,0.529430983254889,True,1,True,0,,CHEMBL5202782,2100.0,nM,=,5.68,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.6778,0,inactive,LogP=5.62 > 5.0
b98bdfe5,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc([N+](=O)[O-])cc3)C(c3ccccc3)C2)cc1,,,raw,,486.5280000000002,486.19031993199997,5.933300000000005,114.14000000000001,1,6,5,4,3,0.2222222222222222,36,0.35439529979645484,True,1,True,0,,CHEMBL5179160,439.0,nM,=,6.36,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.3575,1,active,LogP=5.93 > 5.0
f890cbc6,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,520.4270000000001,519.1157537920001,6.787600000000006,71.0,1,4,4,4,3,0.2222222222222222,34,0.41202995293472167,False,2,True,0,,CHEMBL5188416,262.0,nM,=,6.58,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.5817,1,active,MW=520.4 > 500.0; LogP=6.79 > 5.0
5a2645eb,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccncc3)C2)cc1,,,raw,,521.4150000000002,520.11100276,6.182600000000005,83.89,1,5,4,4,3,0.23076923076923078,34,0.4444179968682752,False,2,True,0,,CHEMBL5201820,2780.0,nM,=,5.56,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.556,0,inactive,MW=521.4 > 500.0; LogP=6.18 > 5.0
06f23e7c,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3cccnc3)C2)cc1,,,raw,,521.4150000000002,520.11100276,6.182600000000005,83.89,1,5,4,4,3,0.23076923076923078,34,0.4444179968682752,False,2,True,0,,CHEMBL5190824,1630.0,nM,=,5.79,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.7878,0,inactive,MW=521.4 > 500.0; LogP=6.18 > 5.0
bda47dee,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccn3)C2)cc1,,,raw,,521.4150000000002,520.11100276,6.182600000000005,83.89,1,5,4,4,3,0.23076923076923078,34,0.4444179968682752,False,2,True,0,,CHEMBL5196601,650.0,nM,=,6.19,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.1871,1,active,MW=521.4 > 500.0; LogP=6.18 > 5.0
018ab7e4,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3cncs3)C2)cc1,,,raw,,527.4440000000002,526.067423696,6.244100000000005,83.89,1,6,4,4,3,0.25,33,0.4352633092441412,False,2,True,0,,CHEMBL5170050,4360.0,nM,=,5.36,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.3605,0,inactive,MW=527.4 > 500.0; LogP=6.24 > 5.0
9e1571a7,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3nccs3)C2)cc1,,,raw,,527.4440000000002,526.067423696,6.244100000000005,83.89,1,6,4,4,3,0.25,33,0.4352633092441412,False,2,True,0,,CHEMBL5203025,1610.0,nM,=,5.79,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.7932,0,inactive,MW=527.4 > 500.0; LogP=6.24 > 5.0
2d1b2446,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccoc3)C2)cc1,,,raw,,510.38800000000015,509.095018348,6.380600000000006,84.14,1,5,4,4,3,0.24,33,0.44157437477598754,False,2,True,0,,CHEMBL5185435,3820.0,nM,=,5.42,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.4179,0,inactive,MW=510.4 > 500.0; LogP=6.38 > 5.0
f2c31eb4,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccco3)C2)cc1,,,raw,,510.38800000000015,509.095018348,6.380600000000006,84.14,1,5,4,4,3,0.24,33,0.44157437477598754,False,2,True,0,,CHEMBL5184993,1260.0,nM,=,5.9,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.8996,0,inactive,MW=510.4 > 500.0; LogP=6.38 > 5.0
d0f9d6fe,,Cc1ccc(C(=O)N2N=C(c3ccc(NC(=O)OC(C)(C)C)cc3)CC2c2ccco2)cc1,,,raw,,445.51900000000023,445.200156344,5.926520000000006,84.14,1,5,4,4,3,0.2692307692307692,33,0.5396653921385229,True,1,True,0,,CHEMBL5201389,3290.0,nM,=,5.48,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.4828,0,inactive,LogP=5.93 > 5.0
1beec906,,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C#N)cc3)C(c3ccco3)C2)cc1,,,raw,,434.4770000000002,434.104876056,3.514280000000002,115.77,1,6,5,4,3,0.13636363636363635,31,0.6596146867486372,True,0,True,0,,CHEMBL5183128,7440.0,nM,=,5.13,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.1284,0,inactive,
1732a66c,,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc([N+](=O)[O-])cc3)C(c3ccco3)C2)cc1,,,raw,,454.4640000000002,454.0947052959999,3.5508000000000024,135.12,1,7,6,4,3,0.14285714285714285,32,0.4469197244181334,True,0,True,0,,CHEMBL5204089,1970.0,nM,=,5.71,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.7055,0,inactive,
17b6967a,,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C(F)(F)F)cc3)C(c3ccco3)C2)cc1,,,raw,,477.46400000000017,477.097011716,4.661400000000003,91.98,1,5,5,4,3,0.18181818181818182,33,0.5786069986761421,True,0,True,0,,CHEMBL5204882,2880.0,nM,=,5.54,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.5406,0,inactive,
9a3500d4,,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccco3)C2)cc1,,,raw,,488.36300000000017,487.02013915599997,4.405100000000003,91.98,1,5,5,4,3,0.14285714285714285,30,0.5763388703022903,True,0,True,0,,CHEMBL5183356,2470.0,nM,=,5.61,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.6073,0,inactive,
003b4eae,,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Cl)cc3)C(c3ccco3)C2)cc1,,,raw,,443.9120000000002,443.07065473599994,4.296000000000003,91.98,1,5,5,4,3,0.14285714285714285,30,0.6360142780206917,True,0,True,0,,CHEMBL5198074,2720.0,nM,=,5.57,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.5654,0,inactive,
976bd566,,CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,492.3730000000001,491.084453664,6.009000000000005,71.0,1,4,5,4,3,0.16,32,0.4744583227484093,True,1,True,0,,CHEMBL5182854,3326.4,nM,=,7.48,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,2,5.478,0,inactive,LogP=6.01 > 5.0
1947e14c,,CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,506.40000000000015,505.100103728,6.397500000000005,71.0,1,4,5,4,3,0.19230769230769232,33,0.4356311068894571,False,2,True,0,,CHEMBL5202594,442.7,nM,=,8.36,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,2,6.3539,1,active,MW=506.4 > 500.0; LogP=6.40 > 5.0
a8164efc,,CC(C)COC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,520.4270000000001,519.1157537920001,6.6451000000000064,71.0,1,4,6,4,3,0.2222222222222222,34,0.3959941078353645,False,2,True,0,,CHEMBL5201326,164.0,nM,=,6.79,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.7852,1,active,MW=520.4 > 500.0; LogP=6.65 > 5.0
9856c775,,C=CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,504.3840000000001,503.084453664,6.175100000000005,71.0,1,4,6,4,3,0.11538461538461539,33,0.4081383519353021,False,2,True,0,,CHEMBL5187331,4430.9,nM,=,7.5,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,2,5.3535,0,inactive,MW=504.4 > 500.0; LogP=6.18 > 5.0
432fa6d3,,C#CCCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,516.3950000000002,515.0844536640001,6.012400000000005,71.0,1,4,6,4,3,0.14814814814814814,34,0.3222560311213771,False,2,True,0,,CHEMBL5182395,65.0,nM,=,7.19,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,7.1871,1,active,MW=516.4 > 500.0; LogP=6.01 > 5.0
b54fb958,,CNC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,477.36200000000014,476.084788012,5.191900000000004,73.80000000000001,2,3,4,4,3,0.125,31,0.542898016180021,True,1,True,0,,CHEMBL5174166,5530.0,nM,=,5.26,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.2573,0,inactive,LogP=5.19 > 5.0
ae81a319,,CN(C)C(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,491.38900000000007,490.100438076,5.534100000000005,65.01,1,3,4,4,3,0.16,32,0.5215135956694776,True,1,True,0,,CHEMBL5201193,2410.0,nM,=,5.62,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.618,0,inactive,LogP=5.53 > 5.0
1ab83508,,CC(C)NC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,505.4160000000001,504.11608814,5.970500000000005,73.80000000000001,2,3,5,4,3,0.19230769230769232,33,0.44854286236428026,False,2,True,0,,CHEMBL5203263,350.0,nM,=,6.46,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.4559,1,active,MW=505.4 > 500.0; LogP=5.97 > 5.0
ac9492a1,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cn1,,,raw,,521.4150000000001,520.11100276,6.182600000000005,83.89,1,5,4,4,3,0.23076923076923078,34,0.44441799686827566,False,2,True,0,,CHEMBL5170955,309.0,nM,=,6.51,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.51,1,active,MW=521.4 > 500.0; LogP=6.18 > 5.0
e77766bc,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)nc1,,,raw,,521.4150000000002,520.11100276,6.182600000000005,83.89,1,5,4,4,3,0.23076923076923078,34,0.4444179968682752,False,2,True,0,,CHEMBL5205655,372.0,nM,=,6.43,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.4295,1,active,MW=521.4 > 500.0; LogP=6.18 > 5.0
9ccaf9b8,,CC1C(c2ccc(NC(=O)OC(C)(C)C)cc2)=NN(C(=O)c2ccc(Br)cc2)C1c1ccccc1,,,raw,,534.4540000000002,533.131403856,7.033600000000007,71.0,1,4,4,4,3,0.25,35,0.39066525630091936,False,2,True,0,,CHEMBL5196944,27.4,nM,=,7.56,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,7.5622,1,active,MW=534.5 > 500.0; LogP=7.03 > 5.0
41db4d9b,,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2c2ccccc2)cc1,,,raw,,596.5250000000002,595.1470539200001,8.181300000000006,71.0,1,4,5,5,4,0.18181818181818182,40,0.25267270798113706,False,2,True,0,,CHEMBL5193713,172.0,nM,=,6.76,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,6.7645,1,active,MW=596.5 > 500.0; LogP=8.18 > 5.0
c0c0d45e,,CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2C)cn1,,,raw,,521.4150000000001,520.11100276,6.038500000000005,83.89,1,5,5,4,3,0.23076923076923078,34,0.4440041233987801,False,2,True,0,,CHEMBL5183315,79.5,nM,=,8.7,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,2,7.0996,1,active,MW=521.4 > 500.0; LogP=6.04 > 5.0
a4179996,,CC1C(c2ccc(N3CCOC3=O)cc2)=NN(C(=O)c2ccc(Br)cc2)C1c1ccccc1,,,raw,,504.3840000000001,503.084453664,5.6432000000000055,62.21,0,4,4,5,3,0.19230769230769232,33,0.46201843511527607,False,2,True,0,,CHEMBL5195576,5160.0,nM,=,5.29,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.2874,0,inactive,MW=504.4 > 500.0; LogP=5.64 > 5.0
599facf6,,COC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,463.3310000000001,462.057904568,5.227200000000004,58.97,0,4,4,4,3,0.125,30,0.4984348890619983,True,1,True,0,,CHEMBL5176214,1640.0,nM,=,5.79,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.7852,0,inactive,LogP=5.23 > 5.0
0b00279a,,CC(C)OC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,491.3850000000001,490.089204696,6.005800000000005,58.97,0,4,5,4,3,0.19230769230769232,32,0.41129222344115157,True,1,True,0,,CHEMBL5197785,2235.0,nM,=,6.96,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,2,5.6507,0,inactive,LogP=6.01 > 5.0
8dbbbfd6,,CC(C)C(=O)Oc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,491.38500000000005,490.089204696,6.002000000000005,58.97,0,4,5,4,3,0.19230769230769232,32,0.3249527520068013,True,1,True,0,,CHEMBL5200411,5450.0,nM,=,5.26,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.2636,0,inactive,LogP=6.00 > 5.0
d6592b47,,CN(C)C(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,raw,,476.3740000000001,475.089539044,5.142400000000005,52.980000000000004,0,3,4,4,3,0.16,31,0.5237140275960733,True,1,True,0,,CHEMBL5174227,5910.0,nM,=,5.23,CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,0.8,1,5.2284,0,inactive,LogP=5.14 > 5.0
b555c875,,CCCn1cc(/C=N/N=C2\C(=O)Nc3ccc(C)cc32)c2ccccc21,,,raw,,344.41800000000006,344.16371126,4.135020000000003,58.75,1,4,4,4,3,0.19047619047619047,26,0.5612155627366041,True,0,False,1,PAINS match: imine_one_isatin(189),CHEMBL5196783,460.0,nM,=,6.34,CHEMBL5150894,Inhibition of BCL2 (unknown origin),0.8,2,6.3372,1,active,
b6faf4cd,,Cc1ccc(Nc2nnc(-c3cc(-c4ccc(Br)cc4)nc4ccccc34)o2)cc1,,,raw,,457.33100000000013,456.058573264,6.766320000000004,63.84,1,5,4,5,5,0.041666666666666664,30,0.32288863965101794,True,1,True,0,,CHEMBL5276080,1930.0,nM,=,5.71,CHEMBL5232571,Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin),0.8,1,5.7144,0,inactive,LogP=6.77 > 5.0
0a6a517e,,COc1ccc2nc(-c3ccc(Br)cc3)cc(-c3nnc(Nc4ccc([N+](=O)[O-])cc4)o3)c2c1,,,raw,,518.3270000000002,517.0385660920001,6.374700000000004,116.21000000000001,1,8,6,5,5,0.041666666666666664,34,0.20354039731117327,False,2,True,0,,CHEMBL5291477,150.0,nM,=,6.82,CHEMBL5232571,Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin),0.8,1,6.8239,1,active,MW=518.3 > 500.0; LogP=6.37 > 5.0
8b280658,,CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(=C[C@@H]4C[C@H]1C(C)(C)O[C@@]2(C/C=C(/C)C(=O)O)C4=O)C3=O,,,raw,,628.7620000000004,628.303618368,7.239300000000007,119.36000000000001,2,7,8,7,1,0.5,46,0.22848135203833123,False,2,True,0,,CHEMBL555017,141.0,nM,=,6.91,CHEMBL5241841,Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,2,6.8508,1,active,MW=628.8 > 500.0; LogP=7.24 > 5.0
b516187b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(Cl)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,807.3290000000002,806.228946268,8.882500000000004,168.79,3,10,12,8,6,0.23809523809523808,57,0.08022996847170942,False,2,True,0,,CHEMBL5560407,140.0,nM,=,7.55,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,6.8539,1,active,MW=807.3 > 500.0; LogP=8.88 > 5.0
063bd128,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(Cl)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,807.3290000000002,806.228946268,8.882500000000004,168.79,3,10,12,8,6,0.23809523809523808,57,0.08022996847170942,False,2,True,0,,CHEMBL5560077,122.0,nM,=,7.29,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,6.9136,1,active,MW=807.3 > 500.0; LogP=8.88 > 5.0
ca276473,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,807.3290000000002,806.228946268,8.882500000000004,168.79,3,10,12,8,6,0.23809523809523808,57,0.08022996847170942,False,2,True,0,,CHEMBL5542608,16.0,nM,=,8.26,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,7.7959,1,active,MW=807.3 > 500.0; LogP=8.88 > 5.0
20580a89,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3c(F)cccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,825.3190000000002,824.219524456,9.021600000000001,168.79,3,10,12,8,6,0.23809523809523808,58,0.07999306944561564,False,2,True,0,,CHEMBL5557529,18.5,nM,=,7.96,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.7328,1,active,MW=825.3 > 500.0; LogP=9.02 > 5.0
e54533ff,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,772.8840000000002,772.2679186199999,8.229100000000006,168.79,3,10,12,8,6,0.23809523809523808,56,0.08139623411034959,False,2,True,0,,CHEMBL5559481,9.3,nM,=,8.03,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.0315,1,active,MW=772.9 > 500.0; LogP=8.23 > 5.0
792190d8,,CC1(c2ccccc2)CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,786.911,786.283568684,8.403200000000005,168.79,3,10,12,8,6,0.2558139534883721,57,0.0809140070243694,False,2,True,0,,CHEMBL5560980,10.0,nM,=,8.48,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,8.0,1,active,MW=786.9 > 500.0; LogP=8.40 > 5.0
4412e2fe,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,758.8570000000003,758.252268556,7.8390000000000075,168.79,3,10,12,8,6,0.21951219512195122,55,0.08259427798783697,False,2,True,0,,CHEMBL5557096,613.0,nM,=,6.6,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,6.2125,1,active,MW=758.9 > 500.0; LogP=7.84 > 5.0
ee51e7b1,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,786.9110000000003,786.283568684,8.619200000000005,168.79,3,10,12,8,6,0.2558139534883721,57,0.08067331597029095,False,2,True,0,,CHEMBL5567852,51.5,nM,=,7.64,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.2882,1,active,MW=786.9 > 500.0; LogP=8.62 > 5.0
bb846e74,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC(c4ccccc4)C3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,772.8840000000002,772.2679186199999,7.881500000000008,168.79,3,10,12,8,6,0.23809523809523808,56,0.08219663639794844,False,2,True,0,,CHEMBL5563244,163.5,nM,=,7.34,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,6.7865,1,active,MW=772.9 > 500.0; LogP=7.88 > 5.0
012cf8ec,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,772.8840000000002,772.2679186199999,8.229100000000006,168.79,3,10,12,8,6,0.23809523809523808,56,0.08139623411034959,False,2,True,0,,CHEMBL5568324,55.0,nM,=,7.47,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.2596,1,active,MW=772.9 > 500.0; LogP=8.23 > 5.0
b93b40e1,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccnc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,773.8720000000002,773.2631675879999,7.624100000000007,181.68000000000004,3,11,12,8,6,0.24390243902439024,56,0.08218411850210011,False,3,True,0,,CHEMBL5532222,16.6,nM,=,8.14,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.7799,1,active,MW=773.9 > 500.0; LogP=7.62 > 5.0; HBA=11 > 10
c68ba6e9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3C3CCCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,778.9319999999999,778.314868812,8.436700000000007,168.79,3,10,12,8,5,0.38095238095238093,56,0.08256683360307038,False,2,True,0,,CHEMBL5527871,131.0,nM,=,7.39,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,6.8827,1,active,MW=778.9 > 500.0; LogP=8.44 > 5.0
9899fdf4,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3F)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,790.8740000000003,790.2584968079999,8.368200000000005,168.79,3,10,12,8,6,0.23809523809523808,57,0.08090782740292,False,2,True,0,,CHEMBL5518078,15.0,nM,=,7.82,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,7.8239,1,active,MW=790.9 > 500.0; LogP=8.37 > 5.0
6362a1ec,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3-c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,848.9820000000002,848.2992187479999,9.896099999999997,168.79,3,10,13,9,7,0.20833333333333334,62,0.07502243322040647,False,2,True,0,,CHEMBL5561570,29.0,nM,=,7.82,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.5376,1,active,MW=849.0 > 500.0; LogP=9.90 > 5.0
41363403,,Cc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,786.9110000000001,786.283568684,8.537520000000004,168.79,3,10,12,8,6,0.2558139534883721,57,0.08075455245398984,False,2,True,0,,CHEMBL5566790,8.5,nM,=,8.52,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.0706,1,active,MW=786.9 > 500.0; LogP=8.54 > 5.0
3cb91b1d,,CCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,800.9379999999999,800.2992187479999,8.791500000000005,168.79,3,10,13,8,6,0.2727272727272727,58,0.07583546297787794,False,2,True,0,,CHEMBL5562291,4.1,nM,=,8.39,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.3872,1,active,MW=800.9 > 500.0; LogP=8.79 > 5.0
1e6feb55,,CC(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,814.9649999999998,814.314868812,9.352500000000001,168.79,3,10,13,8,6,0.28888888888888886,59,0.07546151979679491,False,2,True,0,,CHEMBL5557735,4.8,nM,=,8.52,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.3188,1,active,MW=815.0 > 500.0; LogP=9.35 > 5.0
4d51eefa,,CC(C)(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,828.9919999999997,828.3305188759999,9.5266,168.79,3,10,12,8,6,0.30434782608695654,60,0.0798046774647616,False,2,True,0,,CHEMBL5517916,19.95,nM,=,8.05,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.7001,1,active,MW=829.0 > 500.0; LogP=9.53 > 5.0
797e4c08,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000001,812.2992187479999,9.106500000000002,168.79,3,10,13,9,6,0.28888888888888886,59,0.0755570295485051,False,2,True,0,,CHEMBL5542692,7.2,nM,=,8.68,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,4,8.1427,1,active,MW=812.9 > 500.0; LogP=9.11 > 5.0
1ba219bd,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000001,812.2992187479999,9.106500000000002,168.79,3,10,13,9,6,0.28888888888888886,59,0.0755570295485051,False,2,True,0,,CHEMBL5557016,16.81,nM,=,9.21,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.7744,1,active,MW=812.9 > 500.0; LogP=9.11 > 5.0
ec7314c7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000001,812.2992187479999,9.106500000000002,168.79,3,10,13,9,6,0.28888888888888886,59,0.0755570295485051,False,2,True,0,,CHEMBL5543056,1.9,nM,=,7.92,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,8.7212,1,active,MW=812.9 > 500.0; LogP=9.11 > 5.0
972a3277,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.976,826.314868812,9.496599999999999,168.79,3,10,13,9,6,0.30434782608695654,60,0.07533364803534225,False,2,True,0,,CHEMBL5532439,9.85,nM,=,8.17,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.0066,1,active,MW=827.0 > 500.0; LogP=9.50 > 5.0
6c344045,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,841.0029999999999,840.3305188759999,9.886699999999998,168.79,3,10,13,9,6,0.3191489361702128,61,0.07518537648074461,False,2,True,0,,CHEMBL5562934,9.8,nM,=,8.01,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.0088,1,active,MW=841.0 > 500.0; LogP=9.89 > 5.0
d26f861e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,855.0299999999999,854.34616894,10.276799999999996,168.79,3,10,13,9,6,0.3333333333333333,62,0.07508212047997584,False,2,True,0,,CHEMBL5558697,40.0,nM,=,7.4,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,7.3979,1,active,MW=855.0 > 500.0; LogP=10.28 > 5.0
5cbf525b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3Cc3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.976,826.314868812,8.976500000000003,168.79,3,10,14,9,6,0.30434782608695654,60,0.07120721837059299,False,2,True,0,,CHEMBL5563903,513.0,nM,=,7.08,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,6.2899,1,active,MW=827.0 > 500.0; LogP=8.98 > 5.0
c513323e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)c(F)c2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.9390000000001,830.2897969359999,9.245600000000001,168.79,3,10,13,9,6,0.28888888888888886,60,0.07536794930522502,False,2,True,0,,CHEMBL5557944,23.75,nM,=,8.12,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.6243,1,active,MW=830.9 > 500.0; LogP=9.25 > 5.0
c72093fb,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2F)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.9390000000001,830.2897969359999,9.245600000000001,168.79,3,10,13,9,6,0.28888888888888886,60,0.07536794930522502,False,2,True,0,,CHEMBL5567807,8.05,nM,=,8.51,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.0942,1,active,MW=830.9 > 500.0; LogP=9.25 > 5.0
223965b4,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cn2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.937,813.2944677159999,8.501500000000005,181.68000000000004,3,11,13,9,6,0.29545454545454547,59,0.0751211216245136,False,3,True,0,,CHEMBL5532350,4.1,nM,=,8.85,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.3872,1,active,MW=813.9 > 500.0; LogP=8.50 > 5.0; HBA=11 > 10
6447e32e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.9760000000001,826.314868812,9.102100000000002,168.79,3,10,14,9,6,0.30434782608695654,60,0.07115586014464566,False,2,True,0,,CHEMBL5523489,85.0,nM,=,7.64,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,7.0706,1,active,MW=827.0 > 500.0; LogP=9.10 > 5.0
a8252fb2,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CCN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,841.003,840.3305188759999,9.144600000000002,168.79,3,10,15,9,6,0.3191489361702128,61,0.06698654031295999,False,2,True,0,,CHEMBL5568336,8.1,nM,=,8.09,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.0915,1,active,MW=841.0 > 500.0; LogP=9.14 > 5.0
fdcc1a92,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Cc2ccc(CN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,841.003,840.3305188759999,9.025900000000004,168.79,3,10,15,9,6,0.3191489361702128,61,0.06702881742417718,False,2,True,0,,CHEMBL5561459,47.0,nM,=,7.33,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.3279,1,active,MW=841.0 > 500.0; LogP=9.03 > 5.0
4ec81e28,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Cc2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.9760000000001,826.314868812,9.030300000000004,168.79,3,10,14,9,6,0.30434782608695654,60,0.07118387962075966,False,2,False,1,PAINS match: anil_di_alk_E(186),CHEMBL5559280,11.0,nM,=,7.96,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,7.9586,1,active,MW=827.0 > 500.0; LogP=9.03 > 5.0
aa6049b6,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(N4CCCC4c4ccccc4C4CC4)C3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,868.0289999999999,867.3414179079999,8.790700000000006,172.03,3,11,14,10,6,0.3333333333333333,63,0.07059836640529583,False,3,True,0,,CHEMBL5565358,24.0,nM,=,7.62,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.6198,1,active,MW=868.0 > 500.0; LogP=8.79 > 5.0; HBA=11 > 10
b5c927c4,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.997,818.34616894,8.961300000000005,168.79,3,10,13,9,5,0.4222222222222222,59,0.07704142073174182,False,2,True,0,,CHEMBL5531998,0.88,nM,=,9.06,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,9.0555,1,active,MW=819.0 > 500.0; LogP=8.96 > 5.0
bec545cf,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,816.981,816.3305188759999,8.871000000000006,168.79,3,10,13,9,5,0.37777777777777777,59,0.07710761536380115,False,2,True,0,,CHEMBL5564159,1.1,nM,=,8.96,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.9586,1,active,MW=817.0 > 500.0; LogP=8.87 > 5.0
6cfe9fc9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,819.985,819.3414179079999,7.903900000000009,172.03,3,11,13,9,5,0.4090909090909091,59,0.07790410895049596,False,3,True,0,,CHEMBL5566724,4.095,nM,=,9.0,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.3877,1,active,MW=820.0 > 500.0; LogP=7.90 > 5.0; HBA=11 > 10
bf0ca43f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(CN3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,9.118600000000004,168.79,3,10,14,9,5,0.391304347826087,60,0.07250893124395665,False,2,True,0,,CHEMBL5559354,1.3,nM,=,8.89,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.8861,1,active,MW=831.0 > 500.0; LogP=9.12 > 5.0
c2907179,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC(CN3CCCC3c3ccccc3C3CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,805.9580000000001,805.3257678439999,7.371300000000009,172.03,3,11,14,9,5,0.3953488372093023,58,0.07560327413358064,False,3,True,0,,CHEMBL5568386,9.2,nM,=,8.62,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.0362,1,active,MW=806.0 > 500.0; LogP=7.37 > 5.0; HBA=11 > 10
75c7428e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(CN3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.012,833.3570679719999,8.151500000000008,172.03,3,11,14,9,5,0.4222222222222222,60,0.07284696593017362,False,3,True,0,,CHEMBL5564702,2.785,nM,=,9.57,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.5552,1,active,MW=834.0 > 500.0; LogP=8.15 > 5.0; HBA=11 > 10
76d509e7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,860.0499999999998,859.3727180359999,8.684100000000006,172.03,3,11,13,10,5,0.44680851063829785,62,0.07642415225680049,False,3,True,0,,CHEMBL5564343,1.2,nM,=,8.92,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.9208,1,active,MW=860.0 > 500.0; LogP=8.68 > 5.0; HBA=11 > 10
b757d5d3,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.9959999999999,831.3414179079999,7.903900000000009,172.03,3,11,13,10,5,0.4222222222222222,60,0.07781259784844878,False,3,True,0,,CHEMBL5560955,0.12,nM,=,9.92,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,9.9208,1,active,MW=832.0 > 500.0; LogP=7.90 > 5.0; HBA=11 > 10
889f0da7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(CN4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,846.0229999999998,845.3570679719999,8.151500000000008,172.03,3,11,14,10,5,0.43478260869565216,61,0.07277739267713706,False,3,True,0,,CHEMBL5565924,7.8,nM,=,8.21,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,8.1079,1,active,MW=846.0 > 500.0; LogP=8.15 > 5.0; HBA=11 > 10
ede8bf48,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(CN2CCCC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999998,873.3883680999999,8.931700000000005,172.03,3,11,14,10,5,0.4583333333333333,63,0.07187370259213911,False,3,True,0,,CHEMBL5562147,6.4,nM,=,8.19,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.1938,1,active,MW=874.1 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
648ad5c6,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(C3CC(N4CCCC4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999997,873.3883680999999,8.930100000000005,172.03,3,11,14,10,5,0.4583333333333333,63,0.07187449364464595,False,3,True,0,,CHEMBL5562740,8.9,nM,=,8.05,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,8.0506,1,active,MW=874.1 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
ce4ae38c,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC(N3CC(N4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,847.0109999999997,846.35231694,6.807900000000007,175.27,3,12,14,10,5,0.4222222222222222,61,0.07884091287190158,False,3,True,0,,CHEMBL5559198,9.0,nM,=,8.05,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.0458,1,active,MW=847.0 > 500.0; LogP=6.81 > 5.0; HBA=12 > 10
92731a21,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3CC(N4CCC[C@H]4c4ccccc4C4CC4)CC3C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,846.0229999999999,845.3570679719999,8.149900000000008,172.03,3,11,13,10,5,0.43478260869565216,61,0.07716773326582976,False,3,True,0,,CHEMBL5561898,26.0,nM,=,7.58,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,7.585,1,active,MW=846.0 > 500.0; LogP=8.15 > 5.0; HBA=11 > 10
1eeb6dba,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,854.43,853.302445556,8.460100000000006,172.03,3,11,12,9,5,0.4090909090909091,60,0.08123684667299502,False,3,True,0,,CHEMBL5565335,0.3349999999999999,nM,=,9.44,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,4,9.475,1,active,MW=854.4 > 500.0; LogP=8.46 > 5.0; HBA=11 > 10
219e8a3c,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,854.43,853.302445556,8.460100000000006,172.03,3,11,12,9,5,0.4090909090909091,60,0.08123684667299502,False,3,True,0,,CHEMBL5557109,4.8,nM,=,8.8,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,4,8.3188,1,active,MW=854.4 > 500.0; LogP=8.46 > 5.0; HBA=11 > 10
ed658d99,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccc(Cl)cc2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,854.43,853.302445556,8.460100000000006,172.03,3,11,12,9,5,0.4090909090909091,60,0.08123684667299502,False,3,True,0,,CHEMBL5554998,7.7,nM,=,8.55,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,4,8.1135,1,active,MW=854.4 > 500.0; LogP=8.46 > 5.0; HBA=11 > 10
89e5b9c8,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Br)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,898.881,897.2519299759999,8.569200000000007,172.03,3,11,12,9,5,0.4090909090909091,60,0.08094714494009458,False,3,True,0,,CHEMBL5562355,0.43,nM,=,9.8,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,9.3665,1,active,MW=898.9 > 500.0; LogP=8.57 > 5.0; HBA=11 > 10
4c4f02c9,,Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,834.0119999999996,833.3570679719999,8.115120000000008,172.03,3,11,12,9,5,0.4222222222222222,60,0.0819184991826831,False,3,True,0,,CHEMBL5564290,0.11,nM,=,10.29,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,9.9586,1,active,MW=834.0 > 500.0; LogP=8.12 > 5.0; HBA=11 > 10
e45331d4,,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,848.0389999999995,847.3727180359999,8.369100000000007,172.03,3,11,13,9,5,0.43478260869565216,61,0.07680999642009365,False,3,True,0,,CHEMBL5542719,0.078,nM,=,10.42,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,4,10.1079,1,active,MW=848.0 > 500.0; LogP=8.37 > 5.0; HBA=11 > 10
f53c6709,,CC(C)Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,876.0929999999995,875.404018164,9.005200000000002,172.03,3,11,14,9,5,0.4583333333333333,63,0.07183274888585517,False,3,True,0,,CHEMBL5568440,1.6,nM,=,9.26,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,8.7959,1,active,MW=876.1 > 500.0; LogP=9.01 > 5.0; HBA=11 > 10
5bdb4de6,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999998,873.3883680999999,9.074200000000005,172.03,3,11,13,10,5,0.4583333333333333,63,0.07614025941863069,False,3,True,0,,CHEMBL5555045,8.79,nM,=,9.24,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.056,1,active,MW=874.1 > 500.0; LogP=9.07 > 5.0; HBA=11 > 10
6e2f5dac,,COc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,850.0109999999995,849.3519825919999,7.815300000000009,181.26000000000002,3,12,13,9,5,0.4222222222222222,61,0.07735298958091795,False,3,True,0,,CHEMBL5567413,0.12,nM,=,10.21,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,9.9208,1,active,MW=850.0 > 500.0; LogP=7.82 > 5.0; HBA=12 > 10
94dfe0a9,,CCOc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,864.0379999999996,863.367632656,8.205400000000008,181.26000000000002,3,12,14,9,5,0.43478260869565216,62,0.07203971623900104,False,3,True,0,,CHEMBL5556265,0.095,nM,=,10.02,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,10.0223,1,active,MW=864.0 > 500.0; LogP=8.21 > 5.0; HBA=12 > 10
43ff9b45,,CC(C)Oc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,878.0649999999995,877.3832827199999,8.593900000000005,181.26000000000002,3,12,14,9,5,0.44680851063829785,63,0.0715250031012741,False,3,True,0,,CHEMBL5562626,0.076,nM,=,10.12,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,10.1192,1,active,MW=878.1 > 500.0; LogP=8.59 > 5.0; HBA=12 > 10
b0218e52,,COCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,864.0379999999996,863.367632656,7.953100000000009,181.26000000000002,3,12,14,9,5,0.43478260869565216,62,0.07253306325050483,False,3,True,0,,CHEMBL5561534,5.085,nM,=,9.77,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.2937,1,active,MW=864.0 > 500.0; LogP=7.95 > 5.0; HBA=12 > 10
b964ea4d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2N2CCCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,889.0919999999996,888.3992671319999,8.406900000000007,175.27,3,12,13,10,5,0.4583333333333333,64,0.07618980519517987,False,3,True,0,,CHEMBL5523480,2.19,nM,=,9.74,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.6596,1,active,MW=889.1 > 500.0; LogP=8.41 > 5.0; HBA=12 > 10
318c7572,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CC6COCC6C5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,888.1039999999995,887.404018164,9.176100000000002,172.03,3,11,13,10,5,0.46938775510204084,64,0.07605574518888814,False,3,True,0,,CHEMBL5562694,1.871,nM,=,10.38,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.7279,1,active,MW=888.1 > 500.0; LogP=9.18 > 5.0; HBA=11 > 10
361c4682,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCN(C)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,875.1089999999994,874.420002576,8.845300000000003,166.04,3,11,13,9,5,0.4583333333333333,63,0.0764436440500364,False,3,True,0,,CHEMBL5567889,0.8200000000000001,nM,=,10.4,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,9.0862,1,active,MW=875.1 > 500.0; LogP=8.85 > 5.0; HBA=11 > 10
2de10027,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCC(F)(F)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,896.0739999999995,895.39025992,10.328999999999995,162.79999999999998,3,10,13,9,5,0.4583333333333333,64,0.07658604534522954,False,2,True,0,,CHEMBL5559861,1.315,nM,=,9.89,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.8811,1,active,MW=896.1 > 500.0; LogP=10.33 > 5.0
cd393123,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,890.1199999999994,889.4196682280001,9.444700000000001,183.03,4,11,13,9,5,0.46938775510204084,64,0.06527078762854406,False,3,True,0,,CHEMBL5314951,0.1795,nM,=,10.72,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,4,9.7459,1,active,MW=890.1 > 500.0; LogP=9.44 > 5.0; HBA=11 > 10
f79edd57,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,890.1199999999994,889.4196682280001,9.444700000000001,183.03,4,11,13,9,5,0.46938775510204084,64,0.06527078762854406,False,3,True,0,,CHEMBL5560668,0.074,nM,=,10.77,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,5,10.1308,1,active,MW=890.1 > 500.0; LogP=9.44 > 5.0; HBA=11 > 10
5b4df929,,CO[C@]1(C)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C(C)C)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,904.147,903.435318292,10.098799999999997,172.02999999999997,3,11,14,9,5,0.48,65,0.0715405269869023,False,3,True,0,,CHEMBL5561680,0.087,nM,=,10.06,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,10.0605,1,active,MW=904.1 > 500.0; LogP=10.10 > 5.0; HBA=11 > 10
3e7d3af9,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)NC(CN4CCOCC4)C5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,889.0919999999993,888.3992671319997,7.760400000000008,175.27,3,12,12,10,5,0.4583333333333333,64,0.08218719086846218,False,3,True,0,,CHEMBL5558905,1.2145,nM,=,10.54,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,8.9156,1,active,MW=889.1 > 500.0; LogP=7.76 > 5.0; HBA=12 > 10
87f1b9d6,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)NC(C4CCOCC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,890.0759999999995,889.3832827199998,8.691100000000004,181.25999999999996,3,12,11,10,5,0.4583333333333333,64,0.08494189306168301,False,3,True,0,,CHEMBL5568435,0.862,nM,=,10.62,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,9.0645,1,active,MW=890.1 > 500.0; LogP=8.69 > 5.0; HBA=12 > 10
82b37792,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)N[C@H](C4CCC(C)(O)CC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,918.1299999999994,917.4145828479998,9.205700000000002,192.25999999999996,4,12,11,10,5,0.48,66,0.07266473575534935,False,3,True,0,,CHEMBL5532549,0.353,nM,=,10.82,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,4,9.4522,1,active,MW=918.1 > 500.0; LogP=9.21 > 5.0; HBA=12 > 10
741fc32d,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,882.4399999999996,881.2973601760001,7.792800000000009,181.26000000000002,3,12,13,9,5,0.37777777777777777,62,0.07728642828682362,False,3,True,0,,CHEMBL5567397,2.0,nM,=,9.46,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,3,8.699,1,active,MW=882.4 > 500.0; LogP=7.79 > 5.0; HBA=12 > 10
b9b7c372,,C[C@@H]1CN(c2cc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC(C)(C)CC4)CC3)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)c2cc3cc[nH]c3nc2O1,,,raw,,923.5369999999998,922.3602947799999,8.786600000000005,175.27,3,12,12,9,5,0.4166666666666667,65,0.08028010017001842,False,3,True,0,,CHEMBL5314523,10.6,nM,=,8.92,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,2,7.9747,1,active,MW=923.5 > 500.0; LogP=8.79 > 5.0; HBA=12 > 10
8b4d38d5,,CC1(C)CCC(CN2CCCn3nc(-c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)cc32)=C(c2ccc(Cl)cc2)C1,,,raw,,905.478,904.3133445880001,9.6115,186.60999999999999,3,12,13,9,6,0.3404255319148936,64,0.07400786570209048,False,3,True,0,,CHEMBL5560115,45.0,nM,=,7.35,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,7.3468,1,active,MW=905.5 > 500.0; LogP=9.61 > 5.0; HBA=12 > 10
0563568a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3n(n2)C(c2ccc(Cl)cc2)CCN3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,783.2669999999999,782.2037941399999,7.142500000000006,195.4,4,12,11,8,6,0.23684210526315788,55,0.07703144142487893,False,3,True,0,,CHEMBL5558230,205.0,nM,=,6.69,CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,0.8,1,6.6882,1,active,MW=783.3 > 500.0; LogP=7.14 > 5.0; HBA=12 > 10
0e6b02b6,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5(CN6CC(F)(F)C6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,raw,,901.4169999999998,900.2416605920001,6.884400000000008,125.56,1,10,13,7,3,0.4878048780487805,60,0.18166722981668312,False,2,True,0,,CHEMBL5647478,17.3,nM,=,7.76,CHEMBL5635886,Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay,0.8,1,7.762,1,active,MW=901.4 > 500.0; LogP=6.88 > 5.0
624c78b0,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,710.8310000000004,710.3104350640001,6.8035000000000085,96.71000000000001,1,8,7,9,5,0.3023255813953488,53,0.19853648934948273,False,2,True,0,,CHEMBL3958369,19.5,nM,=,7.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.71,1,active,MW=710.8 > 500.0; LogP=6.80 > 5.0
8885f10e,,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1,,,raw,,724.8580000000002,724.3260851279999,7.11192000000001,96.71000000000002,1,8,7,9,5,0.3181818181818182,54,0.1912281683975983,False,2,True,0,,CHEMBL3983424,20.0,nM,=,7.7,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.699,1,active,MW=724.9 > 500.0; LogP=7.11 > 5.0
da4d1140,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(Cl)cc1,,,raw,,745.2760000000003,744.2714627120001,7.45690000000001,96.71000000000001,1,8,7,9,5,0.3023255813953488,54,0.1849746612359995,False,2,True,0,,CHEMBL3927695,20.0,nM,=,7.7,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.699,1,active,MW=745.3 > 500.0; LogP=7.46 > 5.0
62ba7627,,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1F,,,raw,,742.8480000000002,742.3166633159999,7.25102000000001,96.71000000000002,1,8,7,9,5,0.3181818181818182,55,0.18780331995273597,False,2,True,0,,CHEMBL3899673,25.5,nM,=,7.72,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.5935,1,active,MW=742.8 > 500.0; LogP=7.25 > 5.0
a81ceb5d,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(OC(F)(F)F)cc1,,,raw,,794.8270000000005,794.2927343120001,7.702100000000009,105.94000000000001,1,9,8,9,5,0.3181818181818182,58,0.17055710678485209,False,2,True,0,,CHEMBL3940396,51.0,nM,=,7.29,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2924,1,active,MW=794.8 > 500.0; LogP=7.70 > 5.0
543f7193,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(O)cc1,,,raw,,726.8300000000004,726.3053496840001,6.509100000000009,116.94000000000001,2,9,7,9,5,0.3023255813953488,54,0.1952052178274076,False,2,True,0,,CHEMBL3943706,15.0,nM,=,7.82,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=726.8 > 500.0; LogP=6.51 > 5.0
7624e38c,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCN2,,,raw,,751.8840000000001,751.33698416,6.7715000000000085,108.74000000000001,2,9,7,10,5,0.3333333333333333,56,0.18777626786015908,False,2,True,0,,CHEMBL3934859,15.0,nM,=,7.82,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=751.9 > 500.0; LogP=6.77 > 5.0
d8b47172,,CN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,765.9110000000001,765.352634224,6.795800000000009,99.95000000000003,1,9,7,10,5,0.34782608695652173,57,0.19348472586573404,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3939864,13.0,nM,=,7.89,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8861,1,active,MW=765.9 > 500.0; LogP=6.80 > 5.0
cfc440d4,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,763.895,763.33698416,7.29520000000001,101.64000000000003,1,9,7,10,6,0.30434782608695654,57,0.18232824946307205,False,2,True,0,,CHEMBL3959149,18.5,nM,=,7.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.7328,1,active,MW=763.9 > 500.0; LogP=7.30 > 5.0
7aa128ed,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5[nH]ccc5c4)c4n2CCCC4)OCO3)CC1,,,raw,,762.9109999999997,762.352968572,7.200000000000009,106.51000000000002,2,8,7,10,6,0.30434782608695654,57,0.17735457939377128,False,2,True,0,,CHEMBL5780777,12.0,nM,=,7.92,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=762.9 > 500.0; LogP=7.20 > 5.0
66e8edde,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,777.922,777.352634224,7.6853000000000105,101.64000000000003,1,9,7,10,6,0.3191489361702128,58,0.177559993552562,False,2,True,0,,CHEMBL3921211,16.0,nM,=,7.8,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=777.9 > 500.0; LogP=7.69 > 5.0
379d5db3,,C[C@@H]1COCCN1C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n1CCCC3)OCO2,,,raw,,777.9219999999998,777.352634224,7.683700000000011,101.64000000000001,1,9,7,10,6,0.3191489361702128,58,0.17757333015159701,False,2,True,0,,CHEMBL3949045,17.0,nM,=,7.77,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7696,1,active,MW=777.9 > 500.0; LogP=7.68 > 5.0
d9482c97,,C[C@H]1COCCN1C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n1CCCC3)OCO2,,,raw,,777.9219999999998,777.352634224,7.683700000000011,101.64000000000001,1,9,7,10,6,0.3191489361702128,58,0.17757333015159701,False,2,True,0,,CHEMBL3904445,18.0,nM,=,7.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=777.9 > 500.0; LogP=7.68 > 5.0
62e185bd,,C[C@H]1COC[C@H](C)N1C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n1CCCC3)OCO2,,,raw,,791.9489999999998,791.368284288,8.072200000000011,101.64000000000001,1,9,7,10,6,0.3333333333333333,59,0.1746438324843045,False,2,True,0,,CHEMBL3935948,81.0,nM,=,7.09,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0915,1,active,MW=791.9 > 500.0; LogP=8.07 > 5.0
c662646a,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Br)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,798.7819999999997,797.2576669880001,8.32900000000001,83.18,1,7,7,9,6,0.28888888888888886,55,0.1758247236304371,False,2,True,0,,CHEMBL3918235,32.0,nM,=,7.5,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4949,1,active,MW=798.8 > 500.0; LogP=8.33 > 5.0
b13178f9,,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Br)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,800.7979999999997,799.2733170520002,7.829600000000009,81.49000000000001,1,7,7,9,5,0.3333333333333333,55,0.18096509504327124,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3916185,27.0,nM,=,7.57,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5686,1,active,MW=800.8 > 500.0; LogP=7.83 > 5.0
1a58de0d,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,701.2670000000004,700.2816334720001,7.728200000000009,78.25000000000001,1,6,7,8,5,0.2857142857142857,51,0.18815054223600947,False,2,True,0,,CHEMBL3933816,35.0,nM,=,7.46,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4559,1,active,MW=701.3 > 500.0; LogP=7.73 > 5.0
ad0aae8b,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCN2,,,raw,,742.3200000000002,741.308182568,7.696200000000009,90.28000000000002,2,7,7,9,5,0.3181818181818182,54,0.17789320526435654,False,2,True,0,,CHEMBL3961292,22.0,nM,=,7.66,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6576,1,active,MW=742.3 > 500.0; LogP=7.70 > 5.0
31fc2b6b,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,754.3309999999999,753.308182568,8.21990000000001,83.18,1,7,7,9,6,0.28888888888888886,55,0.17780195571022447,False,2,True,0,,CHEMBL3924899,27.0,nM,=,7.57,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5686,1,active,MW=754.3 > 500.0; LogP=8.22 > 5.0
b4285dc6,,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,756.3469999999999,755.3238326320001,7.720500000000009,81.49000000000001,1,7,7,9,5,0.3333333333333333,55,0.18338614317212548,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3955979,14.0,nM,=,7.85,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8539,1,active,MW=756.3 > 500.0; LogP=7.72 > 5.0
771ff236,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,737.876,737.3377331080001,7.705600000000009,83.18,1,7,7,9,6,0.28888888888888886,55,0.18170948360602157,False,2,True,0,,CHEMBL3919460,17.0,nM,=,7.77,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7696,1,active,MW=737.9 > 500.0; LogP=7.71 > 5.0
1eb59712,,O=C(c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,684.8120000000005,684.3111840120001,7.213900000000009,78.25000000000001,1,6,7,8,5,0.2857142857142857,51,0.1961294407948966,False,2,True,0,,CHEMBL3944500,29.0,nM,=,7.54,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5376,1,active,MW=684.8 > 500.0; LogP=7.21 > 5.0
ead48524,,CN1CCCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,770.3739999999999,769.339482696,8.110600000000009,81.49000000000001,1,7,7,9,5,0.34782608695652173,56,0.1803232944332097,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3953784,17.0,nM,=,7.77,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7696,1,active,MW=770.4 > 500.0; LogP=8.11 > 5.0
985d0ca3,,CN1CCOc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,772.3459999999998,771.3187472520001,7.556800000000009,90.72000000000001,1,8,7,9,5,0.3333333333333333,56,0.18283854039664743,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3979356,17.0,nM,=,7.77,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7696,1,active,MW=772.3 > 500.0; LogP=7.56 > 5.0
9a94704b,,CCN(CC)c1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1,,,raw,,772.3899999999998,771.3551327600001,8.574400000000004,81.49000000000001,1,7,10,8,5,0.34782608695652173,56,0.15335798883762375,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3962005,25.0,nM,=,7.6,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6021,1,active,MW=772.4 > 500.0; LogP=8.57 > 5.0
df4c4015,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCC2,,,raw,,741.3320000000001,740.3129336000001,8.216900000000008,78.25000000000001,1,6,7,9,5,0.3333333333333333,54,0.18210787827322014,False,2,True,0,,CHEMBL3934509,35.0,nM,=,7.46,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4559,1,active,MW=741.3 > 500.0; LogP=8.22 > 5.0
7ee8083d,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)CC1,,,raw,,767.3739999999996,766.3398170439998,8.135100000000008,77.19,1,7,7,9,6,0.30434782608695654,56,0.17772525586119275,False,2,True,0,,CHEMBL3923492,13.0,nM,=,7.89,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8861,1,active,MW=767.4 > 500.0; LogP=8.14 > 5.0
ceed2f91,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,738.8850000000002,738.341735192,7.23610000000001,96.71000000000001,1,8,7,9,5,0.3333333333333333,55,0.18826662976011574,False,2,True,0,,CHEMBL3918945,33.0,nM,=,7.48,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4815,1,active,MW=738.9 > 500.0; LogP=7.24 > 5.0
1629a7df,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,791.9489999999998,791.368284288,7.727800000000011,101.64000000000003,1,9,7,10,6,0.3333333333333333,59,0.17677565048626395,False,2,True,0,,CHEMBL3947942,34.0,nM,=,7.47,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4685,1,active,MW=791.9 > 500.0; LogP=7.73 > 5.0
c8228948,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)c1,,,raw,,749.9119999999999,749.3577196039998,7.575100000000011,92.41000000000003,1,8,8,9,6,0.30434782608695654,56,0.1727184827275456,False,2,True,0,,CHEMBL3920154,23.0,nM,=,7.64,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6383,1,active,MW=749.9 > 500.0; LogP=7.58 > 5.0
89c743b0,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,724.8580000000003,724.326085128,6.846000000000009,96.71000000000001,1,8,7,9,5,0.3181818181818182,54,0.19637822315231007,False,2,True,0,,CHEMBL3904944,27.0,nM,=,7.57,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5686,1,active,MW=724.9 > 500.0; LogP=6.85 > 5.0
ec4418ee,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,777.9219999999999,777.352634224,7.3377000000000105,101.64000000000003,1,9,7,10,6,0.3191489361702128,58,0.18121382996304194,False,2,True,0,,CHEMBL3911061,15.0,nM,=,7.82,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=777.9 > 500.0; LogP=7.34 > 5.0
1028e2fb,,CCOc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)c1,,,raw,,763.939,763.3733696679999,7.965200000000011,92.41000000000003,1,8,9,9,6,0.3191489361702128,57,0.16079491871803472,False,2,True,0,,CHEMBL3962412,43.0,nM,=,7.37,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3665,1,active,MW=763.9 > 500.0; LogP=7.97 > 5.0
a67c9cb5,,Cn1ncc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,778.91,778.347883192,6.732700000000008,114.53000000000002,1,10,7,10,6,0.32608695652173914,58,0.18993634257621864,False,2,True,0,,CHEMBL3983908,16.0,nM,=,7.8,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=778.9 > 500.0; LogP=6.73 > 5.0
802f62fe,,CN1CCCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,793.9649999999999,793.383934352,7.228400000000009,99.95000000000003,1,9,7,10,5,0.375,59,0.1845225488993838,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3956101,15.0,nM,=,7.82,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=794.0 > 500.0; LogP=7.23 > 5.0
50973738,,CN1CCOc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,795.9369999999999,795.363198908,6.674600000000008,109.18000000000002,1,10,7,10,5,0.3617021276595745,59,0.19328303687952664,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3976773,26.0,nM,=,7.58,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.585,1,active,MW=795.9 > 500.0; LogP=6.67 > 5.0
14e4d645,,Cn1ncc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,755.3189999999998,754.303431536,7.614900000000009,96.07000000000001,1,8,7,9,6,0.29545454545454547,55,0.1803750053721579,False,2,True,0,,CHEMBL3909703,13.0,nM,=,7.89,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8861,1,active,MW=755.3 > 500.0; LogP=7.61 > 5.0
354f42eb,,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)c4n3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,756.3469999999999,755.3238326320001,7.720500000000009,81.49000000000001,1,7,7,9,5,0.3333333333333333,55,0.18338614317212548,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3963693,110.0,nM,=,6.96,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.9586,1,active,MW=756.3 > 500.0; LogP=7.72 > 5.0
b8912d97,,Cn1ncc2cc(N(C(=O)c3cc(-c4cc(F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,738.864,738.332982076,7.100600000000008,96.07000000000001,1,8,7,9,6,0.29545454545454547,55,0.18791737649798343,False,2,True,0,,CHEMBL3915037,14.0,nM,=,7.85,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8539,1,active,MW=738.9 > 500.0; LogP=7.10 > 5.0
e4d1396f,,CN1CC2(CC2)c2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,782.3849999999998,781.339482696,8.209600000000009,81.49000000000001,1,7,7,10,5,0.3617021276595745,57,0.17946598087284696,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3899534,47.0,nM,=,7.33,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3279,1,active,MW=782.4 > 500.0; LogP=8.21 > 5.0
ec78da58,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,768.358,767.3238326320001,8.610000000000005,83.18,1,7,7,9,6,0.30434782608695654,56,0.1760672283192619,False,2,True,0,,CHEMBL3901829,21.0,nM,=,7.68,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=768.4 > 500.0; LogP=8.61 > 5.0
2cafdf6f,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(C(F)(F)F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,787.8829999999997,787.334539548,8.585300000000005,83.18,1,7,7,9,6,0.30434782608695654,58,0.1754474419393374,False,2,True,0,,CHEMBL3961905,58.0,nM,=,7.24,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2366,1,active,MW=787.9 > 500.0; LogP=8.59 > 5.0
f015d3c0,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(OC(F)(F)F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,803.8819999999996,803.3294541680001,8.465100000000005,92.41000000000001,1,8,8,9,6,0.30434782608695654,59,0.16617749631402173,False,2,True,0,,CHEMBL3892886,45.0,nM,=,6.89,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,3,7.3468,1,active,MW=803.9 > 500.0; LogP=8.47 > 5.0
cab9c192,,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-c1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)c2n1CCCC2,,,raw,,712.2939999999996,711.2976178839999,8.449300000000006,73.95000000000002,1,6,7,8,6,0.2558139534883721,52,0.18046667287444523,False,2,True,0,,CHEMBL3896532,16.0,nM,=,7.8,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=712.3 > 500.0; LogP=8.45 > 5.0
3f663e35,,COc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1C(F)(F)F,,,raw,,799.29,798.279582784,8.755600000000001,87.48,1,7,8,8,5,0.3181818181818182,57,0.16909733348405076,False,2,True,0,,CHEMBL3919115,180.0,nM,=,6.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.7447,1,active,MW=799.3 > 500.0; LogP=8.76 > 5.0
f86cacb1,,CSc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1C(F)(F)F,,,raw,,815.358,814.256739164,9.4689,78.25,1,7,8,8,5,0.3181818181818182,57,0.15747459248109638,False,2,True,0,,CHEMBL3951630,180.0,nM,=,6.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.7447,1,active,MW=815.4 > 500.0; LogP=9.47 > 5.0
ca82b7cc,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)c(F)c3)ccc21,,,raw,,772.3209999999999,771.298760756,8.359000000000005,83.18,1,7,7,9,6,0.28888888888888886,56,0.17655326173213765,False,2,True,0,,CHEMBL3910202,34.0,nM,=,7.47,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4685,1,active,MW=772.3 > 500.0; LogP=8.36 > 5.0
98dbe3bf,,Cn1ccc2cc(N(C(=O)c3cc(-c4ccccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,715.8540000000004,715.3158547920001,7.681400000000008,82.66000000000001,1,7,7,9,7,0.2,54,0.1832200556684818,False,2,True,0,,CHEMBL3980328,20.0,nM,=,7.7,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.699,1,active,MW=715.9 > 500.0; LogP=7.68 > 5.0
0b7b0516,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)c4ccccn24)OCO3)CC1,,,raw,,772.906,772.337318508,7.32530000000001,95.13,1,9,7,10,7,0.23404255319148937,58,0.18153670055732732,False,2,True,0,,CHEMBL5895579,12.0,nM,=,7.92,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=772.9 > 500.0; LogP=7.33 > 5.0
5e783878,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,raw,,706.7990000000003,706.2791349360001,6.918400000000008,96.19000000000001,1,8,7,9,6,0.20930232558139536,53,0.19271524313870403,False,2,True,0,,CHEMBL3986763,22.0,nM,=,7.66,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6576,1,active,MW=706.8 > 500.0; LogP=6.92 > 5.0
d53cb674,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,759.8630000000003,759.305684032,7.41010000000001,101.12000000000002,1,9,7,10,7,0.21739130434782608,57,0.18078284792276728,False,2,True,0,,CHEMBL3959528,13.0,nM,=,7.89,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8861,1,active,MW=759.9 > 500.0; LogP=7.41 > 5.0
83d5a793,,CCn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,773.8900000000003,773.321334096,7.8930000000000105,101.12000000000002,1,9,8,10,7,0.23404255319148937,58,0.1677480025300585,False,2,True,0,,CHEMBL3922165,19.0,nM,=,7.72,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7212,1,active,MW=773.9 > 500.0; LogP=7.89 > 5.0
bbef8111,,CN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,761.8790000000004,761.321334096,6.910700000000008,99.43000000000002,1,9,7,10,6,0.2608695652173913,57,0.18760835228793993,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3954237,22.0,nM,=,7.66,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6576,1,active,MW=761.9 > 500.0; LogP=6.91 > 5.0
e0a5b355,,CC(C)n1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,787.9170000000001,787.33698416,8.454000000000006,101.12000000000002,1,9,8,10,7,0.25,59,0.16507274002864472,False,2,True,0,,CHEMBL3982905,22.0,nM,=,7.66,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6576,1,active,MW=787.9 > 500.0; LogP=8.45 > 5.0
6ccac384,,CCN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,775.9060000000003,775.33698416,7.300800000000009,99.43000000000002,1,9,8,10,6,0.2765957446808511,58,0.17217502408322305,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3912115,21.0,nM,=,7.68,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=775.9 > 500.0; LogP=7.30 > 5.0
eeb850e6,,CC(C)N1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,789.9330000000001,789.352634224,7.689300000000009,99.43000000000002,1,9,8,10,6,0.2916666666666667,59,0.1677899456129984,False,2,True,0,,CHEMBL3936554,31.0,nM,=,7.51,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5086,1,active,MW=789.9 > 500.0; LogP=7.69 > 5.0
ee7aeeec,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccn23)CC1,,,raw,,763.3419999999999,762.3085169159998,8.250000000000007,76.66999999999999,1,7,7,9,7,0.21739130434782608,56,0.17716282792164467,False,2,True,0,,CHEMBL3899558,14.0,nM,=,7.85,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8539,1,active,MW=763.3 > 500.0; LogP=8.25 > 5.0
a8a8cbb4,,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,752.3150000000002,751.2925325040001,7.835400000000009,80.97000000000001,1,7,7,9,6,0.24444444444444444,55,0.1792358897533012,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3927581,16.0,nM,=,7.8,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=752.3 > 500.0; LogP=7.84 > 5.0
b45de405,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,750.2990000000002,749.27688244,8.334800000000008,82.66000000000001,1,7,7,9,7,0.2,55,0.17733119854627596,False,2,True,0,,CHEMBL3924162,24.0,nM,=,7.62,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6198,1,active,MW=750.3 > 500.0; LogP=8.33 > 5.0
30f42c77,,CN1CCCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,789.9330000000002,789.352634224,7.343300000000009,99.43000000000002,1,9,7,10,6,0.2916666666666667,59,0.17957412374105192,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3896415,26.0,nM,=,7.58,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.585,1,active,MW=789.9 > 500.0; LogP=7.34 > 5.0
8eabc4e3,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,773.8900000000002,773.321334096,7.45260000000001,101.12000000000002,1,9,7,10,7,0.23404255319148937,58,0.17971297792817353,False,2,True,0,,CHEMBL3894500,19.0,nM,=,7.72,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7212,1,active,MW=773.9 > 500.0; LogP=7.45 > 5.0
9feed52c,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccn23)c1,,,raw,,745.8800000000002,745.3264194759998,7.69000000000001,91.89000000000001,1,8,8,9,7,0.21739130434782608,56,0.1716776087644285,False,2,True,0,,CHEMBL3965900,21.0,nM,=,7.68,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=745.9 > 500.0; LogP=7.69 > 5.0
0b7043fc,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CN(C(=O)OC(C)(C)C)CC4)c3ccc(O)cc3)ccc21,,,raw,,864.9999999999999,864.384662624,7.7096000000000116,131.18000000000004,1,11,7,10,6,0.34,64,0.17159459382290726,False,3,True,0,,CHEMBL3946893,220.0,nM,=,6.66,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.6576,1,active,MW=865.0 > 500.0; LogP=7.71 > 5.0; HBA=11 > 10
35934025,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CNCC4)c3ccc(O)cc3)ccc21,,,raw,,764.883,764.332233128,6.062100000000008,113.67000000000003,2,10,7,10,6,0.28888888888888886,57,0.2019176204355884,False,2,True,0,,CHEMBL3971090,24.0,nM,=,7.62,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6198,1,active,MW=764.9 > 500.0; LogP=6.06 > 5.0
920674c5,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)c4n2CCC4)OCO3)CC1,,,raw,,762.9109999999997,762.352968572,6.820300000000009,95.65,1,9,7,10,6,0.30434782608695654,57,0.19091276089288708,False,2,True,0,,CHEMBL3937031,17.0,nM,=,7.77,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7696,1,active,MW=762.9 > 500.0; LogP=6.82 > 5.0
a7b1a2d7,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCC3)CC1,,,raw,,753.3469999999996,752.3241669799999,7.74500000000001,77.19,1,7,7,9,6,0.28888888888888886,55,0.1806863873278429,False,2,True,0,,CHEMBL3909105,23.0,nM,=,7.64,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6383,1,active,MW=753.3 > 500.0; LogP=7.75 > 5.0
4f557825,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1COCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,703.2390000000004,702.260898028,6.922100000000008,87.48,1,7,7,8,5,0.2682926829268293,51,0.19823553486924977,False,2,True,0,,CHEMBL3945926,31.0,nM,=,7.51,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5086,1,active,MW=703.2 > 500.0; LogP=6.92 > 5.0
d3054224,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1COCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCN2,,,raw,,744.2920000000001,743.2874471240001,6.890100000000008,99.51,2,8,7,9,5,0.3023255813953488,54,0.18746485294291323,False,2,True,0,,CHEMBL3921561,31.0,nM,=,7.51,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5086,1,active,MW=744.3 > 500.0; LogP=6.89 > 5.0
437cc391,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3COCC4)c3ccc(O)cc3)ccc21,,,raw,,765.8670000000001,765.316248716,6.4891000000000085,110.87000000000003,1,10,7,10,6,0.28888888888888886,57,0.1966462220843522,False,2,True,0,,CHEMBL3955751,18.0,nM,=,7.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=765.9 > 500.0; LogP=6.49 > 5.0
8b2a8352,,CN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3COCC4)c3ccc(O)cc3)ccc21,,,raw,,767.8830000000002,767.3318987800001,5.989700000000006,109.18000000000004,1,10,7,10,5,0.3333333333333333,57,0.21384881790907162,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL3928123,28.0,nM,=,7.55,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5528,1,active,MW=767.9 > 500.0; LogP=5.99 > 5.0
3a8aecd0,,Cc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2COCC3)c2ccc(O)cc2)cc1F,,,raw,,735.2560000000002,734.2671262800001,7.36962000000001,87.48,1,7,7,8,5,0.2857142857142857,53,0.18807409325958488,False,2,True,0,,CHEMBL3952674,33.0,nM,=,7.48,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4815,1,active,MW=735.3 > 500.0; LogP=7.37 > 5.0
5831f84c,,Cn1ccc2ccc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCCC4)c3ccc(O)cc3)cc21,,,raw,,768.3579999999998,767.3238326320001,8.610000000000005,83.18,1,7,7,9,6,0.30434782608695654,56,0.1760672283192619,False,2,True,0,,CHEMBL3925867,18.0,nM,=,7.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=768.4 > 500.0; LogP=8.61 > 5.0
f1c67455,,Cn1ccc2ccc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCCC4)c3ccc(O)cc3)cc21,,,raw,,777.9219999999999,777.352634224,7.6853000000000105,101.64000000000003,1,9,7,10,6,0.3191489361702128,58,0.177559993552562,False,2,True,0,,CHEMBL3928763,18.0,nM,=,7.75,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=777.9 > 500.0; LogP=7.69 > 5.0
5f8d210d,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccsc1,,,raw,,707.2960000000004,706.238054408,7.789700000000009,78.25000000000001,1,7,7,8,5,0.3,50,0.1870719588614986,False,2,True,0,,CHEMBL3964632,41.0,nM,=,7.39,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3872,1,active,MW=707.3 > 500.0; LogP=7.79 > 5.0
591d4892,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3COCC4)c3ccc(O)cc3)ccc21,,,raw,,756.303,755.2874471240001,7.413800000000011,92.41000000000001,1,8,7,9,6,0.2727272727272727,55,0.18258780270650043,False,2,True,0,,CHEMBL3972831,22.0,nM,=,7.66,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6576,1,active,MW=756.3 > 500.0; LogP=7.41 > 5.0
f9333f4c,,CCCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,690.8410000000001,690.341735192,6.271900000000008,96.71000000000002,1,8,9,8,4,0.4146341463414634,51,0.22124663028319175,False,2,True,0,,CHEMBL3901752,27.0,nM,=,7.57,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5686,1,active,MW=690.8 > 500.0; LogP=6.27 > 5.0
ada0c3ac,,Cc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1F,,,raw,,716.8290000000002,716.3174122640002,7.6614200000000094,78.25,1,6,7,8,5,0.3023255813953488,53,0.1872972501420416,False,2,True,0,,CHEMBL3977790,8.0,nM,=,8.1,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0969,1,active,MW=716.8 > 500.0; LogP=7.66 > 5.0
3811a21d,,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2COCC3)c2ccc(O)cc2)cc1F,,,raw,,744.8200000000003,744.295927872,6.4449200000000095,105.94000000000003,1,9,7,9,5,0.3023255813953488,55,0.2030920188429097,False,2,True,0,,CHEMBL3938853,5.0,nM,=,8.3,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.301,1,active,MW=744.8 > 500.0; LogP=6.44 > 5.0
1fdb84cd,,Cn1ncc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,raw,,764.883,764.332233128,6.690200000000009,114.53000000000002,1,10,7,10,6,0.3111111111111111,57,0.19148207599072786,False,2,True,0,,CHEMBL3909288,3.0,nM,=,8.52,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5229,1,active,MW=764.9 > 500.0; LogP=6.69 > 5.0
90231429,,Cc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)c1,,,raw,,733.9129999999999,733.3628049839998,7.87492000000001,83.18,1,7,7,9,6,0.30434782608695654,55,0.18070731621358674,False,2,True,0,,CHEMBL3931918,6.0,nM,=,8.22,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2218,1,active,MW=733.9 > 500.0; LogP=7.87 > 5.0
f99b5353,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCC4)c3ccc(O)cc3)ccc21,,,raw,,749.868,749.321334096,6.90510000000001,101.64000000000003,1,9,7,10,6,0.28888888888888886,56,0.18955443347468903,False,2,True,0,,CHEMBL3948972,11.0,nM,=,7.96,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9586,1,active,MW=749.9 > 500.0; LogP=6.91 > 5.0
ae9e391f,,Cc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1Cl,,,raw,,749.739,748.2583111840001,8.690020000000004,78.25,1,6,7,8,5,0.3023255813953488,53,0.1803218672333449,False,2,True,0,,CHEMBL3917644,20.0,nM,=,7.7,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.699,1,active,MW=749.7 > 500.0; LogP=8.69 > 5.0
4075008d,,Cc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2COCC3)c2ccc(O)cc2)cc1F,,,raw,,718.8010000000003,718.29667682,6.855320000000009,87.48,1,7,7,8,5,0.2857142857142857,53,0.19817586040604374,False,2,True,0,,CHEMBL3940211,12.0,nM,=,7.92,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=718.8 > 500.0; LogP=6.86 > 5.0
e8fbff10,,O=C(c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1COCC2)N(c1ccc(O)cc1)c1ccc(F)cc1,,,raw,,704.7740000000005,704.2810267560001,6.546900000000008,87.48,1,7,7,8,5,0.2682926829268293,52,0.20707249007699866,False,2,True,0,,CHEMBL3912209,23.5,nM,=,7.6,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,2,7.6289,1,active,MW=704.8 > 500.0; LogP=6.55 > 5.0
abab9055,,Cn1ncc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3COCC4)c3ccc(O)cc3)ccc21,,,raw,,757.2909999999999,756.282696092,6.808800000000009,105.30000000000001,1,9,7,9,6,0.27906976744186046,55,0.1910042654279796,False,2,True,0,,CHEMBL3911010,5.0,nM,=,8.3,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.301,1,active,MW=757.3 > 500.0; LogP=6.81 > 5.0
c0e6bda6,,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)cnc21,,,raw,,755.3189999999998,754.303431536,7.614900000000011,96.07000000000001,1,8,7,9,6,0.29545454545454547,55,0.1803750053721579,False,2,True,0,,CHEMBL3889970,6.0,nM,=,8.22,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2218,1,active,MW=755.3 > 500.0; LogP=7.61 > 5.0
6b7da50d,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(cnn4C)c3)c3n2CCCC3)c1,,,raw,,750.8999999999999,750.3529685719999,6.970100000000008,105.30000000000001,1,9,8,9,6,0.3111111111111111,56,0.17929908877685014,False,2,True,0,,CHEMBL3917121,7.0,nM,=,8.15,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1549,1,active,MW=750.9 > 500.0; LogP=6.97 > 5.0
5705ebd7,,COCCN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4n2CCCC4)OCO3)CC1,,,raw,,767.9269999999998,767.368284288,6.7353000000000085,99.95000000000002,1,9,10,9,5,0.34782608695652173,57,0.1671240937117987,False,2,True,0,,CHEMBL3956422,10.0,nM,=,8.0,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0,1,active,MW=767.9 > 500.0; LogP=6.74 > 5.0
f3bf98fa,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)CC1=O,,,raw,,781.3569999999996,780.3190815999999,7.6617000000000095,94.25999999999999,1,7,7,9,6,0.2826086956521739,57,0.17971452947983182,False,2,True,0,,CHEMBL3909919,7.0,nM,=,8.15,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1549,1,active,MW=781.4 > 500.0; LogP=7.66 > 5.0
75f52d92,,COCCN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-c1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)c2n1CCCC2,,,raw,,756.3469999999998,755.323832632,8.465900000000007,83.18,1,7,10,8,6,0.28888888888888886,55,0.15181201156950236,False,2,True,0,,CHEMBL3976786,9.0,nM,=,8.05,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=756.3 > 500.0; LogP=8.47 > 5.0
12d7cdcd,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C[N+]2([O-])CCOCC2)OCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,726.8300000000003,726.305349684,6.816100000000009,116.53,1,8,7,9,5,0.3023255813953488,54,0.1446851612852081,False,2,True,0,,CHEMBL5930470,30.0,nM,=,7.52,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5229,1,active,MW=726.8 > 500.0; LogP=6.82 > 5.0
6c01048f,,CCN(CCOC)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-c1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)c2n1CCCC2,,,raw,,770.3739999999998,769.3394826959999,8.856000000000005,83.18,1,7,11,8,6,0.30434782608695654,56,0.142486790998475,False,2,True,0,,CHEMBL3902613,29.0,nM,=,7.54,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5376,1,active,MW=770.4 > 500.0; LogP=8.86 > 5.0
91b328c8,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(F)cc1,,,raw,,719.2570000000004,718.27221166,7.867300000000009,78.25000000000001,1,6,7,8,5,0.2857142857142857,52,0.18547576374551594,False,2,True,0,,CHEMBL3962639,15.0,nM,=,7.82,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=719.3 > 500.0; LogP=7.87 > 5.0
f27ac92f,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n2CCCC3)c1,,,raw,,696.8480000000001,696.331170508,7.083400000000009,87.48000000000002,1,7,8,8,5,0.3023255813953488,52,0.18668418266209305,False,2,True,0,,CHEMBL3914379,9.0,nM,=,8.05,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=696.8 > 500.0; LogP=7.08 > 5.0
f00a5be1,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CC(O)CC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,726.8300000000003,726.305349684,5.774300000000008,116.94000000000001,2,9,7,9,5,0.3023255813953488,54,0.2172526665276972,False,2,True,0,,CHEMBL3953887,16.0,nM,=,7.8,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=726.8 > 500.0; LogP=5.77 > 5.0
c5b9d807,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc(C)c(F)c3)c3n2CCCC3)c1,,,raw,,728.865,728.3373987599999,7.53092000000001,87.48000000000002,1,7,8,8,5,0.3181818181818182,54,0.1779189489505373,False,2,True,0,,CHEMBL3985932,9.0,nM,=,8.05,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=728.9 > 500.0; LogP=7.53 > 5.0
271e3688,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccccc1F,,,raw,,719.2570000000004,718.27221166,7.867300000000009,78.25000000000001,1,6,7,8,5,0.2857142857142857,52,0.18547576374551594,False,2,True,0,,CHEMBL3948585,8.0,nM,=,8.1,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0969,1,active,MW=719.3 > 500.0; LogP=7.87 > 5.0
261a08bc,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1cccc(F)c1,,,raw,,719.2570000000004,718.27221166,7.867300000000009,78.25000000000001,1,6,7,8,5,0.2857142857142857,52,0.18547576374551594,False,2,True,0,,CHEMBL3977784,10.0,nM,=,8.0,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0,1,active,MW=719.3 > 500.0; LogP=7.87 > 5.0
811b06e7,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(F)cc1F,,,raw,,737.2470000000004,736.262789848,8.006400000000008,78.25000000000001,1,6,7,8,5,0.2857142857142857,53,0.18334594170263008,False,2,True,0,,CHEMBL3939826,15.0,nM,=,7.82,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=737.2 > 500.0; LogP=8.01 > 5.0
667e4604,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(F)c(F)c1,,,raw,,737.2470000000004,736.262789848,8.006400000000008,78.25000000000001,1,6,7,8,5,0.2857142857142857,53,0.18334594170263008,False,2,True,0,,CHEMBL3966070,15.0,nM,=,7.82,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=737.2 > 500.0; LogP=8.01 > 5.0
787a9514,,N#Cc1cccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)c1,,,raw,,726.2769999999999,725.27688244,7.59988000000001,102.04,1,7,7,8,5,0.27906976744186046,53,0.18554417588579397,False,2,True,0,,CHEMBL3894316,9.0,nM,=,8.05,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=726.3 > 500.0; LogP=7.60 > 5.0
3616f7c1,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2ccncc12)N(c1ccc(O)cc1)c1cccc(F)c1,,,raw,,725.7770000000004,725.2649620920001,6.452500000000008,109.08000000000001,1,9,7,9,6,0.21428571428571427,54,0.20017542268358646,False,2,True,0,,CHEMBL3965758,34.0,nM,=,7.47,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4685,1,active,MW=725.8 > 500.0; LogP=6.45 > 5.0
e48ea808,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1cccc(F)c1,,,raw,,728.8210000000004,728.3010132520001,6.942600000000009,96.71000000000001,1,8,7,9,5,0.3023255813953488,54,0.19406336504926933,False,2,True,0,,CHEMBL3903292,16.0,nM,=,7.8,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=728.8 > 500.0; LogP=6.94 > 5.0
1d425a40,,CS(=O)(=O)N1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4n2CCCC4)OCO3)CC1,,,raw,,787.9389999999999,787.30396978,6.048500000000008,124.86000000000001,1,9,8,9,5,0.3181818181818182,57,0.20184131070022884,False,2,True,0,,CHEMBL3977431,22.0,nM,=,7.66,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6576,1,active,MW=787.9 > 500.0; LogP=6.05 > 5.0
c5f07704,,COc1cccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)c1,,,raw,,731.2929999999999,730.2921981559999,7.73680000000001,87.48,1,7,8,8,5,0.3023255813953488,53,0.17592842040485382,False,2,True,0,,CHEMBL3929493,28.0,nM,=,7.55,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5528,1,active,MW=731.3 > 500.0; LogP=7.74 > 5.0
8e07871c,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1cc(F)cc(F)c1,,,raw,,737.2470000000004,736.262789848,8.006400000000008,78.25000000000001,1,6,7,8,5,0.2857142857142857,53,0.18334594170263008,False,2,True,0,,CHEMBL3949282,38.0,nM,=,7.42,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4202,1,active,MW=737.2 > 500.0; LogP=8.01 > 5.0
11e7e9ab,,Cc1cccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)c1,,,raw,,715.294,714.297283536,8.036620000000012,78.25,1,6,7,8,5,0.3023255813953488,52,0.18478115502810974,False,2,True,0,,CHEMBL3983630,26.0,nM,=,7.58,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.585,1,active,MW=715.3 > 500.0; LogP=8.04 > 5.0
8c954351,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(CC(F)(F)F)CC2)OCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,791.871,791.329454168,7.65120000000001,90.72,1,8,8,9,5,0.3333333333333333,58,0.17283859563402068,False,2,True,0,,CHEMBL3954544,26.0,nM,=,7.58,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.585,1,active,MW=791.9 > 500.0; LogP=7.65 > 5.0
7971c647,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4n2CCCC4)OCO3)CC1=O,,,raw,,737.8569999999999,737.321334096,6.245300000000007,107.78999999999999,1,8,7,9,5,0.29545454545454547,55,0.2107434433557352,False,2,True,0,,CHEMBL3927836,10.0,nM,=,8.0,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0,1,active,MW=737.9 > 500.0; LogP=6.25 > 5.0
655965a3,,N#Cc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1,,,raw,,726.277,725.27688244,7.59988000000001,102.04,1,7,7,8,5,0.27906976744186046,53,0.18554417588579397,False,2,True,0,,CHEMBL3899834,9.0,nM,=,8.05,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=726.3 > 500.0; LogP=7.60 > 5.0
a20dffb8,,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1cccc(Cl)c1,,,raw,,735.7120000000003,734.2426611200001,8.381600000000006,78.25000000000001,1,6,7,8,5,0.2857142857142857,52,0.18187397625972748,False,2,True,0,,CHEMBL3964991,30.0,nM,=,7.52,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5229,1,active,MW=735.7 > 500.0; LogP=8.38 > 5.0
425c47c6,,N#Cc1ccccc1N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)c1ccc(O)cc1,,,raw,,726.2769999999998,725.27688244,7.59988000000001,102.04,1,7,7,8,5,0.27906976744186046,53,0.18554417588579397,False,2,True,0,,CHEMBL3937283,37.0,nM,=,7.43,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4318,1,active,MW=726.3 > 500.0; LogP=7.60 > 5.0
e7d86b12,,Cn1cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cn1,,,raw,,705.259,704.2877814720001,6.4617000000000075,96.07000000000001,1,8,7,8,5,0.325,51,0.2090428603421413,False,2,True,0,,CHEMBL3896666,6.0,nM,=,8.22,CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2218,1,active,MW=705.3 > 500.0; LogP=6.46 > 5.0
b2fe07b5,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)cn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,raw,,540.6670000000001,540.252526264,6.290020000000008,71.57000000000001,1,4,6,6,5,0.14285714285714285,41,0.2751761770440659,False,2,True,0,,CHEMBL5763892,213.0,nM,=,6.67,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.6716,1,active,MW=540.7 > 500.0; LogP=6.29 > 5.0
79b6fa43,,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)cn1-c1cc(O)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,raw,,556.6660000000002,556.247440884,5.995620000000007,91.8,2,5,6,6,5,0.14285714285714285,42,0.2685818545172929,False,2,True,0,,CHEMBL6008213,50.5,nM,=,7.3,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2967,1,active,MW=556.7 > 500.0; LogP=6.00 > 5.0
b0ef9959,,Cc1cc(C(=O)N(c2ccccc2)c2ccc3[nH]ccc3c2)cn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,607.758,607.2947254239999,7.37422000000001,64.58,1,4,7,7,6,0.1794871794871795,46,0.20610761398558636,False,2,True,0,,CHEMBL5960474,146.0,nM,=,6.84,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.8356,1,active,MW=607.8 > 500.0; LogP=7.37 > 5.0
c7373d7f,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(C(F)(F)F)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,652.717,652.26612564,7.61732000000001,69.02,1,5,7,6,5,0.21052631578947367,48,0.19655816474864163,False,2,True,0,,CHEMBL5965013,120.0,nM,=,6.92,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.9208,1,active,MW=652.7 > 500.0; LogP=7.62 > 5.0
ab9ab2eb,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,619.165,618.23976866,7.25192000000001,69.02,1,5,7,6,5,0.1891891891891892,45,0.20857807651953317,False,2,True,0,,CHEMBL6057025,16.2,nM,=,7.79,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7905,1,active,MW=619.2 > 500.0; LogP=7.25 > 5.0
f33e52ce,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(F)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,602.71,602.2693192,6.737620000000008,69.02,1,5,7,6,5,0.1891891891891892,45,0.22418993514236119,False,2,True,0,,CHEMBL5781944,24.8,nM,=,7.61,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6055,1,active,MW=602.7 > 500.0; LogP=6.74 > 5.0
d0d92ff0,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(O)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCOCC1,,,raw,,642.7559999999999,642.2842203160001,6.074720000000008,98.48,2,7,7,7,5,0.23076923076923078,48,0.22362648385900818,False,2,True,0,,CHEMBL5991810,22.1,nM,=,7.66,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6556,1,active,MW=642.8 > 500.0; LogP=6.07 > 5.0
41c6bb40,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)c(Br)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,797.5919999999994,795.141964308,7.809320000000012,72.25999999999999,1,6,7,7,5,0.25,50,0.1821579251738828,False,2,True,0,,CHEMBL5966587,29.6,nM,=,7.53,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5287,1,active,MW=797.6 > 500.0; LogP=7.81 > 5.0
9206c706,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(O)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,655.7989999999998,655.315854792,5.989920000000009,92.49,2,7,7,7,5,0.25,49,0.2239813812577427,False,2,True,0,,CHEMBL5865515,11.4,nM,=,7.94,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9431,1,active,MW=655.8 > 500.0; LogP=5.99 > 5.0
d07e1b79,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cccc(Cl)c1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,619.165,618.23976866,7.25192000000001,69.02,1,5,7,6,5,0.1891891891891892,45,0.20857807651953317,False,2,True,0,,CHEMBL6019016,44.6,nM,=,7.35,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3507,1,active,MW=619.2 > 500.0; LogP=7.25 > 5.0
fd074799,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1ccc(OC(F)(F)F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,723.7959999999997,723.30323942,7.182920000000011,81.49,1,7,8,7,5,0.2682926829268293,53,0.18284009706298385,False,2,True,0,,CHEMBL6016116,245.0,nM,=,6.61,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.6108,1,active,MW=723.8 > 500.0; LogP=7.18 > 5.0
0746d3a2,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(F)c(F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,675.7799999999997,675.302096548,6.56252000000001,72.25999999999999,1,6,7,7,5,0.25,50,0.2116950618440474,False,2,True,0,,CHEMBL6033601,74.3,nM,=,7.13,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.129,1,active,MW=675.8 > 500.0; LogP=6.56 > 5.0
b36dd769,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(F)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,657.7899999999997,657.31151836,6.423420000000009,72.25999999999999,1,6,7,7,5,0.25,49,0.21878757944148888,False,2,True,0,,CHEMBL5896937,24.6,nM,=,7.61,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6091,1,active,MW=657.8 > 500.0; LogP=6.42 > 5.0
7367770f,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,718.6959999999997,717.23145224,7.04682000000001,72.25999999999999,1,6,7,7,5,0.25,49,0.19556641653422085,False,2,True,0,,CHEMBL5918227,10.7,nM,=,7.97,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9706,1,active,MW=718.7 > 500.0; LogP=7.05 > 5.0
0ab55fa3,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,623.7570000000001,623.2896400440001,7.079820000000009,84.81,2,5,7,7,6,0.1794871794871795,47,0.1991268814739019,False,2,True,0,,CHEMBL5763414,26.1,nM,=,7.58,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5834,1,active,MW=623.8 > 500.0; LogP=7.08 > 5.0
b8286c70,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,raw,,683.8089999999999,683.3107694120001,6.013020000000009,90.72,1,8,7,8,5,0.2682926829268293,51,0.22478284088753317,False,2,True,0,,CHEMBL5898529,15.6,nM,=,7.81,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8069,1,active,MW=683.8 > 500.0; LogP=6.01 > 5.0
93fc524b,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1ccc(Cl)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,674.2449999999997,673.28196782,6.93772000000001,72.25999999999999,1,6,7,7,5,0.25,49,0.20280952838901067,False,2,True,0,,CHEMBL5983669,87.6,nM,=,7.06,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0575,1,active,MW=674.2 > 500.0; LogP=6.94 > 5.0
3dcd630f,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,674.2449999999997,673.28196782,6.93772000000001,72.25999999999999,1,6,7,7,5,0.25,49,0.20280952838901067,False,2,True,0,,CHEMBL6054106,7.5,nM,=,8.12,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1249,1,active,MW=674.2 > 500.0; LogP=6.94 > 5.0
ddf9ef3e,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)c(Cl)c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,708.6899999999997,707.2429954679999,7.591120000000012,72.25999999999999,1,6,7,7,5,0.25,50,0.1888177866681284,False,2,True,0,,CHEMBL6029111,20.5,nM,=,7.69,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6882,1,active,MW=708.7 > 500.0; LogP=7.59 > 5.0
7cf9cdab,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Cl)c(F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,692.2349999999997,691.272546008,7.07682000000001,72.25999999999999,1,6,7,7,5,0.25,50,0.19769010104682525,False,2,True,0,,CHEMBL5985247,8.0,nM,=,8.1,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0969,1,active,MW=692.2 > 500.0; LogP=7.08 > 5.0
aee0d91c,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1ccc(Br)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,718.6959999999997,717.23145224,7.04682000000001,72.25999999999999,1,6,7,7,5,0.25,49,0.19556641653422085,False,2,True,0,,CHEMBL5953508,44.6,nM,=,7.35,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3507,1,active,MW=718.7 > 500.0; LogP=7.05 > 5.0
583203a4,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(Cl)cc4)c4ccccc42)OCO3)CC1,,,raw,,754.287,753.2717970600002,7.511200000000008,90.72000000000001,1,8,7,9,6,0.22727272727272727,55,0.18059199944563098,False,2,True,0,,CHEMBL5922530,5.5,nM,=,8.26,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2596,1,active,MW=754.3 > 500.0; LogP=7.51 > 5.0
1a5ec90f,,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)cc2)cc1,,,raw,,733.8690000000004,733.326419476,7.166220000000009,90.72000000000001,1,8,7,9,6,0.24444444444444444,55,0.18627551434424736,False,2,True,0,,CHEMBL5875901,3.5,nM,=,8.46,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4559,1,active,MW=733.9 > 500.0; LogP=7.17 > 5.0
4f9f3209,,CCCCN(C(=O)c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)c2ccccc12)c1ccc(O)cc1,,,raw,,699.8520000000003,699.34206954,6.326200000000008,90.72000000000001,1,8,9,8,5,0.3333333333333333,52,0.19255606507501766,False,2,True,0,,CHEMBL6034767,4.4,nM,=,8.36,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=699.9 > 500.0; LogP=6.33 > 5.0
32084ddb,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)c(F)c4)c4ccccc42)OCO3)CC1,,,raw,,737.8320000000001,737.3013476000001,6.996900000000009,90.72000000000001,1,8,7,9,6,0.22727272727272727,55,0.18892932188416656,False,2,True,0,,CHEMBL5906111,7.7,nM,=,8.11,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1135,1,active,MW=737.8 > 500.0; LogP=7.00 > 5.0
62d61b52,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(F)cc4)c4ccccc42)OCO3)CC1,,,raw,,737.8320000000001,737.3013476000001,6.996900000000009,90.72000000000001,1,8,7,9,6,0.22727272727272727,55,0.18892932188416656,False,2,True,0,,CHEMBL5929135,3.5,nM,=,8.46,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4559,1,active,MW=737.8 > 500.0; LogP=7.00 > 5.0
6882f08d,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(CCc4ccccc4)c4ccc(Cl)cc4)c4ccccc42)OCO3)CC1,,,raw,,766.3420000000001,765.308182568,7.7166000000000095,70.49000000000001,0,7,9,9,6,0.2608695652173913,56,0.15031255935798518,False,2,True,0,,CHEMBL6047973,1110.0,nM,=,5.96,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,5.9547,0,inactive,MW=766.3 > 500.0; LogP=7.72 > 5.0
fded8c9c,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5[nH]ccc5c4)c4ccccc42)OCO3)CC1,,,raw,,758.879,758.3216684440001,7.339100000000009,106.51000000000002,2,8,7,10,7,0.21739130434782608,57,0.17537603764007464,False,2,True,0,,CHEMBL5967333,3.8,nM,=,8.42,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4202,1,active,MW=758.9 > 500.0; LogP=7.34 > 5.0
4484392f,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1C[C@H]2CCC[C@H]2C1,,,raw,,729.7189999999997,728.236203272,8.531320000000006,69.02,1,5,7,8,5,0.2857142857142857,50,0.1825124552931551,False,2,True,0,,CHEMBL5977962,238.0,nM,=,6.62,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.6234,1,active,MW=729.7 > 500.0; LogP=8.53 > 5.0
99f7c922,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4cccc(Oc5ccccc5)c4)c4ccccc42)OCO3)CC1,,,raw,,811.9390000000001,811.3369841600002,8.650100000000005,99.95000000000002,1,9,9,10,7,0.2,61,0.15481872750549602,False,2,True,0,,CHEMBL5893493,12.5,nM,=,7.9,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9031,1,active,MW=811.9 > 500.0; LogP=8.65 > 5.0
bb9dcbaf,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(CCc4ccccc4)c4ccc(O)cc4)c4ccccc42)OCO3)CC1,,,raw,,747.8960000000002,747.3420695400001,6.768800000000009,90.72000000000001,1,8,9,9,6,0.2608695652173913,56,0.17479374603861433,False,2,True,0,,CHEMBL5984895,7.8,nM,=,8.11,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1079,1,active,MW=747.9 > 500.0; LogP=6.77 > 5.0
8e52062b,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(O)cc4)c4ccccc42)OCO3)CC1,,,raw,,735.8410000000001,735.3056840320002,6.5634000000000094,110.95000000000002,2,9,7,9,6,0.22727272727272727,55,0.18980968597119866,False,2,True,0,,CHEMBL5753121,3.7,nM,=,8.43,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4318,1,active,MW=735.8 > 500.0; LogP=6.56 > 5.0
78bd0230,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCOCC1,,,raw,,705.6529999999998,704.199817764,7.13162000000001,78.25,1,6,7,7,5,0.23076923076923078,48,0.19512101661441744,False,2,True,0,,CHEMBL5991444,23.1,nM,=,7.64,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6364,1,active,MW=705.7 > 500.0; LogP=7.13 > 5.0
e2e28d30,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5sccc5c4)c4ccccc42)OCO3)CC1,,,raw,,775.931,775.2828404120002,8.072500000000009,90.72000000000001,1,9,7,10,7,0.21739130434782608,57,0.17527678200162752,False,2,True,0,,CHEMBL5858896,7.2,nM,=,8.14,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1427,1,active,MW=775.9 > 500.0; LogP=8.07 > 5.0
ce4b7398,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5occc5c4)c4ccccc42)OCO3)CC1,,,raw,,759.863,759.3056840320002,7.604000000000009,103.86000000000001,1,9,7,10,7,0.21739130434782608,57,0.1773640863615723,False,2,True,0,,CHEMBL6017811,6.8,nM,=,8.17,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1675,1,active,MW=759.9 > 500.0; LogP=7.60 > 5.0
fce72021,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)c4ccccc42)OCO3)CC1,,,raw,,772.906,772.3373185080001,7.34950000000001,95.65,1,9,7,10,7,0.23404255319148937,58,0.18120436373491358,False,2,True,0,,CHEMBL5814743,6.7,nM,=,8.17,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1739,1,active,MW=772.9 > 500.0; LogP=7.35 > 5.0
8c615714,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,757.7329999999995,756.242351272,7.52812000000001,88.05,2,6,7,8,6,0.23809523809523808,52,0.17603106969945767,False,2,True,0,,CHEMBL5954869,8.4,nM,=,8.08,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0757,1,active,MW=757.7 > 500.0; LogP=7.53 > 5.0
b6efb914,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(c4)CCN5)c4ccccc42)OCO3)CC1,,,raw,,760.8949999999999,760.3373185080001,6.825800000000008,102.75000000000001,2,9,7,10,6,0.2608695652173913,57,0.18289436942882317,False,2,True,0,,CHEMBL6030452,9.2,nM,=,8.04,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0362,1,active,MW=760.9 > 500.0; LogP=6.83 > 5.0
67f84ab9,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)c3ccccc32)CC1,,,raw,,793.766,792.242351272,8.372900000000007,88.05000000000001,2,6,7,9,7,0.2,55,0.16951697789273099,False,2,True,0,,CHEMBL5894463,10.5,nM,=,7.98,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9788,1,active,MW=793.8 > 500.0; LogP=8.37 > 5.0
5cccd69b,,COc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)cc2)cc1,,,raw,,749.8680000000004,749.321334096,6.8664000000000085,99.95000000000002,1,9,8,9,6,0.24444444444444444,56,0.18027175252666874,False,2,True,0,,CHEMBL5916895,13.1,nM,=,7.88,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8827,1,active,MW=749.9 > 500.0; LogP=6.87 > 5.0
47da4e8b,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,736.6859999999996,735.2220304279999,7.18592000000001,72.25999999999999,1,6,7,7,5,0.25,50,0.1918199562187732,False,2,True,0,,CHEMBL5855276,7.4,nM,=,8.13,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1308,1,active,MW=736.7 > 500.0; LogP=7.19 > 5.0
f0d50bbe,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(OC(F)(F)F)cc4)c4ccccc42)OCO3)CC1,,,raw,,803.8380000000002,803.2930686600001,7.756400000000008,99.95000000000002,1,9,8,9,6,0.24444444444444444,59,0.16692093573791833,False,2,True,0,,CHEMBL5806110,6.9,nM,=,8.16,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1612,1,active,MW=803.8 > 500.0; LogP=7.76 > 5.0
fcb3550a,,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)cc2)cc1F,,,raw,,751.8590000000004,751.316997664,7.305320000000009,90.72000000000001,1,8,7,9,6,0.24444444444444444,56,0.1831828900484275,False,2,True,0,,CHEMBL6038995,5.4,nM,=,8.27,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2676,1,active,MW=751.9 > 500.0; LogP=7.31 > 5.0
9dec5bc4,,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc(Br)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c2)c2ccc(O)cc2)cc1,,,raw,,732.723,731.2471023040001,7.355240000000011,72.26,1,6,7,7,5,0.2682926829268293,50,0.18961665953666404,False,2,True,0,,CHEMBL5834896,9.0,nM,=,8.05,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=732.7 > 500.0; LogP=7.36 > 5.0
c409c6ac,,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc3[nH]ccc3c2)cc1,,,raw,,756.9070000000003,756.3424038879999,7.941920000000009,86.28,1,7,7,10,7,0.23404255319148937,57,0.17791019899950172,False,2,True,0,,CHEMBL5830921,57.2,nM,=,7.24,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2426,1,active,MW=756.9 > 500.0; LogP=7.94 > 5.0
5029fb77,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(F)c(F)c4)c4ccccc42)OCO3)CC1,,,raw,,755.8220000000001,755.2919257880001,7.136000000000008,90.72000000000001,1,8,7,9,6,0.22727272727272727,56,0.18549472557976607,False,2,True,0,,CHEMBL5828104,5.0,nM,=,8.3,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.301,1,active,MW=755.8 > 500.0; LogP=7.14 > 5.0
c074065b,,Cc1ccc(N(C(=O)c2cn(-c3cc(Br)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c3ccccc23)c2ccc(O)cc2)cc1,,,raw,,768.7560000000001,767.2471023040001,8.20002000000001,72.26,1,6,7,8,6,0.22727272727272727,53,0.17750070947002794,False,2,True,0,,CHEMBL5745145,13.4,nM,=,7.87,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8729,1,active,MW=768.8 > 500.0; LogP=8.20 > 5.0
880add3e,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(F)c(Cl)c4)c4ccccc42)OCO3)CC1,,,raw,,772.277,771.2623752480001,7.650300000000008,90.72000000000001,1,8,7,9,6,0.22727272727272727,56,0.17847474491187637,False,2,True,0,,CHEMBL5925400,20.5,nM,=,7.69,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6882,1,active,MW=772.3 > 500.0; LogP=7.65 > 5.0
1915e7ff,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(Cl)cc3)c3ccccc32)CC1,,,raw,,789.174,787.192479888,8.545000000000005,72.26,1,6,7,8,6,0.20930232558139536,53,0.17574749016800065,False,2,True,0,,CHEMBL5761128,19.2,nM,=,7.72,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7167,1,active,MW=789.2 > 500.0; LogP=8.55 > 5.0
a40aeb68,,CC(=O)Oc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(C)cc2)cc1,,,raw,,775.9060000000002,775.3369841600002,7.3859200000000085,96.78999999999999,0,9,8,9,6,0.2553191489361702,58,0.11681834786610856,False,2,True,0,,CHEMBL5753100,206.0,nM,=,6.69,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.6861,1,active,MW=775.9 > 500.0; LogP=7.39 > 5.0
8979600a,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,734.6949999999995,733.22636686,6.75242000000001,92.49,2,7,7,7,5,0.25,50,0.19239293009630115,False,2,True,0,,CHEMBL5908404,7.7,nM,=,8.11,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1135,1,active,MW=734.7 > 500.0; LogP=6.75 > 5.0
f33e4974,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(Cl)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,753.1409999999995,751.1924798879999,7.7002200000000105,72.25999999999999,1,6,7,7,5,0.25,50,0.18469264861429505,False,2,True,0,,CHEMBL5792411,7.5,nM,=,8.12,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1249,1,active,MW=753.1 > 500.0; LogP=7.70 > 5.0
51406e15,,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)c(Cl)c2)cc1,,,raw,,768.3140000000003,767.287447124,7.819620000000009,90.72000000000001,1,8,7,9,6,0.24444444444444444,56,0.17730386943479332,False,2,True,0,,CHEMBL5880144,168.0,nM,=,6.78,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.7747,1,active,MW=768.3 > 500.0; LogP=7.82 > 5.0
6878b5ed,,CC(C)c1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)c(Cl)c2)cc1,,,raw,,796.3680000000003,795.3187472520002,8.634600000000006,90.72000000000001,1,8,8,9,6,0.2765957446808511,58,0.16508025668653042,False,2,True,0,,CHEMBL5826882,296.0,nM,=,6.53,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.5287,1,active,MW=796.4 > 500.0; LogP=8.63 > 5.0
224cdef9,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(Cl)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,708.6899999999997,707.2429954679999,7.591120000000011,72.25999999999999,1,6,7,7,5,0.25,50,0.1888177866681284,False,2,True,0,,CHEMBL5792914,5.1,nM,=,8.29,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2924,1,active,MW=708.7 > 500.0; LogP=7.59 > 5.0
2c4e2b35,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,692.2349999999997,691.272546008,7.07682000000001,72.25999999999999,1,6,7,7,5,0.25,50,0.19769010104682525,False,2,True,0,,CHEMBL5931438,6.6,nM,=,8.18,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1805,1,active,MW=692.2 > 500.0; LogP=7.08 > 5.0
0fa82fa8,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(O)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,690.2439999999997,689.27688244,6.64332000000001,92.49,2,7,7,7,5,0.25,50,0.19911052192303483,False,2,True,0,,CHEMBL5889255,5.9,nM,=,8.23,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2291,1,active,MW=690.2 > 500.0; LogP=6.64 > 5.0
a76db818,,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc3[nH]ncc3c2)cc1,,,raw,,757.8950000000002,757.3376528559999,7.336920000000008,99.17,1,8,7,10,7,0.2391304347826087,57,0.18186386029054824,False,2,True,0,,CHEMBL6014963,79.7,nM,=,7.1,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0985,1,active,MW=757.9 > 500.0; LogP=7.34 > 5.0
51e7cb79,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)CC1,,,raw,,807.7929999999999,806.2580013359999,8.383300000000007,77.19,1,7,7,9,7,0.21739130434782608,56,0.1753142246777153,False,2,True,0,,CHEMBL5985126,9.0,nM,=,8.05,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=807.8 > 500.0; LogP=8.38 > 5.0
5a10440a,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,771.7599999999994,770.258001336,7.538520000000011,77.18999999999998,1,7,7,8,6,0.2558139534883721,53,0.1817351821721214,False,2,True,0,,CHEMBL6021221,2.9,nM,=,8.54,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5376,1,active,MW=771.8 > 500.0; LogP=7.54 > 5.0
18dd68a3,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(F)cc3)c3ccccc32)CC1,,,raw,,772.719,771.2220304279999,8.030700000000008,72.26,1,6,7,8,6,0.20930232558139536,53,0.1781175871672089,False,2,True,0,,CHEMBL5867960,8.3,nM,=,8.08,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0809,1,active,MW=772.7 > 500.0; LogP=8.03 > 5.0
96ec43a0,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)c3ccccc32)CC1,,,raw,,749.3149999999999,748.292866852,8.263800000000007,88.05000000000001,2,6,7,9,7,0.2,55,0.17151065728711787,False,2,True,0,,CHEMBL5805210,4.5,nM,=,8.35,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3468,1,active,MW=749.3 > 500.0; LogP=8.26 > 5.0
cc0ce8af,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(O)cc3)c3ccccc32)CC1,,,raw,,726.277,725.27688244,7.488100000000009,92.49000000000001,2,7,7,8,6,0.20930232558139536,53,0.17736187832010927,False,2,True,0,,CHEMBL5834331,3.9,nM,=,8.41,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4089,1,active,MW=726.3 > 500.0; LogP=7.49 > 5.0
0b62131a,,Cc1ccc(N(C(=O)c2cn(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c3ccccc23)c2ccc(O)cc2)cc1,,,raw,,724.3050000000003,723.2976178840001,8.09092000000001,72.26,1,6,7,8,6,0.22727272727272727,53,0.18040938957297217,False,2,True,0,,CHEMBL5939713,4.2,nM,=,8.38,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=724.3 > 500.0; LogP=8.09 > 5.0
64394575,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(F)cc3)c3ccccc32)CC1,,,raw,,728.268,727.272546008,7.921600000000009,72.26,1,6,7,8,6,0.20930232558139536,53,0.18104645446198778,False,2,True,0,,CHEMBL5970047,7.1,nM,=,8.15,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1487,1,active,MW=728.3 > 500.0; LogP=7.92 > 5.0
9aa71c03,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(Cl)cc3)c3ccccc32)CC1,,,raw,,744.723,743.2429954679999,8.435900000000006,72.26,1,6,7,8,6,0.20930232558139536,53,0.17784091054923304,False,2,True,0,,CHEMBL6061883,8.7,nM,=,8.06,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0605,1,active,MW=744.7 > 500.0; LogP=8.44 > 5.0
f7a44dca,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Cl)c(F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,745.2989999999995,744.2990951040001,7.568520000000012,77.18999999999998,1,7,7,8,6,0.2558139534883721,54,0.18267437421095487,False,2,True,0,,CHEMBL6033384,4.9,nM,=,8.31,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3098,1,active,MW=745.3 > 500.0; LogP=7.57 > 5.0
a132d0d8,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc(F)c(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)CC1,,,raw,,781.3319999999999,780.299095104,8.413300000000007,77.19,1,7,7,9,7,0.21739130434782608,57,0.17594911159596302,False,2,True,0,,CHEMBL5932092,3.7,nM,=,8.43,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4318,1,active,MW=781.3 > 500.0; LogP=8.41 > 5.0
666e96a6,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCC(F)(F)CC1,,,raw,,778.6979999999996,777.212608616,9.011820000000004,84.81,2,5,7,8,6,0.23809523809523808,53,0.16959624479060653,False,2,True,0,,CHEMBL5964702,85.5,nM,=,7.07,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.068,1,active,MW=778.7 > 500.0; LogP=9.01 > 5.0
4b625523,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C2CCCC2)CC1,,,raw,,811.8249999999992,810.2893014639999,8.840920000000006,88.05,2,6,8,9,6,0.30434782608695654,56,0.16056439755884475,False,2,True,0,,CHEMBL5841406,6.8,nM,=,8.17,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1675,1,active,MW=811.8 > 500.0; LogP=8.84 > 5.0
5c83c231,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)c(Cl)c4)c4ccc5c(ccn5C)c4)c4ccccc42)OCO3)CC1,,,raw,,807.3509999999999,806.298346156,8.00290000000001,95.65,1,9,7,10,7,0.23404255319148937,59,0.17456297349798575,False,2,True,0,,CHEMBL5840578,83.8,nM,=,7.08,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0768,1,active,MW=807.4 > 500.0; LogP=8.00 > 5.0
9879c404,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)c(Cl)c4)c4ccc5[nH]ccc5c4)c4ccccc42)OCO3)CC1,,,raw,,793.324,792.282696092,7.992500000000009,106.51000000000002,2,8,7,10,7,0.21739130434782608,58,0.16866517271679368,False,2,True,0,,CHEMBL6059439,17.6,nM,=,7.75,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7545,1,active,MW=793.3 > 500.0; LogP=7.99 > 5.0
4f45bc91,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,raw,,699.8079999999997,699.305684032,5.718620000000008,110.95,2,9,7,8,5,0.2682926829268293,52,0.22222742994919287,False,2,True,0,,CHEMBL6012410,3.7,nM,=,8.43,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4318,1,active,MW=699.8 > 500.0; LogP=5.72 > 5.0
93312b20,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,raw,,701.7989999999998,701.3013476000001,6.152120000000009,90.72,1,8,7,8,5,0.2682926829268293,52,0.21782323503348647,False,2,True,0,,CHEMBL5813720,6.7,nM,=,8.17,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1739,1,active,MW=701.8 > 500.0; LogP=6.15 > 5.0
cf5dfb24,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(Cl)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,raw,,718.2539999999997,717.2717970599999,6.666420000000011,90.72,1,8,7,8,5,0.2682926829268293,52,0.20134742980270112,False,2,True,0,,CHEMBL5767663,3.7,nM,=,8.43,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4318,1,active,MW=718.3 > 500.0; LogP=6.67 > 5.0
03f81928,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,713.2819999999997,712.292866852,7.41902000000001,88.05,2,6,7,8,6,0.23809523809523808,52,0.18001779618465316,False,2,True,0,,CHEMBL6029737,5.4,nM,=,8.27,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2676,1,active,MW=713.3 > 500.0; LogP=7.42 > 5.0
dfc94f8c,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,raw,,722.8459999999998,722.3216684440001,6.494320000000009,106.51,2,8,7,9,6,0.2558139534883721,54,0.19408695739852194,False,2,True,0,,CHEMBL5990681,4.4,nM,=,8.36,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=722.8 > 500.0; LogP=6.49 > 5.0
e2eb0a32,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5[nH]ccc5c4)c4cc(Cl)ccc42)OCO3)CC1,,,raw,,793.324,792.2826960920002,7.992500000000009,106.51000000000002,2,8,7,10,7,0.21739130434782608,58,0.16866517271679368,False,2,True,0,,CHEMBL5934690,19.6,nM,=,7.71,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7077,1,active,MW=793.3 > 500.0; LogP=7.99 > 5.0
c8fb4402,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,727.3089999999997,726.308516916,7.429420000000011,77.18999999999998,1,7,7,8,6,0.2558139534883721,53,0.1853396087594133,False,2,True,0,,CHEMBL5899243,4.2,nM,=,8.38,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=727.3 > 500.0; LogP=7.43 > 5.0
5b6af1ac,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,raw,,736.8729999999997,736.3373185080001,6.50472000000001,95.64999999999999,1,9,7,9,6,0.2727272727272727,55,0.19999847550786948,False,2,True,0,,CHEMBL5994527,3.6,nM,=,8.44,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4437,1,active,MW=736.9 > 500.0; LogP=6.50 > 5.0
878da5bb,,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c2)c2ccc(O)cc2)cc1,,,raw,,688.2720000000003,687.2976178840001,7.246140000000009,72.26,1,6,7,7,5,0.2682926829268293,50,0.19533244102784275,False,2,True,0,,CHEMBL5863109,5.3,nM,=,8.28,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2757,1,active,MW=688.3 > 500.0; LogP=7.25 > 5.0
0267e5a0,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Cl)cc(Cl)c1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,raw,,747.7269999999995,746.2538944999999,8.07242000000001,88.05,2,6,7,8,6,0.23809523809523808,53,0.17263831557955475,False,2,True,0,,CHEMBL5811940,9.6,nM,=,8.02,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0177,1,active,MW=747.7 > 500.0; LogP=8.07 > 5.0
91cf36be,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)CC1,,,raw,,763.3419999999999,762.3085169159999,8.274200000000008,77.19,1,7,7,9,7,0.21739130434782608,56,0.1770638587953184,False,2,True,0,,CHEMBL5825530,3.3,nM,=,8.48,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4815,1,active,MW=763.3 > 500.0; LogP=8.27 > 5.0
f931d13e,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN(C)C)OCO2,,,raw,,681.793,681.2951193480001,6.818920000000009,92.41,1,8,7,8,6,0.21951219512195122,51,0.198998491202254,False,2,True,0,,CHEMBL5939034,7.9,nM,=,8.1,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1024,1,active,MW=681.8 > 500.0; LogP=6.82 > 5.0
c1cee37d,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,raw,,672.229,671.2663177560001,7.74362000000001,73.94999999999999,1,6,7,7,6,0.2,49,0.1884729781852254,False,2,True,0,,CHEMBL5914561,6.4,nM,=,8.19,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1938,1,active,MW=672.2 > 500.0; LogP=7.74 > 5.0
d13397b5,,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c2)c2ccc(O)cc2)cc1,,,raw,,697.8360000000004,697.3264194760001,6.321440000000008,90.72000000000001,1,8,7,8,5,0.2857142857142857,52,0.21299742975053285,False,2,True,0,,CHEMBL6016149,3.9,nM,=,8.41,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4089,1,active,MW=697.8 > 500.0; LogP=6.32 > 5.0
5dd1e94a,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)c(F)c4)c4ccc5c(ccn5C)c4)c4ccccc42)OCO3)CC1,,,raw,,790.896,790.327896696,7.48860000000001,95.65,1,9,7,10,7,0.23404255319148937,59,0.1789730703884002,False,2,True,0,,CHEMBL6002454,6.1,nM,=,8.21,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2147,1,active,MW=790.9 > 500.0; LogP=7.49 > 5.0
fa9a638b,,CCn1ccc2cc(N(C(=O)c3cn(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCN(C)CC4)OCO5)c4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,786.9330000000002,786.3529685720001,7.8324000000000105,95.65000000000002,1,9,8,10,7,0.25,59,0.1679120853405241,False,2,True,0,,CHEMBL5988003,4.8,nM,=,8.32,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3188,1,active,MW=786.9 > 500.0; LogP=7.83 > 5.0
2d4f524f,,CC(C)n1ccc2cc(N(C(=O)c3cn(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCN(C)CC4)OCO5)c4ccccc34)c3ccc(O)cc3)ccc21,,,raw,,800.9600000000002,800.3686186360002,8.393400000000007,95.65000000000002,1,9,8,10,7,0.2653061224489796,60,0.16509731501661043,False,2,True,0,,CHEMBL5895531,6.9,nM,=,8.16,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1612,1,active,MW=801.0 > 500.0; LogP=8.39 > 5.0
cb03f213,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1C(=O)N1CCN(C)CC1,,,raw,,771.7159999999996,770.2216158279999,7.05472000000001,105.12,2,6,6,8,6,0.21428571428571427,53,0.188983543503763,False,2,True,0,,CHEMBL5836806,99.1,nM,=,7.0,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0039,1,active,MW=771.7 > 500.0; LogP=7.05 > 5.0
ff11e800,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C2CCC2)CC1,,,raw,,797.7979999999993,796.2736514,8.450820000000007,88.05,2,6,8,9,6,0.28888888888888886,55,0.16156985705591467,False,2,True,0,,CHEMBL5897415,8.4,nM,=,8.08,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0757,1,active,MW=797.8 > 500.0; LogP=8.45 > 5.0
c30e716b,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CCN3)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,raw,,724.8619999999997,724.3373185080001,5.981020000000007,102.75,2,9,7,9,5,0.3023255813953488,54,0.2115986581762004,False,2,True,0,,CHEMBL5864999,17.4,nM,=,7.76,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7595,1,active,MW=724.9 > 500.0; LogP=5.98 > 5.0
97fe0523,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCCC1,,,raw,,728.6909999999996,727.215802176,8.376520000000006,84.81,2,5,7,8,6,0.21951219512195122,50,0.1731411463756647,False,2,True,0,,CHEMBL5900815,18.8,nM,=,7.73,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7258,1,active,MW=728.7 > 500.0; LogP=8.38 > 5.0
ce05a824,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCCC1)OCO2,,,raw,,707.8309999999998,707.3107694120001,7.353120000000009,92.41,1,8,7,9,6,0.2558139534883721,53,0.18666598234567824,False,2,True,0,,CHEMBL5821166,13.6,nM,=,7.87,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8665,1,active,MW=707.8 > 500.0; LogP=7.35 > 5.0
cd01fcc9,,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)c2)c2ccc(O)cc2)cc1,,,raw,,684.7930000000005,684.294785,6.406240000000008,96.71000000000002,1,8,7,8,5,0.2682926829268293,51,0.21189392230552503,False,2,True,0,,CHEMBL5861827,19.6,nM,=,7.71,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7077,1,active,MW=684.8 > 500.0; LogP=6.41 > 5.0
74c9df7e,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCC2,,,raw,,666.8219999999998,666.3206058240002,6.85782000000001,78.25,1,6,7,8,5,0.2857142857142857,50,0.2055583930057542,False,2,True,0,,CHEMBL5954156,44.0,nM,=,7.36,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3565,1,active,MW=666.8 > 500.0; LogP=6.86 > 5.0
b2395c1d,,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)OCO2,,,raw,,670.766,670.2791349360002,6.097820000000009,96.71000000000001,1,8,7,8,5,0.25,50,0.22375174966958303,False,2,True,0,,CHEMBL5767875,35.5,nM,=,7.45,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4498,1,active,MW=670.8 > 500.0; LogP=6.10 > 5.0
ad7306c5,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)OCO2,,,raw,,723.8299999999998,723.3056840320002,6.58952000000001,101.64,1,9,7,9,6,0.2558139534883721,54,0.19849350396893545,False,2,True,0,,CHEMBL5907541,4.4,nM,=,8.36,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=723.8 > 500.0; LogP=6.59 > 5.0
87b641a6,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CCN3)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCC2,,,raw,,707.8749999999997,707.3471549200001,6.825820000000009,90.28,2,7,7,9,5,0.3181818181818182,53,0.1930333334175365,False,2,True,0,,CHEMBL6015715,8.1,nM,=,8.09,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0915,1,active,MW=707.9 > 500.0; LogP=6.83 > 5.0
ce816c03,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2cccc(N3CCN(C)CC3)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,raw,,683.8090000000002,683.3107694120001,6.537320000000008,90.72000000000001,1,8,6,8,5,0.2682926829268293,51,0.21759079702927367,False,2,True,0,,CHEMBL6036904,11.8,nM,=,7.93,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9281,1,active,MW=683.8 > 500.0; LogP=6.54 > 5.0
9cfad3cc,,O=C(c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)c2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,raw,,710.8310000000005,710.310435064,6.668200000000009,96.71000000000001,1,8,7,9,5,0.3023255813953488,53,0.20174662231981086,False,2,True,0,,CHEMBL5929262,19.2,nM,=,7.72,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7167,1,active,MW=710.8 > 500.0; LogP=6.67 > 5.0
405cbcf3,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CN(C)C3)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,raw,,640.7400000000002,640.2685702520001,6.730920000000007,87.48,1,7,5,8,5,0.23076923076923078,48,0.229344442355859,False,2,True,0,,CHEMBL6035212,23.7,nM,=,7.62,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6253,1,active,MW=640.7 > 500.0; LogP=6.73 > 5.0
45721351,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CCN3C)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,raw,,640.7400000000002,640.2685702520001,6.777820000000008,87.48,1,7,5,8,5,0.23076923076923078,48,0.22808669541079823,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL6060497,14.5,nM,=,7.84,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8386,1,active,MW=640.7 > 500.0; LogP=6.78 > 5.0
20e66a10,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3CCN3CCOCC3)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,raw,,737.8570000000001,737.3213340960001,7.072420000000009,101.64000000000001,1,9,8,9,6,0.2727272727272727,55,0.17841750475170107,False,2,True,0,,CHEMBL5901675,12.1,nM,=,7.92,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9172,1,active,MW=737.9 > 500.0; LogP=7.07 > 5.0
1a2fc547,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCC2,,,raw,,719.8859999999996,719.3471549200001,7.349520000000011,83.17999999999999,1,7,7,9,6,0.28888888888888886,54,0.18674701529106974,False,2,True,0,,CHEMBL5966539,7.6,nM,=,8.12,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1192,1,active,MW=719.9 > 500.0; LogP=7.35 > 5.0
48f5dd7c,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCO2,,,raw,,721.8579999999997,721.3264194760001,6.79572000000001,92.41,1,8,7,9,6,0.2727272727272727,54,0.1952586378021032,False,2,True,0,,CHEMBL6013088,5.9,nM,=,8.23,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2291,1,active,MW=721.9 > 500.0; LogP=6.80 > 5.0
10b1605b,,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2occc2cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCOCC1,,,raw,,719.8419999999998,719.310769412,7.60702000000001,96.32000000000001,1,8,7,9,7,0.22727272727272727,54,0.1823610611208317,False,2,True,0,,CHEMBL5739898,28.4,nM,=,7.55,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5467,1,active,MW=719.8 > 500.0; LogP=7.61 > 5.0
3db155ff,,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)c2ccccc12,,,raw,,537.7080000000003,537.310375488,5.5937000000000054,84.46000000000001,1,5,10,5,4,0.36363636363636365,40,0.2856785387533018,False,2,True,0,,CHEMBL5746825,448.0,nM,=,6.35,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.3487,1,active,MW=537.7 > 500.0; LogP=5.59 > 5.0
20e9451e,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,raw,,577.6880000000001,577.247775232,6.529800000000006,84.46,1,5,6,7,6,0.10810810810810811,44,0.24400655078129346,False,2,True,0,,CHEMBL5882975,53.3,nM,=,7.27,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2733,1,active,MW=577.7 > 500.0; LogP=6.53 > 5.0
751340b5,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1cc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,raw,,576.7000000000002,576.2525262639999,7.1348000000000065,71.57,1,4,6,7,6,0.10526315789473684,44,0.22923364029954293,False,2,True,0,,CHEMBL6030240,90.0,nM,=,7.05,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0458,1,active,MW=576.7 > 500.0; LogP=7.13 > 5.0
1fc8f191,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,raw,,592.6990000000002,592.247440884,6.840400000000007,91.8,2,5,6,7,6,0.10526315789473684,45,0.22157269342505392,False,2,True,0,,CHEMBL5756948,18.9,nM,=,7.72,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7235,1,active,MW=592.7 > 500.0; LogP=6.84 > 5.0
9b9907c9,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-n1nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc31)OCO2,,,raw,,621.6970000000001,621.237604472,6.258500000000006,102.92,1,7,6,8,6,0.13157894736842105,47,0.23566710708762234,False,2,True,0,,CHEMBL5817613,31.7,nM,=,7.5,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4989,1,active,MW=621.7 > 500.0; LogP=6.26 > 5.0
018afda2,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccc(C(=O)O)cc21,,,raw,,621.6970000000001,621.237604472,6.228000000000006,121.76,2,6,7,7,6,0.10526315789473684,47,0.21810004616258247,False,2,True,0,,CHEMBL6025146,841.0,nM,=,6.08,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.0752,1,active,MW=621.7 > 500.0; LogP=6.23 > 5.0
38bc83dc,,COc1cc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)cc1O,,,raw,,623.7130000000001,623.253254536,6.244000000000008,113.92,2,7,7,7,6,0.13157894736842105,47,0.21759450736735927,False,2,True,0,,CHEMBL5745266,10.4,nM,=,7.98,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.983,1,active,MW=623.7 > 500.0; LogP=6.24 > 5.0
924699a3,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(N)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,raw,,592.7030000000001,592.2586742640001,6.112000000000005,110.48,2,6,6,7,6,0.10810810810810811,45,0.22681285896279363,False,2,True,0,,CHEMBL5924981,52.2,nM,=,7.28,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2823,1,active,MW=592.7 > 500.0; LogP=6.11 > 5.0
0916f8be,,CNc1ccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)c1,,,raw,,606.73,606.274324328,6.5715000000000074,96.49,2,6,7,7,6,0.13157894736842105,46,0.21431882935751323,False,2,True,0,,CHEMBL5884492,25.0,nM,=,7.6,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6021,1,active,MW=606.7 > 500.0; LogP=6.57 > 5.0
19e27b68,,CN(C)c1ccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)c1,,,raw,,620.7570000000001,620.289974392,6.5958000000000085,87.7,1,6,7,7,6,0.15384615384615385,47,0.21750558581791277,False,2,True,0,,CHEMBL5831476,56.7,nM,=,7.25,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2464,1,active,MW=620.8 > 500.0; LogP=6.60 > 5.0
650d1a0b,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NCc2ccccc2)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,raw,,682.8280000000001,682.3056244560001,8.141900000000007,96.49,2,6,9,8,7,0.11363636363636363,52,0.1603210190895699,False,2,True,0,,CHEMBL5760477,70.6,nM,=,7.15,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1512,1,active,MW=682.8 > 500.0; LogP=8.14 > 5.0
0ed03f10,,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,raw,,620.7530000000002,620.278741012,7.443300000000009,69.02,1,5,7,7,6,0.15,47,0.20145819842739646,False,2,True,0,,CHEMBL5870146,71.5,nM,=,7.15,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1457,1,active,MW=620.8 > 500.0; LogP=7.44 > 5.0
3cac0b3e,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NC(=O)COc2ccccc2)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,raw,,726.8370000000002,726.295453696,7.547300000000007,122.79,2,7,10,8,7,0.1111111111111111,55,0.15019984953825102,False,2,True,0,,CHEMBL5831745,35.0,nM,=,7.46,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4559,1,active,MW=726.8 > 500.0; LogP=7.55 > 5.0
e741e7cb,,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)cc1O,,,raw,,638.724,638.2529201880001,6.554600000000009,121.26,3,7,7,7,6,0.1282051282051282,48,0.18232137590460487,False,2,True,0,,CHEMBL5760905,12.2,nM,=,7.91,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9136,1,active,MW=638.7 > 500.0; LogP=6.55 > 5.0
66e12b81,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,raw,,622.7250000000003,622.258005568,6.849000000000007,101.03,2,6,7,7,6,0.1282051282051282,47,0.20291140304533598,False,2,True,0,,CHEMBL5978117,17.2,nM,=,7.76,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7645,1,active,MW=622.7 > 500.0; LogP=6.85 > 5.0
d5c05765,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN)c(-n2cc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c1,,,raw,,606.7260000000002,606.2630909480001,7.143400000000007,80.8,1,5,7,7,6,0.1282051282051282,46,0.20946896269709345,False,2,True,0,,CHEMBL5984436,22.5,nM,=,7.65,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6478,1,active,MW=606.7 > 500.0; LogP=7.14 > 5.0
2f87a470,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,raw,,593.6870000000001,593.242689852,6.2354000000000065,104.69,2,6,6,7,6,0.10810810810810811,45,0.23811998953935928,False,2,True,0,,CHEMBL5928975,28.3,nM,=,7.55,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5482,1,active,MW=593.7 > 500.0; LogP=6.24 > 5.0
654e6f72,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NC(=O)CSc2ccccc2)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,raw,,742.9050000000001,742.2726100760001,8.260600000000005,113.56000000000002,2,7,10,8,7,0.1111111111111111,55,0.13656731968773483,False,2,True,0,,CHEMBL6042065,21.6,nM,=,7.67,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6655,1,active,MW=742.9 > 500.0; LogP=8.26 > 5.0
dd5aceda,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN)c(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c1,,,raw,,607.7140000000002,607.2583399160001,6.538400000000006,93.68999999999998,1,6,7,7,6,0.13157894736842105,46,0.2225577153661202,False,2,True,0,,CHEMBL5917599,51.0,nM,=,7.29,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2924,1,active,MW=607.7 > 500.0; LogP=6.54 > 5.0
2bc1f41e,,COc1cc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)cc1N,,,raw,,622.7289999999999,622.269238948,6.120600000000007,119.71,2,7,7,7,6,0.13157894736842105,47,0.20715049355347664,False,2,True,0,,CHEMBL5858824,218.0,nM,=,6.66,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.6615,1,active,MW=622.7 > 500.0; LogP=6.12 > 5.0
580ffda5,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-n1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc31)OCO2,,,raw,,636.7080000000001,636.237270124,6.569100000000007,110.26,2,7,6,8,6,0.1282051282051282,48,0.21412628480034476,False,2,True,0,,CHEMBL5863038,286.0,nM,=,6.54,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.5436,1,active,MW=636.7 > 500.0; LogP=6.57 > 5.0
52175865,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccccc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,raw,,675.8330000000001,675.3209401720001,7.129100000000009,72.26,1,6,7,8,6,0.20930232558139536,51,0.19510138371445648,False,2,True,0,,CHEMBL5968365,13.2,nM,=,7.88,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8794,1,active,MW=675.8 > 500.0; LogP=7.13 > 5.0
b8aaf9ce,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,raw,,627.1440000000002,626.208468532,7.493800000000007,91.8,2,5,6,7,6,0.10526315789473684,46,0.20032628269184782,False,2,True,0,,CHEMBL5788955,11.7,nM,=,7.93,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9318,1,active,MW=627.1 > 500.0; LogP=7.49 > 5.0
80361c33,,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NC(=O)CSc2ccccc2)ccc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,raw,,757.9160000000002,757.272275728,8.571200000000005,120.9,3,7,10,8,7,0.10869565217391304,56,0.12034776852148221,False,2,True,0,,CHEMBL5819768,16.1,nM,=,7.79,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7932,1,active,MW=757.9 > 500.0; LogP=8.57 > 5.0
9714ee57,,CC(C)CC1Oc2cc(C(=O)N3Cc4ccccc4C[C@H]3CN)c(-n3cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc43)cc2O1,,,raw,,692.8160000000003,692.2998703800001,7.983800000000009,110.26,2,7,8,8,6,0.20930232558139536,52,0.16744921480008698,False,2,True,0,,CHEMBL5906194,54.1,nM,=,7.27,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2668,1,active,MW=692.8 > 500.0; LogP=7.98 > 5.0
479728ee,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,raw,,710.278,709.28196782,7.7825000000000095,72.26,1,6,7,8,6,0.20930232558139536,52,0.18341247126276036,False,2,True,0,,CHEMBL5750459,10.2,nM,=,7.99,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9914,1,active,MW=710.3 > 500.0; LogP=7.78 > 5.0
e7c650c6,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc(NC(=O)CSc3ccccc3)ccc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,raw,,841.05,840.345775016,8.859900000000005,101.36,2,8,11,9,7,0.19607843137254902,62,0.125664320871038,False,2,True,0,,CHEMBL5991985,22.8,nM,=,7.64,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6421,1,active,MW=841.0 > 500.0; LogP=8.86 > 5.0
ab08d2f1,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OCO3)CC1,,,raw,,719.8420000000001,719.3107694120001,6.857800000000009,90.72000000000001,1,8,7,9,6,0.22727272727272727,54,0.1930072857002851,False,2,True,0,,CHEMBL6048662,7.8,nM,=,8.11,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1079,1,active,MW=719.8 > 500.0; LogP=6.86 > 5.0
d1b97d8b,,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,721.8579999999997,721.326419476,6.84330000000001,101.72,2,8,8,8,6,0.22727272727272727,54,0.177555414749802,False,2,True,0,,CHEMBL5994962,3.2,nM,=,8.49,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4949,1,active,MW=721.9 > 500.0; LogP=6.84 > 5.0
0646a100,,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)cc1Cl,,,raw,,740.3040000000003,739.2925325040001,7.791100000000009,81.49000000000001,1,7,8,8,6,0.22727272727272727,54,0.17179468743576448,False,2,True,0,,CHEMBL5830905,37.4,nM,=,7.43,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4271,1,active,MW=740.3 > 500.0; LogP=7.79 > 5.0
7ffcf80b,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,raw,,705.8590000000004,705.331504856,7.137700000000009,81.49000000000001,1,7,8,8,6,0.22727272727272727,53,0.18152072746474743,False,2,True,0,,CHEMBL5757762,11.4,nM,=,7.94,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9431,1,active,MW=705.9 > 500.0; LogP=7.14 > 5.0
5846b3dc,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,raw,,690.8440000000004,690.3206058240002,8.376200000000008,78.25,1,6,8,8,6,0.22727272727272727,52,0.17372519221135785,False,2,True,0,,CHEMBL5799114,108.0,nM,=,6.97,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.9666,1,active,MW=690.8 > 500.0; LogP=8.38 > 5.0
b09d831c,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OCCO3)CC1,,,raw,,733.869,733.3264194760001,6.900300000000009,90.72000000000001,1,8,7,9,6,0.24444444444444444,55,0.19107099805864788,False,2,True,0,,CHEMBL5832526,16.8,nM,=,7.78,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7747,1,active,MW=733.9 > 500.0; LogP=6.90 > 5.0
db69a3de,,O=C(c1cn(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,raw,,695.2630000000004,694.271068788,9.021,69.02000000000001,1,5,7,8,6,0.20930232558139536,51,0.18115106942486361,False,2,True,0,,CHEMBL5809792,71.8,nM,=,7.14,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1439,1,active,MW=695.3 > 500.0; LogP=9.02 > 5.0
a194e8cd,,O=C(c1cn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,raw,,593.6830000000002,593.231456472,6.874000000000008,86.01,2,5,6,7,6,0.10526315789473684,45,0.22066746967915293,False,2,True,0,,CHEMBL5978367,4.2,nM,=,8.38,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=593.7 > 500.0; LogP=6.87 > 5.0
b5cab5a1,,O=C(c1cn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,raw,,660.8180000000004,660.3100411400001,8.367600000000005,69.02000000000001,1,5,7,8,6,0.20930232558139536,50,0.18691438365424234,False,2,True,0,,CHEMBL6062105,168.0,nM,=,6.78,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.7747,1,active,MW=660.8 > 500.0; LogP=8.37 > 5.0
332bc224,,O=C(c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCCCC2)OCO3)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,raw,,704.8270000000005,704.29987038,8.096300000000008,87.48,1,7,7,9,6,0.22727272727272727,53,0.18086544886911773,False,2,True,0,,CHEMBL5908915,41.2,nM,=,7.38,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3851,1,active,MW=704.8 > 500.0; LogP=8.10 > 5.0
be608326,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN(C)C)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,raw,,650.7790000000002,650.289305696,7.451900000000009,78.25,1,6,8,7,6,0.17073170731707318,49,0.18522188382722624,False,2,True,0,,CHEMBL5864277,25.1,nM,=,7.6,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6003,1,active,MW=650.8 > 500.0; LogP=7.45 > 5.0
c0c3ecef,,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)cc1O,,,raw,,706.8429999999997,706.3155204440001,8.081800000000008,98.48,2,7,8,8,6,0.22727272727272727,53,0.16618166204934207,False,2,True,0,,CHEMBL5935254,6.2,nM,=,8.21,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2076,1,active,MW=706.8 > 500.0; LogP=8.08 > 5.0
4534f46f,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccccc4)c4ccccc42)OCO3)CC1,,,raw,,703.8430000000001,703.3158547920001,7.152200000000009,70.49000000000001,0,7,7,9,6,0.22727272727272727,53,0.17603495552224002,False,2,True,0,,CHEMBL5902614,18.8,nM,=,7.73,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7258,1,active,MW=703.8 > 500.0; LogP=7.15 > 5.0
a7d8e160,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)CC1,,,raw,,694.279,693.2870532,8.076900000000009,52.03,0,5,7,8,6,0.20930232558139536,51,0.16977263647623245,False,2,True,0,,CHEMBL6063727,17.5,nM,=,7.76,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.757,1,active,MW=694.3 > 500.0; LogP=8.08 > 5.0
38d507d1,,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,raw,,655.1980000000002,654.23976866,8.096700000000007,69.02,1,5,7,7,6,0.15,48,0.18892616173941973,False,2,True,0,,CHEMBL5910525,18.1,nM,=,7.74,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7423,1,active,MW=655.2 > 500.0; LogP=8.10 > 5.0
926c2956,,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-n1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc31)OCO2,,,raw,,664.7620000000002,664.268570252,7.172000000000009,87.48,1,7,7,8,6,0.17073170731707318,50,0.19481363116415246,False,2,True,0,,CHEMBL5997609,11.0,nM,=,7.96,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9586,1,active,MW=664.8 > 500.0; LogP=7.17 > 5.0
0946789d,,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,705.8589999999997,705.3315048559999,7.137700000000011,81.49000000000001,1,7,8,8,6,0.22727272727272727,53,0.18152072746474734,False,2,True,0,,CHEMBL5886009,6.9,nM,=,8.16,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1612,1,active,MW=705.9 > 500.0; LogP=7.14 > 5.0
6f9633b2,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OC(F)(F)O3)CC1,,,raw,,755.8220000000002,755.2919257880001,7.4506000000000085,90.72000000000001,1,8,7,9,6,0.22727272727272727,56,0.18118103391420423,False,2,True,0,,CHEMBL5857187,111.0,nM,=,6.96,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.9547,1,active,MW=755.8 > 500.0; LogP=7.45 > 5.0
1a0f44bc,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc(O)c(O)cc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,raw,,707.8310000000001,707.310769412,6.540300000000009,112.72,3,8,7,8,6,0.20930232558139536,53,0.1616998938950206,False,2,False,1,PAINS match: catechol_A(92),CHEMBL5750655,8.3,nM,=,8.08,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0809,1,active,MW=707.8 > 500.0; LogP=6.54 > 5.0
1f166620,,O=C(c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,raw,,706.7990000000004,706.279134936,6.942600000000008,96.71000000000001,1,8,7,9,6,0.20930232558139536,53,0.19221026890062004,False,2,True,0,,CHEMBL6046174,14.1,nM,=,7.85,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8508,1,active,MW=706.8 > 500.0; LogP=6.94 > 5.0
c3baa07a,,CCC1COc2cc(-n3cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc43)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)cc2O1,,,raw,,761.9229999999997,761.357719604,7.678900000000013,90.72,1,8,8,9,6,0.2765957446808511,57,0.17032570539868966,False,2,True,0,,CHEMBL5987041,17.3,nM,=,7.76,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.762,1,active,MW=761.9 > 500.0; LogP=7.68 > 5.0
59a8f86a,,O=C(c1cn(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,raw,,697.2350000000004,696.2503333440001,7.867300000000007,78.25,1,6,7,8,6,0.19047619047619047,51,0.18393005728033315,False,2,True,0,,CHEMBL5745694,23.5,nM,=,7.63,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6289,1,active,MW=697.2 > 500.0; LogP=7.87 > 5.0
70f8433e,,COc1cc(-n2cc(C(=O)N(c3ccccc3)C3CCCCC3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,711.9069999999999,711.378455048,7.138700000000011,81.49000000000001,1,7,8,8,5,0.36363636363636365,53,0.18449253136494695,False,2,True,0,,CHEMBL5775349,21.6,nM,=,7.67,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6655,1,active,MW=711.9 > 500.0; LogP=7.14 > 5.0
a95be539,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OC[C@H](COCc2ccccc2)O3)CC1,,,raw,,854.02,853.3839343520001,8.485700000000008,99.95000000000002,1,9,11,10,7,0.24528301886792453,64,0.13849638445303766,False,2,True,0,,CHEMBL5985491,16.8,nM,=,7.78,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7747,1,active,MW=854.0 > 500.0; LogP=8.49 > 5.0
64d21a78,,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(F)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,723.8489999999997,723.322083044,7.276800000000011,81.49000000000001,1,7,8,8,6,0.22727272727272727,54,0.17800440042089616,False,2,True,0,,CHEMBL5798028,13.6,nM,=,7.87,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8665,1,active,MW=723.8 > 500.0; LogP=7.28 > 5.0
d5e75053,,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(C)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,719.8859999999997,719.34715492,7.446120000000011,81.49000000000001,1,7,8,8,6,0.24444444444444444,54,0.17621498870802307,False,2,True,0,,CHEMBL5822872,5.6,nM,=,8.25,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2518,1,active,MW=719.9 > 500.0; LogP=7.45 > 5.0
172d57dc,,CCCCN(C(=O)c1cn(-c2cc(OC)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12)c1ccccc1,,,raw,,685.8690000000001,685.362804984,6.606100000000008,81.49,1,7,10,7,5,0.3333333333333333,51,0.17844542612743325,False,2,True,0,,CHEMBL5757201,6.7,nM,=,8.17,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1739,1,active,MW=685.9 > 500.0; LogP=6.61 > 5.0
1438125b,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4cc(F)ccc42)OCO3)CC1,,,raw,,737.8320000000001,737.3013476000001,6.996900000000009,90.72000000000001,1,8,7,9,6,0.22727272727272727,55,0.18892932188416656,False,2,True,0,,CHEMBL5972946,31.1,nM,=,7.51,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5072,1,active,MW=737.8 > 500.0; LogP=7.00 > 5.0
9d52467b,,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccc(F)cc42)OCO3)CC1,,,raw,,737.8320000000001,737.3013476000001,6.996900000000009,90.72000000000001,1,8,7,9,6,0.22727272727272727,55,0.18892932188416656,False,2,True,0,,CHEMBL6022916,9.8,nM,=,8.01,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0088,1,active,MW=737.8 > 500.0; LogP=7.00 > 5.0
a2ef77ea,,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc4[nH]ccc4c3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,744.8959999999997,744.342403888,7.619000000000011,97.27999999999999,2,7,8,9,7,0.21739130434782608,56,0.16635794620115288,False,2,True,0,,CHEMBL5987519,3.4,nM,=,8.47,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4685,1,active,MW=744.9 > 500.0; LogP=7.62 > 5.0
2718ba92,,CCCCN(CCCC)C(=O)c1cn(-c2ccc(NC(=O)CSc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12,,,raw,,785.0709999999997,784.4134606519999,8.218200000000008,81.12999999999998,1,7,15,7,5,0.3829787234042553,57,0.10792112419150922,False,2,True,0,,CHEMBL6043187,57.7,nM,=,7.24,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2388,1,active,MW=785.1 > 500.0; LogP=8.22 > 5.0
fe78aa8b,,CCCCN(CCCC)C(=O)c1cn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12,,,raw,,769.0029999999997,768.4363042719999,7.504900000000009,90.36,1,7,15,7,5,0.3829787234042553,57,0.11873950097377069,False,2,True,0,,CHEMBL6055064,155.0,nM,=,6.81,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.8097,1,active,MW=769.0 > 500.0; LogP=7.50 > 5.0
c879a846,,COc1cc(-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(F)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,739.8479999999997,739.316997664,6.98240000000001,101.72,2,8,8,8,6,0.22727272727272727,55,0.1738072532602824,False,2,True,0,,CHEMBL6020153,3.1,nM,=,8.51,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5086,1,active,MW=739.8 > 500.0; LogP=6.98 > 5.0
06e0cb20,,COc1cc(-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,760.8949999999998,760.337318508,7.32460000000001,117.50999999999999,3,8,8,9,7,0.21739130434782608,57,0.1486755765100753,False,2,True,0,,CHEMBL5990271,4.4,nM,=,8.36,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=760.9 > 500.0; LogP=7.32 > 5.0
fbfa44f8,,CCCCN(C(=O)c1cn(-c2cc(OC)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12)c1ccc(O)cc1,,,raw,,701.8680000000002,701.3577196040001,6.311700000000008,101.72,2,8,10,7,5,0.3333333333333333,52,0.1760799507102188,False,2,True,0,,CHEMBL5800065,10.0,nM,=,8.0,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0,1,active,MW=701.9 > 500.0; LogP=6.31 > 5.0
2a08ec71,,COc1cc(-n2cc(C(=O)N(c3ccc(O)cc3)C3CCCCC3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,raw,,727.906,727.373369668,6.84430000000001,101.72,2,8,8,8,5,0.36363636363636365,54,0.180555973597978,False,2,True,0,,CHEMBL5961933,4.7,nM,=,8.33,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3279,1,active,MW=727.9 > 500.0; LogP=6.84 > 5.0
e44c5f2d,,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)c1,,,raw,,758.9230000000002,758.358053952,7.629400000000009,86.42000000000002,1,8,8,9,7,0.23404255319148937,57,0.17172601729953177,False,2,True,0,,CHEMBL5908462,4.3,nM,=,8.37,CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3665,1,active,MW=758.9 > 500.0; LogP=7.63 > 5.0
17c5b0b6,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC(C)(C)C)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,759.9479999999999,759.3995844159999,6.666100000000009,107.79,1,8,6,8,4,0.4444444444444444,56,0.2343173115881428,False,2,True,0,,CHEMBL5866497,13.0,nM,=,7.89,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8861,1,active,MW=759.9 > 500.0; LogP=6.67 > 5.0
8b084397,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CNCC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,659.8310000000002,659.3471549200001,5.0186000000000055,90.28000000000002,2,7,6,8,4,0.4,49,0.3024880538978466,False,2,True,0,,CHEMBL5982560,397.0,nM,=,6.4,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.4012,1,active,MW=659.8 > 500.0; LogP=5.02 > 5.0
0ec3f245,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,799.9939999999999,799.340355288,6.119900000000008,115.63000000000001,1,8,8,9,5,0.34782608695652173,58,0.20132873326477996,False,2,True,0,,CHEMBL5798521,18.0,nM,=,7.75,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=800.0 > 500.0; LogP=6.12 > 5.0
76c15b62,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)Cc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,814.0209999999998,813.3560053519999,6.261000000000008,115.63000000000001,1,8,9,9,5,0.3617021276595745,59,0.1869920182680223,False,2,True,0,,CHEMBL5943881,9.2,nM,=,8.04,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0362,1,active,MW=814.0 > 500.0; LogP=6.26 > 5.0
a74dcd5d,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2ccc4ccccc4c2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,850.0539999999999,849.3560053519999,7.27310000000001,115.63000000000001,1,8,8,10,6,0.32,62,0.17143463848087714,False,2,True,0,,CHEMBL5847053,43.0,nM,=,7.37,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3665,1,active,MW=850.1 > 500.0; LogP=7.27 > 5.0
6e469a1d,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC(C)(C)C)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,745.9209999999999,745.3839343519999,6.623600000000009,107.79,1,8,6,8,4,0.4318181818181818,55,0.23648158186481524,False,2,True,0,,CHEMBL6061142,95.0,nM,=,7.02,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0223,1,active,MW=745.9 > 500.0; LogP=6.62 > 5.0
d577202c,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CNC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,645.8040000000003,645.331504856,4.976100000000005,90.28000000000002,2,7,6,8,4,0.38461538461538464,48,0.30783995587535323,True,1,True,0,,CHEMBL5883522,3300.0,nM,=,5.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,5.4815,0,inactive,MW=645.8 > 500.0
b809f21c,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,763.9390000000001,763.373369668,6.457800000000009,98.56000000000002,1,7,8,9,5,0.3404255319148936,57,0.19512039328271033,False,2,True,0,,CHEMBL6002401,7.3,nM,=,8.14,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1367,1,active,MW=763.9 > 500.0; LogP=6.46 > 5.0
a5149483,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CCc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,777.9660000000001,777.389019732,6.847900000000009,98.56000000000002,1,7,9,9,5,0.3541666666666667,58,0.17606696523010895,False,2,True,0,,CHEMBL5887132,9.0,nM,=,8.05,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0458,1,active,MW=778.0 > 500.0; LogP=6.85 > 5.0
05369d53,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CNC2,,,raw,,560.6980000000001,560.2787410120001,5.6638000000000055,77.81,2,5,4,7,4,0.3142857142857143,42,0.33758341501573896,False,2,True,0,,CHEMBL5977746,127.0,nM,=,6.9,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.8962,1,active,MW=560.7 > 500.0; LogP=5.66 > 5.0
5cb76119,,CCC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,raw,,701.868,701.357719604,5.625100000000007,98.56,1,7,7,8,4,0.40476190476190477,52,0.26869258475237473,False,2,True,0,,CHEMBL5925901,22.0,nM,=,7.66,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6576,1,active,MW=701.9 > 500.0; LogP=5.63 > 5.0
11149a4b,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)c2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,749.912,749.357719604,6.528900000000009,98.56000000000002,1,7,7,9,5,0.32608695652173914,56,0.203463411862555,False,2,True,0,,CHEMBL5930893,43.0,nM,=,7.37,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3665,1,active,MW=749.9 > 500.0; LogP=6.53 > 5.0
bef18bb6,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OC(C)(C)C)C2,,,raw,,660.8149999999999,660.3311705080001,7.311300000000009,95.32000000000001,1,6,4,7,4,0.375,49,0.24779159549224744,False,2,True,0,,CHEMBL5996625,108.0,nM,=,6.97,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.9666,1,active,MW=660.8 > 500.0; LogP=7.31 > 5.0
6d2b999a,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Cc1ccccc1)C2,,,raw,,678.833,678.3206058240002,7.145500000000009,86.09,1,5,6,8,5,0.27906976744186046,51,0.2069167892076197,False,2,True,0,,CHEMBL5783636,7.9,nM,=,8.1,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1024,1,active,MW=678.8 > 500.0; LogP=7.15 > 5.0
e52e8889,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CCc1ccccc1)C2,,,raw,,692.8599999999999,692.3362558880001,7.535600000000009,86.09,1,5,7,8,5,0.29545454545454547,52,0.1911536356228008,False,2,True,0,,CHEMBL5911445,19.0,nM,=,7.72,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7212,1,active,MW=692.9 > 500.0; LogP=7.54 > 5.0
18b660c7,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,765.9110000000001,765.3526342239999,6.887500000000009,107.79,1,8,7,9,5,0.32608695652173914,57,0.19251096842293075,False,2,True,0,,CHEMBL5889756,6.0,nM,=,8.22,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2218,1,active,MW=765.9 > 500.0; LogP=6.89 > 5.0
31e8fe58,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)NC(C)(C)C)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,744.9369999999999,744.399918764,6.196600000000007,110.59000000000002,2,7,6,8,4,0.4318181818181818,55,0.2436860494333126,False,2,True,0,,CHEMBL5879405,91.0,nM,=,7.04,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.041,1,active,MW=744.9 > 500.0; LogP=6.20 > 5.0
2cc5f993,,CCS(=O)(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,raw,,737.923,737.324705224,5.038200000000005,115.63000000000002,1,8,8,8,4,0.4146341463414634,53,0.2697461125900323,False,2,True,0,,CHEMBL5789940,38.0,nM,=,7.42,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4202,1,active,MW=737.9 > 500.0; LogP=5.04 > 5.0
13cdcf61,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,785.967,785.3247052239999,6.077400000000008,115.63000000000001,1,8,8,9,5,0.3333333333333333,57,0.20305542654563408,False,2,True,0,,CHEMBL5755708,47.0,nM,=,7.33,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3279,1,active,MW=786.0 > 500.0; LogP=6.08 > 5.0
c93b15f2,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)C1CC1)C2,,,raw,,628.7729999999999,628.3049557600001,6.312800000000007,86.09,1,5,5,8,4,0.358974358974359,47,0.2807141974760824,False,2,True,0,,CHEMBL6015543,20.0,nM,=,7.7,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.699,1,active,MW=628.8 > 500.0; LogP=6.31 > 5.0
0c82e30b,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)CCc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,814.0209999999998,813.3560053519999,6.261000000000008,115.63000000000001,1,8,10,9,5,0.3617021276595745,59,0.17717133844435073,False,2,True,0,,CHEMBL5906827,14.0,nM,=,7.85,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8539,1,active,MW=814.0 > 500.0; LogP=6.26 > 5.0
6b289f9b,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2cccnc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,786.9549999999999,786.319954192,5.472400000000007,128.51999999999998,1,9,8,9,5,0.3409090909090909,57,0.2195224031986743,False,2,True,0,,CHEMBL5987615,70.0,nM,=,7.16,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1549,1,active,MW=787.0 > 500.0; LogP=5.47 > 5.0
56e51fcc,,CC(Cc1ccccc1)C(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,raw,,706.887,706.351905952,7.78160000000001,86.09,1,5,7,8,5,0.3111111111111111,53,0.18742998979751435,False,2,True,0,,CHEMBL5806867,13.0,nM,=,7.89,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8861,1,active,MW=706.9 > 500.0; LogP=7.78 > 5.0
67996cf2,,CC(Cc1ccc(Cl)cc1)C(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,raw,,741.3319999999999,740.3129336,8.435000000000006,86.09,1,5,7,8,5,0.3111111111111111,54,0.18162334962246213,False,2,True,0,,CHEMBL5954684,19.0,nM,=,7.72,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7212,1,active,MW=741.3 > 500.0; LogP=8.44 > 5.0
72d696d6,,Cc1ccc(CC(C)C(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)cc3C2)cc1,,,raw,,720.914,720.367556016,8.09002000000001,86.09,1,5,7,8,5,0.32608695652173914,54,0.18430891065480579,False,2,True,0,,CHEMBL6052420,29.0,nM,=,7.54,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5376,1,active,MW=720.9 > 500.0; LogP=8.09 > 5.0
814ebce8,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Cc1ccc(OC(F)(F)F)cc1)C2,,,raw,,762.8290000000001,762.3029050720002,8.04410000000001,95.32000000000001,1,6,7,8,5,0.29545454545454547,56,0.18126889445445743,False,2,True,0,,CHEMBL5990443,30.0,nM,=,7.52,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5229,1,active,MW=762.8 > 500.0; LogP=8.04 > 5.0
2425c340,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCNC2,,,raw,,574.725,574.294391076,5.706300000000006,77.81,2,5,4,7,4,0.3333333333333333,43,0.3276244427997479,False,2,True,0,,CHEMBL6001407,83.0,nM,=,7.08,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.0809,1,active,MW=574.7 > 500.0; LogP=5.71 > 5.0
650309dc,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(Cc1ccccn1)C2,,,raw,,651.8109999999999,651.3209401720001,6.971400000000009,81.91,1,6,6,8,5,0.2926829268292683,49,0.21455622542580677,False,2,True,0,,CHEMBL5842152,23.0,nM,=,7.64,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6383,1,active,MW=651.8 > 500.0; LogP=6.97 > 5.0
f6848918,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CCC1CCCCC1)C2,,,raw,,670.8979999999996,670.3882914600001,8.346600000000008,69.02,1,5,7,8,4,0.4418604651162791,50,0.2147190229477669,False,2,True,0,,CHEMBL5987623,28.0,nM,=,7.55,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5528,1,active,MW=670.9 > 500.0; LogP=8.35 > 5.0
fe473a91,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CCCc1ccccc1)C2,,,raw,,678.8769999999998,678.3569913320001,8.009000000000011,69.02,1,5,8,8,5,0.3181818181818182,51,0.1806552889904059,False,2,True,0,,CHEMBL5890570,16.0,nM,=,7.8,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=678.9 > 500.0; LogP=8.01 > 5.0
545a1c06,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Cc1csc(-c3cnccn3)n1)C2,,,raw,,763.9239999999998,763.2940737920001,7.059000000000009,124.76,1,9,7,9,6,0.2727272727272727,56,0.1847483300733322,False,2,True,0,,CHEMBL5742098,7.4,nM,=,8.13,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1308,1,active,MW=763.9 > 500.0; LogP=7.06 > 5.0
f196ea33,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CCC1CCCCC1)C2,,,raw,,698.9079999999996,698.3832060800001,8.263300000000008,86.09,1,5,7,8,4,0.4318181818181818,52,0.21068931914541503,False,2,True,0,,CHEMBL5859886,47.0,nM,=,7.33,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3279,1,active,MW=698.9 > 500.0; LogP=8.26 > 5.0
fe164118,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(Cc1ccccc1)C2,,,raw,,650.823,650.3256912040001,7.576400000000009,69.02,1,5,6,8,5,0.2857142857142857,49,0.20587287805480964,False,2,True,0,,CHEMBL5851747,33.0,nM,=,7.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4815,1,active,MW=650.8 > 500.0; LogP=7.58 > 5.0
239c36e5,,CCC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,raw,,630.7890000000002,630.320605824,6.355300000000007,86.08999999999999,1,5,5,7,4,0.358974358974359,47,0.27839502895744755,False,2,True,0,,CHEMBL5754652,4.9,nM,=,8.31,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3098,1,active,MW=630.8 > 500.0; LogP=6.36 > 5.0
a27c95e0,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)c1ccccc1)C2,,,raw,,678.833,678.320605824,7.259100000000009,86.09,1,5,5,8,5,0.27906976744186046,51,0.21218855387118618,False,2,True,0,,CHEMBL5935434,4.7,nM,=,8.33,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3279,1,active,MW=678.8 > 500.0; LogP=7.26 > 5.0
d4daf25c,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccccc1)C2,,,raw,,692.8599999999999,692.336255888,7.1880000000000095,86.09,1,5,6,8,5,0.29545454545454547,52,0.20431239269355772,False,2,True,0,,CHEMBL5959510,4.8,nM,=,8.32,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3188,1,active,MW=692.9 > 500.0; LogP=7.19 > 5.0
7b50413f,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)CCc1ccccc1)C2,,,raw,,706.8869999999998,706.351905952,7.57810000000001,86.09,1,5,7,8,5,0.3111111111111111,53,0.1892436583203436,False,2,True,0,,CHEMBL5824869,4.9,nM,=,8.31,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3098,1,active,MW=706.9 > 500.0; LogP=7.58 > 5.0
63042168,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)Cc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,799.9939999999999,799.340355288,6.218500000000009,115.63000000000001,1,8,9,9,5,0.34782608695652173,58,0.18849054503603446,False,2,True,0,,CHEMBL5832240,23.0,nM,=,7.64,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6383,1,active,MW=800.0 > 500.0; LogP=6.22 > 5.0
4128bc9b,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(S(=O)(=O)c1ccccc1)C2,,,raw,,714.888,714.2875914440001,6.807600000000009,103.16,1,6,6,8,5,0.2857142857142857,52,0.20841029256220384,False,2,True,0,,CHEMBL5807850,14.0,nM,=,7.85,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8539,1,active,MW=714.9 > 500.0; LogP=6.81 > 5.0
f411fde3,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(S(=O)(=O)Cc1ccccc1)C2,,,raw,,728.915,728.303241508,6.948700000000009,103.16,1,6,7,8,5,0.3023255813953488,53,0.19559033710980922,False,2,True,0,,CHEMBL5873539,3.6,nM,=,8.44,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4437,1,active,MW=728.9 > 500.0; LogP=6.95 > 5.0
74c2b83d,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(S(=O)(=O)c1ccc3ccccc3c1)C2,,,raw,,764.948,764.303241508,7.9608000000000105,103.16,1,6,6,9,6,0.2608695652173913,56,0.1855499840178664,False,2,True,0,,CHEMBL6027901,26.0,nM,=,7.58,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.585,1,active,MW=764.9 > 500.0; LogP=7.96 > 5.0
3c8137a5,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2cccnc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,764.927,764.368618636,5.852800000000007,111.45,1,8,8,9,5,0.34782608695652173,57,0.21117075693831916,False,2,True,0,,CHEMBL5988387,38.0,nM,=,7.42,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4202,1,active,MW=764.9 > 500.0; LogP=5.85 > 5.0
d47c1839,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OC(C)(C)C)C2,,,raw,,722.8859999999996,722.3468205720001,9.013200000000003,95.32000000000001,1,6,5,8,5,0.3111111111111111,54,0.1954838237887695,False,2,True,0,,CHEMBL5991327,77.0,nM,=,7.11,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1135,1,active,MW=722.9 > 500.0; LogP=9.01 > 5.0
76f8015d,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CNC2,,,raw,,622.7689999999998,622.294391076,7.365700000000008,77.81,2,5,5,8,5,0.25,47,0.21471928506052598,False,2,True,0,,CHEMBL5942386,13.0,nM,=,7.89,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8861,1,active,MW=622.8 > 500.0; LogP=7.37 > 5.0
72ea0f15,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Oc1ccccc1)C2,,,raw,,680.8050000000001,680.2998703800001,7.5752000000000095,95.32000000000001,1,6,5,8,5,0.2619047619047619,51,0.20668207166977212,False,2,True,0,,CHEMBL5876253,15.0,nM,=,7.82,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=680.8 > 500.0; LogP=7.58 > 5.0
1883e1b4,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccccc1)C2,,,raw,,694.832,694.3155204440001,7.61770000000001,95.32000000000001,1,6,5,8,5,0.27906976744186046,52,0.20440147346923943,False,2,True,0,,CHEMBL5802285,3.7,nM,=,8.43,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4318,1,active,MW=694.8 > 500.0; LogP=7.62 > 5.0
a7ba631c,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)OC(C)(C)C)C2,,,raw,,674.8419999999999,674.3468205720001,7.353800000000009,95.32000000000001,1,6,4,7,4,0.3902439024390244,50,0.24432676945753398,False,2,True,0,,CHEMBL5774912,12.0,nM,=,7.92,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=674.8 > 500.0; LogP=7.35 > 5.0
874d1d0d,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)NC(C)(C)C)C2,,,raw,,673.8579999999998,673.3628049839999,6.926800000000008,98.12,2,5,4,7,4,0.3902439024390244,50,0.24571439377261836,False,2,True,0,,CHEMBL5885945,8.7,nM,=,8.06,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0605,1,active,MW=673.9 > 500.0; LogP=6.93 > 5.0
6d45e0e7,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1ccc(Cl)cc1)C2,,,raw,,729.2769999999999,728.2765480920002,7.635200000000009,95.32000000000001,1,6,7,8,5,0.27906976744186046,53,0.1860414151672204,False,2,True,0,,CHEMBL6034173,23.0,nM,=,7.64,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6383,1,active,MW=729.3 > 500.0; LogP=7.64 > 5.0
43e5f156,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1cccc(Cl)c1)C2,,,raw,,729.2769999999999,728.2765480920002,7.635200000000008,95.32000000000001,1,6,7,8,5,0.27906976744186046,53,0.1860414151672204,False,2,True,0,,CHEMBL5989389,18.0,nM,=,7.75,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=729.3 > 500.0; LogP=7.64 > 5.0
8cbd87ed,,COc1ccc(CC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)cc3C2)cc1,,,raw,,708.8589999999999,708.3311705079999,7.154100000000009,95.32,1,6,7,8,5,0.29545454545454547,53,0.19386614824011297,False,2,True,0,,CHEMBL5772057,5.5,nM,=,8.26,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2596,1,active,MW=708.9 > 500.0; LogP=7.15 > 5.0
6fe9057e,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1ccccc1)C2,,,raw,,694.832,694.3155204440002,6.981800000000009,95.32000000000001,1,6,7,8,5,0.27906976744186046,52,0.1984767262184138,False,2,True,0,,CHEMBL6050685,3.8,nM,=,8.42,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4202,1,active,MW=694.8 > 500.0; LogP=6.98 > 5.0
d79b11d8,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(C#N)cc1)C2,,,raw,,717.8699999999998,717.3315048559999,7.059680000000009,109.88,1,6,6,8,5,0.28888888888888886,54,0.20241875434169304,False,2,True,0,,CHEMBL5747376,2.4,nM,=,8.62,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6198,1,active,MW=717.9 > 500.0; LogP=7.06 > 5.0
babba04f,,Cc1ccc(CC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4C)cc3C2)cc1,,,raw,,706.8870000000001,706.351905952,7.496420000000009,86.08999999999999,1,5,6,8,5,0.3111111111111111,53,0.19835456520384517,False,2,True,0,,CHEMBL5808360,4.0,nM,=,8.4,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3979,1,active,MW=706.9 > 500.0; LogP=7.50 > 5.0
a2b7ed60,,CNC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,raw,,617.7499999999999,617.3002047279999,5.715600000000007,98.12,2,5,4,7,4,0.32432432432432434,46,0.3064103726196136,False,2,True,0,,CHEMBL5830631,16.0,nM,=,7.8,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=617.7 > 500.0; LogP=5.72 > 5.0
9df78fd1,,CCS(=O)(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,raw,,666.8440000000002,666.2875914440001,5.768400000000007,103.15999999999998,1,6,6,7,4,0.3684210526315789,48,0.281736831743359,False,2,True,0,,CHEMBL5862634,3.8,nM,=,8.42,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4202,1,active,MW=666.8 > 500.0; LogP=5.77 > 5.0
5a2d85f1,,CCN1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,raw,,602.7790000000001,602.3256912040001,6.438600000000008,69.02,1,5,5,7,4,0.3684210526315789,45,0.28563406277133657,False,2,True,0,,CHEMBL5923406,65.0,nM,=,7.19,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1871,1,active,MW=602.8 > 500.0; LogP=6.44 > 5.0
c32423ca,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccc(N)cc1)C2,,,raw,,709.8469999999999,709.326419476,7.199900000000009,121.34,2,7,5,8,5,0.27906976744186046,53,0.1863778552394029,False,2,False,1,PAINS match: anil_no_alk(40),CHEMBL5945004,4.2,nM,=,8.38,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=709.8 > 500.0; LogP=7.20 > 5.0
f45dc3ee,,CC(=O)Nc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4C)cc3C2)cc1,,,raw,,751.8839999999999,751.33698416,7.576100000000008,124.42,2,7,6,8,5,0.28888888888888886,56,0.1845279769900852,False,2,True,0,,CHEMBL5758769,3.2,nM,=,8.49,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4949,1,active,MW=751.9 > 500.0; LogP=7.58 > 5.0
26dc9b7c,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Nc1ccccc1)C2,,,raw,,679.821,679.3158547920001,7.608300000000009,98.12,2,5,5,8,5,0.2619047619047619,51,0.19991852453283052,False,2,True,0,,CHEMBL5745898,5.9,nM,=,8.23,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2291,1,active,MW=679.8 > 500.0; LogP=7.61 > 5.0
a3b93c70,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)NCc1ccccc1)C2,,,raw,,693.848,693.331504856,7.286000000000009,98.12,2,5,6,8,5,0.27906976744186046,52,0.19535937098592487,False,2,True,0,,CHEMBL5975714,4.4,nM,=,8.36,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=693.8 > 500.0; LogP=7.29 > 5.0
1f22ceed,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OCc1ccccc1)C2,,,raw,,694.832,694.3155204440002,7.71300000000001,95.32000000000001,1,6,6,8,5,0.27906976744186046,52,0.19657252965056285,False,2,True,0,,CHEMBL5765320,20.0,nM,=,7.7,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.699,1,active,MW=694.8 > 500.0; LogP=7.71 > 5.0
ebe83382,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)C3)n1C,,,raw,,654.7670000000002,654.284220316,7.084320000000009,95.32,1,6,5,7,5,0.225,49,0.21857216901746485,False,2,True,0,,CHEMBL6057321,4.4,nM,=,8.36,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=654.8 > 500.0; LogP=7.08 > 5.0
a4aae7ed,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OCc1cnc3[nH]ccc3c1)C2,,,raw,,734.8569999999999,734.3216684440001,7.5893000000000095,124.0,2,7,6,9,6,0.2727272727272727,55,0.1818733590118516,False,2,True,0,,CHEMBL6061074,27.0,nM,=,7.57,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5686,1,active,MW=734.9 > 500.0; LogP=7.59 > 5.0
afa37344,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Nc1ccc(N3CCN(C)CC3)cc1)C2,,,raw,,777.9699999999996,777.400253112,7.360100000000008,104.6,2,7,6,9,5,0.3404255319148936,58,0.18693332688442374,False,2,False,1,PAINS match: anil_di_alk_A(478),CHEMBL6061404,6.5,nM,=,8.19,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1871,1,active,MW=778.0 > 500.0; LogP=7.36 > 5.0
fb32d974,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N1CCC(c3ccccc3)C1)C2,,,raw,,733.9129999999998,733.362804984,7.985700000000011,89.33,1,5,5,9,5,0.32608695652173914,55,0.19851144545723495,False,2,True,0,,CHEMBL5832336,16.0,nM,=,7.8,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7959,1,active,MW=733.9 > 500.0; LogP=7.99 > 5.0
0e7baa33,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)N1CCC(c3ccccc3)C1)C2,,,raw,,747.9399999999997,747.378455048,8.02820000000001,89.33,1,5,5,9,5,0.3404255319148936,56,0.19735468068737272,False,2,True,0,,CHEMBL5830561,9.4,nM,=,8.03,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0269,1,active,MW=747.9 > 500.0; LogP=8.03 > 5.0
aacc09a4,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,668.7940000000001,668.2998703799999,7.126820000000009,95.32,1,6,5,7,5,0.24390243902439024,50,0.2151966624343109,False,2,True,0,,CHEMBL5780970,2.9,nM,=,8.54,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5376,1,active,MW=668.8 > 500.0; LogP=7.13 > 5.0
6b65fa05,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,779.938,779.3682842879999,6.9300000000000095,107.79,1,8,7,9,5,0.3404255319148936,58,0.19108483756070085,False,2,True,0,,CHEMBL5966110,3.1,nM,=,8.51,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5086,1,active,MW=779.9 > 500.0; LogP=6.93 > 5.0
12b761d9,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,777.966,777.389019732,6.500300000000009,98.56000000000002,1,7,8,9,5,0.3541666666666667,58,0.1934183562992286,False,2,True,0,,CHEMBL6052590,5.1,nM,=,8.29,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2924,1,active,MW=778.0 > 500.0; LogP=6.50 > 5.0
79cafca7,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Nc1ccccc1)C2,,,raw,,693.848,693.3315048559999,7.65080000000001,98.12,2,5,5,8,5,0.27906976744186046,52,0.19771091051713893,False,2,True,0,,CHEMBL5980019,3.7,nM,=,8.43,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4318,1,active,MW=693.8 > 500.0; LogP=7.65 > 5.0
d1533912,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CCc1ccccc1)C2,,,raw,,664.8499999999999,664.3413412680001,7.61890000000001,69.02,1,5,7,8,5,0.3023255813953488,50,0.1944943385066926,False,2,True,0,,CHEMBL5744802,21.0,nM,=,7.68,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=664.8 > 500.0; LogP=7.62 > 5.0
2c3c07b1,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)NCc1ccccc1)C2,,,raw,,707.8749999999999,707.34715492,7.328500000000009,98.12,2,5,6,8,5,0.29545454545454547,53,0.19327398028440432,False,2,True,0,,CHEMBL5767350,4.3,nM,=,8.37,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3665,1,active,MW=707.9 > 500.0; LogP=7.33 > 5.0
d0a1c975,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)N(C)c1ccccc1)C2,,,raw,,707.8749999999999,707.34715492,7.67510000000001,89.33,1,5,5,8,5,0.29545454545454547,53,0.20314779340789824,False,2,True,0,,CHEMBL5924068,6.1,nM,=,8.21,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2147,1,active,MW=707.9 > 500.0; LogP=7.68 > 5.0
3164596f,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)CC3)n1C,,,raw,,666.822,666.320605824,6.69712000000001,86.09,1,5,6,7,5,0.2619047619047619,50,0.21878029043926947,False,2,True,0,,CHEMBL5921277,4.0,nM,=,8.4,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3979,1,active,MW=666.8 > 500.0; LogP=6.70 > 5.0
4127cebb,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)NC(C)(C)C)C2,,,raw,,659.8309999999999,659.3471549200001,6.884300000000008,98.12,2,5,4,7,4,0.375,49,0.24958976001764563,False,2,True,0,,CHEMBL6032199,24.0,nM,=,7.62,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6198,1,active,MW=659.8 > 500.0; LogP=6.88 > 5.0
6c65420e,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Nc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,778.954,778.3842687,6.963100000000009,110.59000000000002,2,7,7,9,5,0.3404255319148936,58,0.18501478295428073,False,2,True,0,,CHEMBL6008881,4.0,nM,=,8.4,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3979,1,active,MW=779.0 > 500.0; LogP=6.96 > 5.0
66a8bf53,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)NCc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,792.9809999999999,792.399918764,6.6408000000000085,110.59000000000002,2,7,8,9,5,0.3541666666666667,59,0.18252177813968998,False,2,True,0,,CHEMBL5910678,4.4,nM,=,8.36,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=793.0 > 500.0; LogP=6.64 > 5.0
85be288d,,CNC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,raw,,631.7770000000002,631.315854792,5.758100000000006,98.11999999999999,2,5,4,7,4,0.34210526315789475,47,0.29950273870822564,False,2,True,0,,CHEMBL5988103,5.6,nM,=,8.25,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2518,1,active,MW=631.8 > 500.0; LogP=5.76 > 5.0
b87d5e1c,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)C3)n1C,,,raw,,652.7950000000001,652.30495576,6.654620000000009,86.09,1,5,6,7,5,0.24390243902439024,49,0.22257681277672223,False,2,True,0,,CHEMBL5836984,5.5,nM,=,8.26,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2596,1,active,MW=652.8 > 500.0; LogP=6.65 > 5.0
05fced30,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N(C)C(C)(C)C)C2,,,raw,,673.8579999999998,673.362804984,7.2265000000000095,89.33,1,5,4,7,4,0.3902439024390244,50,0.24776413842840456,False,2,True,0,,CHEMBL5758353,21.0,nM,=,7.68,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=673.9 > 500.0; LogP=7.23 > 5.0
4a6f1cdd,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N(C)c1ccccc1)C2,,,raw,,693.848,693.331504856,7.63260000000001,89.33,1,5,5,8,5,0.27906976744186046,52,0.2051239587188647,False,2,True,0,,CHEMBL5966512,17.0,nM,=,7.77,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7696,1,active,MW=693.8 > 500.0; LogP=7.63 > 5.0
48474782,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N1CC(c3ccccc3)C1)C2,,,raw,,719.8859999999999,719.3471549200001,7.59560000000001,89.33,1,5,5,9,5,0.3111111111111111,54,0.20282879597771128,False,2,True,0,,CHEMBL5951994,15.0,nM,=,7.82,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=719.9 > 500.0; LogP=7.60 > 5.0
ca03294a,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)N1CC(c3ccccc3)C1)C2,,,raw,,733.9129999999998,733.3628049839999,7.63810000000001,89.33,1,5,5,9,5,0.32608695652173914,55,0.20127863128642107,False,2,True,0,,CHEMBL5786581,4.9,nM,=,8.31,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3098,1,active,MW=733.9 > 500.0; LogP=7.64 > 5.0
b71f52f3,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N(C)Cc1ccccc1)C2,,,raw,,707.8749999999999,707.3471549200001,7.628200000000009,89.33,1,5,6,8,5,0.29545454545454547,53,0.19671695233365327,False,2,True,0,,CHEMBL5978766,6.1,nM,=,8.21,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2147,1,active,MW=707.9 > 500.0; LogP=7.63 > 5.0
937c9069,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1ccccc1Cl)C2,,,raw,,729.2769999999999,728.2765480920002,7.635200000000008,95.32000000000001,1,6,7,8,5,0.27906976744186046,53,0.1860414151672204,False,2,True,0,,CHEMBL5818630,5.5,nM,=,8.26,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2596,1,active,MW=729.3 > 500.0; LogP=7.64 > 5.0
cdfc3228,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CNc1ccccc1)C2,,,raw,,693.848,693.331504856,7.014900000000009,98.12,2,6,7,8,5,0.27906976744186046,52,0.19118603733181955,False,2,True,0,,CHEMBL5746270,5.1,nM,=,8.29,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2924,1,active,MW=693.8 > 500.0; LogP=7.01 > 5.0
74187d32,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,753.8999999999999,753.352634224,6.439120000000008,107.78999999999999,1,8,7,8,5,0.3111111111111111,56,0.20405166895205146,False,2,True,0,,CHEMBL6023571,3.5,nM,=,8.46,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4559,1,active,MW=753.9 > 500.0; LogP=6.44 > 5.0
c53af1dc,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,raw,,751.9279999999998,751.373369668,6.0094200000000075,98.56,1,7,8,8,5,0.32608695652173914,56,0.208834820124501,False,2,True,0,,CHEMBL6020028,3.5,nM,=,8.46,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4559,1,active,MW=751.9 > 500.0; LogP=6.01 > 5.0
270c949d,,C[C@H](C(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1)c1ccccc1,,,raw,,706.8870000000002,706.351905952,7.74900000000001,86.08999999999999,1,5,6,8,5,0.3111111111111111,53,0.19581659289502418,False,2,True,0,,CHEMBL5937563,6.2,nM,=,8.21,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2076,1,active,MW=706.9 > 500.0; LogP=7.75 > 5.0
a42f7464,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)[C@H](C)c1ccccc1)C2,,,raw,,706.887,706.351905952,7.74900000000001,86.09,1,5,6,8,5,0.3111111111111111,53,0.19581659289502418,False,2,True,0,,CHEMBL5910246,7.0,nM,=,8.15,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1549,1,active,MW=706.9 > 500.0; LogP=7.75 > 5.0
b81a0e6d,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CC(=O)Nc1ccccc1)C2,,,raw,,693.848,693.331504856,7.014900000000009,98.12,2,6,7,8,5,0.27906976744186046,52,0.19118603733181955,False,2,True,0,,CHEMBL5794438,20.0,nM,=,7.7,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.699,1,active,MW=693.8 > 500.0; LogP=7.01 > 5.0
e608f436,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)OCc1ccccc1)C2,,,raw,,708.8589999999999,708.331170508,7.75550000000001,95.32000000000001,1,6,6,8,5,0.29545454545454547,53,0.1947367456205549,False,2,True,0,,CHEMBL5880025,5.1,nM,=,8.29,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2924,1,active,MW=708.9 > 500.0; LogP=7.76 > 5.0
4715d7a3,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OCc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,793.9649999999999,793.3839343519999,7.06780000000001,107.79,1,8,8,9,5,0.3541666666666667,59,0.1792938598741527,False,2,True,0,,CHEMBL5859126,5.6,nM,=,8.25,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2518,1,active,MW=794.0 > 500.0; LogP=7.07 > 5.0
2ac64f71,,CCC(C(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1)c1ccccc1,,,raw,,720.9140000000002,720.367556016,8.13910000000001,86.08999999999999,1,5,7,8,5,0.32608695652173914,54,0.18407807585303182,False,2,True,0,,CHEMBL5768211,14.0,nM,=,7.85,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8539,1,active,MW=720.9 > 500.0; LogP=8.14 > 5.0
920b9b22,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(NCCN3CCOCC3)cc1)C2,,,raw,,821.0349999999994,820.431218892,6.932100000000007,110.59,2,8,10,9,5,0.38,61,0.15737726959702183,False,2,True,0,,CHEMBL5743666,3.9,nM,=,8.41,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4089,1,active,MW=821.0 > 500.0; LogP=6.93 > 5.0
34733580,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(N3CCN(C)CC3)cc1)C2,,,raw,,791.0089999999994,790.420654208,6.939800000000008,92.57,1,7,7,9,5,0.3673469387755102,59,0.1923036343749303,False,2,False,1,PAINS match: anil_di_alk_E(186),CHEMBL5913609,4.9,nM,=,8.31,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3098,1,active,MW=791.0 > 500.0; LogP=6.94 > 5.0
4eb39096,,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,793.9649999999997,793.383934352,7.2384200000000085,107.78999999999998,1,8,7,9,5,0.3541666666666667,59,0.18532037436408821,False,2,True,0,,CHEMBL6017111,3.8,nM,=,8.42,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4202,1,active,MW=794.0 > 500.0; LogP=7.24 > 5.0
9d747dd5,,Cc1cccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)c1,,,raw,,793.9649999999997,793.383934352,7.2384200000000085,107.78999999999998,1,8,7,9,5,0.3541666666666667,59,0.18532037436408821,False,2,True,0,,CHEMBL5991247,5.5,nM,=,8.26,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2596,1,active,MW=794.0 > 500.0; LogP=7.24 > 5.0
fa01fa12,,Cc1ccccc1OC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)cc2C1,,,raw,,793.9649999999997,793.383934352,7.2384200000000085,107.78999999999998,1,8,7,9,5,0.3541666666666667,59,0.18532037436408821,False,2,True,0,,CHEMBL5911983,3.9,nM,=,8.41,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4089,1,active,MW=794.0 > 500.0; LogP=7.24 > 5.0
31826be8,,COc1ccc(CC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)cc3C2)cc1,,,raw,,682.8210000000001,682.315520444,6.663220000000009,95.32,1,6,7,7,5,0.2619047619047619,51,0.20723743515335089,False,2,True,0,,CHEMBL6036174,2.6,nM,=,8.59,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.585,1,active,MW=682.8 > 500.0; LogP=6.66 > 5.0
bacc99d2,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(F)cc2)C3)n1C,,,raw,,670.7850000000001,670.295533948,6.793720000000008,86.09,1,5,6,7,5,0.24390243902439024,50,0.21563676066366033,False,2,True,0,,CHEMBL6040541,5.0,nM,=,8.3,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.301,1,active,MW=670.8 > 500.0; LogP=6.79 > 5.0
0060db57,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)COc2ccccc2)C3)n1C,,,raw,,668.7940000000001,668.29987038,6.490920000000009,95.32,1,6,7,7,5,0.24390243902439024,50,0.21405648026961807,False,2,True,0,,CHEMBL6009488,3.6,nM,=,8.44,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4437,1,active,MW=668.8 > 500.0; LogP=6.49 > 5.0
f68240a4,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)C(C)Oc2ccccc2)C3)n1C,,,raw,,682.8210000000001,682.3155204440001,6.879420000000009,95.32,1,6,7,7,5,0.2619047619047619,51,0.20210778817921934,False,2,True,0,,CHEMBL5788493,6.7,nM,=,8.17,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1739,1,active,MW=682.8 > 500.0; LogP=6.88 > 5.0
e0dbcb98,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(Cl)cc2)C3)n1C,,,raw,,689.2120000000001,688.245247964,7.73772000000001,95.32,1,6,5,7,5,0.225,50,0.20393023697692036,False,2,True,0,,CHEMBL5906047,7.3,nM,=,8.14,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1367,1,active,MW=689.2 > 500.0; LogP=7.74 > 5.0
fd376e8d,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(F)cc2)C3)n1C,,,raw,,672.7570000000002,672.2747985039999,7.223420000000009,95.32,1,6,5,7,5,0.225,50,0.2128111966719154,False,2,True,0,,CHEMBL6054224,5.3,nM,=,8.28,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2757,1,active,MW=672.8 > 500.0; LogP=7.22 > 5.0
53b35156,,Cc1ccc(OC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)cc3C2)cc1,,,raw,,668.7940000000001,668.2998703799999,7.39274000000001,95.32,1,6,5,7,5,0.24390243902439024,50,0.21081296551254022,False,2,True,0,,CHEMBL5961751,3.5,nM,=,8.46,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4559,1,active,MW=668.8 > 500.0; LogP=7.39 > 5.0
c1c549fe,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(NCCN(C)C)cc1)C2,,,raw,,778.9979999999996,778.420654208,7.161500000000008,101.36,2,7,10,8,5,0.3541666666666667,58,0.1562162848396744,False,2,True,0,,CHEMBL5771935,2.7,nM,=,8.57,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5686,1,active,MW=779.0 > 500.0; LogP=7.16 > 5.0
bf8d6f63,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)C1(c3ccccc3)CC1)C2,,,raw,,718.8979999999998,718.351905952,7.677100000000009,86.09,1,5,6,9,5,0.32608695652173914,54,0.1953535175954429,False,2,True,0,,CHEMBL5886123,8.6,nM,=,8.07,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0655,1,active,MW=718.9 > 500.0; LogP=7.68 > 5.0
fa61105a,,CCNC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)cc2C1,,,raw,,605.739,605.3002047279999,5.614820000000007,98.12,2,5,5,6,4,0.3055555555555556,45,0.30889992231795405,False,2,True,0,,CHEMBL5824288,19.0,nM,=,7.72,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7212,1,active,MW=605.7 > 500.0; LogP=5.61 > 5.0
82ba9cba,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)NCc2ccccc2)C3)n1C,,,raw,,667.8100000000001,667.315854792,6.795120000000009,98.12,2,5,6,7,5,0.24390243902439024,50,0.20836086013855082,False,2,True,0,,CHEMBL5767189,8.4,nM,=,8.08,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0757,1,active,MW=667.8 > 500.0; LogP=6.80 > 5.0
fc54cd1e,,CC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)cc2C1,,,raw,,576.6970000000001,576.273655632,5.431820000000006,86.09,1,5,4,6,4,0.2857142857142857,43,0.351089902808977,False,2,True,0,,CHEMBL5970546,42.0,nM,=,7.38,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.3768,1,active,MW=576.7 > 500.0; LogP=5.43 > 5.0
bd4f19d1,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(CN3CCN(C)CC3)cc1)C2,,,raw,,805.0359999999994,804.4363042719999,6.9354000000000084,92.57,1,7,8,9,5,0.38,60,0.18304822827296185,False,2,True,0,,CHEMBL6059840,3.6,nM,=,8.44,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4437,1,active,MW=805.0 > 500.0; LogP=6.94 > 5.0
7362ce7d,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,652.7950000000001,652.30495576,7.421220000000009,75.09,0,5,5,7,5,0.24390243902439024,49,0.19813173487721752,False,2,True,0,,CHEMBL5994212,3.8,nM,=,8.42,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4202,1,active,MW=652.8 > 500.0; LogP=7.42 > 5.0
a4c2d9e7,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,737.901,737.357719604,6.7335200000000075,87.56,0,7,7,8,5,0.3111111111111111,55,0.1842284243948983,False,2,True,0,,CHEMBL5864714,3.4,nM,=,8.47,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4685,1,active,MW=737.9 > 500.0; LogP=6.73 > 5.0
6c6f2893,,COc1ccc(CCCN2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)cc3C2)cc1,,,raw,,682.8650000000001,682.351905952,7.52672000000001,78.25,1,6,9,7,5,0.3023255813953488,51,0.17406353515465314,False,2,True,0,,CHEMBL6056802,21.0,nM,=,7.68,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=682.9 > 500.0; LogP=7.53 > 5.0
b612af6b,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,raw,,735.9289999999999,735.378455048,6.303820000000008,78.33000000000001,0,6,8,8,5,0.32608695652173914,55,0.18705918446294517,False,2,True,0,,CHEMBL5872522,2.5,nM,=,8.6,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6021,1,active,MW=735.9 > 500.0; LogP=6.30 > 5.0
d93e93f5,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)CC3)n1C,,,raw,,650.8230000000001,650.325691204,6.991520000000008,65.86000000000001,0,4,6,7,5,0.2619047619047619,49,0.19906768410735406,False,2,True,0,,CHEMBL6037009,3.4,nM,=,8.47,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4685,1,active,MW=650.8 > 500.0; LogP=6.99 > 5.0
c34a3014,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CNCC3)n1C,,,raw,,532.6880000000003,532.283826392,5.509820000000006,57.580000000000005,1,4,4,6,4,0.29411764705882354,40,0.377173457109577,False,2,True,0,,CHEMBL5906342,622.0,nM,=,6.21,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,6.2062,1,active,MW=532.7 > 500.0; LogP=5.51 > 5.0
6afa4cf5,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(F)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,797.928,797.3588624759999,7.0691000000000095,107.79,1,8,7,9,5,0.3404255319148936,59,0.1879211152142267,False,2,True,0,,CHEMBL5929538,2.5,nM,=,8.6,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6021,1,active,MW=797.9 > 500.0; LogP=7.07 > 5.0
17e6d020,,COc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,809.9639999999996,809.378848972,6.938600000000007,117.02,1,9,8,9,5,0.3541666666666667,60,0.17943254890771498,False,2,True,0,,CHEMBL5885093,2.9,nM,=,8.54,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5376,1,active,MW=810.0 > 500.0; LogP=6.94 > 5.0
a3f8b9ce,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Cl)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,814.3829999999999,813.329311936,7.583400000000011,107.79,1,8,7,9,5,0.3404255319148936,59,0.18065944268116124,False,2,True,0,,CHEMBL5903986,2.6,nM,=,8.59,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.585,1,active,MW=814.4 > 500.0; LogP=7.58 > 5.0
8a2566ac,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1cccc(NCCN(C)C)c1)C2,,,raw,,778.9979999999996,778.420654208,7.161500000000008,101.36,2,7,10,8,5,0.3541666666666667,58,0.1562162848396744,False,2,True,0,,CHEMBL5894635,5.3,nM,=,8.28,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2757,1,active,MW=779.0 > 500.0; LogP=7.16 > 5.0
a92f117c,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C(F)(F)F)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,847.9350000000001,847.3556689159999,7.948800000000011,107.79,1,8,7,9,5,0.3541666666666667,62,0.1773364422542428,False,2,True,0,,CHEMBL5773807,12.0,nM,=,7.92,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=847.9 > 500.0; LogP=7.95 > 5.0
a5185872,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(OC(F)(F)F)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,863.9340000000001,863.3505835359999,7.82860000000001,117.02000000000002,1,9,8,9,5,0.3541666666666667,63,0.16799477608757188,False,2,True,0,,CHEMBL5878109,8.7,nM,=,8.06,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0605,1,active,MW=863.9 > 500.0; LogP=7.83 > 5.0
4bc9ea1b,,CCc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,807.9919999999996,807.399584416,7.492400000000009,107.78999999999998,1,8,8,9,5,0.3673469387755102,60,0.17326437503367725,False,2,True,0,,CHEMBL5772453,5.9,nM,=,8.23,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2291,1,active,MW=808.0 > 500.0; LogP=7.49 > 5.0
646c9044,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,804.9479999999999,804.3635332559999,6.801680000000009,131.58,1,9,7,9,5,0.3333333333333333,60,0.19021786049936268,False,2,True,0,,CHEMBL5824401,3.3,nM,=,8.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4815,1,active,MW=804.9 > 500.0; LogP=6.80 > 5.0
d806dbb9,,COc1ccccc1OC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)cc2C1,,,raw,,809.9639999999996,809.3788489719999,6.938600000000008,117.02,1,9,8,9,5,0.3541666666666667,60,0.17943254890771498,False,2,True,0,,CHEMBL5814241,3.5,nM,=,8.46,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4559,1,active,MW=810.0 > 500.0; LogP=6.94 > 5.0
65a13ce2,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(CN3CCOCC3)cc1)C2,,,raw,,791.9929999999995,791.404669796,7.020200000000009,98.56,1,7,8,9,5,0.3673469387755102,59,0.1816202823627645,False,2,True,0,,CHEMBL6009560,3.3,nM,=,8.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4815,1,active,MW=792.0 > 500.0; LogP=7.02 > 5.0
2b7fedff,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CCc2ccccc2)CC3)n1C,,,raw,,765.9549999999997,765.389019732,6.399520000000009,98.56,1,7,9,8,5,0.3404255319148936,57,0.1867500270470689,False,2,True,0,,CHEMBL5777249,3.1,nM,=,8.51,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5086,1,active,MW=766.0 > 500.0; LogP=6.40 > 5.0
9c7bb1f3,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)/C=C/c2ccccc2)CC3)n1C,,,raw,,763.9389999999999,763.373369668,6.480120000000008,98.56,1,7,8,8,5,0.2978723404255319,57,0.18197679072572698,False,2,True,0,,CHEMBL5976126,4.0,nM,=,8.4,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3979,1,active,MW=763.9 > 500.0; LogP=6.48 > 5.0
40cfc048,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CCC2CCCCC2)CC3)n1C,,,raw,,772.0029999999994,771.435969924,7.12722000000001,98.56,1,7,9,8,4,0.46808510638297873,57,0.1947014293105559,False,2,True,0,,CHEMBL6050995,4.6,nM,=,8.34,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3372,1,active,MW=772.0 > 500.0; LogP=7.13 > 5.0
2b2a9501,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Oc1ccccc1)C2,,,raw,,742.8759999999997,742.3155204440001,9.2771,95.32000000000001,1,6,6,9,6,0.2127659574468085,56,0.18367808587365933,False,2,True,0,,CHEMBL5855472,7.0,nM,=,8.15,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1549,1,active,MW=742.9 > 500.0; LogP=9.28 > 5.0
f4e341d9,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccccc1)C2,,,raw,,754.9309999999996,754.351905952,8.889900000000004,86.09,1,5,7,9,6,0.24489795918367346,57,0.17655353853289135,False,2,True,0,,CHEMBL5915933,4.3,nM,=,8.37,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3665,1,active,MW=754.9 > 500.0; LogP=8.89 > 5.0
7af6d4c3,,COc1cccc(CCC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)c1,,,raw,,795.9809999999995,795.399584416,6.408120000000007,107.78999999999998,1,8,10,8,5,0.3541666666666667,59,0.17431994333811332,False,2,True,0,,CHEMBL5854152,8.4,nM,=,8.08,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0757,1,active,MW=796.0 > 500.0; LogP=6.41 > 5.0
ae993a92,,COc1cccc(/C=C/C(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)c1,,,raw,,793.9649999999996,793.383934352,6.488720000000007,107.78999999999998,1,8,9,8,5,0.3125,59,0.17027927159740222,False,2,True,0,,CHEMBL5821621,6.7,nM,=,8.17,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1739,1,active,MW=794.0 > 500.0; LogP=6.49 > 5.0
51118135,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)/C=C/c2ccc(Cl)c(Cl)c2)CC3)n1C,,,raw,,832.8289999999997,831.295424964,7.78692000000001,98.56,1,7,8,8,5,0.2978723404255319,59,0.1605835536355299,False,2,True,0,,CHEMBL5975661,9.4,nM,=,8.03,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0269,1,active,MW=832.8 > 500.0; LogP=7.79 > 5.0
d0babb1a,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)CCc1ccc(NCCN(C)C)cc1)C2,,,raw,,793.0249999999995,792.4363042719999,7.5516000000000085,101.36,2,7,11,8,5,0.3673469387755102,59,0.14341317351987307,False,2,True,0,,CHEMBL5967193,12.0,nM,=,7.92,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=793.0 > 500.0; LogP=7.55 > 5.0
7384f340,,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,767.9269999999998,767.368284288,6.747540000000007,107.78999999999998,1,8,7,8,5,0.32608695652173914,57,0.19547772151930237,False,2,True,0,,CHEMBL5927352,5.1,nM,=,8.29,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2924,1,active,MW=767.9 > 500.0; LogP=6.75 > 5.0
e08e2962,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Cl)cc2)CC3)n1C,,,raw,,788.3449999999998,787.3136618720001,7.09252000000001,107.78999999999999,1,8,7,8,5,0.3111111111111111,57,0.18780130387647845,False,2,True,0,,CHEMBL5839241,6.6,nM,=,8.18,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1805,1,active,MW=788.3 > 500.0; LogP=7.09 > 5.0
4fbd0ad9,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C(N)=O)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,822.9629999999999,822.37409794,6.028900000000006,150.88,2,9,8,9,5,0.3333333333333333,61,0.1928291819671072,False,2,True,0,,CHEMBL5878919,5.9,nM,=,8.23,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2291,1,active,MW=823.0 > 500.0; LogP=6.03 > 5.0
158b1c30,,CN(C)C(=O)c1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,851.0169999999995,850.4053980680001,6.631800000000008,128.09999999999997,1,9,8,9,5,0.36,63,0.18449017827308326,False,2,True,0,,CHEMBL5914311,5.5,nM,=,8.26,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2596,1,active,MW=851.0 > 500.0; LogP=6.63 > 5.0
8d63fa48,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(-n4ccnc4)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,846.0009999999999,845.3900823519998,7.11570000000001,125.61,1,10,8,10,6,0.32,63,0.17195948389864096,False,2,True,0,,CHEMBL5918037,5.5,nM,=,8.26,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2596,1,active,MW=846.0 > 500.0; LogP=7.12 > 5.0
2c92e9e5,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(CN(C)C)cc1)C2,,,raw,,749.9559999999997,749.3941051119999,7.249600000000009,89.33,1,6,8,8,5,0.3404255319148936,56,0.1807415456144094,False,2,True,0,,CHEMBL5900526,4.8,nM,=,8.32,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3188,1,active,MW=750.0 > 500.0; LogP=7.25 > 5.0
ef3ba361,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(C#N)cc2)CC3)n1C,,,raw,,691.8319999999999,691.315854792,6.568800000000009,109.88,1,6,6,7,5,0.2558139534883721,52,0.2168057773823214,False,2,True,0,,CHEMBL5937444,4.2,nM,=,8.38,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=691.8 > 500.0; LogP=6.57 > 5.0
eca63269,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,raw,,778.9099999999997,778.347883192,6.310800000000008,131.58,1,9,7,8,5,0.30434782608695654,58,0.20357373949410673,False,2,True,0,,CHEMBL5884005,2.8,nM,=,8.55,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5528,1,active,MW=778.9 > 500.0; LogP=6.31 > 5.0
046d237e,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,raw,,693.804,693.2951193479998,6.99850000000001,119.11000000000001,1,7,5,7,5,0.23809523809523808,52,0.2119019632272177,False,2,True,0,,CHEMBL5982104,3.2,nM,=,8.49,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4949,1,active,MW=693.8 > 500.0; LogP=7.00 > 5.0
39be5dc7,,COc1cc(C#N)ccc1OC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)cc2C1,,,raw,,834.9739999999995,834.3740979400001,6.810280000000008,140.81,1,10,8,9,5,0.3469387755102041,62,0.17863625159170593,False,2,True,0,,CHEMBL5871668,3.0,nM,=,8.52,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5229,1,active,MW=835.0 > 500.0; LogP=6.81 > 5.0
a5dc1261,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(NCCN(C)C)cc2)CC3)n1C,,,raw,,736.9609999999998,736.4100895239999,6.965020000000007,81.13,1,6,10,7,5,0.32608695652173914,55,0.16778231274651267,False,2,True,0,,CHEMBL5914943,11.0,nM,=,7.96,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9586,1,active,MW=737.0 > 500.0; LogP=6.97 > 5.0
87bc522f,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(C#N)cc2)CC3)n1C,,,raw,,675.833,675.320940172,6.863200000000008,89.65,0,5,6,7,5,0.2558139534883721,51,0.1967490569237157,False,2,True,0,,CHEMBL5889287,4.3,nM,=,8.37,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3665,1,active,MW=675.8 > 500.0; LogP=6.86 > 5.0
12a2b4ae,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccc(C#N)cc2)CC3)n1C,,,raw,,760.9389999999997,760.3737040159999,6.1755000000000075,102.12,0,7,8,8,5,0.3191489361702128,57,0.18756156497142487,False,2,True,0,,CHEMBL5751596,5.3,nM,=,8.28,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2757,1,active,MW=760.9 > 500.0; LogP=6.18 > 5.0
20d9af1b,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,raw,,762.9109999999998,762.352968572,6.605200000000008,111.35000000000002,0,8,7,8,5,0.30434782608695654,57,0.18374981000176596,False,2,True,0,,CHEMBL5978810,6.5,nM,=,8.19,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1871,1,active,MW=762.9 > 500.0; LogP=6.61 > 5.0
0addcef2,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccc(NCCN(C)C)cc1)C2,,,raw,,780.9699999999997,780.399918764,7.591200000000009,110.59,2,8,9,8,5,0.3404255319148936,58,0.15872576993084375,False,2,True,0,,CHEMBL5818397,4.2,nM,=,8.38,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=781.0 > 500.0; LogP=7.59 > 5.0
99327c7f,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(OCCN(C)C)cc1)C2,,,raw,,779.9819999999996,779.404669796,7.128400000000008,98.56,1,7,10,8,5,0.3541666666666667,58,0.16217921716834405,False,2,True,0,,CHEMBL5795689,3.9,nM,=,8.41,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4089,1,active,MW=780.0 > 500.0; LogP=7.13 > 5.0
161a17f6,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccc(CCC(=O)N(C)C)cc1)C2,,,raw,,793.9649999999997,793.383934352,7.63850000000001,115.63000000000001,1,7,8,8,5,0.3333333333333333,59,0.17285026746917134,False,2,True,0,,CHEMBL5881894,3.2,nM,=,8.49,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4949,1,active,MW=794.0 > 500.0; LogP=7.64 > 5.0
8affad7a,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)COc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,779.938,779.3682842879999,6.294100000000008,107.79,1,8,9,9,5,0.3404255319148936,58,0.18747400985764756,False,2,True,0,,CHEMBL5792612,6.8,nM,=,8.17,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1675,1,active,MW=779.9 > 500.0; LogP=6.29 > 5.0
3640683a,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)OC2CCS(=O)(=O)C2)C3)n1C,,,raw,,696.826,696.26177062,5.209020000000007,129.46,1,8,5,7,4,0.34210526315789475,50,0.30351152715315277,False,2,True,0,,CHEMBL5741708,21.0,nM,=,7.68,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=696.8 > 500.0; LogP=5.21 > 5.0
af068ca4,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(ccn4C)c3)c3n1CCCC3)CN(C(=O)COc1ccccc1)C2,,,raw,,810.9549999999996,810.3529685720001,8.570400000000008,113.14000000000003,1,8,8,10,7,0.24,61,0.16470346800989935,False,2,True,0,,CHEMBL6007251,4.6,nM,=,8.34,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3372,1,active,MW=811.0 > 500.0; LogP=8.57 > 5.0
e9933f74,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)COc2ccccc2)C3)n1C,,,raw,,753.8999999999999,753.352634224,5.803220000000008,107.78999999999999,1,8,9,8,5,0.3111111111111111,56,0.20285896413885648,False,2,True,0,,CHEMBL5747498,8.5,nM,=,8.07,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0706,1,active,MW=753.9 > 500.0; LogP=5.80 > 5.0
41fbecee,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)COCc2ccccc2)C3)n1C,,,raw,,682.821,682.3155204440001,6.628720000000008,95.32,1,6,8,7,5,0.2619047619047619,51,0.19843333726370188,False,2,True,0,,CHEMBL5751670,6.9,nM,=,8.16,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1612,1,active,MW=682.8 > 500.0; LogP=6.63 > 5.0
0146461e,,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2CCc4ccccc4C2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C,,,raw,,660.8590000000002,660.367556016,7.79852000000001,75.09,0,5,10,6,4,0.3902439024390244,49,0.17406282349382843,False,2,True,0,,CHEMBL5880339,68.0,nM,=,7.17,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1675,1,active,MW=660.9 > 500.0; LogP=7.80 > 5.0
93f8e203,,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2CCc4ccccc4C2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C,,,raw,,658.8870000000002,658.38829146,7.3688200000000075,65.86000000000001,0,4,11,6,4,0.40476190476190477,49,0.1691359969790728,False,2,True,0,,CHEMBL6000962,33.0,nM,=,7.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4815,1,active,MW=658.9 > 500.0; LogP=7.37 > 5.0
64d144f0,,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C,,,raw,,674.886,674.38320608,8.18702000000001,75.09,0,5,10,6,4,0.40476190476190477,50,0.1700976991549621,False,2,True,0,,CHEMBL5996803,27.0,nM,=,7.57,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.5686,1,active,MW=674.9 > 500.0; LogP=8.19 > 5.0
8186a07c,,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C,,,raw,,672.9140000000001,672.403941524,7.757320000000008,65.86000000000001,0,4,11,6,4,0.4186046511627907,50,0.16369913878053513,False,2,True,0,,CHEMBL6054886,14.0,nM,=,7.85,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8539,1,active,MW=672.9 > 500.0; LogP=7.76 > 5.0
4de0c7b2,,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C,,,raw,,758.0199999999998,757.456705368,7.0696200000000085,78.33000000000001,0,6,13,7,4,0.46808510638297873,56,0.14598184294499597,False,2,True,0,,CHEMBL5762647,18.0,nM,=,7.75,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=758.0 > 500.0; LogP=7.07 > 5.0
a6d9154e,,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)COc2ccccc2)C3)n2ccccc12)c1ccc(O)cc1,,,raw,,775.9060000000003,775.3369841599999,6.409000000000009,107.27000000000001,1,8,9,9,6,0.2553191489361702,58,0.1811046430493801,False,2,True,0,,CHEMBL5784186,6.4,nM,=,8.19,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1938,1,active,MW=775.9 > 500.0; LogP=6.41 > 5.0
d6deb252,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3ccccn13)CN(C(=O)COc1ccccc1)C2,,,raw,,690.8,690.2842203160002,7.09670000000001,94.8,1,6,7,8,6,0.18604651162790697,52,0.1930508783267858,False,2,True,0,,CHEMBL5941752,6.5,nM,=,8.19,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1871,1,active,MW=690.8 > 500.0; LogP=7.10 > 5.0
7881b177,,Cc1ccc(OC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)cc3C2)cc1,,,raw,,694.8319999999999,694.315520444,7.883620000000009,95.32,1,6,5,8,5,0.27906976744186046,52,0.20206933851441683,False,2,True,0,,CHEMBL5905897,5.7,nM,=,8.24,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2441,1,active,MW=694.8 > 500.0; LogP=7.88 > 5.0
fb1c6976,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1cccc(N3CCN(C)CC3)c1)C2,,,raw,,791.0089999999994,790.420654208,6.939800000000009,92.57,1,7,7,9,5,0.3673469387755102,59,0.1923036343749303,False,2,True,0,,CHEMBL5831694,3.3,nM,=,8.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4815,1,active,MW=791.0 > 500.0; LogP=6.94 > 5.0
10b983b5,,CNC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)cc2C1,,,raw,,591.7120000000001,591.284554664,5.224720000000006,98.12,2,5,4,6,4,0.2857142857142857,44,0.3399446709060233,False,2,True,0,,CHEMBL6001766,12.0,nM,=,7.92,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=591.7 > 500.0; LogP=5.22 > 5.0
33f785b9,,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CSc1ccccc1)C2,,,raw,,710.9,710.2926768240002,7.69510000000001,86.09,1,6,7,8,5,0.27906976744186046,52,0.17520461686889094,False,2,True,0,,CHEMBL6055416,5.1,nM,=,8.29,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2924,1,active,MW=710.9 > 500.0; LogP=7.70 > 5.0
2cfffb81,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc4c(c2)OCO4)C3)n1C,,,raw,,696.804,696.294785,6.383320000000008,104.55000000000001,1,7,6,8,5,0.2619047619047619,52,0.22104161077575532,False,2,True,0,,CHEMBL5767592,3.4,nM,=,8.47,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4685,1,active,MW=696.8 > 500.0; LogP=6.38 > 5.0
fb3cc251,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@@H](N)c2ccccc2)C3)n1C,,,raw,,667.8100000000001,667.315854792,6.111920000000007,112.10999999999999,2,6,6,7,5,0.24390243902439024,50,0.2270405900573302,False,2,True,0,,CHEMBL5763378,55.0,nM,=,7.26,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2596,1,active,MW=667.8 > 500.0; LogP=6.11 > 5.0
fdf1d4e8,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@H](N)c2ccccc2)C3)n1C,,,raw,,667.8100000000001,667.315854792,6.111920000000007,112.10999999999999,2,6,6,7,5,0.24390243902439024,50,0.2270405900573302,False,2,True,0,,CHEMBL5922941,5.9,nM,=,8.23,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2291,1,active,MW=667.8 > 500.0; LogP=6.11 > 5.0
004003df,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@H](O)c2ccccc2)C3)n1C,,,raw,,668.7940000000002,668.29987038,6.145520000000009,106.32,2,6,6,7,5,0.24390243902439024,50,0.2260931647883457,False,2,True,0,,CHEMBL5908546,4.2,nM,=,8.38,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=668.8 > 500.0; LogP=6.15 > 5.0
24e50cf2,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)CN2CCCCC2)C3)n1C,,,raw,,659.8309999999997,659.34715492,5.897820000000007,89.32999999999998,1,6,6,7,4,0.375,49,0.27874096834185275,False,2,True,0,,CHEMBL5769779,78.0,nM,=,7.11,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.1079,1,active,MW=659.8 > 500.0; LogP=5.90 > 5.0
3f990016,,CCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,raw,,767.9270000000001,767.3682842879999,6.829220000000009,107.79,1,8,8,8,5,0.32608695652173914,57,0.1846305108974082,False,2,True,0,,CHEMBL5749911,3.7,nM,=,8.43,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4318,1,active,MW=767.9 > 500.0; LogP=6.83 > 5.0
70e67c7a,,CCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,raw,,781.9540000000001,781.3839343519999,7.2193200000000095,107.79,1,8,9,8,5,0.3404255319148936,58,0.1684355484744574,False,2,True,0,,CHEMBL5914383,2.5,nM,=,8.6,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6021,1,active,MW=782.0 > 500.0; LogP=7.22 > 5.0
56691e95,,CCCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,raw,,795.9810000000002,795.3995844159999,7.609420000000011,107.79,1,8,10,8,5,0.3541666666666667,59,0.1551890219709725,False,2,True,0,,CHEMBL5963628,3.0,nM,=,8.52,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5229,1,active,MW=796.0 > 500.0; LogP=7.61 > 5.0
71968ebd,,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C,,,raw,,759.9919999999998,759.4359699240001,7.499320000000009,87.56,0,7,12,7,4,0.45652173913043476,56,0.1488402958771438,False,2,True,0,,CHEMBL6021363,26.0,nM,=,7.58,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.585,1,active,MW=760.0 > 500.0; LogP=7.50 > 5.0
d3ee65dd,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN(C)C)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,711.863,711.3420695400001,6.668520000000009,98.56,1,7,7,7,5,0.27906976744186046,53,0.20273582731523684,False,2,True,0,,CHEMBL5863505,3.4,nM,=,8.47,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4685,1,active,MW=711.9 > 500.0; LogP=6.67 > 5.0
dfd8f084,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,766.9429999999999,766.3842687000001,6.354320000000008,101.79999999999998,1,8,7,8,5,0.32608695652173914,57,0.2061065586635585,False,2,True,0,,CHEMBL5978602,2.7,nM,=,8.57,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5686,1,active,MW=766.9 > 500.0; LogP=6.35 > 5.0
450c1e4d,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,767.9269999999999,767.368284288,6.829220000000008,107.78999999999999,1,8,8,8,5,0.32608695652173914,57,0.1846305108974082,False,2,True,0,,CHEMBL5741565,2.4,nM,=,8.62,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6198,1,active,MW=767.9 > 500.0; LogP=6.83 > 5.0
4466c244,,CCCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,raw,,794.0090000000001,793.42031986,7.17972000000001,98.56000000000002,1,7,11,8,5,0.3673469387755102,59,0.15234108428180743,False,2,True,0,,CHEMBL5772479,2.9,nM,=,8.54,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5376,1,active,MW=794.0 > 500.0; LogP=7.18 > 5.0
45a18a58,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Nc2ccccc2)CC3)n1C,,,raw,,752.9159999999998,752.368618636,6.472220000000007,110.59,2,7,7,8,5,0.3111111111111111,56,0.19736715484967393,False,2,True,0,,CHEMBL5813223,4.2,nM,=,8.38,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3768,1,active,MW=752.9 > 500.0; LogP=6.47 > 5.0
ad0968d0,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Nc2ccccc2)CC3)n1C,,,raw,,667.8100000000001,667.315854792,7.159920000000009,98.12,2,5,5,7,5,0.24390243902439024,50,0.20794125046959522,False,2,True,0,,CHEMBL5903712,5.2,nM,=,8.28,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.284,1,active,MW=667.8 > 500.0; LogP=7.16 > 5.0
543854c1,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2OCCN(C)C)CC3)n1C,,,raw,,755.9159999999998,755.3682842879999,7.0672200000000105,107.78999999999999,1,8,9,7,5,0.3111111111111111,56,0.1716656589334131,False,2,True,0,,CHEMBL5879788,2.0,nM,=,8.7,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.699,1,active,MW=755.9 > 500.0; LogP=7.07 > 5.0
06287476,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(OCCN(C)C)c2)CC3)n1C,,,raw,,755.9159999999998,755.3682842879999,7.0672200000000105,107.78999999999999,1,8,9,7,5,0.3111111111111111,56,0.1716656589334131,False,2,True,0,,CHEMBL5760108,2.9,nM,=,8.54,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5376,1,active,MW=755.9 > 500.0; LogP=7.07 > 5.0
d4055c26,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(N(C)CCN(C)C)c2)CC3)n1C,,,raw,,752.9599999999997,752.4050041439999,7.4190200000000095,81.57,0,7,9,7,5,0.32608695652173914,56,0.1560704347887256,False,2,True,0,,CHEMBL5993417,4.3,nM,=,8.37,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3665,1,active,MW=753.0 > 500.0; LogP=7.42 > 5.0
9de80160,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(OCCN(C)C)c2)CC3)n1C,,,raw,,739.9169999999998,739.373369668,7.36162000000001,87.56,0,7,9,7,5,0.3111111111111111,55,0.15714293588227296,False,2,True,0,,CHEMBL5838298,4.0,nM,=,8.4,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3979,1,active,MW=739.9 > 500.0; LogP=7.36 > 5.0
16c07747,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(N(C)CCN(C)C)cc2)CC3)n1C,,,raw,,768.9589999999997,768.3999187639998,7.12462000000001,101.79999999999998,1,8,9,7,5,0.32608695652173914,57,0.17049061468773707,False,2,True,0,,CHEMBL5805677,4.5,nM,=,8.35,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3468,1,active,MW=769.0 > 500.0; LogP=7.12 > 5.0
b5ccd919,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(OCCN(C)C)cc2)CC3)n1C,,,raw,,755.9159999999998,755.3682842879999,7.0672200000000105,107.78999999999999,1,8,9,7,5,0.3111111111111111,56,0.1716656589334131,False,2,True,0,,CHEMBL5955038,1.8,nM,=,8.74,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.7447,1,active,MW=755.9 > 500.0; LogP=7.07 > 5.0
66f4b50b,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(N(C)CCN(C)C)cc2)CC3)n1C,,,raw,,752.9599999999997,752.4050041439999,7.4190200000000095,81.57,0,7,9,7,5,0.32608695652173914,56,0.1560704347887256,False,2,True,0,,CHEMBL5877503,5.3,nM,=,8.28,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2757,1,active,MW=753.0 > 500.0; LogP=7.42 > 5.0
4996ffad,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(NCCN(C)C)cc2)CC3)n1C,,,raw,,738.9329999999998,738.38935408,7.394720000000008,90.36000000000001,1,7,9,7,5,0.3111111111111111,55,0.1697389243012501,False,2,True,0,,CHEMBL5869795,3.2,nM,=,8.49,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4949,1,active,MW=738.9 > 500.0; LogP=7.39 > 5.0
9599829c,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cccc(C#N)c2)CC3)n1C,,,raw,,778.9099999999997,778.347883192,6.3108000000000075,131.58,1,9,7,8,5,0.30434782608695654,58,0.20357373949410684,False,2,True,0,,CHEMBL6025190,8.8,nM,=,8.06,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0555,1,active,MW=778.9 > 500.0; LogP=6.31 > 5.0
26a06a23,,C#Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,777.9219999999997,777.352634224,6.420420000000006,107.78999999999998,1,8,7,8,5,0.2978723404255319,58,0.19030728414575698,False,2,True,0,,CHEMBL5820135,4.5,nM,=,8.35,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3468,1,active,MW=777.9 > 500.0; LogP=6.42 > 5.0
7c169ab4,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Cl)c(Cl)c2)CC3)n1C,,,raw,,822.7899999999997,821.2746895200002,7.74592000000001,107.78999999999999,1,8,7,8,5,0.3111111111111111,58,0.17908462849457094,False,2,True,0,,CHEMBL5981194,18.0,nM,=,7.75,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.7447,1,active,MW=822.8 > 500.0; LogP=7.75 > 5.0
1e4d4af0,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4ccccc4c2)CC3)n1C,,,raw,,803.9599999999998,803.368284288,7.592320000000011,107.78999999999999,1,8,7,9,6,0.2857142857142857,60,0.17735363758729875,False,2,True,0,,CHEMBL5859076,8.8,nM,=,8.06,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0555,1,active,MW=804.0 > 500.0; LogP=7.59 > 5.0
941c9f4a,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4cc[nH]c4c2)CC3)n1C,,,raw,,792.9369999999998,792.363533256,6.920420000000009,123.58000000000001,2,8,7,9,6,0.2978723404255319,59,0.180062872002645,False,2,True,0,,CHEMBL5914305,6.3,nM,=,8.2,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2007,1,active,MW=792.9 > 500.0; LogP=6.92 > 5.0
8eb1fc54,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4[nH]ccc4c2)CC3)n1C,,,raw,,792.9369999999998,792.363533256,6.920420000000009,123.58000000000001,2,8,7,9,6,0.2978723404255319,59,0.180062872002645,False,2,True,0,,CHEMBL5742039,5.9,nM,=,8.23,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2291,1,active,MW=792.9 > 500.0; LogP=6.92 > 5.0
82f13015,,Cc1c(C(=O)NCc2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cnc4[nH]ccc4c2)CC3)n1C,,,raw,,793.9249999999997,793.3587822239999,5.968820000000005,145.26,3,9,8,9,6,0.30434782608695654,59,0.1711613089278801,False,2,True,0,,CHEMBL5861332,4.4,nM,=,8.36,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=793.9 > 500.0; LogP=5.97 > 5.0
fa0ce02f,,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccccc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,751.9279999999998,751.373369668,7.041940000000007,87.55999999999999,0,7,7,8,5,0.32608695652173914,56,0.1774725758527015,False,2,True,0,,CHEMBL6020264,2.5,nM,=,8.6,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6021,1,active,MW=751.9 > 500.0; LogP=7.04 > 5.0
bdc1f958,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4cc[nH]c4c2)CC3)n1C,,,raw,,776.9379999999999,776.368618636,7.2148200000000084,103.35000000000002,1,7,7,9,6,0.2978723404255319,58,0.18394389101936898,False,2,True,0,,CHEMBL5928745,7.2,nM,=,8.14,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1427,1,active,MW=776.9 > 500.0; LogP=7.21 > 5.0
61b5cca6,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4[nH]ccc4c2)CC3)n1C,,,raw,,776.9379999999999,776.368618636,7.2148200000000084,103.35000000000002,1,7,7,9,6,0.2978723404255319,58,0.18394389101936898,False,2,True,0,,CHEMBL5740858,5.2,nM,=,8.28,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.284,1,active,MW=776.9 > 500.0; LogP=7.21 > 5.0
78330096,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cnc4[nH]ccc4c2)CC3)n1C,,,raw,,777.9259999999998,777.3638676039999,6.609820000000007,116.24000000000001,1,8,7,9,6,0.30434782608695654,58,0.19413098944211368,False,2,True,0,,CHEMBL5818506,6.1,nM,=,8.21,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2147,1,active,MW=777.9 > 500.0; LogP=6.61 > 5.0
4cd9246b,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cnc4c(ccn4C)c2)CC3)n1C,,,raw,,791.9529999999997,791.379517668,6.620220000000008,105.38000000000002,0,9,7,9,6,0.3191489361702128,59,0.1791463630955023,False,2,True,0,,CHEMBL6007828,6.9,nM,=,8.16,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.1612,1,active,MW=792.0 > 500.0; LogP=6.62 > 5.0
aadc5b43,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cnc4[nH]ccc4c2)CC3)n1C,,,raw,,692.8199999999999,692.3111037599999,7.2975200000000084,103.77000000000001,1,6,5,8,6,0.23809523809523808,52,0.2043915095589494,False,2,True,0,,CHEMBL6063634,11.0,nM,=,7.96,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9586,1,active,MW=692.8 > 500.0; LogP=7.30 > 5.0
0d57ee4f,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,raw,,797.9089999999999,797.342463464,6.137320000000007,145.09,2,9,8,8,5,0.30434782608695654,59,0.1893565572529978,False,2,True,0,,CHEMBL5920610,4.8,nM,=,8.32,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3188,1,active,MW=797.9 > 500.0; LogP=6.14 > 5.0
ce8f3f8b,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,raw,,712.8030000000001,712.28969962,6.825020000000009,132.62,2,7,6,7,5,0.23809523809523808,53,0.1974260959530173,False,2,True,0,,CHEMBL5914402,2.2,nM,=,8.66,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6576,1,active,MW=712.8 > 500.0; LogP=6.83 > 5.0
3c9e345c,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C(=O)O)cc2)CC3)n1C,,,raw,,797.9089999999999,797.342463464,6.137320000000007,145.09,2,9,8,8,5,0.30434782608695654,59,0.1893565572529978,False,2,True,0,,CHEMBL5901939,4.9,nM,=,8.31,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3098,1,active,MW=797.9 > 500.0; LogP=6.14 > 5.0
a9deaccb,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,raw,,810.9519999999999,810.3740979400002,6.0525200000000074,139.1,2,9,8,8,5,0.3191489361702128,60,0.19187312999047698,False,2,True,0,,CHEMBL5959165,1.5,nM,=,8.82,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.8239,1,active,MW=811.0 > 500.0; LogP=6.05 > 5.0
85c946af,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,raw,,794.9529999999999,794.3791833200002,6.346920000000007,118.87,1,8,8,8,5,0.3191489361702128,59,0.19338790810900863,False,2,True,0,,CHEMBL5979822,12.0,nM,=,7.92,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.9208,1,active,MW=795.0 > 500.0; LogP=6.35 > 5.0
273fb6d2,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2CCC(=O)N(C)C)CC3)n1C,,,raw,,767.9269999999998,767.3682842879999,7.14762000000001,115.63,1,7,8,7,5,0.30434782608695654,57,0.17954087240339195,False,2,True,0,,CHEMBL5947068,2.4,nM,=,8.62,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6198,1,active,MW=767.9 > 500.0; LogP=7.15 > 5.0
f5517af8,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(CCC(=O)N(C)C)c2)CC3)n1C,,,raw,,767.9269999999998,767.3682842879999,7.14762000000001,115.63,1,7,8,7,5,0.30434782608695654,57,0.17954087240339195,False,2,True,0,,CHEMBL5957233,2.2,nM,=,8.66,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.6576,1,active,MW=767.9 > 500.0; LogP=7.15 > 5.0
7c28acee,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN(C)C)CN(C(=O)Cc2ccccc2)CC3)n1C,,,raw,,709.891,709.362804984,6.238820000000008,89.33000000000001,1,6,8,7,5,0.29545454545454547,53,0.20630780897608045,False,2,True,0,,CHEMBL6018795,4.1,nM,=,8.39,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3872,1,active,MW=709.9 > 500.0; LogP=6.24 > 5.0
8376c45b,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,raw,,764.9709999999998,764.405004144,5.924620000000008,92.57,1,7,8,8,5,0.3404255319148936,57,0.21106799222838754,False,2,True,0,,CHEMBL5814775,3.1,nM,=,8.51,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5086,1,active,MW=765.0 > 500.0; LogP=5.92 > 5.0
a3e6b37e,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,raw,,765.9549999999998,765.389019732,6.399520000000008,98.56,1,7,9,8,5,0.3404255319148936,57,0.18675002704706897,False,2,True,0,,CHEMBL5957217,2.9,nM,=,8.54,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5376,1,active,MW=766.0 > 500.0; LogP=6.40 > 5.0
c5424069,,CCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,raw,,765.9550000000002,765.389019732,6.399520000000009,98.56000000000002,1,7,9,8,5,0.3404255319148936,57,0.1867500270470689,False,2,True,0,,CHEMBL5911510,3.5,nM,=,8.46,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4559,1,active,MW=766.0 > 500.0; LogP=6.40 > 5.0
4ce5c066,,CCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,raw,,779.9820000000001,779.404669796,6.789620000000009,98.56000000000002,1,7,10,8,5,0.3541666666666667,58,0.167852083462365,False,2,True,0,,CHEMBL5747447,2.6,nM,=,8.59,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.585,1,active,MW=780.0 > 500.0; LogP=6.79 > 5.0
2b16e9d9,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN(C)C)CN(C(=O)C(F)(F)F)CC3)n1C,,,raw,,687.7630000000001,687.3032394200001,5.558420000000007,89.33000000000001,1,6,6,6,4,0.34210526315789475,50,0.2871045124638875,False,2,True,0,,CHEMBL5862127,51.0,nM,=,7.29,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.2924,1,active,MW=687.8 > 500.0; LogP=5.56 > 5.0
4b583e89,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)C(F)(F)F)CC3)n1C,,,raw,,742.843,742.3454385800001,5.2442200000000065,92.57,1,7,6,7,4,0.3902439024390244,54,0.29078979782535397,False,2,True,0,,CHEMBL5787910,23.0,nM,=,7.64,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6383,1,active,MW=742.8 > 500.0; LogP=5.24 > 5.0
afe218ce,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Br)cc2)CC3)n1C,,,raw,,832.7959999999998,831.2631462920001,7.20162000000001,107.78999999999999,1,8,7,8,5,0.3111111111111111,57,0.18501283888145714,False,2,True,0,,CHEMBL6010857,5.1,nM,=,8.29,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2924,1,active,MW=832.8 > 500.0; LogP=7.20 > 5.0
bbffd2d4,,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccccc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4C)cc3C2)cc1,,,raw,,666.8220000000001,666.320605824,7.729640000000009,75.08999999999999,0,5,5,7,5,0.2619047619047619,50,0.19252760045142137,False,2,True,0,,CHEMBL5874228,3.3,nM,=,8.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4815,1,active,MW=666.8 > 500.0; LogP=7.73 > 5.0
643945d7,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,raw,,677.805,677.3002047279999,7.292900000000009,98.88000000000002,0,6,5,7,5,0.23809523809523808,51,0.19462094822476408,False,2,True,0,,CHEMBL5872583,8.4,nM,=,8.08,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0757,1,active,MW=677.8 > 500.0; LogP=7.29 > 5.0
9bfa27cf,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(CCC(=O)N(C)C)c2)CC3)n1C,,,raw,,751.9279999999998,751.373369668,7.442020000000009,95.4,0,6,8,7,5,0.30434782608695654,56,0.16438276553812362,False,2,True,0,,CHEMBL5917372,5.0,nM,=,8.3,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.301,1,active,MW=751.9 > 500.0; LogP=7.44 > 5.0
f10c5cf3,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(CCC(=O)N(C)C)cc2)CC3)n1C,,,raw,,751.9279999999998,751.373369668,7.442020000000009,95.4,0,6,8,7,5,0.30434782608695654,56,0.16438276553812362,False,2,True,0,,CHEMBL5949935,4.4,nM,=,8.36,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=751.9 > 500.0; LogP=7.44 > 5.0
be4e1ee4,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc4[nH]ccc4c2)CC3)n1C,,,raw,,691.832,691.315854792,7.902520000000009,90.88000000000002,1,5,5,8,6,0.23255813953488372,52,0.19910744928528515,False,2,True,0,,CHEMBL5979212,8.9,nM,=,8.05,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.0506,1,active,MW=691.8 > 500.0; LogP=7.90 > 5.0
6c876bc8,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)OC2CCCCC2)CC3)n1C,,,raw,,674.8419999999998,674.346820572,7.39712000000001,95.32,1,6,5,7,4,0.3902439024390244,50,0.23822749671184695,False,2,True,0,,CHEMBL5992723,3.4,nM,=,8.47,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4685,1,active,MW=674.8 > 500.0; LogP=7.40 > 5.0
2efd6415,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,raw,,759.9479999999995,759.399584416,6.709420000000009,107.78999999999999,1,8,7,8,4,0.4444444444444444,56,0.22340677387510122,False,2,True,0,,CHEMBL5967330,2.8,nM,=,8.55,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5528,1,active,MW=759.9 > 500.0; LogP=6.71 > 5.0
b8901d81,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)NC2CCCCC2)CC3)n1C,,,raw,,673.8579999999997,673.3628049839999,6.9701200000000085,98.12,2,5,5,7,4,0.3902439024390244,50,0.23922697483518507,False,2,True,0,,CHEMBL6010750,4.6,nM,=,8.34,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3372,1,active,MW=673.9 > 500.0; LogP=6.97 > 5.0
f6b6e43f,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)NC2CCCCC2)CC3)n1C,,,raw,,758.9639999999995,758.415568828,6.282420000000008,110.59,2,7,7,8,4,0.4444444444444444,56,0.22977122605747768,False,2,True,0,,CHEMBL6042482,4.4,nM,=,8.36,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3565,1,active,MW=759.0 > 500.0; LogP=6.28 > 5.0
52861ab3,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CC2CCCCC2)CC3)n1C,,,raw,,757.9759999999994,757.42031986,6.737120000000009,98.56,1,7,8,8,4,0.45652173913043476,56,0.21412101948540832,False,2,True,0,,CHEMBL5910501,4.6,nM,=,8.34,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3372,1,active,MW=758.0 > 500.0; LogP=6.74 > 5.0
d92b635f,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)CC2CCCCC2)CC3)n1C,,,raw,,672.8699999999997,672.367556016,7.42482000000001,86.09,1,5,6,7,4,0.40476190476190477,50,0.23105734263929023,False,2,True,0,,CHEMBL5926064,5.3,nM,=,8.28,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2757,1,active,MW=672.9 > 500.0; LogP=7.42 > 5.0
86c7038a,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC2CCCC2)CC3)n1C,,,raw,,745.9209999999996,745.383934352,6.319320000000008,107.78999999999999,1,8,7,8,4,0.4318181818181818,55,0.23616262342329636,False,2,True,0,,CHEMBL5779078,6.2,nM,=,8.21,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.2076,1,active,MW=745.9 > 500.0; LogP=6.32 > 5.0
1beb3bc8,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)O[C@@H]2C[C@H](C)CC[C@H]2C(C)C)CC3)n1C,,,raw,,816.0559999999996,815.462184672,7.83752000000001,107.78999999999999,1,8,8,8,4,0.4897959183673469,60,0.19330095740839728,False,2,True,0,,CHEMBL5748092,21.0,nM,=,7.68,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.6778,1,active,MW=816.1 > 500.0; LogP=7.84 > 5.0
8b421e9f,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CC24CC5CC(CC(C5)C2)C4)CC3)n1C,,,raw,,810.0519999999993,809.451619988,7.3732200000000105,98.56,1,7,8,11,4,0.5,60,0.19981142360378526,False,2,True,0,,CHEMBL5902574,9.1,nM,=,8.04,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.041,1,active,MW=810.1 > 500.0; LogP=7.37 > 5.0
fa34c27c,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)CN2CCCCC2)CC3)n1C,,,raw,,673.8579999999996,673.3628049839999,5.940320000000007,89.32999999999998,1,6,6,7,4,0.3902439024390244,50,0.27389399845037493,False,2,True,0,,CHEMBL5878085,15.0,nM,=,7.82,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.8239,1,active,MW=673.9 > 500.0; LogP=5.94 > 5.0
d04f4113,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)O[C@H]2CC[C@H](NC(=O)OC(C)(C)C)CC2)CC3)n1C,,,raw,,789.9739999999997,789.4101490999999,7.9003200000000104,133.65,2,8,6,7,4,0.43478260869565216,58,0.20301533589242027,False,2,True,0,,CHEMBL5782918,2.0,nM,=,8.7,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.699,1,active,MW=790.0 > 500.0; LogP=7.90 > 5.0
8afce361,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)O[C@H]2CC[C@H](N)CC2)CC3)n1C,,,raw,,689.8569999999997,689.3577196039998,6.334320000000008,121.34,2,7,5,7,4,0.3902439024390244,51,0.25264275092794475,False,2,True,0,,CHEMBL5924588,2.7,nM,=,8.57,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5686,1,active,MW=689.9 > 500.0; LogP=6.33 > 5.0
ea23f198,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)O[C@H]2CC[C@H](N(C)C)CC2)CC3)n1C,,,raw,,717.9109999999997,717.3890197319998,6.93722000000001,98.56,1,7,6,7,4,0.4186046511627907,53,0.23232541363288386,False,2,True,0,,CHEMBL5802833,4.0,nM,=,8.4,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3979,1,active,MW=717.9 > 500.0; LogP=6.94 > 5.0
98568986,,CC(=O)N(C)c1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,824.9789999999996,824.389748004,6.421820000000007,128.09999999999997,1,9,8,8,5,0.3333333333333333,61,0.1900830826913106,False,2,True,0,,CHEMBL5775598,4.6,nM,=,8.34,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.3372,1,active,MW=825.0 > 500.0; LogP=6.42 > 5.0
7926838c,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(CCC(=O)N(C)C)cc2)CC3)n1C,,,raw,,767.9269999999998,767.3682842879999,7.14762000000001,115.63,1,7,8,7,5,0.30434782608695654,57,0.17954087240339195,False,2,True,0,,CHEMBL5871630,3.6,nM,=,8.44,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4437,1,active,MW=767.9 > 500.0; LogP=7.15 > 5.0
cdcd7f6f,,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(c5ccc(O)cc5)c5cc(C#N)n(C)c5C)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,raw,,872.0389999999994,871.4057324160001,7.968040000000011,136.51,1,10,8,9,6,0.3076923076923077,65,0.16282142963430746,False,2,True,0,,CHEMBL5740273,3.1,nM,=,8.51,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5086,1,active,MW=872.0 > 500.0; LogP=7.97 > 5.0
c21a6020,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@@H](O)c2ccccc2)C3)n1C,,,raw,,668.7940000000002,668.29987038,6.145520000000009,106.32,2,6,6,7,5,0.24390243902439024,50,0.2260931647883457,False,2,True,0,,CHEMBL5902233,33.0,nM,=,7.48,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,7.4815,1,active,MW=668.8 > 500.0; LogP=6.15 > 5.0
ac54e00f,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,raw,,773.9749999999996,773.41523448,7.099520000000009,107.78999999999999,1,8,8,8,4,0.45652173913043476,57,0.20373747504225978,False,2,True,0,,CHEMBL6016389,3.9,nM,=,8.41,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4089,1,active,MW=774.0 > 500.0; LogP=7.10 > 5.0
d612d10a,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCCN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,raw,,781.9539999999998,781.383934352,7.219320000000009,107.78999999999999,1,8,9,8,5,0.3404255319148936,58,0.1684355484744574,False,2,True,0,,CHEMBL6056476,2.7,nM,=,8.57,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5686,1,active,MW=782.0 > 500.0; LogP=7.22 > 5.0
cb1f38d5,,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCCN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,raw,,788.0019999999995,787.430884544,7.489620000000009,107.78999999999999,1,8,9,8,4,0.46808510638297873,58,0.18747745398587345,False,2,True,0,,CHEMBL5828406,3.1,nM,=,8.51,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.5086,1,active,MW=788.0 > 500.0; LogP=7.49 > 5.0
b88be222,,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCCN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,raw,,772.0029999999996,771.435969924,7.78402000000001,87.56,0,7,9,8,4,0.46808510638297873,57,0.17288981274956824,False,2,True,0,,CHEMBL5979408,3.8,nM,=,8.42,CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",0.8,1,8.4202,1,active,MW=772.0 > 500.0; LogP=7.78 > 5.0
0b45d51b,,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,879.4359999999996,878.2864611439999,8.759900000000005,178.02,3,11,13,9,5,0.34782608695652173,62,0.07610166732259946,False,3,True,0,,CHEMBL5872170,1.4,nM,=,8.85,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.8539,1,active,MW=879.4 > 500.0; LogP=8.76 > 5.0; HBA=11 > 10
6fe13e5a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,882.4399999999997,881.297360176,7.6503000000000085,181.26000000000002,3,12,13,9,5,0.37777777777777777,62,0.07778080574566355,False,3,True,0,,CHEMBL5915070,0.76,nM,=,9.12,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,9.1192,1,active,MW=882.4 > 500.0; LogP=7.65 > 5.0; HBA=12 > 10
adb8754d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,880.4679999999996,879.31809562,8.804000000000006,172.03,3,11,13,9,5,0.391304347826087,62,0.07625891320399376,False,3,True,0,,CHEMBL5862961,1.2,nM,=,8.92,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.9208,1,active,MW=880.5 > 500.0; LogP=8.80 > 5.0; HBA=11 > 10
1226872f,,O=C(NS(=O)(=O)c1cccc([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,767.3079999999998,766.234031648,7.965500000000008,150.76999999999998,2,9,10,8,5,0.3,54,0.10658070616350707,False,2,True,0,,CHEMBL5846384,3.1,nM,=,8.51,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.5086,1,active,MW=767.3 > 500.0; LogP=7.97 > 5.0
b0420fad,,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,881.4079999999997,880.2657257,7.606200000000008,187.24999999999997,3,12,13,9,5,0.3333333333333333,62,0.0777685318501569,False,3,True,0,,CHEMBL5995747,2.1,nM,=,8.68,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.6778,1,active,MW=881.4 > 500.0; LogP=7.61 > 5.0; HBA=12 > 10
644379d8,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,877.4639999999996,876.307196588,9.771099999999997,168.79,3,10,13,9,5,0.3617021276595745,62,0.0764949350611829,False,2,True,0,,CHEMBL5925473,2.4,nM,=,8.62,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.6198,1,active,MW=877.5 > 500.0; LogP=9.77 > 5.0
d6680119,,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,884.4119999999997,883.2766247320002,6.639100000000007,190.48999999999998,3,13,13,9,5,0.36363636363636365,62,0.08439319048739648,False,3,True,0,,CHEMBL5753919,2.4,nM,=,8.62,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.6198,1,active,MW=884.4 > 500.0; LogP=6.64 > 5.0; HBA=13 > 10
f9e087d7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,879.4359999999997,878.286461144,8.617400000000005,178.02,3,11,13,9,5,0.34782608695652173,62,0.0762134997254343,False,3,True,0,,CHEMBL6018977,1.9,nM,=,8.72,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.7212,1,active,MW=879.4 > 500.0; LogP=8.62 > 5.0; HBA=11 > 10
9316c862,,CNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC5(CCC5)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,raw,,796.35,795.2605807440001,8.007200000000008,162.8,3,10,11,8,5,0.3170731707317073,56,0.08820290052115153,False,2,True,0,,CHEMBL6064691,3.3,nM,=,8.48,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.4815,1,active,MW=796.4 > 500.0; LogP=8.01 > 5.0
422b1073,,CN(C)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC5(CCC5)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,raw,,810.377,809.276230808,8.031500000000008,154.01000000000002,2,10,11,8,5,0.3333333333333333,57,0.09904230635644261,False,2,True,0,,CHEMBL5857346,11.9,nM,=,7.92,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,7.9245,1,active,MW=810.4 > 500.0; LogP=8.03 > 5.0
060b3f0b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,879.4799999999997,878.322846652,9.861399999999998,168.79,3,10,13,9,5,0.40425531914893614,62,0.0764775096924548,False,2,True,0,,CHEMBL6022853,4.4,nM,=,8.36,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.3565,1,active,MW=879.5 > 500.0; LogP=9.86 > 5.0
a5ed1d9a,,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,882.4399999999996,881.2973601760001,7.792800000000009,181.26000000000002,3,12,13,9,5,0.37777777777777777,62,0.07728642828682362,False,3,True,0,,CHEMBL5896213,1.3,nM,=,8.89,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.8861,1,active,MW=882.4 > 500.0; LogP=7.79 > 5.0; HBA=12 > 10
9acedb61,,CC(C)c1nc2cc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC6(CCC6)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc([N+](=O)[O-])c2[nH]1,,,raw,,849.4139999999998,848.28712984,8.965200000000006,179.45,3,10,11,9,6,0.3409090909090909,60,0.08417278476877275,False,2,True,0,,CHEMBL5888847,3.8,nM,=,8.42,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.4202,1,active,MW=849.4 > 500.0; LogP=8.97 > 5.0
7d590e28,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2[nH]c(C3CC3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,847.3979999999997,846.271479776,8.719200000000004,179.45000000000002,3,10,11,10,6,0.3409090909090909,60,0.08435114475551889,False,2,True,0,,CHEMBL6055136,5.0,nM,=,8.3,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.301,1,active,MW=847.4 > 500.0; LogP=8.72 > 5.0
2c2db042,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2c(cnn2CC2CCOCC2)c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,905.4779999999997,904.313344588,8.741800000000007,177.81999999999996,2,12,12,10,6,0.3829787234042553,64,0.08866525139861196,False,3,True,0,,CHEMBL5815622,2.1,nM,=,8.68,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.6778,1,active,MW=905.5 > 500.0; LogP=8.74 > 5.0; HBA=12 > 10
8fc4fcbe,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2nn(CC3CCOCC3)cc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,905.4779999999997,904.313344588,8.741800000000005,177.81999999999996,2,12,12,10,6,0.3829787234042553,64,0.08866525139861196,False,3,True,0,,CHEMBL5958618,2.1,nM,=,8.68,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.6778,1,active,MW=905.5 > 500.0; LogP=8.74 > 5.0; HBA=12 > 10
bdb85ae3,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cnn(CC3CCOCC3)c2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,905.4779999999997,904.313344588,8.741800000000007,177.81999999999996,2,12,12,10,6,0.3829787234042553,64,0.08866525139861196,False,3,True,0,,CHEMBL5923329,1.6,nM,=,8.8,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.7959,1,active,MW=905.5 > 500.0; LogP=8.74 > 5.0; HBA=12 > 10
585d9709,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cn(CC3CCOCC3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,905.4779999999997,904.313344588,8.741800000000007,177.82000000000002,2,12,12,10,6,0.3829787234042553,64,0.08866525139861196,False,3,True,0,,CHEMBL5953504,1.3,nM,=,8.89,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.8861,1,active,MW=905.5 > 500.0; LogP=8.74 > 5.0; HBA=12 > 10
d4edb7c5,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cnn(C3CCOCC3)c2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,891.4509999999998,890.2976945239999,8.666700000000008,177.81999999999996,2,12,11,10,6,0.3695652173913043,63,0.09398352723164097,False,3,True,0,,CHEMBL5776346,2.4,nM,=,8.62,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.6198,1,active,MW=891.5 > 500.0; LogP=8.67 > 5.0; HBA=12 > 10
c1e0c8fe,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cn(C3CCOCC3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,891.4509999999997,890.2976945239999,8.666700000000008,177.82000000000002,2,12,11,10,6,0.3695652173913043,63,0.09398352723164097,False,3,True,0,,CHEMBL5821856,1.4,nM,=,8.85,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.8539,1,active,MW=891.5 > 500.0; LogP=8.67 > 5.0; HBA=12 > 10
461921d7,,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2[nH]c(-c3ccncc3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,884.4189999999995,883.266728744,8.903800000000002,192.34,3,11,11,10,7,0.2608695652173913,63,0.0830137656293277,False,3,True,0,,CHEMBL5827545,2.7,nM,=,8.57,CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",0.8,1,8.5686,1,active,MW=884.4 > 500.0; LogP=8.90 > 5.0; HBA=11 > 10
a269c7f6,,CC(C)(C)OC(=O)c1ccc(-c2ccc(N3CCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,531.6560000000002,531.252191916,8.319000000000004,67.44999999999999,1,5,6,6,5,0.23529411764705882,40,0.22319046563482833,False,2,True,0,,CHEMBL5859755,43.0,nM,=,7.37,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3665,1,active,MW=531.7 > 500.0; LogP=8.32 > 5.0
f48d93f1,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,807.3290000000002,806.228946268,8.882500000000004,168.79,3,10,12,8,6,0.23809523809523808,57,0.08022996847170942,False,2,True,0,,CHEMBL6009922,3.8,nM,=,8.42,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4202,1,active,MW=807.3 > 500.0; LogP=8.88 > 5.0
2e63f462,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,807.3290000000002,806.228946268,8.882500000000004,168.79,3,10,12,8,6,0.23809523809523808,57,0.08022996847170942,False,2,True,0,,CHEMBL5822566,36.0,nM,=,7.44,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4437,1,active,MW=807.3 > 500.0; LogP=8.88 > 5.0
d42ab2ad,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)c(Cl)c2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,841.7740000000001,840.1899739160001,9.535899999999998,168.79,3,10,12,8,6,0.23809523809523808,58,0.07971595794643314,False,2,True,0,,CHEMBL6016027,449.0,nM,=,6.35,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.3478,1,active,MW=841.8 > 500.0; LogP=9.54 > 5.0
d0bb1386,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3)c(C(F)(F)F)c2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,840.8810000000003,840.2553032479999,9.2479,168.79,3,10,12,8,6,0.2558139534883721,60,0.07979463858662701,False,2,True,0,,CHEMBL5933296,3689.0,nM,=,5.43,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.4331,0,inactive,MW=840.9 > 500.0; LogP=9.25 > 5.0
75834fe2,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(C(F)(F)F)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,840.8810000000003,840.2553032479999,9.2479,168.79,3,10,12,8,6,0.2558139534883721,60,0.07979463858662701,False,2,True,0,,CHEMBL5751353,417.0,nM,=,6.38,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.3799,1,active,MW=840.9 > 500.0; LogP=9.25 > 5.0
92b72e67,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(C(F)(F)F)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,840.8810000000003,840.2553032479999,9.247900000000001,168.79,3,10,12,8,6,0.2558139534883721,60,0.07979463858662701,False,2,True,0,,CHEMBL5954413,1884.0,nM,=,5.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.7249,0,inactive,MW=840.9 > 500.0; LogP=9.25 > 5.0
f835b5f1,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(C4CC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000001,812.2992187479999,9.106500000000002,168.79,3,10,13,9,6,0.28888888888888886,59,0.0755570295485051,False,2,True,0,,CHEMBL6046208,1075.0,nM,=,5.97,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,5.9686,0,inactive,MW=812.9 > 500.0; LogP=9.11 > 5.0
ab39d6dd,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(C4CC4)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000001,812.2992187479999,9.106500000000002,168.79,3,10,13,9,6,0.28888888888888886,59,0.0755570295485051,False,2,True,0,,CHEMBL5878519,133.0,nM,=,6.88,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,6.8761,1,active,MW=812.9 > 500.0; LogP=9.11 > 5.0
5a40167a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,800.9380000000002,800.2992187479999,9.009300000000001,168.79,3,10,12,8,6,0.2727272727272727,58,0.08023057875556992,False,2,True,0,,CHEMBL5849462,31.0,nM,=,7.51,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5086,1,active,MW=800.9 > 500.0; LogP=9.01 > 5.0
7264bbac,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(Cl)c(Cl)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,841.7740000000001,840.1899739160001,9.535899999999998,168.79,3,10,12,8,6,0.23809523809523808,58,0.07971595794643314,False,2,True,0,,CHEMBL5946898,1122.0,nM,=,5.95,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.95,0,inactive,MW=841.8 > 500.0; LogP=9.54 > 5.0
32b1613a,,COc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,802.91,802.278483304,8.237700000000006,178.02,3,11,13,8,6,0.2558139534883721,58,0.07568462699354753,False,3,True,0,,CHEMBL5972023,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=802.9 > 500.0; LogP=8.24 > 5.0; HBA=11 > 10
c31fafd6,,COc1ccc(C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)cc1,,,raw,,802.9100000000001,802.278483304,8.237700000000007,178.02,3,11,13,8,6,0.2558139534883721,58,0.07568462699354753,False,3,True,0,,CHEMBL5806787,191.0,nM,=,6.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.719,1,active,MW=802.9 > 500.0; LogP=8.24 > 5.0; HBA=11 > 10
22a6b3f8,,CC1(C)CC(c2ccccc2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1=O,,,raw,,814.921,814.278483304,8.391800000000005,185.85999999999999,3,10,12,8,6,0.25,59,0.0800409319730539,False,2,True,0,,CHEMBL6045461,71.0,nM,=,7.15,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.1487,1,active,MW=814.9 > 500.0; LogP=8.39 > 5.0
0f65294b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C(=O)CC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,772.8400000000003,772.2315331119999,7.365600000000007,185.85999999999999,3,10,12,8,6,0.1951219512195122,56,0.06445652951323042,False,2,True,0,,CHEMBL5884281,41.0,nM,=,7.39,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3872,1,active,MW=772.8 > 500.0; LogP=7.37 > 5.0
bd001b93,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3Cc3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,786.9110000000002,786.283568684,8.224700000000007,168.79,3,10,13,8,6,0.2558139534883721,57,0.07661758696808324,False,2,True,0,,CHEMBL5754545,241.0,nM,=,6.62,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.618,1,active,MW=786.9 > 500.0; LogP=8.22 > 5.0
7b804c7d,,CCc1cccc(CC2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)c1,,,raw,,814.9649999999999,814.314868812,8.661500000000004,168.79,3,10,14,8,6,0.28888888888888886,59,0.07148583521113593,False,2,True,0,,CHEMBL5910360,13.0,nM,=,7.89,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8861,1,active,MW=815.0 > 500.0; LogP=8.66 > 5.0
72c37007,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3Cc3cccc(C4CCCC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,855.0299999999999,854.34616894,9.756699999999999,168.79,3,10,14,9,6,0.3333333333333333,62,0.07085421350184151,False,2,True,0,,CHEMBL6059224,34.0,nM,=,7.47,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4685,1,active,MW=855.0 > 500.0; LogP=9.76 > 5.0
3f1fa692,,Cc1ccccc1N1CCCC1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,786.9110000000001,786.283568684,8.537520000000006,168.79,3,10,12,8,6,0.2558139534883721,57,0.08075455245398984,False,2,True,0,,CHEMBL5742232,20.0,nM,=,7.7,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.699,1,active,MW=786.9 > 500.0; LogP=8.54 > 5.0
016c4ebe,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3)c(F)c2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,790.8740000000003,790.2584968079999,8.368200000000005,168.79,3,10,12,8,6,0.23809523809523808,57,0.08090782740292,False,2,True,0,,CHEMBL5858004,87.0,nM,=,7.06,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0605,1,active,MW=790.9 > 500.0; LogP=8.37 > 5.0
4cbe2ef3,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3(c3ccccc3)C(F)(F)F)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,840.8810000000004,840.2553032479999,8.945600000000004,168.79,3,10,12,8,6,0.2558139534883721,60,0.07992161480299337,False,2,True,0,,CHEMBL5785783,9.0,nM,=,8.05,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0458,1,active,MW=840.9 > 500.0; LogP=8.95 > 5.0
c9598b2c,,CCC1(c2ccccc2)CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,800.9379999999999,800.2992187479999,8.793300000000004,168.79,3,10,13,8,6,0.2727272727272727,58,0.07583428029755555,False,2,True,0,,CHEMBL5978045,36.0,nM,=,7.44,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4437,1,active,MW=800.9 > 500.0; LogP=8.79 > 5.0
5de3afaa,,CN1CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C(c2ccccc2)C1,,,raw,,801.9260000000003,801.2944677159999,7.380700000000008,172.03,3,11,12,8,6,0.2558139534883721,58,0.08330964852275627,False,3,True,0,,CHEMBL5784373,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=801.9 > 500.0; LogP=7.38 > 5.0; HBA=11 > 10
67a17fe7,,CC(C)c1ccccc1C1CCCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,828.9919999999997,828.3305188759999,9.7426,168.79,3,10,13,8,6,0.30434782608695654,60,0.07527939857571155,False,2,True,0,,CHEMBL6040153,27.0,nM,=,7.57,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5686,1,active,MW=829.0 > 500.0; LogP=9.74 > 5.0
8d04a043,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000001,812.2992187479999,9.106500000000002,168.79,3,10,13,9,6,0.28888888888888886,59,0.0755570295485051,False,2,True,0,,CHEMBL5876808,59.0,nM,=,7.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2291,1,active,MW=812.9 > 500.0; LogP=9.11 > 5.0
22ab5910,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3c3ccccc3[N+](=O)[O-])cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,817.8810000000002,817.2529968279999,8.137300000000007,211.92999999999998,3,12,13,8,6,0.23809523809523808,59,0.07446037185888814,False,3,True,0,,CHEMBL5900945,29.0,nM,=,7.54,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5376,1,active,MW=817.9 > 500.0; LogP=8.14 > 5.0; HBA=12 > 10
62da7b3f,,CN(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,815.9529999999999,815.3101177799999,8.295100000000007,172.03,3,11,13,8,6,0.2727272727272727,59,0.07566266918349655,False,3,True,0,,CHEMBL5836637,8.5,nM,=,8.07,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0706,1,active,MW=816.0 > 500.0; LogP=8.30 > 5.0; HBA=11 > 10
eebd8554,,CS(=O)(=O)Nc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,865.9909999999998,865.256367956,7.600600000000007,214.95999999999995,4,12,14,8,6,0.2558139534883721,61,0.06153600908524515,False,3,True,0,,CHEMBL5938561,18.0,nM,=,7.75,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7447,1,active,MW=866.0 > 500.0; LogP=7.60 > 5.0; HBA=12 > 10
11aadb88,,CN1CC=C(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,868.0289999999997,867.3414179079999,8.948000000000004,172.03,3,11,13,9,6,0.2916666666666667,63,0.07476440221751503,False,3,True,0,,CHEMBL5804195,3.9,nM,=,8.41,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4089,1,active,MW=868.0 > 500.0; LogP=8.95 > 5.0; HBA=11 > 10
d1438228,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(F)CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.939,830.2897969359999,9.054500000000003,168.79,3,10,13,9,6,0.28888888888888886,60,0.0754367740246174,False,2,True,0,,CHEMBL5889012,2.9,nM,=,8.54,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.5376,1,active,MW=830.9 > 500.0; LogP=9.05 > 5.0
0baf6b8c,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(Cl)CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,847.3939999999999,846.260246396,9.3238,168.79,3,10,13,9,6,0.28888888888888886,60,0.05786966408107407,False,2,True,0,,CHEMBL5834695,5.3,nM,=,8.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2757,1,active,MW=847.4 > 500.0; LogP=9.32 > 5.0
b627ee3c,,COC1CC(c2ccccc2C2CC2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,842.9749999999997,842.309783432,8.731400000000004,178.02,3,11,14,9,6,0.30434782608695654,61,0.07057249112587281,False,3,True,0,,CHEMBL5899122,17.0,nM,=,7.77,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7696,1,active,MW=843.0 > 500.0; LogP=8.73 > 5.0; HBA=11 > 10
67713046,,CC1CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1c1ccccc1C1CC1,,,raw,,826.9760000000001,826.3148688119999,9.3525,168.79,3,10,13,9,6,0.30434782608695654,60,0.07536610184612778,False,2,True,0,,CHEMBL5967713,5.2,nM,=,8.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.284,1,active,MW=827.0 > 500.0; LogP=9.35 > 5.0
91651d37,,CC1(C)CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1c1ccccc1C1CC1,,,raw,,841.003,840.3305188759998,9.742599999999996,168.79,3,10,13,9,6,0.3191489361702128,61,0.07520196092479244,False,2,True,0,,CHEMBL5982840,23.0,nM,=,7.64,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6383,1,active,MW=841.0 > 500.0; LogP=9.74 > 5.0
ddd10b56,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,736.8510000000001,736.2679186199999,7.266400000000007,168.79,3,10,12,8,5,0.3333333333333333,53,0.08752685465821687,False,2,True,0,,CHEMBL6006767,56.0,nM,=,7.25,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2518,1,active,MW=736.9 > 500.0; LogP=7.27 > 5.0
f363b137,,CCC1CCCCC1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,806.986,806.34616894,9.072800000000004,168.79,3,10,13,8,5,0.4090909090909091,58,0.07709977274804301,False,2,True,0,,CHEMBL5848564,186.0,nM,=,6.73,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.7305,1,active,MW=807.0 > 500.0; LogP=9.07 > 5.0
2cb8c3e7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cnccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.937,813.2944677159999,8.501500000000007,181.68000000000004,3,11,13,9,6,0.29545454545454547,59,0.0751211216245136,False,3,True,0,,CHEMBL6022796,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8239,1,active,MW=813.9 > 500.0; LogP=8.50 > 5.0; HBA=11 > 10
196af93c,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccnn3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,802.914,802.2897166839999,7.7605000000000075,186.61000000000004,3,12,13,9,6,0.30952380952380953,58,0.07653625844254566,False,3,True,0,,CHEMBL5938623,43.0,nM,=,7.37,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3665,1,active,MW=802.9 > 500.0; LogP=7.76 > 5.0; HBA=12 > 10
2cb5fe84,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(Cl)c3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,847.394,846.260246396,9.759899999999996,168.79,3,10,13,9,6,0.28888888888888886,60,0.07516385254367004,False,2,True,0,,CHEMBL5858367,283.0,nM,=,6.55,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.5482,1,active,MW=847.4 > 500.0; LogP=9.76 > 5.0
fd017eca,,Cc1ccc(C2CC2)c(C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)c1,,,raw,,826.9759999999999,826.314868812,9.41492,168.79,3,10,13,9,6,0.30434782608695654,60,0.07535105705467213,False,2,True,0,,CHEMBL6024224,125.0,nM,=,6.9,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9031,1,active,MW=827.0 > 500.0; LogP=9.41 > 5.0
e0eae061,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,786.9110000000003,786.283568684,8.224700000000007,168.79,3,10,13,8,6,0.2558139534883721,57,0.07661758696808324,False,2,True,0,,CHEMBL5828646,49.0,nM,=,7.31,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.3098,1,active,MW=786.9 > 500.0; LogP=8.22 > 5.0
1834a3ae,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,821.3560000000002,820.244596332,8.878100000000003,168.79,3,10,13,8,6,0.2558139534883721,58,0.07559405308852671,False,2,True,0,,CHEMBL6057930,83.0,nM,=,7.08,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.0809,1,active,MW=821.4 > 500.0; LogP=8.88 > 5.0
dff43327,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3CCCN3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,791.931,791.3101177799999,6.978700000000008,172.03,3,11,13,8,5,0.3333333333333333,57,0.08302382182963228,False,3,True,0,,CHEMBL5919993,95.0,nM,=,7.02,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.0223,1,active,MW=791.9 > 500.0; LogP=6.98 > 5.0; HBA=11 > 10
3e03724f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccc(Cl)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,821.3560000000002,820.244596332,8.878100000000003,168.79,3,10,13,8,6,0.2558139534883721,58,0.07559405308852671,False,2,True,0,,CHEMBL5793276,141.0,nM,=,6.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,6.8508,1,active,MW=821.4 > 500.0; LogP=8.88 > 5.0
e3c0f662,,CC1(C)CCC(Cc2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)=C(c2ccc(Cl)cc2)C1,,,raw,,860.4330000000001,859.280647492,10.747399999999992,165.54999999999998,3,9,13,8,6,0.2765957446808511,61,0.07566655334116162,False,2,True,0,,CHEMBL5839944,17.0,nM,=,7.77,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.7696,1,active,MW=860.4 > 500.0; LogP=10.75 > 5.0
9c3e488e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(C(=O)C3CCCN3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,805.9139999999999,805.2893823359999,6.505300000000007,189.1,3,11,12,8,5,0.30952380952380953,58,0.09217809588537369,False,3,True,0,,CHEMBL5783061,64.0,nM,=,7.19,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.1938,1,active,MW=805.9 > 500.0; LogP=6.51 > 5.0; HBA=11 > 10
a873a062,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(CN3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.012,833.3570679719999,8.151500000000008,172.03,3,11,14,9,5,0.4222222222222222,60,0.07284696593017362,False,3,True,0,,CHEMBL5893602,2.2,nM,=,8.66,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.6576,1,active,MW=834.0 > 500.0; LogP=8.15 > 5.0; HBA=11 > 10
077ecd03,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCC[C@H]3c3cccc(C4CC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.9760000000001,826.314868812,9.102100000000002,168.79,3,10,14,9,6,0.30434782608695654,60,0.07115586014464566,False,2,True,0,,CHEMBL5845601,94.5,nM,=,7.05,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.0246,1,active,MW=827.0 > 500.0; LogP=9.10 > 5.0
0cf6c5e0,,COC(=O)c1ccc(C2=CCC(N3CCCC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,493.6070000000002,493.2365418520001,6.914800000000007,67.44999999999999,1,5,6,6,4,0.2903225806451613,37,0.29553921126929883,True,1,True,0,,CHEMBL5868833,5.9,nM,=,8.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2291,1,active,LogP=6.91 > 5.0
ea360159,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Br)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,855.8120000000001,854.2097308159999,8.756100000000004,168.79,3,10,12,8,5,0.3333333333333333,57,0.08151522751007001,False,2,True,0,,CHEMBL5905439,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=855.8 > 500.0; LogP=8.76 > 5.0
c488591f,,COC(=O)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,533.6720000000003,533.2678419800001,7.7922000000000065,67.44999999999999,1,5,7,7,4,0.35294117647058826,40,0.2456374499434789,False,2,True,0,,CHEMBL5953429,7.3,nM,=,8.14,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,3,8.1367,1,active,MW=533.7 > 500.0; LogP=7.79 > 5.0
189e3046,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,816.981,816.3305188759999,8.871000000000006,168.79,3,10,13,9,5,0.37777777777777777,59,0.07710761536380115,False,2,True,0,,CHEMBL5841782,7.9,nM,=,8.1,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.1024,1,active,MW=817.0 > 500.0; LogP=8.87 > 5.0
7e2310ad,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccnc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,777.9040000000001,777.2944677159999,7.388600000000008,181.68000000000004,3,11,12,8,5,0.34146341463414637,56,0.08488556575322842,False,3,True,0,,CHEMBL5997904,53.0,nM,=,7.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2757,1,active,MW=777.9 > 500.0; LogP=7.39 > 5.0; HBA=11 > 10
f97e291b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,790.9430000000001,790.314868812,7.863600000000009,168.79,3,10,13,8,5,0.3488372093023256,57,0.07886922258902405,False,2,True,0,,CHEMBL5908012,24.0,nM,=,7.62,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6198,1,active,MW=790.9 > 500.0; LogP=7.86 > 5.0
ec7bb1bc,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccn3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,777.9040000000001,777.2944677159999,7.388600000000008,181.68000000000004,3,11,12,8,5,0.34146341463414637,56,0.08488556575322842,False,3,True,0,,CHEMBL5976895,30.0,nM,=,7.52,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5229,1,active,MW=777.9 > 500.0; LogP=7.39 > 5.0; HBA=11 > 10
771b6189,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3-c3ccoc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,842.9750000000001,842.309783432,9.2536,181.93000000000004,3,11,13,9,6,0.30434782608695654,61,0.07445735078299957,False,3,True,0,,CHEMBL5932525,58.0,nM,=,7.24,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2366,1,active,MW=843.0 > 500.0; LogP=9.25 > 5.0; HBA=11 > 10
263b54ce,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,811.3610000000001,810.260246396,8.647000000000006,168.79,3,10,12,8,5,0.3333333333333333,57,0.08192803710724877,False,2,True,0,,CHEMBL5936446,26.0,nM,=,7.58,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.585,1,active,MW=811.4 > 500.0; LogP=8.65 > 5.0
697639bb,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C(F)(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,844.9130000000002,844.2866033759999,9.012400000000003,168.79,3,10,12,8,5,0.3488372093023256,60,0.08141937643005455,False,2,True,0,,CHEMBL5920168,31.0,nM,=,7.51,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5086,1,active,MW=844.9 > 500.0; LogP=9.01 > 5.0
83cab123,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4ccccc34)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.9760000000001,826.314868812,9.146800000000002,168.79,3,10,12,9,6,0.30434782608695654,60,0.07992683403938548,False,2,True,0,,CHEMBL5815573,89.0,nM,=,7.05,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0506,1,active,MW=827.0 > 500.0; LogP=9.15 > 5.0
ad359952,,CC1(C)CC(c2ccccc2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,804.9699999999998,804.3305188759999,8.629700000000003,168.79,3,10,12,8,5,0.36363636363636365,58,0.08201034098312791,False,2,True,0,,CHEMBL5910978,226.0,nM,=,6.65,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.6459,1,active,MW=805.0 > 500.0; LogP=8.63 > 5.0
351749cb,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(Cl)cccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,845.806,844.2212740440001,9.300400000000002,168.79,3,10,12,8,5,0.3333333333333333,58,0.08130272179349401,False,2,True,0,,CHEMBL5791810,78.0,nM,=,7.11,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.1079,1,active,MW=845.8 > 500.0; LogP=9.30 > 5.0
faf1c034,,CCCc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,818.9969999999997,818.34616894,8.946100000000003,168.79,3,10,14,8,5,0.37777777777777777,59,0.07266838975952596,False,2,True,0,,CHEMBL5756431,18.0,nM,=,7.75,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7447,1,active,MW=819.0 > 500.0; LogP=8.95 > 5.0
798825a0,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3-c3cccs3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,859.0430000000001,858.286939812,9.7221,168.79,3,11,13,9,6,0.30434782608695654,61,0.07511155159176944,False,3,True,0,,CHEMBL5741586,62.0,nM,=,7.21,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2076,1,active,MW=859.0 > 500.0; LogP=9.72 > 5.0; HBA=11 > 10
eeead587,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,867.041,866.34616894,9.584399999999999,168.79,3,10,14,9,6,0.30612244897959184,63,0.07082866837130267,False,2,True,0,,CHEMBL5954289,57.0,nM,=,7.24,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2441,1,active,MW=867.0 > 500.0; LogP=9.58 > 5.0
65488d8d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccncc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,777.9040000000001,777.2944677159999,7.388600000000008,181.68000000000004,3,11,12,8,5,0.34146341463414637,56,0.08488556575322842,False,3,True,0,,CHEMBL5998503,124.0,nM,=,6.91,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9066,1,active,MW=777.9 > 500.0; LogP=7.39 > 5.0; HBA=11 > 10
6e99bf25,,CC(C)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,818.9969999999997,818.34616894,9.117000000000003,168.79,3,10,13,8,5,0.37777777777777777,59,0.07697245999988017,False,2,True,0,,CHEMBL6016863,21.0,nM,=,7.68,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6778,1,active,MW=819.0 > 500.0; LogP=9.12 > 5.0
0857c750,,C=C(C)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,816.9809999999997,816.3305188759999,9.026700000000002,168.79,3,10,13,8,5,0.3333333333333333,59,0.0770272989834693,False,2,True,0,,CHEMBL5875766,28.0,nM,=,7.55,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5528,1,active,MW=817.0 > 500.0; LogP=9.03 > 5.0
0f0ce943,,CC(C)Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,833.0239999999997,832.3618190039999,9.192100000000003,168.79,3,10,14,8,5,0.391304347826087,60,0.07247073099835709,False,2,True,0,,CHEMBL5857178,49.0,nM,=,7.31,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3098,1,active,MW=833.0 > 500.0; LogP=9.19 > 5.0
1df8a312,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3CC3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,8.946100000000005,168.79,3,10,14,9,5,0.391304347826087,60,0.07258178074759532,False,2,True,0,,CHEMBL5748708,60.0,nM,=,7.22,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2218,1,active,MW=831.0 > 500.0; LogP=8.95 > 5.0
3dc3131a,,N#C[C@H]1C[C@H]1c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,841.9909999999996,841.3257678439999,8.620680000000004,192.58,3,11,13,9,5,0.3695652173913043,61,0.07593285006718933,False,3,True,0,,CHEMBL5982871,3.0,nM,=,8.52,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.5229,1,active,MW=842.0 > 500.0; LogP=8.62 > 5.0; HBA=11 > 10
a8abb269,,N#C[C@H]1C[C@@H]1c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,841.9909999999996,841.3257678439999,8.620680000000004,192.58,3,11,13,9,5,0.3695652173913043,61,0.07593285006718933,False,3,True,0,,CHEMBL5826225,20.0,nM,=,7.7,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.699,1,active,MW=842.0 > 500.0; LogP=8.62 > 5.0; HBA=11 > 10
cd311eb3,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3[C@H]3CC3(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,852.9610000000001,852.311675252,9.116200000000003,168.79,3,10,13,9,5,0.37777777777777777,61,0.07675034148055737,False,2,True,0,,CHEMBL5869282,32.0,nM,=,7.5,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4949,1,active,MW=853.0 > 500.0; LogP=9.12 > 5.0
e88e441e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3[C@@H]3CC3(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,852.9610000000001,852.311675252,9.116200000000003,168.79,3,10,13,9,5,0.37777777777777777,61,0.07675034148055737,False,2,True,0,,CHEMBL5890286,62.0,nM,=,7.21,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2076,1,active,MW=853.0 > 500.0; LogP=9.12 > 5.0
7094a87b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,9.261100000000003,168.79,3,10,13,9,5,0.391304347826087,60,0.0768312950686333,False,2,True,0,,CHEMBL5834233,29.0,nM,=,7.54,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5376,1,active,MW=831.0 > 500.0; LogP=9.26 > 5.0
17875c62,,CN(C)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,819.9849999999997,819.3414179079999,8.059600000000009,172.03,3,11,13,8,5,0.36363636363636365,59,0.07752737119849594,False,3,True,0,,CHEMBL6006213,3.3,nM,=,8.48,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4815,1,active,MW=820.0 > 500.0; LogP=8.06 > 5.0; HBA=11 > 10
f3a9e8e3,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3OC(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,842.9220000000003,842.290939808,8.595000000000006,178.02,3,11,14,8,5,0.3488372093023256,60,0.07205341920537256,False,3,True,0,,CHEMBL5957647,41.0,nM,=,7.39,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3872,1,active,MW=842.9 > 500.0; LogP=8.60 > 5.0; HBA=11 > 10
d8e8abce,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3OC(F)(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,860.9120000000003,860.2815179959999,8.892200000000003,178.02,3,11,13,8,5,0.3488372093023256,61,0.07609068107923457,False,3,True,0,,CHEMBL5874645,51.0,nM,=,7.29,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2924,1,active,MW=860.9 > 500.0; LogP=8.89 > 5.0; HBA=11 > 10
6e8019ed,,CCCOc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,834.9959999999996,834.34108356,8.782400000000003,178.02,3,11,15,8,5,0.37777777777777777,60,0.06784087660000884,False,3,True,0,,CHEMBL6063832,19.0,nM,=,7.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7212,1,active,MW=835.0 > 500.0; LogP=8.78 > 5.0; HBA=11 > 10
71da5397,,COCCOc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,850.9949999999997,850.3359981800002,8.018800000000008,187.24999999999997,3,12,16,8,5,0.37777777777777777,61,0.049385673963107,False,3,True,0,,CHEMBL5780526,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=851.0 > 500.0; LogP=8.02 > 5.0; HBA=12 > 10
6148237d,,CC(C)Oc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,834.9959999999996,834.34108356,8.780800000000003,178.02,3,11,14,8,5,0.37777777777777777,60,0.07196126147901943,False,3,True,0,,CHEMBL6059936,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=835.0 > 500.0; LogP=8.78 > 5.0; HBA=11 > 10
3690b535,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3OC3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,832.98,832.325433496,8.534800000000008,178.02,3,11,14,9,5,0.37777777777777777,60,0.07216685705031008,False,3,True,0,,CHEMBL5971182,18.0,nM,=,7.75,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7447,1,active,MW=833.0 > 500.0; LogP=8.53 > 5.0; HBA=11 > 10
52c6181d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(Cl)cccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,851.4259999999999,850.291546524,9.5244,168.79,3,10,13,9,5,0.37777777777777777,60,0.07664441629346877,False,2,True,0,,CHEMBL5983625,48.0,nM,=,7.32,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3188,1,active,MW=851.4 > 500.0; LogP=9.52 > 5.0
5add72b3,,Cc1cccc(C)c1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,804.9699999999998,804.3305188759999,8.610440000000004,168.79,3,10,12,8,5,0.36363636363636365,58,0.0820285160613656,False,2,True,0,,CHEMBL5955049,30.0,nM,=,7.52,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5229,1,active,MW=805.0 > 500.0; LogP=8.61 > 5.0
1aeec3be,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(F)c3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,829.3510000000001,828.250824584,8.786100000000005,168.79,3,10,12,8,5,0.3333333333333333,58,0.08165941496905028,False,2,True,0,,CHEMBL5862498,222.0,nM,=,6.65,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.6536,1,active,MW=829.4 > 500.0; LogP=8.79 > 5.0
0cc10046,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(Cl)c3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,845.806,844.2212740440001,9.300400000000002,168.79,3,10,12,8,5,0.3333333333333333,58,0.08130272179349401,False,2,True,0,,CHEMBL6018319,117.0,nM,=,6.93,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9318,1,active,MW=845.8 > 500.0; LogP=9.30 > 5.0
637ec8c1,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(Cl)c3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,851.4259999999999,850.291546524,9.5244,168.79,3,10,13,9,5,0.37777777777777777,60,0.07664441629346877,False,2,True,0,,CHEMBL5833010,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=851.4 > 500.0; LogP=9.52 > 5.0
a1a18262,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(F)c3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.971,834.3210970639999,9.010100000000003,168.79,3,10,13,9,5,0.37777777777777777,60,0.07689915938728803,False,2,True,0,,CHEMBL5835008,92.0,nM,=,7.04,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0362,1,active,MW=835.0 > 500.0; LogP=9.01 > 5.0
b3898b91,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(F)cc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.971,834.3210970639999,9.010100000000003,168.79,3,10,13,9,5,0.37777777777777777,60,0.07689915938728803,False,2,True,0,,CHEMBL5969360,23.0,nM,=,7.64,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6383,1,active,MW=835.0 > 500.0; LogP=9.01 > 5.0
364a938d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(F)ccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.971,834.3210970639999,9.010100000000003,168.79,3,10,13,9,5,0.37777777777777777,60,0.07689915938728803,False,2,True,0,,CHEMBL5862976,41.0,nM,=,7.39,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3872,1,active,MW=835.0 > 500.0; LogP=9.01 > 5.0
ee66cbd3,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(F)cccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.971,834.3210970639999,9.010100000000003,168.79,3,10,13,9,5,0.37777777777777777,60,0.07689915938728803,False,2,True,0,,CHEMBL5932341,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=835.0 > 500.0; LogP=9.01 > 5.0
4f6bb232,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3sccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,823.01,822.286939812,8.932500000000005,168.79,3,11,13,9,5,0.3953488372093023,58,0.07702376656218544,False,3,True,0,,CHEMBL6063626,30.0,nM,=,7.52,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5229,1,active,MW=823.0 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
f703245c,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3C3CCCCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,782.9639999999998,782.34616894,8.201200000000007,168.79,3,10,12,8,4,0.47619047619047616,56,0.09410129899097848,False,2,True,0,,CHEMBL5901849,7.3,nM,=,8.14,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1367,1,active,MW=783.0 > 500.0; LogP=8.20 > 5.0
59acda46,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4ccsc34)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,833.0050000000001,832.271289748,9.208300000000001,168.79,3,11,12,9,6,0.3181818181818182,59,0.07986012068400465,False,3,True,0,,CHEMBL5928106,147.0,nM,=,6.83,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.8327,1,active,MW=833.0 > 500.0; LogP=9.21 > 5.0; HBA=11 > 10
db748988,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3C#Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,800.9380000000001,800.2992187479999,7.672600000000008,168.79,3,10,11,8,5,0.3181818181818182,58,0.06849112498316805,False,2,True,0,,CHEMBL6057270,69.0,nM,=,7.16,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.1612,1,active,MW=800.9 > 500.0; LogP=7.67 > 5.0
82a1889c,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CCNCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,860.0499999999998,859.3727180359999,8.460600000000007,180.82000000000002,4,11,13,9,5,0.40425531914893614,62,0.06589962679333776,False,3,True,0,,CHEMBL5940828,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=860.0 > 500.0; LogP=8.46 > 5.0; HBA=11 > 10
0bbbf05f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Oc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,869.0130000000001,868.325433496,9.785899999999998,178.02,3,11,14,9,6,0.2916666666666667,63,0.07012388005591068,False,3,True,0,,CHEMBL5968888,110.0,nM,=,6.96,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9586,1,active,MW=869.0 > 500.0; LogP=9.79 > 5.0; HBA=11 > 10
86c15033,,COc1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,847.0069999999996,846.34108356,8.879600000000003,178.02,3,11,14,9,5,0.391304347826087,61,0.07183569092719332,False,3,True,0,,CHEMBL5740413,28.0,nM,=,7.55,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5528,1,active,MW=847.0 > 500.0; LogP=8.88 > 5.0; HBA=11 > 10
8eef120c,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC=CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.9649999999999,814.314868812,8.647000000000006,168.79,3,10,13,9,5,0.3333333333333333,59,0.059437599906096664,False,2,True,0,,CHEMBL5854884,18.0,nM,=,7.75,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7447,1,active,MW=815.0 > 500.0; LogP=8.65 > 5.0
f58f26f6,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3Cc4ccccc4C3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,865.0249999999999,864.3305188759999,9.6391,168.79,3,10,13,10,6,0.30612244897959184,63,0.07509781854285819,False,2,True,0,,CHEMBL5967423,96.0,nM,=,7.02,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0177,1,active,MW=865.0 > 500.0; LogP=9.64 > 5.0
0edc5b9d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(O)CC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,792.915,792.2941333679998,6.9644000000000075,189.02,4,11,12,8,5,0.3333333333333333,57,0.07549449930565534,False,3,True,0,,CHEMBL5935001,11.0,nM,=,7.96,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9586,1,active,MW=792.9 > 500.0; LogP=6.96 > 5.0; HBA=11 > 10
81522c9a,,CO[C@@H]1CC(c2ccccc2C2CC2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,847.0069999999996,846.34108356,8.495900000000006,178.02,3,11,14,9,5,0.391304347826087,61,0.07212455977081705,False,3,True,0,,CHEMBL6007118,20.0,nM,=,7.7,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.699,1,active,MW=847.0 > 500.0; LogP=8.50 > 5.0; HBA=11 > 10
e836e0c3,,CO[C@H]1CC(c2ccccc2C2CC2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,847.0069999999996,846.34108356,8.495900000000006,178.02,3,11,14,9,5,0.391304347826087,61,0.07212455977081705,False,3,True,0,,CHEMBL5992113,26.0,nM,=,7.58,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.585,1,active,MW=847.0 > 500.0; LogP=8.50 > 5.0; HBA=11 > 10
5c5c7676,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(F)CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.9709999999998,834.3210970639999,8.819000000000006,168.79,3,10,13,9,5,0.37777777777777777,60,0.07700354577715976,False,2,True,0,,CHEMBL5795683,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8239,1,active,MW=835.0 > 500.0; LogP=8.82 > 5.0
67bd8c5d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(F)(F)CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,852.9609999999998,852.311675252,9.116200000000003,168.79,3,10,13,9,5,0.37777777777777777,61,0.07675034148055737,False,2,True,0,,CHEMBL5947397,63.0,nM,=,7.2,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2007,1,active,MW=853.0 > 500.0; LogP=9.12 > 5.0
02cb34c2,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,762.8890000000001,762.283568684,7.6035000000000075,168.79,3,10,12,8,5,0.3170731707317073,55,0.08501247971242921,False,2,True,0,,CHEMBL5999290,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8239,1,active,MW=762.9 > 500.0; LogP=7.60 > 5.0
2caa1c24,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3Cc3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,8.741000000000005,168.79,3,10,14,9,5,0.391304347826087,60,0.0727009029581012,False,2,True,0,,CHEMBL5775752,11.0,nM,=,7.96,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9586,1,active,MW=831.0 > 500.0; LogP=8.74 > 5.0
1017d60f,,Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,790.9429999999999,790.314868812,8.302020000000006,168.79,3,10,12,8,5,0.3488372093023256,57,0.08258273660399956,False,2,True,0,,CHEMBL5791517,13.0,nM,=,7.89,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8861,1,active,MW=790.9 > 500.0; LogP=8.30 > 5.0
4a07caee,,CCc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,804.9699999999998,804.3305188759999,8.556000000000004,168.79,3,10,13,8,5,0.36363636363636365,58,0.07746363327354498,False,2,True,0,,CHEMBL6010468,3.7,nM,=,8.43,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4318,1,active,MW=805.0 > 500.0; LogP=8.56 > 5.0
ff1fd4c0,,C=Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,802.9539999999997,802.314868812,8.636600000000003,168.79,3,10,13,8,5,0.3181818181818182,58,0.07740998538337186,False,2,True,0,,CHEMBL5830005,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=803.0 > 500.0; LogP=8.64 > 5.0
1593bc98,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(F)cc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,829.3510000000001,828.250824584,8.786100000000005,168.79,3,10,12,8,5,0.3333333333333333,58,0.08165941496905028,False,2,True,0,,CHEMBL5819835,58.0,nM,=,7.24,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2366,1,active,MW=829.4 > 500.0; LogP=8.79 > 5.0
fe81e213,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(Cl)cccc3Br)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,890.2570000000001,888.1707584640001,9.4095,168.79,3,10,12,8,5,0.3333333333333333,58,0.08108063981579088,False,2,True,0,,CHEMBL5820024,92.0,nM,=,7.04,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0362,1,active,MW=890.3 > 500.0; LogP=9.41 > 5.0
d9160c6a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3C3CCCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,768.9369999999999,768.3305188759999,7.811100000000009,168.79,3,10,12,8,4,0.4634146341463415,55,0.09549059598661674,False,2,True,0,,CHEMBL5848464,19.0,nM,=,7.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7212,1,active,MW=768.9 > 500.0; LogP=7.81 > 5.0
9eca6906,,CCCCc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,833.0239999999997,832.3618190039999,9.336200000000002,168.79,3,10,15,8,5,0.391304347826087,60,0.068283471167188,False,2,True,0,,CHEMBL5898424,50.0,nM,=,7.3,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.301,1,active,MW=833.0 > 500.0; LogP=9.34 > 5.0
f8eb40e5,,CC(C)Oc1ccc(Br)cc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,913.8919999999996,912.251595628,9.5433,178.02,3,11,14,8,5,0.37777777777777777,61,0.07140454314532628,False,3,True,0,,CHEMBL6007921,756.0,nM,=,6.12,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.1215,1,active,MW=913.9 > 500.0; LogP=9.54 > 5.0; HBA=11 > 10
3f6fa78c,,Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,790.943,790.314868812,8.302020000000006,168.79,3,10,12,8,5,0.3488372093023256,57,0.08258273660399956,False,2,True,0,,CHEMBL6020371,8.7,nM,=,8.06,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0605,1,active,MW=790.9 > 500.0; LogP=8.30 > 5.0
35dd7194,,CC(C)c1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,818.9969999999997,818.34616894,9.117,168.79,3,10,13,8,5,0.37777777777777777,59,0.07697245999988017,False,2,True,0,,CHEMBL6011371,11.0,nM,=,7.96,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9586,1,active,MW=819.0 > 500.0; LogP=9.12 > 5.0
b2070e84,,COc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,806.9419999999999,806.309783432,8.002200000000007,178.02,3,11,13,8,5,0.3488372093023256,58,0.07758135309018387,False,3,True,0,,CHEMBL5794713,16.0,nM,=,7.8,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7959,1,active,MW=806.9 > 500.0; LogP=8.00 > 5.0; HBA=11 > 10
062971c3,,N#Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,801.9259999999998,801.2944677159999,7.865280000000007,192.58,3,11,12,8,5,0.32558139534883723,58,0.0821563465001865,False,3,True,0,,CHEMBL6034421,174.0,nM,=,6.76,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.7595,1,active,MW=801.9 > 500.0; LogP=7.87 > 5.0; HBA=11 > 10
b29e3ba5,,C=Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,802.9539999999998,802.314868812,8.636600000000003,168.79,3,10,13,8,5,0.3181818181818182,58,0.07740998538337186,False,2,True,0,,CHEMBL5876206,28.0,nM,=,7.55,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5528,1,active,MW=803.0 > 500.0; LogP=8.64 > 5.0
872103e5,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4c3OCO4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,820.9250000000001,820.289047988,7.722300000000008,187.24999999999997,3,12,12,9,5,0.3488372093023256,59,0.0822915119731436,False,3,True,0,,CHEMBL5787141,27.0,nM,=,7.57,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5686,1,active,MW=820.9 > 500.0; LogP=7.72 > 5.0; HBA=12 > 10
2df19db0,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4c3OC(F)(F)O4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,856.9050000000002,856.270204364,8.315100000000006,187.24999999999997,3,12,12,9,5,0.3488372093023256,61,0.08059406238517756,False,3,True,0,,CHEMBL5879749,135.0,nM,=,6.87,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.8697,1,active,MW=856.9 > 500.0; LogP=8.32 > 5.0; HBA=12 > 10
25755e26,,CC1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,raw,,831.0079999999999,830.3461689399999,9.117,168.79,3,10,13,9,5,0.391304347826087,60,0.07688072122971448,False,2,True,0,,CHEMBL5861984,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=831.0 > 500.0; LogP=9.12 > 5.0
f9dbe50d,,CC1(C)CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,raw,,845.035,844.3618190039998,9.5071,168.79,3,10,13,9,5,0.40425531914893614,61,0.07668227158435162,False,2,True,0,,CHEMBL5980151,34.0,nM,=,7.47,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4685,1,active,MW=845.0 > 500.0; LogP=9.51 > 5.0
37a7c8fd,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(Cl)cc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,851.4259999999999,850.291546524,9.5244,168.79,3,10,13,9,5,0.37777777777777777,60,0.07664441629346877,False,2,True,0,,CHEMBL5892515,59.0,nM,=,7.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2291,1,active,MW=851.4 > 500.0; LogP=9.52 > 5.0
a4c9e870,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(Cl)ccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,851.4259999999999,850.291546524,9.5244,168.79,3,10,13,9,5,0.37777777777777777,60,0.07664441629346877,False,2,True,0,,CHEMBL6021718,80.0,nM,=,7.1,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0969,1,active,MW=851.4 > 500.0; LogP=9.52 > 5.0
3f945f55,,CC(F)(F)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,840.9499999999997,840.311675252,9.105300000000003,168.79,3,10,13,8,5,0.36363636363636365,60,0.07682078746631589,False,2,True,0,,CHEMBL5748367,45.0,nM,=,7.35,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3468,1,active,MW=840.9 > 500.0; LogP=9.11 > 5.0
194258f9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3CC(F)(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,858.9400000000002,858.30225344,9.098400000000002,168.79,3,10,13,8,5,0.36363636363636365,61,0.07672855191333558,False,2,True,0,,CHEMBL5814085,79.0,nM,=,7.1,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.1024,1,active,MW=858.9 > 500.0; LogP=9.10 > 5.0
cb27e624,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CCCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,845.0349999999999,844.3618190039999,9.651200000000001,168.79,3,10,13,9,5,0.40425531914893614,61,0.0766569271315654,False,2,True,0,,CHEMBL5912154,93.0,nM,=,7.03,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0315,1,active,MW=845.0 > 500.0; LogP=9.65 > 5.0
ee778317,,CC1(C)Oc2cccc(C3CCCN3C3CC=C(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)c2O1,,,raw,,848.9789999999997,848.320348116,8.500900000000005,187.25,3,12,12,9,5,0.37777777777777777,61,0.08039290668399957,False,3,True,0,,CHEMBL5967521,51.0,nM,=,7.29,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2924,1,active,MW=849.0 > 500.0; LogP=8.50 > 5.0; HBA=12 > 10
89266d02,,C#Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,800.9379999999999,800.2992187479999,7.974900000000008,168.79,3,10,12,8,5,0.3181818181818182,58,0.06393368164554744,False,2,True,0,,CHEMBL5843645,90.0,nM,=,7.05,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0458,1,active,MW=800.9 > 500.0; LogP=7.97 > 5.0
78c783b9,,N#CC1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,raw,,841.991,841.3257678439999,8.620680000000004,192.58,3,11,13,9,5,0.3695652173913043,61,0.07593285006718933,False,3,True,0,,CHEMBL5823455,16.0,nM,=,7.8,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7959,1,active,MW=842.0 > 500.0; LogP=8.62 > 5.0; HBA=11 > 10
4cf0b6db,,C#CC1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,raw,,841.003,840.3305188759998,8.730300000000003,168.79,3,10,13,9,5,0.3617021276595745,61,0.05923923327089936,False,2,True,0,,CHEMBL6063904,21.0,nM,=,7.68,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6778,1,active,MW=841.0 > 500.0; LogP=8.73 > 5.0
f4dbd22e,,COc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,806.9419999999998,806.309783432,8.002200000000007,178.02,3,11,13,8,5,0.3488372093023256,58,0.07758135309018387,False,3,True,0,,CHEMBL6037680,6.7,nM,=,8.17,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1739,1,active,MW=806.9 > 500.0; LogP=8.00 > 5.0; HBA=11 > 10
c77316a0,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3csc4ccccc34)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,833.0050000000001,832.271289748,9.208300000000001,168.79,3,11,12,9,6,0.3181818181818182,59,0.07986012068400465,False,3,True,0,,CHEMBL6058162,72.0,nM,=,7.14,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.1427,1,active,MW=833.0 > 500.0; LogP=9.21 > 5.0; HBA=11 > 10
f60baebf,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC(c4ccccc4Cl)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,811.361,810.260246396,8.299400000000006,168.79,3,10,12,8,5,0.3333333333333333,57,0.0823496575593803,False,2,True,0,,CHEMBL5758771,92.0,nM,=,7.04,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0362,1,active,MW=811.4 > 500.0; LogP=8.30 > 5.0
6a4dea31,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(C4CC4)ccc3F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.971,834.3210970639999,9.010100000000003,168.79,3,10,13,9,5,0.37777777777777777,60,0.07689915938728803,False,2,True,0,,CHEMBL5747296,17.0,nM,=,7.77,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7696,1,active,MW=835.0 > 500.0; LogP=9.01 > 5.0
2f6e49d9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(C4CC4)ccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,851.4259999999999,850.291546524,9.5244,168.79,3,10,13,9,5,0.37777777777777777,60,0.07664441629346877,False,2,True,0,,CHEMBL5770314,52.0,nM,=,7.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.284,1,active,MW=851.4 > 500.0; LogP=9.52 > 5.0
9da22981,,Cc1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,831.0079999999997,830.34616894,9.179420000000002,168.79,3,10,13,9,5,0.391304347826087,60,0.07685781882987434,False,2,True,0,,CHEMBL6033879,6.4,nM,=,8.19,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1938,1,active,MW=831.0 > 500.0; LogP=9.18 > 5.0
f019d0bc,,CN(C)CCN(C)c1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,917.1459999999996,916.43056726,8.868800000000004,175.27,3,12,17,9,5,0.44,66,0.059801560130546154,False,3,True,0,,CHEMBL5743310,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8239,1,active,MW=917.1 > 500.0; LogP=8.87 > 5.0; HBA=12 > 10
fdb6ead2,,CN(C)CCNc1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,raw,,903.1189999999996,902.414917196,8.844500000000004,184.05999999999997,4,12,17,9,5,0.42857142857142855,65,0.05145374118363563,False,3,True,0,,CHEMBL5934655,5.2,nM,=,8.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.284,1,active,MW=903.1 > 500.0; LogP=8.84 > 5.0; HBA=12 > 10
70f2f096,,CC/C=C/c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,831.0079999999996,830.34616894,9.4168,168.79,3,10,14,8,5,0.34782608695652173,60,0.07242386611383703,False,2,True,0,,CHEMBL5805896,121.0,nM,=,6.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9172,1,active,MW=831.0 > 500.0; LogP=9.42 > 5.0
407f7f8d,,CN(c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1)C1CC1,,,raw,,846.0229999999996,845.3570679719999,8.592200000000005,172.03,3,11,14,9,5,0.391304347826087,61,0.07221941387993157,False,3,True,0,,CHEMBL5965178,23.0,nM,=,7.64,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6383,1,active,MW=846.0 > 500.0; LogP=8.59 > 5.0; HBA=11 > 10
9d7bbc65,,CN1CC=C(c2ccccc2C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)CC1,,,raw,,872.0609999999995,871.3727180359999,8.712500000000004,172.03,3,11,13,9,5,0.375,63,0.07635267258302311,False,3,True,0,,CHEMBL5781330,20.0,nM,=,7.7,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.699,1,active,MW=872.1 > 500.0; LogP=8.71 > 5.0; HBA=11 > 10
0b5dd584,,CC(=O)N1CC=C(c2ccccc2C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)CC1,,,raw,,900.0709999999995,899.367632656,8.629200000000004,189.1,3,11,13,9,5,0.3673469387755102,65,0.07580167877204344,False,3,True,0,,CHEMBL6064593,39.0,nM,=,7.41,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4089,1,active,MW=900.1 > 500.0; LogP=8.63 > 5.0; HBA=11 > 10
a0fc2643,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(C4CC4)cs3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,823.01,822.286939812,8.932500000000005,168.79,3,11,13,9,5,0.3953488372093023,58,0.07702376656218544,False,3,True,0,,CHEMBL6049964,27.0,nM,=,7.57,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5686,1,active,MW=823.0 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
b53e53a7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccn(C4CC4)n3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,806.9459999999999,806.3210168119999,7.525000000000008,186.61000000000004,3,12,13,9,5,0.40476190476190477,58,0.07890354817275498,False,3,True,0,,CHEMBL5881143,97.0,nM,=,7.01,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0132,1,active,MW=806.9 > 500.0; LogP=7.53 > 5.0; HBA=12 > 10
6b516063,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(Cl)CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,851.4259999999998,850.291546524,9.088300000000002,168.79,3,10,13,9,5,0.37777777777777777,60,0.05904134694663631,False,2,True,0,,CHEMBL5766474,36.0,nM,=,7.44,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4437,1,active,MW=851.4 > 500.0; LogP=9.09 > 5.0
87d02b45,,C=C1CC(c2ccccc2C2CC2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,828.9919999999997,828.3305188759999,9.037100000000002,168.79,3,10,13,9,5,0.34782608695652173,60,0.05916354864490409,False,2,True,0,,CHEMBL6026974,23.0,nM,=,7.64,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6383,1,active,MW=829.0 > 500.0; LogP=9.04 > 5.0
092162bb,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC4CCCC4C3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,857.0459999999998,856.3618190039999,9.507100000000001,168.79,3,10,13,10,5,0.4166666666666667,62,0.07662009156562372,False,2,True,0,,CHEMBL5816689,45.0,nM,=,7.35,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3468,1,active,MW=857.0 > 500.0; LogP=9.51 > 5.0
1bb57f4b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3Cc4ccccc4C3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,824.96,824.2992187479999,8.761700000000005,168.79,3,10,12,9,6,0.2608695652173913,60,0.08014992747738758,False,2,True,0,,CHEMBL5947024,226.0,nM,=,6.65,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.6459,1,active,MW=825.0 > 500.0; LogP=8.76 > 5.0
563f5cf8,,COC(c1ccccc1C1CC1)C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,861.0339999999995,860.356733624,8.886000000000003,178.02,3,11,15,9,5,0.40425531914893614,62,0.06765884969003762,False,3,True,0,,CHEMBL5874403,4.7,nM,=,8.33,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3279,1,active,MW=861.0 > 500.0; LogP=8.89 > 5.0; HBA=11 > 10
516ae444,,CC(C)c1ccccc1CC1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,833.0239999999995,832.3618190039999,8.987000000000004,168.79,3,10,14,8,5,0.391304347826087,60,0.0725494613651389,False,2,True,0,,CHEMBL6031098,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8239,1,active,MW=833.0 > 500.0; LogP=8.99 > 5.0
2658a009,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC(c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,816.9809999999999,816.3305188759999,8.523400000000008,168.79,3,10,13,9,5,0.37777777777777777,59,0.07738336378621405,False,2,True,0,,CHEMBL5809113,109.0,nM,=,6.96,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9626,1,active,MW=817.0 > 500.0; LogP=8.52 > 5.0
64c0836c,,CC(C)c1ccccc1[C@@H]1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,818.9969999999997,818.34616894,8.769400000000003,168.79,3,10,13,8,5,0.37777777777777777,59,0.07715543373526935,False,2,True,0,,CHEMBL6056722,98.0,nM,=,7.01,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0088,1,active,MW=819.0 > 500.0; LogP=8.77 > 5.0
cf41723e,,CC(C)c1ccccc1[C@H]1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,818.9969999999997,818.34616894,8.769400000000003,168.79,3,10,13,8,5,0.37777777777777777,59,0.07715543373526935,False,2,True,0,,CHEMBL5796449,61.0,nM,=,7.21,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2147,1,active,MW=819.0 > 500.0; LogP=8.77 > 5.0
cbdad9fa,,Cc1c(F)cccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,808.9329999999998,808.305447,8.441120000000005,168.79,3,10,12,8,5,0.3488372093023256,58,0.08217344463188823,False,2,True,0,,CHEMBL5910758,29.0,nM,=,7.54,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5376,1,active,MW=808.9 > 500.0; LogP=8.44 > 5.0
f6b8070d,,CC(C)=Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,831.0079999999996,830.34616894,9.4168,168.79,3,10,13,8,5,0.34782608695652173,60,0.0767899101324556,False,2,True,0,,CHEMBL5779029,57.0,nM,=,7.24,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2441,1,active,MW=831.0 > 500.0; LogP=9.42 > 5.0
0b11aeca,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc4ccccc4s3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,833.0050000000001,832.271289748,9.208300000000001,168.79,3,11,12,9,6,0.3181818181818182,59,0.07986012068400465,False,3,True,0,,CHEMBL5896435,93.0,nM,=,7.03,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.0315,1,active,MW=833.0 > 500.0; LogP=9.21 > 5.0; HBA=11 > 10
69e42ebc,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,816.981,816.3305188759999,8.871000000000006,168.79,3,10,13,9,5,0.37777777777777777,59,0.07710761536380115,False,2,True,0,,CHEMBL6058975,21.0,nM,=,7.68,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.6778,1,active,MW=817.0 > 500.0; LogP=8.87 > 5.0
ccf6a27d,,CCCCC1C2CCCC2CN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,796.9909999999999,796.3618190039999,8.447200000000006,168.79,3,10,14,8,4,0.4883720930232558,57,0.08318118399771389,False,2,True,0,,CHEMBL5854462,19.0,nM,=,7.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7212,1,active,MW=797.0 > 500.0; LogP=8.45 > 5.0
be792e95,,Cc1c(Cl)cccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,825.3879999999997,824.27589646,8.955420000000002,168.79,3,10,12,8,5,0.3488372093023256,58,0.08158494904505802,False,2,True,0,,CHEMBL5874610,61.0,nM,=,7.21,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2147,1,active,MW=825.4 > 500.0; LogP=8.96 > 5.0
2d6e41b1,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3=CCNCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,858.0339999999999,857.3570679719999,8.370300000000007,180.82000000000002,4,11,13,9,5,0.3617021276595745,62,0.06600297360883568,False,3,True,0,,CHEMBL6007862,19.0,nM,=,7.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7212,1,active,MW=858.0 > 500.0; LogP=8.37 > 5.0; HBA=11 > 10
a2bccefc,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.3770000000001,812.27589646,8.737300000000005,168.79,3,10,12,8,5,0.38095238095238093,57,0.08183268467242584,False,2,True,0,,CHEMBL5766318,27.0,nM,=,5.51,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,3,7.5686,1,active,MW=813.4 > 500.0; LogP=8.74 > 5.0
965ce90b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.997,818.34616894,8.961300000000005,168.79,3,10,13,9,5,0.4222222222222222,59,0.07704142073174182,False,2,True,0,,CHEMBL6043986,939.0,nM,=,6.06,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,6.0273,1,active,MW=819.0 > 500.0; LogP=8.96 > 5.0
b9434810,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.997,818.34616894,8.961300000000005,168.79,3,10,13,9,5,0.4222222222222222,59,0.07704142073174182,False,2,True,0,,CHEMBL6009632,6.5,nM,=,8.19,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,6,8.1871,1,active,MW=819.0 > 500.0; LogP=8.96 > 5.0
41f74589,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.997,818.34616894,8.961300000000005,168.79,3,10,13,9,5,0.4222222222222222,59,0.07704142073174182,False,2,True,0,,CHEMBL5869985,865.0,nM,=,6.06,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.063,1,active,MW=819.0 > 500.0; LogP=8.96 > 5.0
a93e57d6,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.997,818.34616894,8.961300000000005,168.79,3,10,13,9,5,0.4222222222222222,59,0.07704142073174182,False,2,True,0,,CHEMBL6059159,4.0,nM,=,8.4,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.3979,1,active,MW=819.0 > 500.0; LogP=8.96 > 5.0
28ae5179,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.997,818.34616894,8.961300000000005,168.79,3,10,13,9,5,0.4222222222222222,59,0.07704142073174182,False,2,True,0,,CHEMBL5830611,2418.0,nM,=,5.62,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.6165,0,inactive,MW=819.0 > 500.0; LogP=8.96 > 5.0
71861e97,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.997,818.34616894,8.961300000000005,168.79,3,10,13,9,5,0.4222222222222222,59,0.07704142073174182,False,2,True,0,,CHEMBL5924557,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.8239,1,active,MW=819.0 > 500.0; LogP=8.96 > 5.0
3b0667e9,,CC(C)c1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,821.0129999999997,820.3618190039999,9.207300000000002,168.79,3,10,13,8,5,0.4222222222222222,59,0.07692349742644486,False,2,True,0,,CHEMBL5881653,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=821.0 > 500.0; LogP=9.21 > 5.0
d44cbaa5,,C=C(C)c1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,818.9969999999997,818.34616894,9.117000000000003,168.79,3,10,13,8,5,0.37777777777777777,59,0.07697245999988017,False,2,True,0,,CHEMBL5995096,19.0,nM,=,7.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7212,1,active,MW=819.0 > 500.0; LogP=9.12 > 5.0
d1255bd0,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3cccc(Cl)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.3770000000001,812.27589646,8.737300000000005,168.79,3,10,12,8,5,0.38095238095238093,57,0.08183268467242584,False,2,True,0,,CHEMBL5776977,3846.0,nM,=,5.42,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.415,0,inactive,MW=813.4 > 500.0; LogP=8.74 > 5.0
e52685e7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3cccc(Cl)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.3770000000001,812.27589646,8.737300000000005,168.79,3,10,12,8,5,0.38095238095238093,57,0.08183268467242584,False,2,True,0,,CHEMBL5867556,22.0,nM,=,7.66,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.6576,1,active,MW=813.4 > 500.0; LogP=8.74 > 5.0
9156575b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.3770000000001,812.27589646,8.737300000000005,168.79,3,10,12,8,5,0.38095238095238093,57,0.08183268467242584,False,2,True,0,,CHEMBL5788044,2181.0,nM,=,5.66,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.6613,0,inactive,MW=813.4 > 500.0; LogP=8.74 > 5.0
66cced08,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.3770000000001,812.27589646,8.737300000000005,168.79,3,10,12,8,5,0.38095238095238093,57,0.08183268467242584,False,2,True,0,,CHEMBL5976482,23.0,nM,=,7.64,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.6383,1,active,MW=813.4 > 500.0; LogP=8.74 > 5.0
49abeea7,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,778.9320000000001,778.314868812,8.083900000000009,168.79,3,10,12,8,5,0.38095238095238093,56,0.08317061644740494,False,2,True,0,,CHEMBL5774475,2020.0,nM,=,5.7,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.6946,0,inactive,MW=778.9 > 500.0; LogP=8.08 > 5.0
1ebbfe4b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,778.9320000000001,778.314868812,8.083900000000009,168.79,3,10,12,8,5,0.38095238095238093,56,0.08317061644740494,False,2,True,0,,CHEMBL5818476,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=778.9 > 500.0; LogP=8.08 > 5.0
1f345204,,Cc1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,792.9589999999998,792.3305188759999,8.392320000000005,168.79,3,10,12,8,5,0.3953488372093023,57,0.08242312556230612,False,2,True,0,,CHEMBL5902426,5.9,nM,=,8.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2291,1,active,MW=793.0 > 500.0; LogP=8.39 > 5.0
3bf551b2,,CCc1ccccc1[C@H]1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,806.9859999999998,806.34616894,8.646300000000004,168.79,3,10,13,8,5,0.4090909090909091,58,0.07736018598471435,False,2,True,0,,CHEMBL5801811,631.0,nM,=,6.2,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.2,1,active,MW=807.0 > 500.0; LogP=8.65 > 5.0
ee947cb0,,CCc1ccccc1[C@@H]1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,806.9859999999998,806.34616894,8.646300000000004,168.79,3,10,13,8,5,0.4090909090909091,58,0.07736018598471435,False,2,True,0,,CHEMBL5996455,4.0,nM,=,8.4,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3979,1,active,MW=807.0 > 500.0; LogP=8.65 > 5.0
6ed43b7f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3Oc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,871.0290000000001,870.34108356,9.876199999999997,178.02,3,11,14,9,6,0.3333333333333333,63,0.0701072934660284,False,3,True,0,,CHEMBL5765475,107.0,nM,=,6.97,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9706,1,active,MW=871.0 > 500.0; LogP=9.88 > 5.0; HBA=11 > 10
b9ab0555,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3/C=C/c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,845.035,844.3618190039999,9.302000000000003,168.79,3,10,14,9,5,0.40425531914893614,61,0.07236835566601735,False,2,True,0,,CHEMBL5977830,66.0,nM,=,7.18,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.1805,1,active,MW=845.0 > 500.0; LogP=9.30 > 5.0
038cc8a2,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3/C=C/c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,804.9700000000001,804.3305188759999,8.424600000000007,168.79,3,10,13,8,5,0.36363636363636365,58,0.07760853200963348,False,2,True,0,,CHEMBL5975953,36.0,nM,=,7.44,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4437,1,active,MW=805.0 > 500.0; LogP=8.42 > 5.0
bd7a66d9,,COc1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,808.9579999999997,808.325433496,8.092500000000008,178.02,3,11,13,8,5,0.3953488372093023,58,0.0773638966606327,False,3,True,0,,CHEMBL5767470,6.7,nM,=,8.17,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1739,1,active,MW=809.0 > 500.0; LogP=8.09 > 5.0; HBA=11 > 10
fa02ee14,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N(Cc3ccccc3)Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,828.9920000000001,828.3305188759999,8.949200000000005,168.79,3,10,15,8,6,0.30434782608695654,60,0.06713006169254074,False,2,True,0,,CHEMBL6024819,1150.0,nM,=,5.94,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,5.9393,0,inactive,MW=829.0 > 500.0; LogP=8.95 > 5.0
dd4b099d,,CC(C)(C)OC(=O)c1ccc(-c2ccc(N3CCCC3c3ccccc3)nc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,532.6440000000001,532.2474408840001,7.714000000000007,80.34,1,6,6,6,5,0.24242424242424243,40,0.22562355917841687,False,2,True,0,,CHEMBL6025905,54.0,nM,=,7.27,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2676,1,active,MW=532.6 > 500.0; LogP=7.71 > 5.0
42a31a05,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,779.9200000000002,779.3101177799999,7.0265000000000075,172.03,3,11,12,8,5,0.36585365853658536,56,0.08774748691228339,False,3,True,0,,CHEMBL5943875,20.0,nM,=,7.7,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.699,1,active,MW=779.9 > 500.0; LogP=7.03 > 5.0; HBA=11 > 10
306b852f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.3650000000001,813.271145428,7.679900000000008,172.03,3,11,12,8,5,0.36585365853658536,57,0.08335919881190075,False,3,True,0,,CHEMBL6048355,16.0,nM,=,7.8,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7959,1,active,MW=814.4 > 500.0; LogP=7.68 > 5.0; HBA=11 > 10
e27b63c6,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3cccc(Cl)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.3650000000001,813.271145428,7.679900000000008,172.03,3,11,12,8,5,0.36585365853658536,57,0.08335919881190075,False,3,True,0,,CHEMBL5984992,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8239,1,active,MW=814.4 > 500.0; LogP=7.68 > 5.0; HBA=11 > 10
0e812251,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3nc(N4CCCC4c4ccccc4)ccn3n2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.8970000000002,813.2693155879998,7.271800000000007,198.98000000000005,3,13,12,9,7,0.23809523809523808,59,0.08248176464679374,False,3,True,0,,CHEMBL5919132,49.0,nM,=,7.31,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.3098,1,active,MW=813.9 > 500.0; LogP=7.27 > 5.0; HBA=13 > 10
2c3e983a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3cc(N4CCCC4c4ccccc4)ccc3s2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,828.9730000000003,828.23998962,9.4438,168.79,3,11,12,9,7,0.22727272727272727,59,0.07969754719710913,False,3,True,0,,CHEMBL6060414,755.0,nM,=,6.12,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.1221,1,active,MW=829.0 > 500.0; LogP=9.44 > 5.0; HBA=11 > 10
b73e5b7e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(OC2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.9959999999999,834.3410835599999,8.625100000000007,178.02,3,11,14,9,5,0.4222222222222222,60,0.07207417380243626,False,3,True,0,,CHEMBL5893176,91.0,nM,=,7.04,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.041,1,active,MW=835.0 > 500.0; LogP=8.63 > 5.0; HBA=11 > 10
6b9a3e29,,CN(c1ccc(C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)c(Oc2cnc3[nH]ccc3c2)c1)C1CCC(N2CCCC2c2ccccc2C2CC2)CC1,,,raw,,848.0389999999998,847.372718036,8.682500000000006,172.03,3,11,14,9,5,0.43478260869565216,61,0.07213603499059146,False,3,True,0,,CHEMBL5817128,37.0,nM,=,7.43,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4318,1,active,MW=848.0 > 500.0; LogP=8.68 > 5.0; HBA=11 > 10
28ddb088,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CCC(N4CCC[C@H]4c4ccccc4C4CC4)CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,860.0499999999997,859.3727180359999,8.684100000000006,172.03,3,11,13,10,5,0.44680851063829785,62,0.07642415225680049,False,3,True,0,,CHEMBL5881285,34.0,nM,=,7.47,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4685,1,active,MW=860.0 > 500.0; LogP=8.68 > 5.0; HBA=11 > 10
898719cd,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CCC(N4CCC[C@@H]4c4ccccc4C4CC4)CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,860.0499999999997,859.3727180359999,8.684100000000006,172.03,3,11,13,10,5,0.44680851063829785,62,0.07642415225680049,False,3,True,0,,CHEMBL5926296,107.0,nM,=,6.97,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9706,1,active,MW=860.0 > 500.0; LogP=8.68 > 5.0; HBA=11 > 10
4222ba31,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCC(N4CCC[C@H]4c4ccccc4C4CC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,888.1039999999996,887.4040181639999,9.464300000000001,172.03,3,11,13,10,5,0.46938775510204084,64,0.07597692690470058,False,3,True,0,,CHEMBL5891780,13.0,nM,=,7.89,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8861,1,active,MW=888.1 > 500.0; LogP=9.46 > 5.0; HBA=11 > 10
59d9c51f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCC(N4CCC[C@@H]4c4ccccc4C4CC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,888.1039999999996,887.4040181639999,9.464300000000001,172.03,3,11,13,10,5,0.46938775510204084,64,0.07597692690470058,False,3,True,0,,CHEMBL5978292,149.0,nM,=,6.83,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.8268,1,active,MW=888.1 > 500.0; LogP=9.46 > 5.0; HBA=11 > 10
5c61eff8,,CN(C)c1c(Cl)cccc1C1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,897.4989999999996,896.3446447160001,8.526100000000005,175.27,3,12,13,9,5,0.43478260869565216,63,0.07603287319685995,False,3,True,0,,CHEMBL5828065,4.6,nM,=,8.34,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.3372,1,active,MW=897.5 > 500.0; LogP=8.53 > 5.0; HBA=12 > 10
8236c4e1,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.3030000000001,825.203540044,8.941500000000003,165.98999999999998,2,10,12,8,6,0.23809523809523808,58,0.08987310142076399,False,2,True,0,,CHEMBL6050481,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=826.3 > 500.0; LogP=8.94 > 5.0
4ff29238,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,835.9549999999998,835.305112652,8.930000000000005,165.98999999999998,2,10,13,9,5,0.37777777777777777,60,0.08639901705784628,False,2,True,0,,CHEMBL6037348,6.9,nM,=,8.16,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1612,1,active,MW=836.0 > 500.0; LogP=8.93 > 5.0
1dc6f0de,,CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCCC5c5ccccc5Cl)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,820.3720000000001,819.2605807440001,8.797700000000003,162.8,3,10,12,8,6,0.2558139534883721,58,0.0803641904713301,False,2,True,0,,CHEMBL6049523,16.0,nM,=,7.8,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7959,1,active,MW=820.4 > 500.0; LogP=8.80 > 5.0
1d7b417c,,CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,830.0239999999998,829.362153352,8.786200000000004,162.8,3,10,13,9,5,0.391304347826087,60,0.07725314777224936,False,2,True,0,,CHEMBL5882786,14.0,nM,=,7.85,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8539,1,active,MW=830.0 > 500.0; LogP=8.79 > 5.0
48e9a033,,O=C(NS(=O)(=O)c1ccc(NC2CN(C3CCOCC3)C2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,848.3820000000001,847.255495364,8.319100000000006,172.03,3,11,12,9,6,0.2727272727272727,60,0.07990451661380672,False,3,True,0,,CHEMBL5926155,33.0,nM,=,7.48,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.4815,1,active,MW=848.4 > 500.0; LogP=8.32 > 5.0; HBA=11 > 10
13050e59,,O=C(NS(=O)(=O)c1ccc(NC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,848.3820000000001,847.255495364,8.319100000000006,172.03,3,11,12,9,6,0.2727272727272727,60,0.07990451661380672,False,3,True,0,,CHEMBL5760818,24.0,nM,=,7.62,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.6198,1,active,MW=848.4 > 500.0; LogP=8.32 > 5.0; HBA=11 > 10
81844283,,O=C(NS(=O)(=O)c1ccc(NCC2(O)COC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,795.2740000000002,794.1925607599999,7.217200000000006,189.02,4,11,12,8,6,0.2,56,0.07234193906150443,False,3,True,0,,CHEMBL5869539,19.0,nM,=,7.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7212,1,active,MW=795.3 > 500.0; LogP=7.22 > 5.0; HBA=11 > 10
3c175498,,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,822.3400000000001,821.2286119199999,8.973900000000002,176.98999999999998,3,10,12,8,6,0.2558139534883721,58,0.07976644566925266,False,2,True,0,,CHEMBL5781678,13.0,nM,=,7.89,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8861,1,active,MW=822.3 > 500.0; LogP=8.97 > 5.0
fe8d419f,,O=C(NS(=O)(=O)c1ccc(N2CC3(CCOCC3)C2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,819.3400000000001,818.228946268,8.660800000000005,160.00000000000003,2,10,10,9,6,0.2558139534883721,58,0.10117327983177539,False,2,True,0,,CHEMBL6010999,125.0,nM,=,6.9,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.9031,1,active,MW=819.3 > 500.0; LogP=8.66 > 5.0
1e943246,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.953,818.309783432,7.859800000000009,178.02,3,11,13,9,5,0.36363636363636365,59,0.07784141395142323,False,3,True,0,,CHEMBL5906030,6.4,nM,=,8.19,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1938,1,active,MW=819.0 > 500.0; LogP=7.86 > 5.0; HBA=11 > 10
417118e2,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.953,818.309783432,7.859800000000009,178.02,3,11,13,9,5,0.36363636363636365,59,0.07784141395142323,False,3,True,0,,CHEMBL5975530,4.5,nM,=,8.32,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.3468,1,active,MW=819.0 > 500.0; LogP=7.86 > 5.0; HBA=11 > 10
d99b7c7b,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.953,818.309783432,7.859800000000009,178.02,3,11,13,9,5,0.36363636363636365,59,0.07784141395142323,False,3,True,0,,CHEMBL5916255,6.199999999999999,nM,=,8.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,4,8.2076,1,active,MW=819.0 > 500.0; LogP=7.86 > 5.0; HBA=11 > 10
a4e561fb,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.953,818.309783432,7.859800000000009,178.02,3,11,13,9,5,0.36363636363636365,59,0.07784141395142323,False,3,True,0,,CHEMBL5841596,5.1,nM,=,8.37,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,4,8.2924,1,active,MW=819.0 > 500.0; LogP=7.86 > 5.0; HBA=11 > 10
f126d6f0,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,818.953,818.309783432,7.859800000000009,178.02,3,11,13,9,5,0.36363636363636365,59,0.07784141395142323,False,3,True,0,,CHEMBL5756316,6.2,nM,=,8.21,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2076,1,active,MW=819.0 > 500.0; LogP=7.86 > 5.0; HBA=11 > 10
18f5b3a4,,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,846.0189999999998,845.345834592,9.352500000000003,176.98999999999998,3,10,13,9,5,0.40425531914893614,61,0.07644913410735206,False,2,True,0,,CHEMBL5856073,5.5,nM,=,8.26,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2596,1,active,MW=846.0 > 500.0; LogP=9.35 > 5.0
71779603,,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,846.0189999999998,845.345834592,9.352500000000003,176.98999999999998,3,10,13,9,5,0.40425531914893614,61,0.07644913410735206,False,2,True,0,,CHEMBL5799821,4.6,nM,=,7.77,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,6,8.3372,1,active,MW=846.0 > 500.0; LogP=9.35 > 5.0
f64e0620,,O=C(NS(=O)(=O)c1ccc(NCC2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0329999999997,873.3519825919999,7.544000000000009,181.26000000000002,3,12,14,10,5,0.40425531914893614,63,0.07379717863904107,False,3,True,0,,CHEMBL5975083,4.5,nM,=,8.35,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3468,1,active,MW=874.0 > 500.0; LogP=7.54 > 5.0; HBA=12 > 10
ba3432a9,,O=C(NS(=O)(=O)c1ccc(OCC2CCC3(CC2)COC3)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,858.0299999999997,857.3458345919998,9.6181,165.98999999999998,2,10,13,10,5,0.4166666666666667,62,0.08602053109948408,False,2,True,0,,CHEMBL5858076,18.0,nM,=,7.75,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7447,1,active,MW=858.0 > 500.0; LogP=9.62 > 5.0
67e1708c,,O=C(NS(=O)(=O)c1ccc(N[C@H]2CC[C@H](N(CC3CC3)CC3CC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,924.1809999999997,923.440403672,10.877599999999992,162.79999999999998,3,10,17,11,5,0.4716981132075472,67,0.060422413103645975,False,2,True,0,,CHEMBL5957356,5.0,nM,=,8.3,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.301,1,active,MW=924.2 > 500.0; LogP=10.88 > 5.0
9b84f57b,,O=C(NS(=O)(=O)c1ccc(NCC2CN(C3CC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,858.0339999999998,857.3570679719999,8.307600000000008,172.03,3,11,14,10,5,0.40425531914893614,62,0.07247595251133473,False,3,True,0,,CHEMBL5842246,27.0,nM,=,7.57,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5686,1,active,MW=858.0 > 500.0; LogP=8.31 > 5.0; HBA=11 > 10
9014964c,,CN(C)CC(=O)N1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,raw,,903.0749999999998,902.3785316880001,7.2334000000000085,192.34,3,12,15,9,5,0.3958333333333333,65,0.07065215832774725,False,3,True,0,,CHEMBL5826691,3.4,nM,=,8.47,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4685,1,active,MW=903.1 > 500.0; LogP=7.23 > 5.0; HBA=12 > 10
4fc19953,,O=C(NS(=O)(=O)c1ccc(OCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,817.9649999999999,817.314534464,8.837900000000005,165.98999999999998,2,10,13,9,5,0.37777777777777777,59,0.08660871149581624,False,2,True,0,,CHEMBL5810057,15.0,nM,=,7.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8239,1,active,MW=818.0 > 500.0; LogP=8.84 > 5.0
1d652aac,,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,845.0349999999997,844.3618190039999,9.385600000000002,179.79,4,10,13,9,5,0.40425531914893614,61,0.06589908157330236,False,2,True,0,,CHEMBL6016691,6.7,nM,=,8.17,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1739,1,active,MW=845.0 > 500.0; LogP=9.39 > 5.0
2e3242fb,,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,845.0349999999997,844.3618190039999,9.385600000000002,179.79,4,10,13,9,5,0.40425531914893614,61,0.06589908157330236,False,2,True,0,,CHEMBL5956618,2.6,nM,=,8.68,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,5,8.585,1,active,MW=845.0 > 500.0; LogP=9.39 > 5.0
864798f3,,C[C@]1(O)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,845.0349999999997,844.3618190039999,9.385600000000002,179.79,4,10,13,9,5,0.40425531914893614,61,0.06589908157330236,False,2,True,0,,CHEMBL5922058,7.0,nM,=,8.15,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1549,1,active,MW=845.0 > 500.0; LogP=9.39 > 5.0
d9a72db0,,O=C(NS(=O)(=O)c1ccc(NCC2CNCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,817.9689999999999,817.3257678439999,7.432800000000008,180.82000000000002,4,11,13,9,5,0.36363636363636365,59,0.06854941034984756,False,3,True,0,,CHEMBL5818747,9.5,nM,=,8.02,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0223,1,active,MW=818.0 > 500.0; LogP=7.43 > 5.0; HBA=11 > 10
5a6121fc,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.9709999999999,834.3210970639999,8.963100000000004,168.79,3,10,13,9,5,0.37777777777777777,60,0.07692181362084172,False,2,True,0,,CHEMBL5971190,4.9,nM,=,8.31,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3098,1,active,MW=835.0 > 500.0; LogP=8.96 > 5.0
65cdcf5d,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.9709999999999,834.3210970639999,8.963100000000004,168.79,3,10,13,9,5,0.37777777777777777,60,0.07692181362084172,False,2,True,0,,CHEMBL5856844,3.4,nM,=,8.46,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,3,8.4685,1,active,MW=835.0 > 500.0; LogP=8.96 > 5.0
8e85098d,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,834.9709999999999,834.3210970639999,8.963100000000004,168.79,3,10,13,9,5,0.37777777777777777,60,0.07692181362084172,False,2,True,0,,CHEMBL5972666,4.5,nM,=,8.35,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,3,8.3468,1,active,MW=835.0 > 500.0; LogP=8.96 > 5.0
731313dd,,CN1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,raw,,831.9959999999999,831.341417908,7.775000000000008,172.03,3,11,13,9,5,0.37777777777777777,60,0.07819573404940439,False,3,True,0,,CHEMBL5867513,6.0,nM,=,8.22,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2218,1,active,MW=832.0 > 500.0; LogP=7.78 > 5.0; HBA=11 > 10
5de3e17b,,CC(=O)N1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,raw,,860.0059999999999,859.3363325280001,7.691700000000009,189.1,3,11,13,9,5,0.3695652173913043,62,0.07777593082021232,False,3,True,0,,CHEMBL6016585,10.0,nM,=,8.0,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0,1,active,MW=860.0 > 500.0; LogP=7.69 > 5.0; HBA=11 > 10
ad0785d0,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,891.0349999999996,890.3473118119998,8.614200000000007,169.23,2,11,14,10,5,0.4166666666666667,64,0.08089190902082424,False,3,True,0,,CHEMBL6019072,2.4,nM,=,8.62,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.6198,1,active,MW=891.0 > 500.0; LogP=8.61 > 5.0; HBA=11 > 10
22b0de00,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,891.0349999999996,890.3473118119998,8.614200000000007,169.23,2,11,14,10,5,0.4166666666666667,64,0.08089190902082424,False,3,True,0,,CHEMBL5861196,1.9,nM,=,8.72,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.7212,1,active,MW=891.0 > 500.0; LogP=8.61 > 5.0; HBA=11 > 10
04f8f169,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CC[C@H](N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,891.0349999999996,890.3473118119998,8.614200000000007,169.23,2,11,14,10,5,0.4166666666666667,64,0.08089190902082424,False,3,True,0,,CHEMBL5899109,2.2,nM,=,8.66,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.6576,1,active,MW=891.0 > 500.0; LogP=8.61 > 5.0; HBA=11 > 10
480e079b,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3CCOCC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,919.0889999999996,918.3786119399998,9.394400000000003,169.23,2,11,14,10,5,0.44,66,0.08041397478054099,False,3,True,0,,CHEMBL5802937,5.9,nM,=,8.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2291,1,active,MW=919.1 > 500.0; LogP=9.39 > 5.0; HBA=11 > 10
8b5bff5b,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CCN(C3COC3)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,858.0339999999998,857.3570679719999,8.165100000000008,172.03,3,11,14,10,5,0.40425531914893614,62,0.07269561337964861,False,3,True,0,,CHEMBL5982940,4.3,nM,=,8.37,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3665,1,active,MW=858.0 > 500.0; LogP=8.17 > 5.0; HBA=11 > 10
4c499f7c,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2CCN(C3COC3)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,858.0339999999998,857.3570679719999,8.165100000000008,172.03,3,11,14,10,5,0.40425531914893614,62,0.07269561337964861,False,3,True,0,,CHEMBL5828543,17.0,nM,=,7.77,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7696,1,active,MW=858.0 > 500.0; LogP=8.17 > 5.0; HBA=11 > 10
d2765cb1,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3CC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,875.0359999999996,874.3523971919999,9.377800000000002,159.99999999999997,2,10,14,10,5,0.4166666666666667,63,0.08131134436345809,False,2,True,0,,CHEMBL5782018,20.0,nM,=,7.7,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.699,1,active,MW=875.0 > 500.0; LogP=9.38 > 5.0
add03cce,,O=C(NS(=O)(=O)c1ccc(NC2CCN(C(CF)CF)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,866.0039999999997,865.343309728,8.826300000000005,162.79999999999998,3,10,15,9,5,0.391304347826087,62,0.06849040025276565,False,2,True,0,,CHEMBL5962842,8.9,nM,=,8.05,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0506,1,active,MW=866.0 > 500.0; LogP=8.83 > 5.0
587a025f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c(Cl)c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,806.4289999999999,805.306468316,9.6162,125.65,3,8,12,9,5,0.37777777777777777,57,0.11391636355989544,False,2,True,0,,CHEMBL6020098,353.0,nM,=,6.45,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.4522,1,active,MW=806.4 > 500.0; LogP=9.62 > 5.0
cbf1161a,,N#Cc1cc(S(=O)(=O)NC(=O)c2ccc(C3=CCC(N4CCCC4c4ccccc4C4CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)ccc1NCC1CCOCC1,,,raw,,796.9939999999999,796.3406896359999,8.834480000000005,149.44,3,9,12,9,5,0.3695652173913043,58,0.1126065904223381,False,2,True,0,,CHEMBL5843415,431.0,nM,=,6.37,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.3655,1,active,MW=797.0 > 500.0; LogP=8.83 > 5.0
1b6a0636,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,904.0459999999995,903.2947255359999,9.256300000000003,159.79,3,10,13,9,5,0.391304347826087,63,0.10398830816592738,False,2,True,0,,CHEMBL5775373,252.0,nM,=,6.6,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.5986,1,active,MW=904.0 > 500.0; LogP=9.26 > 5.0
91d6336c,,O=C(NS(=O)(=O)c1ccc(NCC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,872.0609999999997,871.3727180359999,8.555200000000008,172.03,3,11,14,10,5,0.4166666666666667,63,0.07213935254064065,False,3,True,0,,CHEMBL6032884,4.6,nM,=,8.34,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3372,1,active,MW=872.1 > 500.0; LogP=8.56 > 5.0; HBA=11 > 10
94e3c7d4,,O=C(NS(=O)(=O)c1ccc(NCC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,872.0609999999997,871.3727180359999,8.555200000000008,172.03,3,11,14,10,5,0.4166666666666667,63,0.07213935254064065,False,3,True,0,,CHEMBL5940140,3.6,nM,=,8.44,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4437,1,active,MW=872.1 > 500.0; LogP=8.56 > 5.0; HBA=11 > 10
9c5601a7,,O=C(NS(=O)(=O)c1ccc(NCC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,872.0609999999997,871.3727180359999,8.555200000000008,172.03,3,11,14,10,5,0.4166666666666667,63,0.07213935254064065,False,3,True,0,,CHEMBL5933907,5.2,nM,=,8.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.284,1,active,MW=872.1 > 500.0; LogP=8.56 > 5.0; HBA=11 > 10
4832c846,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,820.9689999999999,820.325433496,7.950100000000009,178.02,3,11,13,9,5,0.4090909090909091,59,0.07758095484119085,False,3,True,0,,CHEMBL5805930,5.3,nM,=,8.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2757,1,active,MW=821.0 > 500.0; LogP=7.95 > 5.0; HBA=11 > 10
05e5e07c,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,820.9689999999999,820.325433496,7.950100000000009,178.02,3,11,13,9,5,0.4090909090909091,59,0.07758095484119085,False,3,True,0,,CHEMBL5995925,4.2,nM,=,8.38,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.3768,1,active,MW=821.0 > 500.0; LogP=7.95 > 5.0; HBA=11 > 10
d4e06772,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,820.9689999999999,820.325433496,7.950100000000009,178.02,3,11,13,9,5,0.4090909090909091,59,0.07758095484119085,False,3,True,0,,CHEMBL5860139,5.0,nM,=,8.3,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.301,1,active,MW=821.0 > 500.0; LogP=7.95 > 5.0; HBA=11 > 10
b2d77b85,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,820.9689999999999,820.325433496,7.950100000000009,178.02,3,11,13,9,5,0.4090909090909091,59,0.07758095484119085,False,3,True,0,,CHEMBL5966228,3.1,nM,=,8.51,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.5086,1,active,MW=821.0 > 500.0; LogP=7.95 > 5.0; HBA=11 > 10
0c43d190,,CC(C)(C)[Si](C)(C)OC1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,946.2559999999995,945.4166615060001,11.991899999999987,165.99,2,10,15,9,5,0.46153846153846156,67,0.058577176850686065,False,2,True,0,,CHEMBL5753141,849.0,nM,=,6.07,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.0711,1,active,MW=946.3 > 500.0; LogP=11.99 > 5.0
c22652e4,,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.9919999999998,831.330184528,8.962400000000004,176.98999999999998,3,10,13,9,5,0.391304347826087,60,0.07667868517900875,False,2,True,0,,CHEMBL5929872,16.0,nM,=,7.8,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7959,1,active,MW=832.0 > 500.0; LogP=8.96 > 5.0
7a097045,,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.9919999999998,831.330184528,8.962400000000004,176.98999999999998,3,10,13,9,5,0.391304347826087,60,0.07667868517900875,False,2,True,0,,CHEMBL5812387,5.3,nM,=,8.28,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2757,1,active,MW=832.0 > 500.0; LogP=8.96 > 5.0
7b7a8431,,O=C(NS(=O)(=O)c1ccc(NC(=O)N2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.9519999999999,831.3050324,7.896600000000008,189.1,3,10,11,9,5,0.3409090909090909,60,0.08719723980242061,False,2,True,0,,CHEMBL6063527,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=832.0 > 500.0; LogP=7.90 > 5.0
ddcd5007,,CC(C)c1ccccc1[C@@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,832.9549999999997,832.305447,9.4446,168.79,3,10,13,8,6,0.28888888888888886,60,0.07530292140093994,False,2,True,0,,CHEMBL6055951,59.0,nM,=,7.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2291,1,active,MW=833.0 > 500.0; LogP=9.44 > 5.0
86fd4dd2,,CC(C)c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,832.9549999999997,832.305447,9.4446,168.79,3,10,13,8,6,0.28888888888888886,60,0.07530292140093994,False,2,True,0,,CHEMBL5912155,2.75,nM,=,8.54,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.5607,1,active,MW=833.0 > 500.0; LogP=9.44 > 5.0
bf73b900,,COCC1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,859.0619999999998,858.377469068,9.897199999999998,168.79,3,10,15,9,5,0.4166666666666667,62,0.06806848794307158,False,2,True,0,,CHEMBL6018441,18.0,nM,=,7.75,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7447,1,active,MW=859.1 > 500.0; LogP=9.90 > 5.0
aa2732f2,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2CCN(C3CCOCC3)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,886.0879999999997,885.3883680999999,8.945300000000005,172.03,3,11,14,10,5,0.42857142857142855,64,0.07182932522977774,False,3,True,0,,CHEMBL5782710,18.0,nM,=,7.75,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.7447,1,active,MW=886.1 > 500.0; LogP=8.95 > 5.0; HBA=11 > 10
d25178f9,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.921,814.278483304,8.095300000000009,178.02,3,11,13,9,6,0.2727272727272727,59,0.07582532034218283,False,3,True,0,,CHEMBL6006690,36.5,nM,=,7.21,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.4377,1,active,MW=814.9 > 500.0; LogP=8.10 > 5.0; HBA=11 > 10
ab54664b,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.921,814.278483304,8.095300000000009,178.02,3,11,13,9,6,0.2727272727272727,59,0.07582532034218283,False,3,True,0,,CHEMBL5762148,39.0,nM,=,7.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,7.4089,1,active,MW=814.9 > 500.0; LogP=8.10 > 5.0; HBA=11 > 10
3b81981a,,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,822.9599999999997,822.3210970639999,8.648100000000005,168.79,3,10,13,8,5,0.36363636363636365,59,0.0772165385808632,False,2,True,0,,CHEMBL5979382,3.3,nM,=,8.55,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,3,8.4815,1,active,MW=823.0 > 500.0; LogP=8.65 > 5.0
cd29e02c,,CCc1ccccc1[C@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,822.9599999999997,822.3210970639999,8.648100000000005,168.79,3,10,13,8,5,0.36363636363636365,59,0.0772165385808632,False,2,True,0,,CHEMBL5917184,2.3,nM,=,8.64,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.6383,1,active,MW=823.0 > 500.0; LogP=8.65 > 5.0
4d386aa2,,CC(C)c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,843.0189999999998,842.34616894,9.867099999999997,179.79,4,10,13,8,6,0.3191489361702128,61,0.06458178808567756,False,2,True,0,,CHEMBL5765058,1.95,nM,=,8.62,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.71,1,active,MW=843.0 > 500.0; LogP=9.87 > 5.0
6f5c1dd6,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,841.0029999999999,840.3305188759999,9.621099999999998,179.79,4,10,13,9,6,0.3191489361702128,61,0.06461943078291617,False,2,True,0,,CHEMBL5901355,1.4500000000000002,nM,=,8.74,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,4,8.8386,1,active,MW=841.0 > 500.0; LogP=9.62 > 5.0
3284797b,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,841.0029999999999,840.3305188759999,9.621099999999998,179.79,4,10,13,9,6,0.3191489361702128,61,0.06461943078291617,False,2,True,0,,CHEMBL5747331,10.0,nM,=,8.0,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0,1,active,MW=841.0 > 500.0; LogP=9.62 > 5.0
2d9979bf,,C[C@]1(O)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,841.0029999999999,840.3305188759999,9.621099999999998,179.79,4,10,13,9,6,0.3191489361702128,61,0.06461943078291617,False,2,True,0,,CHEMBL5818419,3.6,nM,=,8.44,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4437,1,active,MW=841.0 > 500.0; LogP=9.62 > 5.0
888f4dff,,C[C@]1(O)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,841.0029999999999,840.3305188759999,9.621099999999998,179.79,4,10,13,9,6,0.3191489361702128,61,0.06461943078291617,False,2,True,0,,CHEMBL5954667,29.0,nM,=,7.54,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.5376,1,active,MW=841.0 > 500.0; LogP=9.62 > 5.0
7c9c6cde,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.939,830.2897969359999,9.1986,168.79,3,10,13,9,6,0.28888888888888886,60,0.07538286521808986,False,2,True,0,,CHEMBL5928484,2.1,nM,=,8.57,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,4,8.6778,1,active,MW=830.9 > 500.0; LogP=9.20 > 5.0
a0cb4478,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.939,830.2897969359999,9.1986,168.79,3,10,13,9,6,0.28888888888888886,60,0.07538286521808986,False,2,True,0,,CHEMBL5945870,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=830.9 > 500.0; LogP=9.20 > 5.0
f8a1de1b,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.921,814.278483304,8.095300000000009,178.02,3,11,13,9,6,0.2727272727272727,59,0.07582532034218283,False,3,True,0,,CHEMBL5787701,2.55,nM,=,8.46,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,4,8.5935,1,active,MW=814.9 > 500.0; LogP=8.10 > 5.0; HBA=11 > 10
dd3e2a1e,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.921,814.278483304,8.095300000000009,178.02,3,11,13,9,6,0.2727272727272727,59,0.07582532034218283,False,3,True,0,,CHEMBL5828583,4.9,nM,=,8.31,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.3098,1,active,MW=814.9 > 500.0; LogP=8.10 > 5.0; HBA=11 > 10
0118b69a,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,887.0029999999997,886.3160116839998,8.849700000000006,169.23,2,11,14,10,6,0.3333333333333333,64,0.07917822308312392,False,3,True,0,,CHEMBL6039862,2.2,nM,=,8.66,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.6576,1,active,MW=887.0 > 500.0; LogP=8.85 > 5.0; HBA=11 > 10
ebc97d2d,,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,887.0029999999997,886.3160116839998,8.849700000000006,169.23,2,11,14,10,6,0.3333333333333333,64,0.07917822308312392,False,3,True,0,,CHEMBL5985785,8.3,nM,=,8.08,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0809,1,active,MW=887.0 > 500.0; LogP=8.85 > 5.0; HBA=11 > 10
da2bc3bb,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,886.0189999999998,885.3319960959999,8.882800000000005,172.03,3,11,14,10,6,0.3333333333333333,64,0.07048781874397052,False,3,True,0,,CHEMBL5794896,1.5,nM,=,8.82,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.8239,1,active,MW=886.0 > 500.0; LogP=8.88 > 5.0; HBA=11 > 10
96a89fc8,,CC1(O)CCC(F)(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,858.9929999999999,858.3210970639999,9.713199999999999,179.79,4,10,13,9,6,0.3191489361702128,62,0.06452790392618275,False,2,True,0,,CHEMBL5846135,2.8,nM,=,8.55,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.5528,1,active,MW=859.0 > 500.0; LogP=9.71 > 5.0
d237bb5d,,CC1(O)CCC(F)(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,858.9929999999999,858.3210970639999,9.713199999999999,179.79,4,10,13,9,6,0.3191489361702128,62,0.06452790392618275,False,2,True,0,,CHEMBL5982143,3.3,nM,=,8.48,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4815,1,active,MW=859.0 > 500.0; LogP=9.71 > 5.0
ec1680c6,,CCc1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,828.992,828.3305188759999,9.306100000000002,179.79,4,10,13,8,6,0.30434782608695654,60,0.06474350516510494,False,2,True,0,,CHEMBL6019566,13.0,nM,=,7.89,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.8861,1,active,MW=829.0 > 500.0; LogP=9.31 > 5.0
f6fa9c3f,,CCc1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(OCC4(F)CCN(C5COC5)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,874.9919999999997,874.3160116839999,8.534700000000004,169.23,2,11,14,9,6,0.3191489361702128,63,0.07947746961837311,False,3,True,0,,CHEMBL6008607,6.5,nM,=,8.19,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1871,1,active,MW=875.0 > 500.0; LogP=8.53 > 5.0; HBA=11 > 10
0bd1b845,,CC(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(OCC4(F)CCN(C5COC5)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,889.0189999999996,888.331661748,9.095700000000003,169.23,2,11,14,9,6,0.3333333333333333,64,0.07904636823721845,False,3,True,0,,CHEMBL5924691,51.0,nM,=,7.29,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.2924,1,active,MW=889.0 > 500.0; LogP=9.10 > 5.0; HBA=11 > 10
63f226e0,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5cccc(Cl)c5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,879.4799999999998,878.322846652,10.038999999999996,179.79,4,10,13,9,5,0.40425531914893614,62,0.0656859823469955,False,2,True,0,,CHEMBL6055850,6.0,nM,=,8.22,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2218,1,active,MW=879.5 > 500.0; LogP=10.04 > 5.0
9ca125df,,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,833.0239999999998,832.3618190039999,9.070600000000004,179.79,4,10,13,8,5,0.391304347826087,60,0.06605065471229572,False,2,True,0,,CHEMBL5740186,1.6,nM,=,8.8,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.7959,1,active,MW=833.0 > 500.0; LogP=9.07 > 5.0
2f769821,,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,raw,,833.0239999999998,832.3618190039999,9.070600000000004,179.79,4,10,13,8,5,0.391304347826087,60,0.06605065471229572,False,2,True,0,,CHEMBL5762696,1.2,nM,=,8.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.9208,1,active,MW=833.0 > 500.0; LogP=9.07 > 5.0
ef0d14f1,,CCC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,859.0619999999998,858.377469068,9.7757,179.79,4,10,14,9,5,0.4166666666666667,62,0.06203796937071283,False,2,True,0,,CHEMBL5910719,8.2,nM,=,8.09,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0862,1,active,MW=859.1 > 500.0; LogP=9.78 > 5.0
b81e1fd7,,CCC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,859.0619999999998,858.377469068,9.7757,179.79,4,10,14,9,5,0.4166666666666667,62,0.06203796937071283,False,2,True,0,,CHEMBL6065902,3.7,nM,=,8.43,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4318,1,active,MW=859.1 > 500.0; LogP=9.78 > 5.0
55e60b3d,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,848.9979999999997,848.336747128,9.087600000000004,179.79,4,10,13,9,5,0.391304347826087,61,0.06596190249857427,False,2,True,0,,CHEMBL5842983,4.25,nM,=,8.49,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,8.3716,1,active,MW=849.0 > 500.0; LogP=9.09 > 5.0
acfad10a,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,848.9979999999997,848.336747128,9.087600000000004,179.79,4,10,13,9,5,0.391304347826087,61,0.06596190249857427,False,2,True,0,,CHEMBL6041868,5.7,nM,=,8.24,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2441,1,active,MW=849.0 > 500.0; LogP=9.09 > 5.0
240bda92,,O=C(NS(=O)(=O)c1ccc(NCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,8.995500000000005,179.79,4,10,13,9,5,0.391304347826087,60,0.06609133941670697,False,2,True,0,,CHEMBL5976824,3.3,nM,=,8.48,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4815,1,active,MW=831.0 > 500.0; LogP=9.00 > 5.0
0ebe5fc8,,O=C(NS(=O)(=O)c1ccc(NCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,8.995500000000005,179.79,4,10,13,9,5,0.391304347826087,60,0.06609133941670697,False,2,True,0,,CHEMBL5824698,6.8,nM,=,8.17,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1675,1,active,MW=831.0 > 500.0; LogP=9.00 > 5.0
e9b15171,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CC[C@H](O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,8.995500000000005,179.79,4,10,13,9,5,0.391304347826087,60,0.06609133941670697,False,2,True,0,,CHEMBL5854104,5.9,nM,=,8.23,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2291,1,active,MW=831.0 > 500.0; LogP=9.00 > 5.0
0146a490,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CC[C@@H](O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,8.995500000000005,179.79,4,10,13,9,5,0.391304347826087,60,0.06609133941670697,False,2,True,0,,CHEMBL5948076,4.4,nM,=,8.36,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3565,1,active,MW=831.0 > 500.0; LogP=9.00 > 5.0
153122a2,,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0329999999997,873.3519825919999,7.544000000000009,181.26000000000002,3,12,14,10,5,0.40425531914893614,63,0.07379717863904107,False,3,True,0,,CHEMBL5932713,6.2,nM,=,8.21,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.2076,1,active,MW=874.0 > 500.0; LogP=7.54 > 5.0; HBA=12 > 10
5c3f6919,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0329999999997,873.3519825919999,7.544000000000009,181.26000000000002,3,12,14,10,5,0.40425531914893614,63,0.07379717863904107,False,3,True,0,,CHEMBL5858258,2.5,nM,=,8.6,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.6021,1,active,MW=874.0 > 500.0; LogP=7.54 > 5.0; HBA=12 > 10
e47fd4bf,,CS(=O)(=O)N1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,raw,,896.0609999999998,895.303318148,7.104800000000008,206.17,3,12,14,9,5,0.37777777777777777,63,0.07539386458129753,False,3,True,0,,CHEMBL6023144,7.4,nM,=,8.13,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.1308,1,active,MW=896.1 > 500.0; LogP=7.10 > 5.0; HBA=12 > 10
8a4c5afd,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,890.0509999999997,889.3632962239999,8.647300000000007,172.03,3,11,14,10,5,0.4166666666666667,64,0.07200456561291799,False,3,True,0,,CHEMBL5825277,3.2,nM,=,8.49,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.4949,1,active,MW=890.1 > 500.0; LogP=8.65 > 5.0; HBA=11 > 10
56e737d9,,CN(C)CC(=O)N1CCC(F)(COc2ncc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2Cl)CC1,,,raw,,910.5129999999997,909.345059316,8.443800000000008,150.05999999999997,2,10,14,9,5,0.4166666666666667,64,0.11119799284579597,False,2,True,0,,CHEMBL5917107,9.0,nM,=,8.05,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.0458,1,active,MW=910.5 > 500.0; LogP=8.44 > 5.0
e8f3ec92,,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(Cl)c3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,866.4369999999998,865.2912121759999,9.6158,176.98999999999998,3,10,13,9,5,0.391304347826087,61,0.07629681190002106,False,2,True,0,,CHEMBL5769886,12.0,nM,=,7.92,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,7.9208,1,active,MW=866.4 > 500.0; LogP=9.62 > 5.0
47617b57,,O=C(NS(=O)(=O)c1ccc(NCC2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,876.0489999999998,875.367632656,7.63430000000001,181.26000000000002,3,12,14,10,5,0.44680851063829785,63,0.07343740982918184,False,3,True,0,,CHEMBL5929201,4.9,nM,=,8.31,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,8.3098,1,active,MW=876.0 > 500.0; LogP=7.63 > 5.0; HBA=12 > 10
b4fd98c0,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1-n1ncc2nc3[nH]ccc3cc21,,,raw,,841.0069999999998,840.3417522559998,8.417600000000006,177.38000000000002,3,11,12,10,6,0.3695652173913043,61,0.08008582764856094,False,3,True,0,,CHEMBL5774230,168.5,nM,=,6.51,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,2,6.7734,1,active,MW=841.0 > 500.0; LogP=8.42 > 5.0; HBA=11 > 10
7a869946,,O=C(NS(=O)(=O)c1ccc(NC(CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,968.2149999999995,967.3760891639998,10.327599999999997,172.03,3,12,18,10,6,0.3584905660377358,69,0.042356492584702164,False,3,True,0,,CHEMBL5988601,134.0,nM,=,6.87,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.8729,1,active,MW=968.2 > 500.0; LogP=10.33 > 5.0; HBA=12 > 10
b47efb58,,O=C(NS(=O)(=O)c1ccc(NC(CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1,,,raw,,836.0929999999996,835.3437264159999,8.659000000000006,134.12,2,10,16,8,4,0.41304347826086957,59,0.06419913209084013,False,2,True,0,,CHEMBL5802150,882.0,nM,=,6.05,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.0545,1,active,MW=836.1 > 500.0; LogP=8.66 > 5.0
3ebb2181,,O=C(NS(=O)(=O)c1ccc(NC(CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1,,,raw,,923.1579999999997,922.3079330759999,9.044300000000003,125.11999999999999,2,10,16,8,4,0.425531914893617,63,0.10529315264149187,False,2,True,0,,CHEMBL5890440,559.0,nM,=,6.25,CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",0.8,1,6.2526,1,active,MW=923.2 > 500.0; LogP=9.04 > 5.0
8a0522c4,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,827.9639999999999,827.3101177799999,8.439200000000007,172.03,3,11,13,9,6,0.28888888888888886,60,0.07538008513422752,False,3,True,0,,CHEMBL5994332,1.7,nM,=,8.77,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.7696,1,active,MW=828.0 > 500.0; LogP=8.44 > 5.0; HBA=11 > 10
e3b0987d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.9760000000001,826.314868812,9.496599999999999,168.79,3,10,13,9,6,0.30434782608695654,60,0.07533364803534225,False,2,True,0,,CHEMBL5823408,33.0,nM,=,7.48,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,7.4815,1,active,MW=827.0 > 500.0; LogP=9.50 > 5.0
7a405b6a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC4CCCC4C3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,853.014,852.3305188759999,9.742599999999998,168.79,3,10,13,10,6,0.3333333333333333,62,0.0751372133420877,False,2,True,0,,CHEMBL5757008,19.0,nM,=,7.72,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.7212,1,active,MW=853.0 > 500.0; LogP=9.74 > 5.0
2ea66a81,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc4c3OCC4)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,814.921,814.278483304,8.164000000000007,178.02,3,11,12,9,6,0.2727272727272727,59,0.08020941402843454,False,3,True,0,,CHEMBL5959671,42.0,nM,=,7.38,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.3768,1,active,MW=814.9 > 500.0; LogP=8.16 > 5.0; HBA=11 > 10
321cdb25,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC4CCCC4C3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000002,812.2992187479999,8.865200000000003,168.79,3,10,12,9,6,0.28888888888888886,59,0.08018489694971012,False,2,True,0,,CHEMBL5822503,30.0,nM,=,7.52,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.5229,1,active,MW=812.9 > 500.0; LogP=8.87 > 5.0
cc9cad6e,,CN1CC=C(c2ccccc2[C@@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,868.0289999999997,867.3414179079999,8.948000000000004,172.03,3,11,13,9,6,0.2916666666666667,63,0.07476440221751503,False,3,True,0,,CHEMBL5920092,4.8,nM,=,8.32,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.3188,1,active,MW=868.0 > 500.0; LogP=8.95 > 5.0; HBA=11 > 10
74af7dd1,,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,868.0289999999997,867.3414179079999,8.948000000000004,172.03,3,11,13,9,6,0.2916666666666667,63,0.07476440221751503,False,3,True,0,,CHEMBL6048606,0.28,nM,=,9.55,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.5528,1,active,MW=868.0 > 500.0; LogP=8.95 > 5.0; HBA=11 > 10
ad9d0599,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cccc(N3CCCC3c3ccccc3C3CC3)c2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,812.9490000000001,812.2992187479999,9.106500000000002,168.79,3,10,13,9,6,0.28888888888888886,59,0.0755570295485051,False,2,True,0,,CHEMBL5841259,32.0,nM,=,7.5,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.4949,1,active,MW=812.9 > 500.0; LogP=9.11 > 5.0
d073289f,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCOCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,857.002,856.325433496,9.123100000000003,178.02,3,11,13,9,6,0.3191489361702128,62,0.07454904213133161,False,3,True,0,,CHEMBL6021289,3.8,nM,=,8.42,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4202,1,active,MW=857.0 > 500.0; LogP=9.12 > 5.0; HBA=11 > 10
86584dff,,CS(=O)(=NC(=O)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1,,,raw,,810.9769999999999,810.3199541920001,10.284899999999997,152.05,2,9,12,9,6,0.30434782608695654,59,0.09085344426312227,False,2,True,0,,CHEMBL5892562,68.0,nM,=,7.17,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.1675,1,active,MW=811.0 > 500.0; LogP=10.28 > 5.0
e939e7ca,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3CC3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.976,826.314868812,9.181600000000001,168.79,3,10,14,9,6,0.30434782608695654,60,0.07112856435346843,False,2,True,0,,CHEMBL6039686,21.0,nM,=,7.68,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.6778,1,active,MW=827.0 > 500.0; LogP=9.18 > 5.0
6723a6c8,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCC(F)(F)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,891.01,890.3273253159999,10.521999999999993,168.79,3,10,13,9,6,0.3333333333333333,64,0.07493919004791505,False,2,True,0,,CHEMBL5821827,28.0,nM,=,7.55,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.5528,1,active,MW=891.0 > 500.0; LogP=10.52 > 5.0
b46fd84d,,CN(C)C1CC1c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,856.0179999999997,855.341417908,8.646600000000005,172.03,3,11,14,9,6,0.3191489361702128,62,0.07074692648280795,False,3,False,1,PAINS match: dyes5A(27),CHEMBL5981833,0.32,nM,=,9.49,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.4949,1,active,MW=856.0 > 500.0; LogP=8.65 > 5.0; HBA=11 > 10
f029a336,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCNCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,856.0179999999999,855.3414179079999,8.696100000000007,180.82000000000002,4,11,13,9,6,0.3191489361702128,62,0.06446763634493438,False,3,True,0,,CHEMBL5909819,0.56,nM,=,9.25,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.2518,1,active,MW=856.0 > 500.0; LogP=8.70 > 5.0; HBA=11 > 10
ad661e92,,CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,870.0449999999996,869.3570679719999,9.038300000000003,172.03,3,11,13,9,6,0.3333333333333333,63,0.07471477278276337,False,3,True,0,,CHEMBL6053673,0.21,nM,=,9.68,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6778,1,active,MW=870.0 > 500.0; LogP=9.04 > 5.0; HBA=11 > 10
7d820b48,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCN(CCC(F)(F)F)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,952.0689999999998,951.3601026639999,10.360899999999996,172.03,3,11,15,9,6,0.36,68,0.0660746230271977,False,3,True,0,,CHEMBL5740818,19.0,nM,=,7.72,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.7212,1,active,MW=952.1 > 500.0; LogP=10.36 > 5.0; HBA=11 > 10
d39c4fb8,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCN(CCO)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,900.0709999999998,899.367632656,8.400800000000007,192.26000000000002,4,12,15,9,6,0.3469387755102041,65,0.05693820284710356,False,3,True,0,,CHEMBL6017993,0.56,nM,=,9.25,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.2518,1,active,MW=900.1 > 500.0; LogP=8.40 > 5.0; HBA=12 > 10
cefc8fe2,,CN(C)C(=O)CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,941.1239999999997,940.3941817519999,8.496700000000006,192.34,3,12,15,9,6,0.35294117647058826,68,0.06581162091832436,False,3,True,0,,CHEMBL5963587,1.2,nM,=,8.92,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9208,1,active,MW=941.1 > 500.0; LogP=8.50 > 5.0; HBA=12 > 10
9acd68ed,,CC(=O)N(C)CCN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,955.1509999999997,954.409831816,8.886800000000004,192.34,3,12,16,9,6,0.36538461538461536,69,0.06176349787948335,False,3,True,0,,CHEMBL5937625,1.3,nM,=,8.89,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.8861,1,active,MW=955.2 > 500.0; LogP=8.89 > 5.0; HBA=12 > 10
70bf0690,,CNCCC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,941.1239999999997,940.3941817519999,8.544600000000006,201.12999999999997,4,12,16,9,6,0.35294117647058826,68,0.053320620427940044,False,3,True,0,,CHEMBL5741823,0.3,nM,=,9.52,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.5229,1,active,MW=941.1 > 500.0; LogP=8.54 > 5.0; HBA=12 > 10
60d31427,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3=CCN(C4CC4)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,894.0669999999998,893.3570679719999,9.4806,172.03,3,11,14,10,6,0.32,65,0.07026885991164757,False,3,True,0,,CHEMBL5980660,3.5,nM,=,8.46,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4559,1,active,MW=894.1 > 500.0; LogP=9.48 > 5.0; HBA=11 > 10
bf2caab4,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3=CCN(Cc4ccccc4)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,944.1269999999998,943.3727180359999,10.518399999999994,172.03,3,11,15,10,7,0.25925925925925924,69,0.06597388371191654,False,3,True,0,,CHEMBL5742365,6.6,nM,=,8.18,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.1805,1,active,MW=944.1 > 500.0; LogP=10.52 > 5.0; HBA=11 > 10
7e6a46dc,,CC(=O)N1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,896.0389999999995,895.336332528,8.864700000000003,189.1,3,11,13,9,6,0.2857142857142857,65,0.07419848572411764,False,3,True,0,,CHEMBL5878897,0.68,nM,=,9.17,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.1675,1,active,MW=896.0 > 500.0; LogP=8.86 > 5.0; HBA=11 > 10
727261e7,,CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,898.0549999999996,897.3519825919999,8.955000000000004,189.1,3,11,13,9,6,0.32653061224489793,65,0.07414566078873958,False,3,True,0,,CHEMBL5873270,3.0,nM,=,8.52,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.5229,1,active,MW=898.1 > 500.0; LogP=8.96 > 5.0; HBA=11 > 10
1a3a18de,,CS(=O)(=O)N1CC=C(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,932.0939999999996,931.303318148,8.277800000000006,206.17,3,12,14,9,6,0.2916666666666667,66,0.06972042152672032,False,3,True,0,,CHEMBL5836762,11.0,nM,=,7.96,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.9586,1,active,MW=932.1 > 500.0; LogP=8.28 > 5.0; HBA=12 > 10
549ee5e6,,CN1CCC(Cc2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,884.0719999999995,883.372718036,9.113400000000002,172.03,3,11,14,9,6,0.3469387755102041,64,0.07039294570884531,False,3,True,0,,CHEMBL5811985,0.11,nM,=,9.96,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.9586,1,active,MW=884.1 > 500.0; LogP=9.11 > 5.0; HBA=11 > 10
c887e704,,CN1CCC(Oc2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,886.0439999999995,885.3519825919999,8.702100000000005,181.26000000000002,3,12,14,9,6,0.3333333333333333,64,0.07005073584344106,False,3,True,0,,CHEMBL6059979,0.24,nM,=,9.62,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6198,1,active,MW=886.0 > 500.0; LogP=8.70 > 5.0; HBA=12 > 10
10bec397,,CN1CCN(Cc2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,885.0599999999996,884.367967004,7.976500000000009,175.27,3,12,14,9,6,0.3333333333333333,64,0.0711988447440947,False,3,True,0,,CHEMBL5779937,1.3945,nM,=,10.05,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,8.8556,1,active,MW=885.1 > 500.0; LogP=7.98 > 5.0; HBA=12 > 10
b7a6613f,,NC(=O)C1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,898.0549999999996,897.3519825919999,8.9882,211.87999999999997,4,11,14,9,6,0.32653061224489793,65,0.05984067293042284,False,3,True,0,,CHEMBL6064098,0.8,nM,=,9.1,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.0969,1,active,MW=898.1 > 500.0; LogP=8.99 > 5.0; HBA=11 > 10
2173de8d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3-c3ccncc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,849.9700000000001,849.2944677159999,9.2911,181.68000000000004,3,11,13,9,7,0.2127659574468085,62,0.07429999306478823,False,3,True,0,,CHEMBL5960930,2.3,nM,=,8.64,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.6383,1,active,MW=850.0 > 500.0; LogP=9.29 > 5.0; HBA=11 > 10
3582adae,,CN1CCC[C@@H](c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,870.0449999999996,869.357067972,9.038300000000003,172.03,3,11,13,9,6,0.3333333333333333,63,0.07471477278276337,False,3,False,1,PAINS match: dyes5A(27),CHEMBL6024503,0.5,nM,=,9.3,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.301,1,active,MW=870.0 > 500.0; LogP=9.04 > 5.0; HBA=11 > 10
2193ec18,,CN1CCC[C@H](c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,870.0449999999996,869.357067972,9.038300000000003,172.03,3,11,13,9,6,0.3333333333333333,63,0.07471477278276337,False,3,False,1,PAINS match: dyes5A(27),CHEMBL5861804,2.5,nM,=,8.6,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.6021,1,active,MW=870.0 > 500.0; LogP=9.04 > 5.0; HBA=11 > 10
1b522781,,CN(C)C1CCCN(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,899.0869999999996,898.383617068,8.759500000000005,175.27,3,12,14,9,6,0.3469387755102041,65,0.07015278521714259,False,3,True,0,,CHEMBL6051337,0.58,nM,=,9.24,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.2366,1,active,MW=899.1 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
27c4e67f,,CN(C)C1CCCN(c2ccccc2[C@@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,899.0869999999996,898.383617068,8.759500000000005,175.27,3,12,14,9,6,0.3469387755102041,65,0.07015278521714259,False,3,True,0,,CHEMBL5802211,0.15,nM,=,9.82,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.8239,1,active,MW=899.1 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
288349f9,,CN1C2CCC1CN(c1ccccc1[C@H]1CCCN1c1ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc1)C2,,,raw,,897.0709999999997,896.367967004,8.511900000000004,175.27,3,12,13,10,6,0.3469387755102041,65,0.07459508659582503,False,3,True,0,,CHEMBL5906987,0.96,nM,=,9.02,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.0177,1,active,MW=897.1 > 500.0; LogP=8.51 > 5.0; HBA=12 > 10
d755276d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCNCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,857.0059999999999,856.3366668759999,7.638700000000009,184.06000000000003,4,12,13,9,6,0.30434782608695654,62,0.06589266227775081,False,3,True,0,,CHEMBL5982217,0.47,nM,=,9.33,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.3279,1,active,MW=857.0 > 500.0; LogP=7.64 > 5.0; HBA=12 > 10
27c022e8,,CN1CCN(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,871.0329999999997,870.35231694,7.980900000000008,175.27,3,12,13,9,6,0.3191489361702128,63,0.07552844779276405,False,3,True,0,,CHEMBL5811460,0.88,nM,=,9.06,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.0555,1,active,MW=871.0 > 500.0; LogP=7.98 > 5.0; HBA=12 > 10
10a8959e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCOCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,857.9899999999999,857.3206824639999,8.065700000000009,181.26000000000002,3,12,13,9,6,0.30434782608695654,62,0.07520887311195505,False,3,True,0,,CHEMBL5806788,3.8,nM,=,8.42,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4202,1,active,MW=858.0 > 500.0; LogP=8.07 > 5.0; HBA=12 > 10
704e725a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCS(=O)(=O)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,905.068,904.292419116,8.521300000000007,202.92999999999998,3,12,13,9,6,0.3191489361702128,64,0.07375999876439945,False,3,True,0,,CHEMBL5997261,0.49,nM,=,9.31,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.3098,1,active,MW=905.1 > 500.0; LogP=8.52 > 5.0; HBA=12 > 10
a399042e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCC(O)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,872.0169999999999,871.336332528,8.190200000000008,192.26000000000002,4,12,13,9,6,0.3191489361702128,63,0.06437143365558576,False,3,True,0,,CHEMBL5907442,4.4,nM,=,8.36,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.3565,1,active,MW=872.0 > 500.0; LogP=8.19 > 5.0; HBA=12 > 10
a39c972f,,CN(C)C1CCN(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,899.0869999999996,898.383617068,8.759500000000005,175.27,3,12,14,9,6,0.3469387755102041,65,0.07015278521714259,False,3,True,0,,CHEMBL5962024,0.23,nM,=,9.64,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6383,1,active,MW=899.1 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
e909ec62,,CN1CCC(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,856.0179999999997,855.3414179079999,8.648200000000005,172.03,3,11,13,9,6,0.3191489361702128,62,0.07501055638225981,False,3,False,1,PAINS match: dyes5A(27),CHEMBL5840340,0.79,nM,=,9.1,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.1024,1,active,MW=856.0 > 500.0; LogP=8.65 > 5.0; HBA=11 > 10
c4232f93,,CN(C)CCOc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,860.0059999999997,859.336332528,8.169500000000008,181.26000000000002,3,12,16,8,6,0.30434782608695654,62,0.06285389333135917,False,3,True,0,,CHEMBL5820634,1.4,nM,=,8.85,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.8539,1,active,MW=860.0 > 500.0; LogP=8.17 > 5.0; HBA=12 > 10
ac207aab,,COCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,816.9369999999999,816.294133368,8.375500000000006,178.02,3,11,14,8,6,0.2727272727272727,59,0.0710708423692315,False,3,True,0,,CHEMBL5908484,4.4,nM,=,8.36,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.3565,1,active,MW=816.9 > 500.0; LogP=8.38 > 5.0; HBA=11 > 10
7cf44d72,,CN(C)Cc1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,829.9799999999998,829.3257678439999,8.290700000000006,172.03,3,11,14,8,6,0.28888888888888886,60,0.07126443011467805,False,3,True,0,,CHEMBL5934464,5.4,nM,=,8.27,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.2676,1,active,MW=830.0 > 500.0; LogP=8.29 > 5.0; HBA=11 > 10
e787e9e7,,CN(C)CCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,844.0069999999998,843.3414179079999,8.333200000000007,172.03,3,11,15,8,6,0.30434782608695654,61,0.06705275979820538,False,3,False,1,PAINS match: dyes5A(27),CHEMBL5943281,1.2,nM,=,8.92,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9208,1,active,MW=844.0 > 500.0; LogP=8.33 > 5.0; HBA=11 > 10
1f750a1f,,CN(C)CCCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,858.0339999999998,857.357067972,8.723300000000005,172.03,3,11,16,8,6,0.3191489361702128,62,0.0628048715105789,False,3,True,0,,CHEMBL5877756,0.14,nM,=,9.85,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.8539,1,active,MW=858.0 > 500.0; LogP=8.72 > 5.0; HBA=11 > 10
32a95fb2,,CN1CCC(Oc2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,872.0169999999996,871.336332528,8.312000000000006,181.26000000000002,3,12,14,9,6,0.3191489361702128,63,0.07047912246565319,False,3,True,0,,CHEMBL5873197,0.63,nM,=,9.2,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.2007,1,active,MW=872.0 > 500.0; LogP=8.31 > 5.0; HBA=12 > 10
0cb7c369,,CN1CCC(N(C)c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,885.0599999999997,884.367967004,8.369400000000006,175.27,3,12,14,9,6,0.3333333333333333,64,0.0705398358850069,False,3,True,0,,CHEMBL6036388,0.38,nM,=,9.42,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.4202,1,active,MW=885.1 > 500.0; LogP=8.37 > 5.0; HBA=12 > 10
060f6e63,,CN1CCCC(N(C)c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,899.0869999999996,898.383617068,8.759500000000005,175.27,3,12,14,9,6,0.3469387755102041,65,0.07015278521714259,False,3,True,0,,CHEMBL5937698,0.35,nM,=,9.46,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.4559,1,active,MW=899.1 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
5d7bf6a6,,CN(CC1CCCN1C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,899.0869999999998,898.383617068,8.759500000000005,175.27,3,12,15,9,6,0.3469387755102041,65,0.06613688413041596,False,3,True,0,,CHEMBL5770993,0.25,nM,=,9.6,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6021,1,active,MW=899.1 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
cf0f373b,,CN1CCC2(CC1)CN(c1ccccc1[C@H]1CCCN1c1ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc1)C2,,,raw,,911.0979999999997,910.383617068,8.761100000000004,175.27,3,12,13,10,6,0.36,66,0.0743540394905053,False,3,True,0,,CHEMBL6039338,0.28,nM,=,9.55,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.5528,1,active,MW=911.1 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
06209d56,,CN(C)CC1CCCN1c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,899.0869999999998,898.383617068,8.759500000000005,175.27,3,12,15,9,6,0.3469387755102041,65,0.06613688413041596,False,3,True,0,,CHEMBL5886990,0.74,nM,=,9.13,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.1308,1,active,MW=899.1 > 500.0; LogP=8.76 > 5.0; HBA=12 > 10
952040e8,,Cn1cc(-c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)cn1,,,raw,,852.9739999999998,852.3053667479999,8.629600000000003,186.61,3,12,13,9,7,0.2391304347826087,62,0.07447454513711593,False,3,False,1,PAINS match: dyes5A(27),CHEMBL6034329,4.2,nM,=,8.38,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.3768,1,active,MW=853.0 > 500.0; LogP=8.63 > 5.0; HBA=12 > 10
dfb4fcd1,,CN1CCC(n2nccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,860.0099999999996,859.347565908,7.692300000000008,189.85,3,13,13,9,6,0.35555555555555557,62,0.07596352991127846,False,3,True,0,,CHEMBL6049502,6.8,nM,=,8.17,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.1675,1,active,MW=860.0 > 500.0; LogP=7.69 > 5.0; HBA=13 > 10
897fae5d,,CN1CC=C(c2ccc(Cl)cc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,902.4739999999996,901.3024455560001,9.6014,172.03,3,11,13,9,6,0.2916666666666667,64,0.07446216531021795,False,3,True,0,,CHEMBL5835085,1.8,nM,=,8.74,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.7447,1,active,MW=902.5 > 500.0; LogP=9.60 > 5.0; HBA=11 > 10
deb77b05,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc4ccncc34)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,823.9320000000001,823.2788176519999,8.777300000000004,181.68000000000004,3,11,12,9,7,0.2222222222222222,60,0.07914442267931272,False,3,True,0,,CHEMBL5815551,49.0,nM,=,7.31,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.3098,1,active,MW=823.9 > 500.0; LogP=8.78 > 5.0; HBA=11 > 10
3a13e979,,Cn1cc2cccc(C3CCCN3c3ccc(-c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)cc3)c2n1,,,raw,,826.9359999999998,826.2897166839999,8.115800000000007,186.61,3,12,12,9,7,0.25,60,0.0797967740848654,False,3,True,0,,CHEMBL6014680,12.0,nM,=,7.92,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.9208,1,active,MW=826.9 > 500.0; LogP=8.12 > 5.0; HBA=12 > 10
aa9df70f,,CN1CCc2cccc(C3CCCN3c3ccc(-c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)cc3)c2C1,,,raw,,841.9909999999998,841.3257678439999,8.217000000000008,172.03,3,11,12,9,6,0.30434782608695654,61,0.08010717498797079,False,3,True,0,,CHEMBL5768126,16.0,nM,=,7.8,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.7959,1,active,MW=842.0 > 500.0; LogP=8.22 > 5.0; HBA=11 > 10
ff2fd442,,CC(C)(c1ccccc1C1CC1)C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,raw,,855.0299999999996,854.3461689400001,9.711599999999999,168.79,3,10,14,9,6,0.3333333333333333,62,0.07085981845556871,False,2,True,0,,CHEMBL6006703,36.0,nM,=,7.44,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.4437,1,active,MW=855.0 > 500.0; LogP=9.71 > 5.0
a78343a5,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@H](F)C[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.939,830.2897969359999,9.054500000000003,168.79,3,10,13,9,6,0.28888888888888886,60,0.0754367740246174,False,2,True,0,,CHEMBL5756700,8.4,nM,=,8.08,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.0757,1,active,MW=830.9 > 500.0; LogP=9.05 > 5.0
dfc97ff9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@H](F)C[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.939,830.2897969359999,9.054500000000003,168.79,3,10,13,9,6,0.28888888888888886,60,0.0754367740246174,False,2,True,0,,CHEMBL6017527,5.8,nM,=,8.24,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.2366,1,active,MW=830.9 > 500.0; LogP=9.05 > 5.0
5cd53212,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@@H](F)C[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.939,830.2897969359999,9.054500000000003,168.79,3,10,13,9,6,0.28888888888888886,60,0.0754367740246174,False,2,True,0,,CHEMBL5795254,0.44,nM,=,9.36,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.3565,1,active,MW=830.9 > 500.0; LogP=9.05 > 5.0
26c8bd0e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@@H](F)C[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,830.939,830.2897969359999,9.054500000000003,168.79,3,10,13,9,6,0.28888888888888886,60,0.0754367740246174,False,2,True,0,,CHEMBL5882599,29.0,nM,=,7.54,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.5376,1,active,MW=830.9 > 500.0; LogP=9.05 > 5.0
65cbc511,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(F)=CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,828.923,828.274146872,9.179700000000002,168.79,3,10,13,9,6,0.24444444444444444,60,0.07540322629830332,False,2,True,0,,CHEMBL5781680,13.0,nM,=,7.89,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.8861,1,active,MW=828.9 > 500.0; LogP=9.18 > 5.0
6bed9b16,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(F)(F)C[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,848.929,848.280375124,9.351700000000001,168.79,3,10,13,9,6,0.28888888888888886,61,0.07523031408069221,False,2,True,0,,CHEMBL6002785,10.9,nM,=,7.7,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,7.9626,1,active,MW=848.9 > 500.0; LogP=9.35 > 5.0
c8c06ce1,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(C4CC4)CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,853.0139999999999,852.3305188759999,9.742599999999998,168.79,3,10,14,10,6,0.3333333333333333,62,0.07086513670699293,False,2,True,0,,CHEMBL5752551,62.0,nM,=,7.21,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.2076,1,active,MW=853.0 > 500.0; LogP=9.74 > 5.0
e4604117,,C=C1CC(c2ccccc2C2CC2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,824.9599999999998,824.2992187479999,9.272600000000002,168.79,3,10,13,9,6,0.2608695652173913,60,0.057990418500932915,False,2,True,0,,CHEMBL5831285,3.3,nM,=,8.48,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4815,1,active,MW=825.0 > 500.0; LogP=9.27 > 5.0
a5f7effd,,CN(C)C1CC(c2ccccc2C2CC2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,raw,,856.0179999999998,855.3414179079999,8.646600000000005,172.03,3,11,14,9,6,0.3191489361702128,62,0.07074692648280795,False,3,True,0,,CHEMBL5866105,2.7,nM,=,8.57,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.5686,1,active,MW=856.0 > 500.0; LogP=8.65 > 5.0; HBA=11 > 10
7839b939,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C(=O)COCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,842.9309999999999,842.2733979239999,7.869500000000008,195.09,3,11,13,9,6,0.26666666666666666,61,0.07564096139007627,False,3,True,0,,CHEMBL5804914,5.9,nM,=,8.23,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.2291,1,active,MW=842.9 > 500.0; LogP=7.87 > 5.0; HBA=11 > 10
27f4a7ba,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCOCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,828.948,828.2941333679998,8.342900000000007,178.02,3,11,13,9,6,0.28888888888888886,60,0.07530569812841317,False,3,True,0,,CHEMBL5860255,22.0,nM,=,7.66,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.6576,1,active,MW=828.9 > 500.0; LogP=8.34 > 5.0; HBA=11 > 10
3ab8f1d3,,CN1CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C(c2ccccc2C2CC2)C1,,,raw,,841.9910000000001,841.3257678439999,8.258100000000006,172.03,3,11,13,9,6,0.30434782608695654,61,0.07553317570728811,False,3,True,0,,CHEMBL5980488,6.0,nM,=,8.22,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.2218,1,active,MW=842.0 > 500.0; LogP=8.26 > 5.0; HBA=11 > 10
7c4ba947,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCN3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,813.937,813.2944677159999,8.396700000000006,172.03,3,11,13,9,6,0.2727272727272727,59,0.07554280459310465,False,3,True,0,,CHEMBL5908080,17.0,nM,=,7.77,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.7696,1,active,MW=813.9 > 500.0; LogP=8.40 > 5.0; HBA=11 > 10
e4543fe6,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CCN3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,841.003,840.3305188759999,9.144600000000002,168.79,3,10,15,9,6,0.3191489361702128,61,0.06698654031295999,False,2,True,0,,CHEMBL5752506,25.0,nM,=,7.6,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.6021,1,active,MW=841.0 > 500.0; LogP=9.14 > 5.0
f029808b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CCN3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,841.003,840.3305188759999,9.144600000000002,168.79,3,10,15,9,6,0.3191489361702128,61,0.06698654031295999,False,2,True,0,,CHEMBL6037553,8.1,nM,=,8.09,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.0915,1,active,MW=841.0 > 500.0; LogP=9.14 > 5.0
a0d69112,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(CN3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.0079999999999,830.34616894,9.118600000000004,168.79,3,10,14,9,5,0.391304347826087,60,0.07250893124395665,False,2,True,0,,CHEMBL5805324,3.9,nM,=,8.41,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4089,1,active,MW=831.0 > 500.0; LogP=9.12 > 5.0
06d6e563,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(C3CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999997,873.3883680999999,8.930100000000005,172.03,3,11,14,10,5,0.4583333333333333,63,0.07187449364464595,False,3,True,0,,CHEMBL5871667,8.9,nM,=,8.05,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.0506,1,active,MW=874.1 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
0e4e8f2e,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Cc2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,826.9760000000001,826.314868812,9.030300000000004,168.79,3,10,14,9,6,0.30434782608695654,60,0.07118387962075966,False,2,False,1,PAINS match: anil_di_alk_E(186),CHEMBL5780703,11.0,nM,=,7.96,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.9586,1,active,MW=827.0 > 500.0; LogP=9.03 > 5.0
4f8666cc,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(CC2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,833.0239999999999,832.3618190039999,9.036400000000004,168.79,3,10,14,9,5,0.43478260869565216,60,0.07252793073078521,False,2,True,0,,CHEMBL5946813,26.0,nM,=,7.58,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.585,1,active,MW=833.0 > 500.0; LogP=9.04 > 5.0
ed88ace4,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Nc2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,827.964,827.3101177799999,9.183100000000001,180.82000000000002,4,11,14,9,6,0.28888888888888886,60,0.06072865191495055,False,3,True,0,,CHEMBL5903784,660.0,nM,=,6.18,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,6.1805,1,active,MW=828.0 > 500.0; LogP=9.18 > 5.0; HBA=11 > 10
9e7f5c40,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCCN3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,805.958,805.3257678439999,7.737400000000008,172.03,3,11,12,9,5,0.3953488372093023,58,0.08322770822307782,False,3,True,0,,CHEMBL5758712,59.0,nM,=,7.23,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.2291,1,active,MW=806.0 > 500.0; LogP=7.74 > 5.0; HBA=11 > 10
52c5f540,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCCN3c3ccccc3Br)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,844.7890000000001,843.204979784,7.622500000000008,172.03,3,11,11,8,5,0.35,56,0.08824905451417166,False,3,True,0,,CHEMBL6013081,33.0,nM,=,7.48,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.4815,1,active,MW=844.8 > 500.0; LogP=7.62 > 5.0; HBA=11 > 10
9f1d1726,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc5c(c4)CCC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,895.0949999999999,894.377469068,9.973999999999998,179.79,4,10,13,10,6,0.37254901960784315,65,0.06439561425935657,False,2,True,0,,CHEMBL5932011,17.0,nM,=,7.77,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.7696,1,active,MW=895.1 > 500.0; LogP=9.97 > 5.0
34caee4d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc3[nH]c(N4CCCC4c4ccccc4C4CC4)nc3c2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,852.9739999999999,852.3053667479999,8.982800000000003,197.47,4,11,13,10,7,0.2826086956521739,62,0.06380912808566157,False,3,True,0,,CHEMBL5831887,87.0,nM,=,7.06,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.0605,1,active,MW=853.0 > 500.0; LogP=8.98 > 5.0; HBA=11 > 10
35cae2c9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cnn(C3CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)c2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,857.0059999999997,856.336666876,8.502100000000008,186.61000000000004,3,12,14,10,6,0.3695652173913043,62,0.07044528233462465,False,3,True,0,,CHEMBL5759943,2.3,nM,=,8.64,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.6383,1,active,MW=857.0 > 500.0; LogP=8.50 > 5.0; HBA=12 > 10
b0c2bf35,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCCN(c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,819.9849999999999,819.3414179079999,7.985000000000008,172.03,3,11,12,9,5,0.4090909090909091,59,0.0823304154750381,False,3,True,0,,CHEMBL5799858,69.0,nM,=,7.16,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.1612,1,active,MW=820.0 > 500.0; LogP=7.99 > 5.0; HBA=11 > 10
ac05f968,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc([C@H]2CC[C@@H](N3CC(N4CCC[C@@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999997,873.3883680999999,8.645500000000007,172.03,3,11,14,10,5,0.4583333333333333,63,0.07205488472303866,False,3,True,0,,CHEMBL6059089,29.0,nM,=,7.54,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.5376,1,active,MW=874.1 > 500.0; LogP=8.65 > 5.0; HBA=11 > 10
e49c9d89,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc([C@H]2CC[C@@H](N3CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999997,873.3883680999999,8.645500000000007,172.03,3,11,14,10,5,0.4583333333333333,63,0.07205488472303866,False,3,True,0,,CHEMBL5856671,1.7,nM,=,8.77,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.7696,1,active,MW=874.1 > 500.0; LogP=8.65 > 5.0; HBA=11 > 10
f616d9e9,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,888.104,887.404018164,9.198700000000002,183.02999999999997,4,11,13,10,5,0.46938775510204084,64,0.06533330064503391,False,3,True,0,,CHEMBL5854463,0.476,nM,=,10.66,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,4,9.3224,1,active,MW=888.1 > 500.0; LogP=9.20 > 5.0; HBA=11 > 10
911f21f5,,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,878.0399999999998,877.3632962239999,8.776200000000006,172.03,3,11,13,10,5,0.44680851063829785,63,0.07628554564572541,False,3,True,0,,CHEMBL5896999,0.98,nM,=,9.01,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.0088,1,active,MW=878.0 > 500.0; LogP=8.78 > 5.0; HBA=11 > 10
9c9096f4,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,888.104,887.404018164,9.198700000000002,183.02999999999997,4,11,13,10,5,0.46938775510204084,64,0.06533330064503391,False,3,True,0,,CHEMBL5792023,0.63,nM,=,9.2,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.2007,1,active,MW=888.1 > 500.0; LogP=9.20 > 5.0; HBA=11 > 10
cf7301aa,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCC[C@@H]4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,831.9959999999999,831.3414179079999,7.903900000000009,172.03,3,11,13,10,5,0.4222222222222222,60,0.07781259784844878,False,3,True,0,,CHEMBL6017239,1.4,nM,=,8.85,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.8539,1,active,MW=832.0 > 500.0; LogP=7.90 > 5.0; HBA=11 > 10
624d7319,,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,862.0219999999998,861.351982592,7.672900000000008,181.26000000000002,3,12,13,10,5,0.43478260869565216,62,0.07777412229573852,False,3,True,0,,CHEMBL5965443,0.07,nM,=,10.15,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,10.1549,1,active,MW=862.0 > 500.0; LogP=7.67 > 5.0; HBA=12 > 10
151c5614,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC[C@@H](N4CCC[C@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999997,873.3883680999999,9.074200000000005,172.03,3,11,13,10,5,0.4583333333333333,63,0.07614025941863069,False,3,True,0,,CHEMBL5854815,0.21,nM,=,9.68,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6778,1,active,MW=874.1 > 500.0; LogP=9.07 > 5.0; HBA=11 > 10
ebf05a6a,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC[C@@H](N4CCC[C@@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999997,873.3883680999999,9.074200000000005,172.03,3,11,13,10,5,0.4583333333333333,63,0.07614025941863069,False,3,True,0,,CHEMBL5812634,3.9,nM,=,8.41,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4089,1,active,MW=874.1 > 500.0; LogP=9.07 > 5.0; HBA=11 > 10
6e2d055f,,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,850.0109999999996,849.3519825919999,7.357900000000008,181.26000000000002,3,12,13,9,5,0.4222222222222222,61,0.07927492410624021,False,3,True,0,,CHEMBL5903988,0.059,nM,=,10.23,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,10.2291,1,active,MW=850.0 > 500.0; LogP=7.36 > 5.0; HBA=12 > 10
3498556d,,COc1ccc(-c2cc(Cn3cnc4c(N)ncnc43)c(N3CCC[C@@H](N)C3)cn2)cc1F,,,raw,,448.50600000000026,448.2135356400001,2.5940000000000003,121.0,2,9,5,5,4,0.30434782608695654,33,0.47790222541788074,True,0,True,0,,CHEMBL6020918,22.0075,nM,=,7.36,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,7.6574,1,active,
f242fbe1,,CC(C)c1ccccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,890.1199999999994,889.4196682280001,9.444700000000001,183.03,4,11,13,9,5,0.46938775510204084,64,0.06527078762854406,False,3,True,0,,CHEMBL5943655,0.74,nM,=,9.13,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.1308,1,active,MW=890.1 > 500.0; LogP=9.44 > 5.0; HBA=11 > 10
745f8095,,CC(C)c1ccccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,890.1199999999994,889.4196682280001,9.444700000000001,183.03,4,11,13,9,5,0.46938775510204084,64,0.06527078762854406,False,3,True,0,,CHEMBL5868656,2.1,nM,=,8.68,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.6778,1,active,MW=890.1 > 500.0; LogP=9.44 > 5.0; HBA=11 > 10
32a63141,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccccc2C2CCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999998,873.3883680999999,9.074200000000005,172.03,3,11,13,10,5,0.4583333333333333,63,0.07614025941863069,False,3,True,0,,CHEMBL5970525,1.1,nM,=,8.96,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9586,1,active,MW=874.1 > 500.0; LogP=9.07 > 5.0; HBA=11 > 10
4f448c21,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2cccc(C4CC4)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,860.0499999999998,859.3727180359999,8.684100000000006,172.03,3,11,13,10,5,0.44680851063829785,62,0.07642415225680049,False,3,True,0,,CHEMBL5766570,1.0,nM,=,9.0,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,9.0,1,active,MW=860.0 > 500.0; LogP=8.68 > 5.0; HBA=11 > 10
656e2343,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,854.43,853.302445556,8.460100000000006,172.03,3,11,12,9,5,0.4090909090909091,60,0.08123684667299502,False,3,True,0,,CHEMBL6045065,4.4,nM,=,8.36,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.3565,1,active,MW=854.4 > 500.0; LogP=8.46 > 5.0; HBA=11 > 10
2c7164e4,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,854.43,853.302445556,8.460100000000006,172.03,3,11,12,9,5,0.4090909090909091,60,0.08123684667299502,False,3,True,0,,CHEMBL6062678,4.7,nM,=,8.33,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.3279,1,active,MW=854.4 > 500.0; LogP=8.46 > 5.0; HBA=11 > 10
32edf7a2,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccccc2N2CCCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,889.0919999999996,888.3992671319999,8.406900000000007,175.27,3,12,13,10,5,0.4583333333333333,64,0.07618980519517987,False,3,True,0,,CHEMBL5875749,0.32,nM,=,9.49,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.4949,1,active,MW=889.1 > 500.0; LogP=8.41 > 5.0; HBA=12 > 10
7b17d234,,CN1CC=C(c2ccccc2[C@@H]2CCCN2C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)CC1,,,raw,,915.1299999999994,914.414917196,8.525600000000006,175.27,3,12,13,10,5,0.44,66,0.07599385945203564,False,3,True,0,,CHEMBL6051188,57.0,nM,=,7.24,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.2441,1,active,MW=915.1 > 500.0; LogP=8.53 > 5.0; HBA=12 > 10
b4524705,,CN1CCC(c2ccccc2[C@@H]2CCCN2C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)CC1,,,raw,,917.1459999999994,916.43056726,8.615900000000005,175.27,3,12,13,10,5,0.48,66,0.07590440710854353,False,3,True,0,,CHEMBL5894601,78.0,nM,=,7.11,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.1079,1,active,MW=917.1 > 500.0; LogP=8.62 > 5.0; HBA=12 > 10
76ab5a20,,COCc1ccccc1C1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,864.0379999999996,863.367632656,7.953100000000009,181.26000000000002,3,12,14,9,5,0.43478260869565216,62,0.07253306325050483,False,3,True,0,,CHEMBL5739744,0.24,nM,=,9.62,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6198,1,active,MW=864.0 > 500.0; LogP=7.95 > 5.0; HBA=12 > 10
63838eca,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccccc2CO)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,850.011,849.3519825919999,7.299000000000009,192.26000000000002,4,12,13,9,5,0.4222222222222222,61,0.06840517642526332,False,3,True,0,,CHEMBL5928650,2.1,nM,=,8.68,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.6778,1,active,MW=850.0 > 500.0; LogP=7.30 > 5.0; HBA=12 > 10
fa83ff43,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2cccc(Cl)c2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,894.4949999999998,893.333745684,9.337500000000002,172.03,3,11,13,10,5,0.44680851063829785,63,0.07598897523877486,False,3,True,0,,CHEMBL5880669,1.65,nM,=,8.89,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,8.7825,1,active,MW=894.5 > 500.0; LogP=9.34 > 5.0; HBA=11 > 10
7f863659,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2cc(Cl)ccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,894.4949999999998,893.333745684,9.337500000000002,172.03,3,11,13,10,5,0.44680851063829785,63,0.07598897523877486,False,3,True,0,,CHEMBL5780722,1.1,nM,=,8.96,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9586,1,active,MW=894.5 > 500.0; LogP=9.34 > 5.0; HBA=11 > 10
149635d2,,CCc1c(Cl)cccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,882.4839999999995,881.3337456840001,9.0225,172.03,3,11,13,9,5,0.43478260869565216,62,0.07613375546000635,False,3,True,0,,CHEMBL5812498,1.9,nM,=,8.72,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.7212,1,active,MW=882.5 > 500.0; LogP=9.02 > 5.0; HBA=11 > 10
54b51d0c,,CCc1c(Cl)cccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,882.4839999999995,881.3337456840001,9.0225,172.03,3,11,13,9,5,0.43478260869565216,62,0.07613375546000635,False,3,True,0,,CHEMBL5925442,1.4,nM,=,8.85,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.8539,1,active,MW=882.5 > 500.0; LogP=9.02 > 5.0; HBA=11 > 10
93018ed3,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccc(C4CC4)cc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,900.1149999999997,899.4040181639999,9.561500000000002,172.03,3,11,14,11,5,0.48,65,0.07160877730475732,False,3,True,0,,CHEMBL5754014,1.5,nM,=,8.82,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.8239,1,active,MW=900.1 > 500.0; LogP=9.56 > 5.0; HBA=11 > 10
ee22fd3b,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2cc(C4CC4)ccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,900.1149999999997,899.4040181639999,9.561500000000002,172.03,3,11,14,11,5,0.48,65,0.07160877730475732,False,3,True,0,,CHEMBL5841055,12.0,nM,=,7.92,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.9208,1,active,MW=900.1 > 500.0; LogP=9.56 > 5.0; HBA=11 > 10
7c1bd3a9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2sccc2-c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,936.5569999999999,935.2901666199999,10.188599999999996,172.03,3,12,13,10,6,0.375,65,0.07433986372701266,False,3,True,0,,CHEMBL5861737,23.0,nM,=,7.64,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.6383,1,active,MW=936.6 > 500.0; LogP=10.19 > 5.0; HBA=12 > 10
b060d13e,,CC1CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,raw,,874.0769999999994,873.3883680999999,8.930100000000003,172.03,3,11,13,10,5,0.4583333333333333,63,0.07620741896204337,False,3,True,0,,CHEMBL5941985,0.21,nM,=,9.68,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6778,1,active,MW=874.1 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
2aa5d0ca,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC(C4CC4)CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,900.1149999999998,899.4040181639999,9.320200000000003,172.03,3,11,14,11,5,0.48,65,0.0716592487320889,False,3,True,0,,CHEMBL5865162,1.1,nM,=,8.96,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9586,1,active,MW=900.1 > 500.0; LogP=9.32 > 5.0; HBA=11 > 10
f8aab938,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC(c4ccccc4)=CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,934.132,933.3883680999999,9.987499999999999,172.03,3,11,14,11,6,0.3584905660377358,68,0.07012984602264051,False,3,True,0,,CHEMBL5921534,32.0,nM,=,7.5,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.4949,1,active,MW=934.1 > 500.0; LogP=9.99 > 5.0; HBA=11 > 10
23f5a511,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC4(CC4)CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,886.0879999999997,885.3883680999999,9.074200000000005,172.03,3,11,13,11,5,0.46938775510204084,64,0.07610027685713401,False,3,True,0,,CHEMBL6057391,0.56,nM,=,9.25,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.2518,1,active,MW=886.1 > 500.0; LogP=9.07 > 5.0; HBA=11 > 10
dc86f743,,CC1(C)CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,raw,,888.1039999999994,887.404018164,9.3202,172.03,3,11,13,10,5,0.46938775510204084,64,0.0760115143133496,False,3,True,0,,CHEMBL5862801,0.82,nM,=,9.09,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.0862,1,active,MW=888.1 > 500.0; LogP=9.32 > 5.0; HBA=11 > 10
af20bfba,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC(F)(F)CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,896.03,895.3538744119999,8.929300000000005,172.03,3,11,13,10,5,0.44680851063829785,64,0.07613976604206917,False,3,True,0,,CHEMBL5959586,6.9,nM,=,8.16,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.1612,1,active,MW=896.0 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
2c5b7028,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CC(C(F)(F)F)CC4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,956.1009999999999,955.391402792,9.987099999999998,183.02999999999997,4,11,13,10,5,0.48,68,0.06510232364004817,False,3,True,0,,CHEMBL5813106,3.8,nM,=,8.42,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4202,1,active,MW=956.1 > 500.0; LogP=9.99 > 5.0; HBA=11 > 10
fc6e2dd8,,CN(C)C1CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,raw,,903.1189999999995,902.414917196,8.224200000000009,175.27,3,12,14,10,5,0.46938775510204084,65,0.07207033578252435,False,3,True,0,,CHEMBL5934720,0.679,nM,=,10.24,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,9.1681,1,active,MW=903.1 > 500.0; LogP=8.22 > 5.0; HBA=12 > 10
43075303,,CN(C)CCOC1CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,raw,,947.1719999999996,946.441131944,8.240800000000009,184.49999999999997,3,13,17,10,5,0.49019607843137253,68,0.059895083280140086,False,3,True,0,,CHEMBL5914817,0.15,nM,=,9.82,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.8239,1,active,MW=947.2 > 500.0; LogP=8.24 > 5.0; HBA=13 > 10
b0919a01,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2C(c4ccccc4C4CC4)CC4CC42)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,872.0609999999999,871.3727180359999,8.682500000000006,172.03,3,11,13,11,5,0.4583333333333333,63,0.07637589131530934,False,3,True,0,,CHEMBL5974384,1.5,nM,=,8.82,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.8239,1,active,MW=872.1 > 500.0; LogP=8.68 > 5.0; HBA=11 > 10
7022c343,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC4CCCC4C2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,900.1149999999998,899.4040181639999,9.320200000000003,172.03,3,11,13,11,5,0.48,65,0.07597919809537844,False,3,True,0,,CHEMBL5987746,1.6,nM,=,8.8,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.7959,1,active,MW=900.1 > 500.0; LogP=9.32 > 5.0; HBA=11 > 10
f288d5cb,,CC1(C)CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1c1ccccc1C1CC1,,,raw,,888.1039999999998,887.4040181639999,9.320200000000002,172.03,3,11,13,10,5,0.46938775510204084,64,0.0760115143133496,False,3,True,0,,CHEMBL5792180,1.7,nM,=,8.77,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.7696,1,active,MW=888.1 > 500.0; LogP=9.32 > 5.0; HBA=11 > 10
27a0dcbc,,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,raw,,889.0919999999998,888.3992671319999,7.835700000000008,175.27,3,12,13,10,5,0.4583333333333333,64,0.07732672367333897,False,3,True,0,,CHEMBL5768701,0.094,nM,=,10.03,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,4,10.0269,1,active,MW=889.1 > 500.0; LogP=7.84 > 5.0; HBA=12 > 10
6e86223e,,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NC[C@H]6CC[C@](C)(O)CC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)[C@H](c2ccccc2C2CC2)C1,,,raw,,917.1459999999997,916.4305672599999,8.350300000000008,186.27,4,12,13,10,5,0.48,66,0.06546369350204921,False,3,True,0,,CHEMBL6011671,0.071,nM,=,10.15,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.1487,1,active,MW=917.1 > 500.0; LogP=8.35 > 5.0; HBA=12 > 10
e96f2832,,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NC[C@H]6CC[C@](C)(O)CC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)[C@@H](c2ccccc2C2CC2)C1,,,raw,,917.1459999999997,916.4305672599999,8.350300000000008,186.27,4,12,13,10,5,0.48,66,0.06546369350204921,False,3,True,0,,CHEMBL5865603,0.063,nM,=,10.2,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,3,10.2007,1,active,MW=917.1 > 500.0; LogP=8.35 > 5.0; HBA=12 > 10
9c9eed50,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(c2ccccc2-c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,867.041,866.34616894,9.929199999999998,168.79,3,10,13,10,6,0.3469387755102041,63,0.07505425230087814,False,2,True,0,,CHEMBL5839129,15.0,nM,=,7.82,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.8239,1,active,MW=867.0 > 500.0; LogP=9.93 > 5.0
8d813e6a,,Cc1ccccc1C1CCCCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,862.0659999999996,861.3883680999999,8.895320000000002,172.03,3,11,12,9,5,0.44680851063829785,62,0.08082272269615556,False,3,True,0,,CHEMBL5992969,0.97,nM,=,9.01,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.0132,1,active,MW=862.1 > 500.0; LogP=8.90 > 5.0; HBA=11 > 10
df75839d,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCCCC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,888.1039999999997,887.4040181639999,9.464300000000001,172.03,3,11,13,10,5,0.46938775510204084,64,0.07597692690470058,False,3,True,0,,CHEMBL5836711,0.28,nM,=,9.55,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.5528,1,active,MW=888.1 > 500.0; LogP=9.46 > 5.0; HBA=11 > 10
40c22b10,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCN2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,861.0379999999998,860.3679670039999,7.974300000000009,175.27,3,12,13,10,5,0.43478260869565216,62,0.07705760395535385,False,3,True,0,,CHEMBL5757679,27.0,nM,=,7.57,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.5686,1,active,MW=861.0 > 500.0; LogP=7.97 > 5.0; HBA=12 > 10
015255ae,,CS(=O)(=NC(=O)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1,,,raw,,858.0779999999997,857.39345348,9.862499999999999,155.29000000000002,2,10,12,10,5,0.4583333333333333,62,0.091519536123905,False,2,True,0,,CHEMBL6014192,3.3,nM,=,8.48,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4815,1,active,MW=858.1 > 500.0; LogP=9.86 > 5.0
f78b33e3,,O=C(NS(=O)(=O)c1ccc(NCC2CCC(O)(C(F)(F)F)CC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,942.0739999999993,941.375752728,9.7411,183.03,4,11,13,10,5,0.46938775510204084,67,0.06513901758123,False,3,True,0,,CHEMBL5931376,0.058,nM,=,10.24,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.2366,1,active,MW=942.1 > 500.0; LogP=9.74 > 5.0; HBA=11 > 10
f808c402,,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](O)(C(F)(F)F)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,944.0899999999996,943.391402792,9.987099999999998,183.03,4,11,13,9,5,0.46938775510204084,67,0.06511417677433616,False,3,True,0,,CHEMBL5847503,0.063,nM,=,10.2,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.2007,1,active,MW=944.1 > 500.0; LogP=9.99 > 5.0; HBA=11 > 10
02679f9e,,CC(C)c1ccccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](O)(C(F)(F)F)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,944.0899999999996,943.391402792,9.987099999999998,183.03,4,11,13,9,5,0.46938775510204084,67,0.06511417677433616,False,3,True,0,,CHEMBL5887445,0.098,nM,=,10.01,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.0088,1,active,MW=944.1 > 500.0; LogP=9.99 > 5.0; HBA=11 > 10
6e7be75c,,CC1=CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C(C)C)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,872.105,871.409103544,10.249899999999997,162.8,3,10,13,9,5,0.42857142857142855,63,0.05896201781785821,False,2,True,0,,CHEMBL5928422,0.57,nM,=,9.24,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.2441,1,active,MW=872.1 > 500.0; LogP=10.25 > 5.0
c509ec98,,CCCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,890.1199999999994,889.4196682280001,9.273800000000003,183.03,4,11,14,9,5,0.46938775510204084,64,0.06159488476042057,False,3,True,0,,CHEMBL5995017,0.091,nM,=,10.04,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.041,1,active,MW=890.1 > 500.0; LogP=9.27 > 5.0; HBA=11 > 10
cbf419e9,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CN(CC4CCCN4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,847.0109999999997,846.35231694,6.8890000000000065,175.27,3,12,14,10,5,0.4222222222222222,61,0.07813922380787158,False,3,True,0,,CHEMBL5899288,2.6,nM,=,8.59,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,8.585,1,active,MW=847.0 > 500.0; LogP=6.89 > 5.0; HBA=12 > 10
2a653893,,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(CN2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999998,873.3883680999999,8.931700000000005,172.03,3,11,14,10,5,0.4583333333333333,63,0.07187370259213911,False,3,True,0,,CHEMBL5888815,6.4,nM,=,8.19,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,8.1938,1,active,MW=874.1 > 500.0; LogP=8.93 > 5.0; HBA=11 > 10
6da4ab10,,O=C(NS(=O)(=O)c1ccc(NCCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,874.0769999999999,873.3883680999999,9.074200000000005,172.03,3,11,14,10,5,0.4583333333333333,63,0.071811152591479,False,3,True,0,,CHEMBL5836404,0.13,nM,=,9.89,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.8861,1,active,MW=874.1 > 500.0; LogP=9.07 > 5.0; HBA=11 > 10
b4a01f1b,,O=C(NS(=O)(=O)c1ccc(NCCN2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,875.0649999999998,874.383617068,7.589700000000009,175.27,3,12,14,10,5,0.44680851063829785,63,0.0737925559963806,False,3,True,0,,CHEMBL6023708,0.15,nM,=,9.82,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.8239,1,active,MW=875.1 > 500.0; LogP=7.59 > 5.0; HBA=12 > 10
f50c13a2,,O=C(NS(=O)(=O)c1ccc(NCCN2CCOCC2=O)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,raw,,889.0479999999998,888.3628816239999,7.116300000000009,192.34,3,12,14,10,5,0.425531914893617,64,0.07572080003159352,False,3,True,0,,CHEMBL5893372,0.13,nM,=,9.89,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.8861,1,active,MW=889.0 > 500.0; LogP=7.12 > 5.0; HBA=12 > 10
f8fff294,,CC1(C)CC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC(C)(C)O1,,,raw,,916.1579999999999,915.435318292,10.241299999999997,172.03,3,11,13,10,5,0.49019607843137253,66,0.0758190521885887,False,3,True,0,,CHEMBL5783645,0.092,nM,=,10.04,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.0362,1,active,MW=916.2 > 500.0; LogP=10.24 > 5.0; HBA=11 > 10
293ef742,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC(N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,874.0769999999999,873.3883681,8.808600000000004,183.02999999999997,4,11,13,10,5,0.4583333333333333,63,0.06553096850745592,False,3,True,0,,CHEMBL5762885,0.74,nM,=,9.13,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.1308,1,active,MW=874.1 > 500.0; LogP=8.81 > 5.0; HBA=11 > 10
a7f1833b,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CC5(CCC(N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,874.0769999999999,873.3883681,8.808600000000004,183.02999999999997,4,11,13,10,5,0.4583333333333333,63,0.06553096850745592,False,3,True,0,,CHEMBL5934956,0.27,nM,=,9.57,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.5686,1,active,MW=874.1 > 500.0; LogP=8.81 > 5.0; HBA=11 > 10
a209a840,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC[C@@H](N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,888.1039999999999,887.404018164,9.198700000000002,183.02999999999997,4,11,13,10,5,0.46938775510204084,64,0.06533330064503391,False,3,True,0,,CHEMBL5857353,1.15,nM,=,9.0,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,8.9393,1,active,MW=888.1 > 500.0; LogP=9.20 > 5.0; HBA=11 > 10
18741066,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,885.1,884.3931191319999,10.165799999999997,179.79,4,10,13,10,5,0.44,64,0.06566262913675046,False,2,True,0,,CHEMBL5757676,0.45,nM,=,9.35,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.3468,1,active,MW=885.1 > 500.0; LogP=10.17 > 5.0
eb678d78,,Nc1ncc(Oc2cc(N3CCC4(CC3)CC(N3CCC[C@H]3c3ccccc3C3CC3)C4)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)cc1Cl,,,raw,,870.4729999999998,869.3337456840001,8.438400000000007,182.25999999999996,3,12,13,9,4,0.4666666666666667,61,0.08629463362980223,False,3,True,0,,CHEMBL5809484,0.076,nM,=,10.12,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,3,10.1192,1,active,MW=870.5 > 500.0; LogP=8.44 > 5.0; HBA=12 > 10
a3258f25,,CC1(C)CC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CCO1,,,raw,,888.1039999999999,887.404018164,9.462700000000002,172.03,3,11,13,10,5,0.46938775510204084,64,0.07597726600324867,False,3,True,0,,CHEMBL5788757,0.084,nM,=,10.08,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.0757,1,active,MW=888.1 > 500.0; LogP=9.46 > 5.0; HBA=11 > 10
faf6667e,,CN(CC1CCOCC1)C(=O)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC4(CC3)CC(N3CCC[C@H]3c3ccccc3C3CC3)C4)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,raw,,917.1019999999997,916.394181752,8.735900000000006,192.33999999999997,3,11,13,10,5,0.4489795918367347,66,0.0755847201904304,False,3,True,0,,CHEMBL5758637,0.12,nM,=,9.92,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.9208,1,active,MW=917.1 > 500.0; LogP=8.74 > 5.0; HBA=11 > 10
366de1bd,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,848.0390000000002,847.372718036,8.321300000000008,183.02999999999997,4,11,12,9,5,0.43478260869565216,61,0.06998282605189875,False,3,True,0,,CHEMBL5950945,0.21,nM,=,9.68,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6778,1,active,MW=848.0 > 500.0; LogP=8.32 > 5.0; HBA=11 > 10
bba3d8d3,,CC(C)c1ccccc1[C@@H]1CN(C)CCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,raw,,919.1619999999995,918.446217324,8.596300000000006,186.27,4,12,13,9,5,0.48,66,0.06522451311233128,False,3,True,0,,CHEMBL6014576,0.17,nM,=,9.77,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.7696,1,active,MW=919.2 > 500.0; LogP=8.60 > 5.0; HBA=12 > 10
ffd5403a,,O=C(NS(=O)(=O)c1ccc(OCC2CCC3(CC2)COC3)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,853.9979999999999,853.3145344639998,9.853599999999998,165.98999999999998,2,10,13,10,6,0.3333333333333333,62,0.08436275046528346,False,2,True,0,,CHEMBL5840822,3.2,nM,=,8.49,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4949,1,active,MW=854.0 > 500.0; LogP=9.85 > 5.0
5488c16c,,COC1(C)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,855.0299999999999,854.34616894,10.275199999999995,168.79,3,10,14,9,6,0.3333333333333333,62,0.0708132542783495,False,2,True,0,,CHEMBL5783644,6.1,nM,=,8.21,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.2147,1,active,MW=855.0 > 500.0; LogP=10.28 > 5.0
60c0a207,,COC1(C)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,855.0299999999999,854.34616894,10.275199999999995,168.79,3,10,14,9,6,0.3333333333333333,62,0.0708132542783495,False,2,True,0,,CHEMBL5845004,7.3,nM,=,8.14,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.1367,1,active,MW=855.0 > 500.0; LogP=10.28 > 5.0
7e3d1d55,,CC1=CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,822.9879999999999,822.3199541920001,10.426299999999994,159.56000000000003,3,9,13,9,6,0.2765957446808511,60,0.05851897628383107,False,2,True,0,,CHEMBL6020672,23.0,nM,=,7.64,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.6383,1,active,MW=823.0 > 500.0; LogP=10.43 > 5.0
2794375f,,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,896.0829999999996,895.372718036,9.462600000000002,183.03,4,11,13,9,6,0.32,65,0.06400630480911917,False,3,True,0,,CHEMBL5871180,0.068,nM,=,10.17,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,2,10.1675,1,active,MW=896.1 > 500.0; LogP=9.46 > 5.0; HBA=11 > 10
759f0e5b,,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,886.0189999999997,885.331996096,9.040100000000002,172.03,3,11,13,9,6,0.2916666666666667,64,0.07466014002823894,False,3,True,0,,CHEMBL5769999,0.099,nM,=,10.0,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.0044,1,active,MW=886.0 > 500.0; LogP=9.04 > 5.0; HBA=11 > 10
a8cb8f63,,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,870.0009999999997,869.3206824639999,7.936800000000009,181.26000000000002,3,12,13,9,6,0.2765957446808511,63,0.07545219145168457,False,3,True,0,,CHEMBL5910275,0.17,nM,=,9.77,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.7696,1,active,MW=870.0 > 500.0; LogP=7.94 > 5.0; HBA=12 > 10
be2e21a8,,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCN(C6COC6)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,941.0989999999995,940.374195256,8.724300000000005,175.27,3,12,14,10,6,0.3333333333333333,68,0.07010453385282121,False,3,True,0,,CHEMBL5841570,0.095,nM,=,10.02,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.0223,1,active,MW=941.1 > 500.0; LogP=8.72 > 5.0; HBA=12 > 10
56c614fa,,CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,926.1089999999996,925.3832827199999,9.469600000000002,200.1,4,11,13,9,6,0.35294117647058826,67,0.06352838617310179,False,3,True,0,,CHEMBL5890230,1.1,nM,=,8.96,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9586,1,active,MW=926.1 > 500.0; LogP=9.47 > 5.0; HBA=11 > 10
c9e1d578,,CN(C)CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,969.1779999999997,968.4254818799999,9.011300000000004,203.34,4,12,15,9,6,0.37735849056603776,70,0.05626657303777044,False,3,True,0,,CHEMBL5936311,0.063,nM,=,10.2,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,3,10.2007,1,active,MW=969.2 > 500.0; LogP=9.01 > 5.0; HBA=12 > 10
343ab946,,CNCC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,955.1509999999996,954.409831816,8.669100000000006,212.12999999999997,5,12,15,9,6,0.36538461538461536,69,0.04835025104834437,False,3,True,0,,CHEMBL5773439,0.064,nM,=,10.19,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.1938,1,active,MW=955.2 > 500.0; LogP=8.67 > 5.0; HBA=12 > 10
efb4cb76,,CN(C)CCC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,983.2049999999996,982.441131944,9.401400000000004,203.34,4,12,16,9,6,0.3888888888888889,71,0.0529332522338149,False,3,True,0,,CHEMBL5981762,0.084,nM,=,10.08,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,10.0757,1,active,MW=983.2 > 500.0; LogP=9.40 > 5.0; HBA=12 > 10
7b711ca8,,CC(C)(N)C(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,raw,,969.1779999999997,968.4254818799999,9.187000000000003,226.11999999999998,5,12,14,9,6,0.37735849056603776,70,0.050878026440222636,False,3,True,0,,CHEMBL5775670,1.2,nM,=,8.92,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9208,1,active,MW=969.2 > 500.0; LogP=9.19 > 5.0; HBA=12 > 10
a915225d,,CC(=O)N1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,854.002,853.325767844,8.938400000000003,179.87,3,10,13,9,6,0.2978723404255319,62,0.07500938664926068,False,2,True,0,,CHEMBL6002443,1.2,nM,=,8.92,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.9208,1,active,MW=854.0 > 500.0; LogP=8.94 > 5.0
84327ec9,,CS(=O)(=O)N1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,890.057,889.2927534639999,8.351500000000007,196.93999999999997,3,11,14,9,6,0.30434782608695654,63,0.07021593794007237,False,3,True,0,,CHEMBL5885190,3.3,nM,=,8.48,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.4815,1,active,MW=890.1 > 500.0; LogP=8.35 > 5.0; HBA=11 > 10
2ce0e2b1,,O=C(NS(=O)(=O)c1ccc(NCCN2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,827.964,827.3101177799999,8.012100000000009,172.03,3,11,14,9,6,0.28888888888888886,60,0.07176205512002937,False,3,True,0,,CHEMBL5848534,9.1,nM,=,8.04,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.041,1,active,MW=828.0 > 500.0; LogP=8.01 > 5.0; HBA=11 > 10
a2af00a6,,O=C(NS(=O)(=O)c1ccc(NC2CC3(C2)CN(C2CCOCC2)C3)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,raw,,894.0669999999998,893.3570679719999,9.323300000000001,172.03,3,11,13,11,6,0.36,65,0.07454142437638173,False,3,True,0,,CHEMBL5824581,14.0,nM,=,7.85,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.8539,1,active,MW=894.1 > 500.0; LogP=9.32 > 5.0; HBA=11 > 10
54fd98f3,,CS(C)(=O)=NC1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,902.1119999999999,901.329138972,9.966299999999999,188.98999999999998,3,11,14,9,6,0.3333333333333333,64,0.0700959618619782,False,3,True,0,,CHEMBL5837669,2.6,nM,=,8.59,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.585,1,active,MW=902.1 > 500.0; LogP=9.97 > 5.0; HBA=11 > 10
4cc375b5,,CS(C)(=O)=NC1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,902.1119999999999,901.329138972,9.966299999999999,188.98999999999998,3,11,14,9,6,0.3333333333333333,64,0.0700959618619782,False,3,True,0,,CHEMBL5910162,0.24,nM,=,9.62,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,9.6198,1,active,MW=902.1 > 500.0; LogP=9.97 > 5.0; HBA=11 > 10
efff5373,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CC(F)(F)CC5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,876.9829999999998,876.311675252,9.866299999999999,179.79,4,10,13,9,6,0.3191489361702128,63,0.06445119230820254,False,2,True,0,,CHEMBL5783794,1.6,nM,=,8.8,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,8.7959,1,active,MW=877.0 > 500.0; LogP=9.87 > 5.0
3f4dab8e,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CC(C(F)(F)F)CC5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,908.9999999999998,908.3179035039999,10.409499999999994,179.79,4,10,13,9,6,0.3333333333333333,65,0.06434463266156991,False,2,True,0,,CHEMBL5753873,13.0,nM,=,7.89,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.8861,1,active,MW=909.0 > 500.0; LogP=10.41 > 5.0
7b38c9d6,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cc(F)cc4[nH]ccc34)cc2[N+](=O)[O-])CC1,,,raw,,858.005,857.325848096,10.365199999999994,166.9,4,9,13,9,6,0.3125,62,0.06528568955399656,False,2,True,0,,CHEMBL6023387,49.0,nM,=,7.31,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,1,7.3098,1,active,MW=858.0 > 500.0; LogP=10.37 > 5.0
a20b3672,,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(=O)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,raw,,716.8170000000002,716.26283324,5.684700000000005,196.85999999999999,4,11,10,7,4,0.4166666666666667,51,0.11631744542288747,False,3,True,0,,CHEMBL5820802,49.0,nM,=,7.31,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,3,7.3098,1,active,MW=716.8 > 500.0; LogP=5.68 > 5.0; HBA=11 > 10
593e46ec,,CC1(C)CCC(COC2CC3(C2)CN(c2ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c2)C3)=C(c2ccc(Cl)cc2)C1,,,raw,,895.4789999999998,894.317761272,9.5233,178.02,3,11,14,9,5,0.40425531914893614,63,0.07144784225227323,False,3,True,0,,CHEMBL5775726,84.0,nM,=,7.08,CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",0.8,3,7.0757,1,active,MW=895.5 > 500.0; LogP=9.52 > 5.0; HBA=11 > 10
2ef68042,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccccc1)c1ccc(O)cc1,,,raw,,724.8580000000003,724.326085128,6.6720000000000095,96.71000000000001,1,8,8,9,5,0.3181818181818182,54,0.1910737337451774,False,2,True,0,,CHEMBL6003093,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=724.9 > 500.0; LogP=6.67 > 5.0
39e11512,,Cc1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,raw,,738.8850000000001,738.341735192,6.98042000000001,96.71000000000002,1,8,8,9,5,0.3333333333333333,55,0.1836505567278147,False,2,True,0,,CHEMBL5788222,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=738.9 > 500.0; LogP=6.98 > 5.0
22bbfac5,,Cc1ccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1,,,raw,,738.8850000000001,738.341735192,6.980420000000009,96.71000000000002,1,8,8,9,5,0.3333333333333333,55,0.1836505567278147,False,2,True,0,,CHEMBL5856529,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=738.9 > 500.0; LogP=6.98 > 5.0
a28ba353,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1cccc(F)c1)c1ccc(O)cc1,,,raw,,742.8480000000003,742.316663316,6.8111000000000095,96.71000000000001,1,8,8,9,5,0.3181818181818182,55,0.1867525106965085,False,2,True,0,,CHEMBL5995264,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=742.8 > 500.0; LogP=6.81 > 5.0
fb5496b9,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccc(F)cc1)c1ccc(O)cc1,,,raw,,742.8480000000003,742.316663316,6.8111000000000095,96.71000000000001,1,8,8,9,5,0.3181818181818182,55,0.1867525106965085,False,2,True,0,,CHEMBL5788840,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=742.8 > 500.0; LogP=6.81 > 5.0
85325f29,,Cc1cccc(F)c1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,756.8749999999999,756.3323133800001,7.119520000000011,96.71000000000002,1,8,8,9,5,0.3333333333333333,56,0.18029223145332549,False,2,True,0,,CHEMBL5837845,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=756.9 > 500.0; LogP=7.12 > 5.0
ae5aa0b5,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1c(F)cccc1F)c1ccc(O)cc1,,,raw,,760.8380000000003,760.3072415040001,6.9502000000000095,96.71000000000001,1,8,8,9,5,0.3181818181818182,56,0.18304515847849037,False,2,True,0,,CHEMBL5853531,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=760.8 > 500.0; LogP=6.95 > 5.0
1336855f,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1cccc(C(F)(F)F)c1)c1ccc(O)cc1,,,raw,,792.8550000000004,792.313469756,7.69080000000001,96.71000000000001,1,8,8,9,5,0.3333333333333333,58,0.1722779598571555,False,2,True,0,,CHEMBL5788063,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=792.9 > 500.0; LogP=7.69 > 5.0
2c940edf,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccc(C(F)(F)F)cc1)c1ccc(O)cc1,,,raw,,792.8550000000004,792.313469756,7.69080000000001,96.71000000000001,1,8,8,9,5,0.3333333333333333,58,0.1722779598571555,False,2,True,0,,CHEMBL5941938,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=792.9 > 500.0; LogP=7.69 > 5.0
516d16cb,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1c(Cl)ccc(F)c1F)c1ccc(O)cc1,,,raw,,795.2830000000002,794.268269152,7.60360000000001,96.71000000000001,1,8,8,9,5,0.3181818181818182,57,0.16179229606604237,False,2,True,0,,CHEMBL5870017,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=795.3 > 500.0; LogP=7.60 > 5.0
84d5d3ba,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccccc1-c1ccccc1)c1ccc(O)cc1,,,raw,,800.9560000000002,800.357385256,8.339000000000008,96.71000000000001,1,8,9,10,6,0.28,60,0.15718760973522775,False,2,True,0,,CHEMBL5963393,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=801.0 > 500.0; LogP=8.34 > 5.0
2f80fda4,,Cc1cc(C(F)(F)F)ccc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,806.8819999999997,806.3291198200001,7.99922000000001,96.71000000000002,1,8,8,9,5,0.34782608695652173,59,0.16992927304402788,False,2,True,0,,CHEMBL5983229,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=806.9 > 500.0; LogP=8.00 > 5.0
9903b777,,Cc1ccc(C(F)(F)F)cc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,raw,,806.8819999999997,806.3291198200001,7.99922000000001,96.71000000000002,1,8,8,9,5,0.34782608695652173,59,0.16992927304402788,False,2,True,0,,CHEMBL5757177,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=806.9 > 500.0; LogP=8.00 > 5.0
07f5111a,,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1cccnc1)c1ccc(O)cc1,,,raw,,725.8460000000002,725.321334096,6.067000000000008,109.60000000000001,1,9,8,9,5,0.32558139534883723,54,0.20563203339636368,False,2,True,0,,CHEMBL5929853,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=725.8 > 500.0; LogP=6.07 > 5.0
35047f57,,COc1c(C)cnc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1C,,,raw,,783.9259999999998,783.3631989080001,6.692440000000008,118.83000000000003,1,10,9,9,5,0.3695652173913043,58,0.174521664703191,False,2,True,0,,CHEMBL6011142,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=783.9 > 500.0; LogP=6.69 > 5.0
c3ad9ba3,,CN1CCN(C(=O)c2cccc(CN(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)c2)CC1,,,raw,,851.0169999999995,850.4053980680002,6.059600000000008,120.26,1,10,9,10,5,0.38,63,0.18895078826002454,False,2,True,0,,CHEMBL5763220,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=851.0 > 500.0; LogP=6.06 > 5.0
a47566f9,,O=C(O)c1ccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(OCc3ccccc3)cc2)cc1,,,raw,,858.9919999999998,858.36286456,8.243600000000008,123.01,1,9,12,10,6,0.28846153846153844,64,0.12972201476417594,False,2,True,0,,CHEMBL5941798,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=859.0 > 500.0; LogP=8.24 > 5.0
ade7f197,,CN1CCN(C(=O)c2ccc(CN(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)cc2)CC1,,,raw,,851.0169999999996,850.4053980680001,6.059600000000008,120.26,1,10,9,10,5,0.38,63,0.18895078826002454,False,2,True,0,,CHEMBL5789676,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=851.0 > 500.0; LogP=6.06 > 5.0
623dccbb,,CS(=O)(=O)NC(=O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(OCc3ccccc3)cc2)c1,,,raw,,936.0999999999995,935.356399276,7.234800000000008,148.95,1,11,13,10,6,0.3018867924528302,68,0.12576990753156683,False,3,True,0,,CHEMBL5857436,7.5,nM,=,8.12,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,8.1249,1,active,MW=936.1 > 500.0; LogP=7.23 > 5.0; HBA=11 > 10
87c0ab0c,,O=C(O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,raw,,768.8669999999998,768.315914368,6.370200000000008,134.01,2,9,9,9,5,0.3111111111111111,57,0.17558786505215826,False,2,True,0,,CHEMBL5949378,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=768.9 > 500.0; LogP=6.37 > 5.0
c5299f22,,CC(C)(C)OC(=O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,raw,,824.9749999999997,824.3785146240001,7.627300000000011,123.01,1,10,9,9,5,0.3673469387755102,61,0.14966085926196088,False,2,True,0,,CHEMBL6010922,30.0,nM,=,7.52,CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",0.8,1,7.5229,1,active,MW=825.0 > 500.0; LogP=7.63 > 5.0
